
<html lang="en"     class="pb-page"  data-request-id="58127b82-1832-4b5d-a599-439ff5df03a2"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/jm5006463;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2014.57.issue-19;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Polypharmacology: Challenges and Opportunities in Drug Discovery" /></meta><meta name="dc.Creator" content="Andrew  Anighoro" /></meta><meta name="dc.Creator" content="Jürgen  Bajorath" /></meta><meta name="dc.Creator" content="Giulio  Rastelli" /></meta><meta name="dc.Description" content="At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biological target, shares the spotlight with an emerging and alternative polypharmacology ap..." /></meta><meta name="Description" content="At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biological target, shares the spotlight with an emerging and alternative polypharmacology ap..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 25, 2014" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm5006463" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm5006463" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm5006463" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm5006463" /></link>
        
    
    

<title>Polypharmacology: Challenges and Opportunities in Drug Discovery | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm5006463" /></meta><meta property="og:title" content="Polypharmacology: Challenges and Opportunities in Drug Discovery" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0006.jpeg" /></meta><meta property="og:description" content="At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biological target, shares the spotlight with an emerging and alternative polypharmacology approach. Polypharmacology suggests that more effective drugs can be developed by specifically modulating multiple targets. It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches. In this respect, a drug that “hits” multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs. In this review, we will compare advantages and disadvantages of multitarget versus combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm5006463"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm5006463">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm5006463&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm5006463&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm5006463&amp;href=/doi/10.1021/jm5006463" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 7874-7887</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm500415t" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm501298k" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Anighoro">Andrew Anighoro</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=J%C3%BCrgen++Bajorath">Jürgen Bajorath</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Giulio++Rastelli">Giulio Rastelli</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Life Sciences Department, University of Modena and Reggio Emilia, Via Campi 183, 41125 Modena, Italy</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität, Dahlmannstrasse 2, D-53113 Bonn, Germany</span></div><div class="corresp-info"><strong>*</strong>Phone: +39 059 2055145. E-mail: <a href="/cdn-cgi/l/email-protection#86e1eff3eaefe9a8f4e7f5f2e3eaeaefc6f3e8efebe9f4e3a8eff2"><span class="__cf_email__" data-cfemail="15727c60797c7a3b677466617079797c55607b7c787a67703b7c61">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm5006463&amp;href=/doi/10.1021%2Fjm5006463" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 7874–7887</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 19, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>25 April 2014</li><li><span class="item_label"><b>Published</b> online</span>25 June 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 October 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm5006463" title="DOI URL">https://doi.org/10.1021/jm5006463</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7874%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAndrew%2BAnighoro%252C%2BJ%25C3%25BCrgen%2BBajorath%252C%2BGiulio%2BRastelli%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D19%26contentID%3Djm5006463%26title%3DPolypharmacology%253A%2BChallenges%2Band%2BOpportunities%2Bin%2BDrug%2BDiscovery%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7887%26publicationDate%3DOctober%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm5006463"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">10580</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">475</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm5006463" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Polypharmacology: Challenges and Opportunities in Drug Discovery&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Anighoro&quot;},{&quot;first_name&quot;:&quot;Jürgen&quot;,&quot;last_name&quot;:&quot;Bajorath&quot;},{&quot;first_name&quot;:&quot;Giulio&quot;,&quot;last_name&quot;:&quot;Rastelli&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;25&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;7874-7887&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm5006463&quot;},&quot;abstract&quot;:&quot;At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biological target, shares the spotlight with an emerging and alternative polypharmacology approach. Polypharmacology suggests that more effective drugs can be developed by specifically modulating multiple targets. It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches. In this respect, a drug that “hits” multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs. In this review, we will compare advantages and disadvantages of multitarget versus combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5006463&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5006463" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5006463&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5006463" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5006463&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5006463" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm5006463&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5006463&amp;href=/doi/10.1021/jm5006463" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm5006463" /></input><a href="/doi/pdf/10.1021/jm5006463" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26pmid%3D24946140%26genre%3Darticle%26aulast%3DAnighoro%26date%3D2014%26atitle%3DPolypharmacology%253A%2BChallenges%2Band%2BOpportunities%2Bin%2BDrug%2BDiscovery%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D19%26spage%3D7874%26epage%3D7887%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292519" title="Cancer therapy">Cancer therapy</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/19" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jmcmar.2014.57.issue-19/20141009/jmcmar.2014.57.issue-19.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/medium/jm-2014-006463_0006.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5006463&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biological target, shares the spotlight with an emerging and alternative polypharmacology approach. Polypharmacology suggests that more effective drugs can be developed by specifically modulating multiple targets. It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches. In this respect, a drug that “hits” multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs. In this review, we will compare advantages and disadvantages of multitarget versus combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15555" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15555" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Modern drug discovery has been strongly focused on the development of drugs intended to act against a specific target with high potency and selectivity. This paradigm is based on a direct cause–effect relationship between the activity of a gene product and a particular phenotype. Consequently, a pharmacological agent able to specifically modulate the activity of a deregulated protein should be able to revert a pathological phenotype. For instance, in the case of an aberrant cellular pathway caused by an augmented activity or overexpression of an enzyme, a potent and selective inhibitor would be able to restore normal cellular functions. Likewise, a multitarget (i.e., promiscuous) drug with a wider and sometimes unpredictable spectrum of biological activities could eventually lead to adverse reactions, making its use unsafe. It is now generally recognized that these concepts may be too simplistic to explain the mechanism of action of some drugs as well as to design therapies for complex multifactorial diseases. Nowadays, designing a single drug molecule able to simultaneously and specifically interact with multiple targets is gaining major consideration in drug discovery.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1-4)</a> In this review, we will refer to this as “polypharmacology” to distinguish the approach from combination therapy in which two or more drugs are typically used in combination. Furthermore, it should also be noted that polypharmacology is not synonymous with “compound promiscuity”. The latter term refers to the presence of specific interactions of a compound with multiple targets and hence represents the molecular basis for polypharmacology including associated functional effects.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Importantly, compound promiscuity as the basis of polypharmacology does not include nonspecific binding events due to compound liabilities.</div><div class="NLM_p">The number of articles and reviews published in the past 10 years containing the term “polypharmacology” in the title, abstract, or keywords (data retrieved from Scopus<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a>) has steadily increased. Out of 194 papers, 100 were published in the past 2 years and more than 60 last year. These data witness an increasing interest in this approach. In a recent review by Jalencas and Mestres, polypharmacology was analyzed from an evolutionary point of view, suggesting that the ability of early biological organisms to adapt to environmental changes might have favored the selection of biomolecular systems intrinsically prone to chemical promiscuity.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The authors speculated that the level of polypharmacology observed in current drugs may well just be a latent signature of evolution. In general, understanding polypharmacology and its origins is an important condition for improving our ability to rationally exploit polypharmacological effects for therapeutic purposes. A drug active on multiple targets may be characterized by an improved efficacy when compared to a highly selective pharmacological agent. In fact, multitarget activities may potentiate efficacy (either additively or synergistically) and be less prone to the insurgence of drug resistance mutations. Furthermore, the inherent redundancy of biological networks, especially within the same protein family, might impede the efforts of shutting down a cellular pathway if a single switch is turned off. Several lines of evidence indicate that complex pathologies are often polygenic in nature and tend to involve the deregulation of complex and extended networks of proteins. Such diseases are unlikely to be successfully treated by pharmacological interventions based on a single target, while the modulation of an optimal array of targets may provide a more efficient strategy.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Notably, modulation of multiple targets may result in a synergistic effect. While this goal is commonly pursued in combination therapies by administrating two or more drugs, multitarget drugs aim at the same goal but use a single drug molecule. Both approaches have strengths and limitations, as it will be further described later on.</div><div class="NLM_p">The analysis of known drug–target associations results in complex networks that were explored in several works.<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13">(9-13)</a> It is by now generally recognized that several approved drugs elicit their therapeutic effect through complex polypharmacology.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Importantly, in most cases, such behavior was discovered only retrospectively<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and the complete set of current drug–target associations is still far from being completely characterized. For example, addressing the issue of drugs with multiple activities, a recent analysis<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> identified through mining of public molecular databases a set of recurrent molecular scaffolds<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> describing small molecules with a tendency for promiscuous activity across different target families (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). Interestingly, such chemotypes (defined here as sets of topologically equivalent scaffolds yielding the same carbon skeleton) were frequently found in approved drugs, suggesting the possibility for unpredicted off-target activities. Specifically, promiscuous scaffolds represented ∼6% of all compounds active against current targets. Thirty-nine of these scaffolds were found in ∼17% of approved drugs, and the seven most promiscuous chemotypes alone covered 190 drugs.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Hence, these drugs represent excellent candidates for experimental polypharmacological profiling. Similar analyses of compound promiscuity through data mining have revealed that there is a clear enrichment of promiscuity along the path from bioactive compounds to drugs,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> for reasons that are currently unknown. For example, while current active compounds from medicinal chemistry sources with available high-confidence activity data are known to bind, on average, to only one to two targets, approved drugs have, on average, close to six known targets.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Of course, approved drugs are typically more extensively characterized than other active compounds. However, one might also speculate that there could be a selection and enrichment process for promiscuous drug candidates during clinical trials, consistent with the idea that clinical efficacy might often correlate with polypharmacology.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/medium/jm-2014-006463_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Scaffolds and promiscuity profiles. Shown is a set of topologically equivalent scaffolds including dipenylmethane, one of the most promiscuous scaffolds found in bioactive compounds, and their promiscuity profiles. Nodes represent scaffolds, and an edge connects two scaffolds if they are active against the same target(s). Edge labels report the number of shared targets (and node labels scaffold IDs). The structure of each scaffold is annotated with its promiscuity profile consisting of “target family: number of relevant targets” expressions. For example, the scaffold at the bottom has the activity profile “1:1; 2:3; 10:7”, which means that this scaffold is present in compounds that are active against one target in target family 1, three targets in family 2, and seven targets in family 10. The figure was adapted from ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">15</a>. Scaffolds and target families are numbered according to the original publication.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5006463&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The success of multitarget approaches will depend on several challenges, most of which still have to be faced. Rational design of multitarget compounds is still in its infancy and surely will need further implementation and methodological development. Areas of high interest include drug repositioning in different therapeutic areas, prediction of off-target toxicities, and rational design of multitarget drugs. From a medicinal chemistry point of view, both the rational identification of multitarget hit or lead compounds and the optimization of complex structure–activity relationship (SAR) profiles are challenging tasks. To this end, several approaches have recently been proposed, and more efforts in this direction will be necessary in the near future.</div><div class="NLM_p last">In this manuscript we will concisely review and discuss major challenges and opportunities of polypharmacology in drug discovery. In particular, we will focus on pros and cons of multitarget vs combination therapies, potential drug promiscuity arising from off-target effects, drug repurposing, and rational design of multitarget drugs.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Combination Therapy vs Multitarget Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31444" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31444" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Single-target therapeutic agents may be affected by side effects and tissue toxicity, resulting in reduced efficacy, drug resistance, and a generally decreased quality of life for patients. In contrast, specific drug combinations are designed to achieve more durable disease control, resulting from simultaneous blockade of disease-relevant targets in properly selected patients. In general, combination drugs should be individually active, yet elicit synergistic effects and have different mechanisms of action, nonoverlapping mechanisms of resistance, and distinct toxicities.</div><div class="NLM_p">There are at least three ways to select an agent for testing in combination with another drug: the drug may act on the same target, an additional target of the same pathway, or a different pathway or cellular process that is involved in the pathogenesis or drug resistance of a specific disease type. For example, the molecular and genetic complexity of advanced-stage diseases such as cancer suggests that targeting a single oncogenic pathway may not be sufficient to achieve durable remissions in patients.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Accordingly, novel drug discovery and development strategies are focusing on targeting multiple signaling pathways, either with drug combinations or through the design and development of a single compound able to target multiple oncoproteins.</div><div class="NLM_p">A few examples of currently investigated combination therapies in different disease areas are reported in the following. For example, combinations of targeted agents with the proteasome inhibitor bortezomib are currently evaluated in cancer clinical trials. Drug combinations include kinase, heat shock protein 90 (Hsp90), and farnesyltransferase inhibitors, as well as other targeted drugs. Preliminary clinical data suggest that some of these combinations have promising clinical efficacy.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Hsp90 inhibitors<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> act additively or synergistically with many other drugs in the treatment of both solid tumors and leukemias. For this reason, several clinical trials in which targeted drugs are combined with Hsp90 inhibitors are currently underway.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> For example, drug combinations involving the Her2/Erb2B inhibitor trastuzumab (Herceptin) and the Hsp90 inhibitor 17-AAG have been explored in clinical trials.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><div class="NLM_p">The implementation of artemisinin-based combination therapies resulted in a great success for treating chloroquine-resistant and sulfadoxine–pyrimethamine-resistant malaria such that the WHO recommends these drug combinations as the preferred first-line antimalarials against <i>P. falciparum</i> malaria.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Interestingly, the mechanism by which artemisinin derivatives exert antimalarial activity is still far from being fully elucidated, and several lines of evidence suggest that these molecules modulate the activity of multiple targets.</div><div class="NLM_p">Combination therapy is also explored in multiple sclerosis (MS), a complex central nervous system (CNS) inflammatory disease process that comprises multiple potential therapeutic targets.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> For example, one drug can be used to reduce inflammation and another to augment neuroprotection or repair or to reduce side effects. However, the advantages of combination therapy in MS are still a matter of debate, as adverse effects of individual drugs can be additive or even synergistic, and drugs might interfere with each other, thereby reducing efficacy.</div><div class="NLM_p">Despite the highly significant therapeutic relevance of combination therapies, potential advantages of a targeted therapy based on a single drug that modulates the activity of multiple targets over single-targeted or combination therapy can be prospected as follows:<table class="listgroup" border="0" width="95%" list-type="label"><tr class="li1"><td valign="top">(i)</td><td colspan="5" valign="top" class="paragraph"><p class="last">A molecule that acts simultaneously on multiple targets often shows superior efficacy against advanced-stage diseases, compared to compounds with high specificity for a single target.</p></td></tr><tr class="li1"><td valign="top">(ii)</td><td colspan="5" valign="top" class="paragraph"><p class="last">A single molecule with dual activity may have a more predictable pharmacokinetic profile compared to multiple molecules administered in combination. Therefore, it may display a superior pharmacokinetic (PK) and safety profile. This is particularly true if adverse effects (AEs) are molecule-based because a single molecule would be administered instead of two. On the other hand, no clear advantage may be obtained if AEs are target-based because having two mechanisms of action may create distinct AEs.</p></td></tr><tr class="li1"><td valign="top">(iii)</td><td colspan="5" valign="top" class="paragraph"><p class="last">Experience is showing that acute and delayed toxicities may be higher in drug combinations, especially when combining drugs that are not particularly selective. This suggests that modifications in the doses/schedule that are applied when the agents are used individually are generally necessary and that phase 1 and phase 2 trial designs may underestimate the toxicity of a combination.</p></td></tr><tr class="li1"><td valign="top">(iv)</td><td colspan="5" valign="top" class="paragraph"><p class="last">The combination of multiple active principles, as typically performed in combination therapies, may result in positive but also negative synergistic effects, thus limiting the number of useful combinations.</p></td></tr><tr class="li1"><td valign="top">(v)</td><td colspan="5" valign="top" class="paragraph"><p class="last">The probability of developing target-based resistance to multitarget drugs is statistically lower than is the probability of developing resistance against single-target drugs.</p></td></tr><tr class="li1"><td valign="top">(vi)</td><td colspan="5" valign="top" class="paragraph"><p class="last">Administering a single compound having multiple biological targets guarantees the simultaneous presence of the molecule in tissues where the active principle is required to work such that the compounds interacts with its multiple targets.</p></td></tr><tr class="li1"><td valign="top">(vii)</td><td colspan="5" valign="top" class="paragraph"><p class="last">In some cases, the risks of drug–drug interactions associated with combination therapies could be mitigated, resulting in a simplified therapeutic regimen.</p></td></tr><tr class="li1"><td valign="top">(viii)</td><td colspan="5" valign="top" class="paragraph"><p class="last">The use of drug cocktails often complicates dosing schedules and negatively impacts patient compliance.</p></td></tr><tr class="li1"><td valign="top">(ix)</td><td colspan="5" valign="top" class="paragraph"><p class="last">A single agent binding to multiple targets might be easier to develop given that the regulatory requirements for demonstrating activity and safety of a combination are more arduous than for a single agent. Regulatory agencies generally require the demonstration of safety of the individual drugs prior to human testing of their combination, which delays the assessment of novel combinations until after the two agents have been assessed as single drugs and in combination with standard therapies. These combination trials may also highlight novel toxicities and adverse effects.</p></td></tr></table></div><div class="NLM_p">In addition to the principal considerations above, problems may also arise when two drugs that are candidates for combination therapy are being developed by different pharma companies because regulatory and intellectual property issues may delay clinical trials of these investigational drug combinations. To facilitate such trials, the Cancer Therapy Evaluation Program (CTEP)<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> at the National Cancer Institute (NCI) has developed data-sharing and patent rights language, which has prompted collaboration between cancer research centers, hospitals, and companies to enter into agreements to develop and test novel combinations.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a></div><div class="NLM_p last">For all these reasons, in the future, the development of single-molecule drugs with a desired multitarget profile may offer an appealing and cost-effective complement or alternative to drug combinations. At present, combination therapy is more extensively explored in the clinic than the use of multitarget drugs. Both approaches are potentially able to yield drugs or drug combinations with improved safety and efficacy profiles. In either case, key to success will likely be the choice of suitable biological targets and molecular pathways that need to be concurrently modulated with drug molecule(s).</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Drug Promiscuity and Off-Target Effects</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55723" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55723" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The balance between a “beneficial polypharmacology” and a “harmful promiscuity” of drugs is an issue that needs to be carefully evaluated in drug discovery. Could multitarget ligands be inherently more prone to side effects and adverse reactions? Adverse reactions are a major concern for drug safety and frequently determine attrition,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> ultimately resulting in the withdrawal of a drug from late-stage clinical trials or the market. Adverse reactions can be mediated by the primary target of the drug or by promiscuous interactions of the drug with detrimental off-targets (also called antitargets).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Challenging situations arise when primary and antitargets share significant homology because it will be harder to achieve the desired selectivity in cases where primary and antitargets are closely related. For example, while carbonic anhydrase (CA) IX is considered a relevant target for cancer therapy, CA II inhibition may cause a series of relevant adverse reactions such as constipation, diarrhea, eye irritation, watering, blurred vision, and taste changes.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> These two CA isoforms share 31% sequence identity, and their three-dimensional structure is very similar. In this case, a difference of only three residues in the active site has been identified as a key feature exploitable for selectivity.</div><div class="NLM_p">Usually, the risk of activity against dangerous off-targets is explored and partially managed by screening drug candidates against a panel of relevant proteins that are known to mediate side effects in humans. However, it is important to note that the size of the human proteome and the only partial understanding of its functional spectrum do currently not permit complete, or even nearly complete, off-target screening. Moreover, many post-translational modifications of proteins have profound and often tissue-specific functional consequences that can hardly be accounted for in typical screening settings. Taking these difficulties into consideration, screening performed against a small panel of representative targets has been suggested as an affordable way to identify dangerous promiscuity of early stage drug candidates.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> To address this issue, different predictive models have also been proposed. For example, Kuhn et al. integrated known drug–target and drug side effect data to predict new target side effects relations emerging from statistically significant correlations.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> They were able to predict and validate in vivo that zolmitriptan (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), a drug used to treat migraine targeting serotonin receptors 5-HT-1B and 5-HT-1D, is responsible for increased pain sensitivity (hyperesthesia) as a consequence of binding to the off-target 5-HT-7 (26% sequence identity with 5-HT-1B and 5-HT-1D). Lounkine et al. applied a computational strategy based on the evaluation of the similarity of several drugs to sets of reference ligands<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> of targets with previously known associations to adverse reactions.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> They were able to predict drug–target interactions confirmed by database annotations or binding assays. Furthermore, they associated in vitro activities with adverse reactions in patients by obtaining drug–target adverse reaction links. For example, the histamine H1 receptor was identified as an off-target of prenylamine (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), a calcium channel blocker.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> This activity was associated with sedation, a reported side effect of this drug. Interestingly, this side effect was not associated with any of the previously known targets of prenylamine, illustrating that ligand-based approaches can be used to discover off-target activities of known drugs and rationalize observed adverse reactions, at least in cases where substantial small molecule ligand information is available for therapeutic targets.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/medium/jm-2014-006463_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of representative drugs and pharmaceutically relevant compounds discussed in the text.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5006463&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">On the basis of these considerations, one would conclude that beneficial polypharmacology approaches should be directed toward the most suitable and promising target combinations, avoiding promiscuous effects likely arising from interaction with harmful antitargets. Thus, prior knowledge inevitably play an important role in devising meaningful polypharmacology approaches. Regardless, the ability to predict off-target interactions and their effect on patients would have a strong impact on drug development, saving time and resources and navigating more efficacious and potentially safer drugs through the discovery pipeline. It is likely that the development of methods for predicting off-target activities will be one of the future key tasks for polypharmacology.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Drug Repurposing</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27157" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27157" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">It has been recognized that drugs used in the treatment of a given pathology may sometimes be “re-discovered” in different therapeutic areas.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> This event may take place if the primary target of a drug is involved in more than one pathology or if the drug is able to modulate the activity of additional targets that are relevant for the new application. Of course, one would hope that predictive approaches might also be applicable to help narrow down potential secondary applications. A perspective on unpredicted off-target effects was given by Keiser et al., who proposed a statistical ligand-based approach to predict new off-targets for approved drugs and relevant pharmaceutical compounds.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> With their approach they were able to capture similarities between ligands of unrelated proteins and to identify previously unreported polypharmacologies. In recent years, pharmaceutical companies in particular were attracted by drug repositioning because the possibility to use an approved or investigational drug in a new therapeutic area avoids the expensive and time-consuming pharmacokinetic and toxicological profiling typically required for new candidates. Furthermore, drugs not approved for use in a given therapeutic area because of adverse reactions may be “rescued” if the benefits obtained in a new therapeutic area justify their administration. Therefore, drug repurposing and rescuing can be regarded as “shortcuts” in the drug discovery process that can potentially lead to major savings in terms of time and economical investments. However, it has proven to be difficult in pharmaceutical R&D to implement widely applicable and robust strategies for drug repurposing. Given that many drugs are active against multiple targets, repurposing might frequently be feasible. However, how to best discern polypharmacology patterns and how to differentiate between target profiles that are relevant for complementary or alternative therapeutic applications are as of yet unsolved problems. Hence, successful drug repositioning campaigns currently are exceptions rather than the rule, despite the conceptual attractiveness of the approach.</div><div class="NLM_p">Famous examples of successfully repositioned drugs are represented by sildenafil from angina to sexual dysfunctions in men,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> thalidomide, a drug rescued from morning sickness to leprosy and multiple myeloma,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and methotrexate from cancer to psoriasis and rheumatoid arthritis (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> In the literature, several studies have put forward new candidates for repositioning. Nygren et al. proposed mebendazole (MBZ, Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), an antihelmintic drug, as a candidate for repositioning in advanced colon cancer treatment.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> MBZ was identified as a hit in a phenotypic screening of 1600 drugs against two colon cancer cell lines. The drug proved to be active against relevant kinases such as ABL and BRAF. This compound was also used to treat a patient with refractory metastatic colon cancer who showed signs of complete or good partial remission of metastases in lungs, lymph nodes, and liver. In a recent review, Corbett et al. described compounds collected from different studies that are currently investigated for a potential repositioning in Alzheimer’s disease (AD).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Interestingly, these compounds originated from very different pathologies and therapeutic applications such as type 2 diabetes mellitus, hypertension, antibiotics, and retinoid therapy.</div><div class="NLM_p last">From a methodological point of view, computational methods are now being actively investigated as tools for identifying candidates for drug repurposing. The speed and scalability of these approaches may have a strong impact on driving experiments on new targets and further reducing the costs involved in this process. Because of the potential advantages offered by drug repositioning, computational methods able to prioritize drug repurposing experiments will surely play an increasingly important role, despite the inherent complexity of the underlying polypharmacology. In addition, experimental approaches such phenotypic screening, which currently experiences a renaissance in drug discovery, are being investigated for repositioning. However, similar to computational approaches, these efforts are also still in their infancy. One would hope that integration of experimental and computational target annotation approaches might ultimately lead to more general drug repositioning strategies.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Polypharmacology in Cancer Therapy</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87108" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87108" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Polypharmacology is mostly relevant for diseases involving wide target networks and cellular pathways. A prime example is provided by cancer. Typically, cancer cells are characterized by a transformed phenotype with excessive proliferation and survival. This abnormal cellular activity can be sustained by deregulation in the expression or activity of different proteins. For example, protein kinases belong to a family of over 500 members in humans and are involved in multiple cellular pathways and networks. Traditionally, the medicinal chemistry gold standard in kinase research was represented by the (putative) development of highly selective inhibitors. For example, many currently known (highly) promiscuous ATP site-directed kinase inhibitors, several of which are marketed as anticancer drugs, were originally thought to be rather specific.<a onclick="showRef(event, 'ref2 ref43'); return false;" href="javascript:void(0);" class="ref ref2 ref43">(2, 43)</a> Today, however, it is becoming increasingly clear that more effective targeted therapies based on kinase inhibitors used for cancer treatment should hit the disease on multiple sensitive target nodes, which explains the observed efficacy of marketed kinase inhibitors in the treatment of several forms of cancer. The architecture of the ATP binding site is largely conserved; hence, achieving the desired selectivity profile with type I inhibitors has always been a major issue.<a onclick="showRef(event, 'ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref44 ref45 ref46">(44-46)</a> In some types of cancers, the deregulation of the activity of a single kinase seems to represent the driving force for the disease, and a selective inhibition can prove to be successful. Nevertheless, appearance of mutations and redundancy in biological networks can compensate the effects of inhibiting one target by overactivating another target or cellular pathway, eventually making a single-target approach ineffective. Again, it is emphasized that kinase inhibitors initially thought to elicit their therapeutic effect by inhibiting a particular kinase actually owe their success to a more complex pattern of activities.<a onclick="showRef(event, 'ref2 ref43'); return false;" href="javascript:void(0);" class="ref ref2 ref43">(2, 43)</a> Simultaneous inhibition of multiple kinases is now established as a successful therapeutic strategy. Sunitinib (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), a promising compound for the therapy of anaplastic thyroid cancer, was tested in vitro and in vivo proving its ability to inhibit Akt and ERK1/2 phosphorylation and to down-regulate cyclin D1.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> The size and complexity of the human kinome with 518 currently known members make the identification of kinases well-suited for multitarget approaches rather challenging. Dar et al. addressed this issue with an integrated approach including whole-animal testing, chemistry, and genetics.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> They put forward an optimized multiple inhibition profile of Ret, Raf, Src, Tor, and S6K, leading to lower toxicity and improved survival in animal models. In another study, Xie et al. proposed that the known inhibition of the proliferation of cancer cells displayed by the HIV-protease inhibitor nelfinavir (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) is due to a weak modulation of multiple kinases upstream of the PI3K/Akt pathway.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The authors suggested nelfinavir as a promising starting point for the design of new kinase inhibitors. Recently, Hearn et al. revealed potential polypharmacology of organometallic complexes containing iridium(III), although specific targets have not yet been identified. Iridium complexes displayed selectivity for different cell lines when different chelating ligands were used, suggesting modulation of different targets.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Going beyond cancer, it should be noted that kinase inhibitor polypharmacology might not always be desirable. For example, for the treatment of a number chronic inflammatory diseases (as well as other chronic diseases) therapeutic requirements fundamentally change and achieving kinase specificity using inhibitors with different mechanisms of action becomes a major issue.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div><div class="NLM_p">Another family of relevant drug targets for cancer therapy is represented by poly(ADP-ribose) polymerases (PARPs).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The activity of these enzymes consists of ADP-ribosylation of target proteins, finally resulting in the regulation of several cellular mechanisms such as DNA repair, protein degradation, and apoptosis. PARP inhibitors have been in clinical trials for several years, both as single drugs and in combination with cytotoxic agents. Most PARP inhibitors bind to the nicotinamide binding pocket, causing polypharmacology throughout this family of targets. The advantages of selective versus a wider activity profile within PARPs are still a matter of investigation and debate, and further work will be necessary to draw more definitive conclusions.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></div><div class="NLM_p last">Hsp90 has been extensively investigated as a cancer drug target, but none of the ATP-competitive inhibitors<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> have so far reached the market, mainly because of toxicity issues. In cancer cells, Hsp90 refolds, stabilizes, and regulates the trafficking of more than 200 client proteins (the Hsp90 interactome), some of which are responsible for uncontrolled proliferation and apoptotic resistance. As a matter of fact, the interest in Hsp90 inhibitors resides mainly in the destabilizing effect of these compounds on oncogenic client proteins relevant for cancer. In addition to the exploration of Hsp90 inhibitors, both alone and in combination with other targeted agents, recent evidence suggests that having a single molecule that simultaneously inhibits Hsp90 and one or more of its client proteins,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> such as kinases, could improve efficacy. Moulick et al. described an affinity-based proteomics approach combined with bioinformatics for the characterization of Hsp90 complexes interacting with specific small molecules in chronic myeloid leukemia.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> They provided evidence that PU-H71<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), a known Hsp90 inhibitor, preferentially targets tumor-enriched Hsp90 complexes and affinity captures Hsp90-dependent oncogenic client proteins. This strategy may be useful for identifying targets for both combination therapies and multitarget inhibitor design. In another study, the discovery of Hsp90/tubulin dual inhibitors has been reported.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Tubulin is an Hsp90 client protein<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> and also a prime cancer drug target.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> A small molecule (MDG892,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) able to interact with both targets was discovered through combined ligand- and structure-based virtual screening including docking and pharmacophore modeling.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Another compound (CDBT,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) targeting Hsp90 and tubulin was discovered through phenotypic screening by observing its activity in non-small-cell lung cancer (NSCLC) cells.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Recently, an ad hoc computational protocol for selecting promising target combinations and building focused compound libraries for polypharmacology approaches within the Hsp90 interactome has also been put forward.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> These investigations indicate that the selection of optimal target combinations is a key aspect in polypharmacology research.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Polypharmacology in CNS Diseases</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21810" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21810" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Another important area of application of polypharmacology is in the field of CNS diseases. The activity of these drugs is often mediated by the interaction with G-protein-coupled receptors (GPCRs). Importantly, progress in the structural biology of GPCRs is providing unprecedented opportunities for determining crystal structures of novel receptors in complex with different ligands,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> thus opening up the way to structure-based drug design investigations.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> It is known that several small molecules bind multiple GPCRs.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Moreover, taking into consideration that some GPCRs are linked to multiple therapeutic areas, drugs targeting GPCRs constitute privileged starting points for drug repurposing. In addition to kinases, GPCRs are another prominent target family whose functional spectrum is substantially influenced by compound promiscuity and drug polypharmacology.</div><div class="NLM_p">CNS drugs used in the therapy of psychosis or depression are usually characterized by very complex mechanisms of action. Both the antipsychotic activity and the side effects elicited by these drugs can be attributed to a complex pattern of biological activities on multiple receptors. A classic example is clozapine (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), an atypical antipsychotic with improved efficacy compared to its predecessors. Clozapine is successful in avoiding extrapyramidal side effects, but it is also associated with some dangerous side effects such as seizures and diabetes.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Many different isoforms of the serotonin, dopamine, muscarinic, and adrenergic receptors are among known targets of clozapine. In particular, histamine H1 receptor is linked to weight gain, and other side effects are caused by activity on adrenergic and muscarinic receptor. On the other hand, dopamine D2 and serotonin 5-HT-2A seem responsible for antipsychotic therapeutic effect. It is worth noting that, besides GPCRs, proteins belonging to other families are also involved in the mechanism of CNS disorders and may represent potential drug targets. For instance, cognitive impairment in schizophrenia is hardly treated by currently available antipsychotics. An approach to address the lack of efficacy in treating cognitive impairment has been recently proposed by Lipina et al.,<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> who described the synergistic effect associated with schizophrenia obtainable by dual inhibition of phosphodiesterase 4 (PDE4) and glycogen synthase kinase 3 (GSK-3).<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Moreover, they described antipsychotic activity and promising effects on cognitive impairment obtained by administrating such dual-inhibitor in vivo.</div><div class="NLM_p">Neurodegenerative diseases such as Parkinson (PD) and Alzheimer (AD) are actively investigated using multitarget approaches. For instance, ladostigil (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) showed good efficacy in models of AD. This effect is due to increased levels of acetylcholine, dopamine, noradrenaline, and 5-HT that in turn are determined by the ability of the compound to inhibit acetylcholine esterase (AChE) and the brain monoamine oxidases (MAO) A and B.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> As a matter of fact, cholineesterases and MAOs are actively pursued as targets for polypharmacology in neurodegenerative diseases. Bolea et al. synthesized and tested a series of novel compounds targeting AChE, butyrylcholinesterase (BuChE), MAO-A, and MAO-B,<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> and molecular modeling studies were performed to hypothesize their binding mode. Inhibitory effects on β-amyloid aggregation were observed, suggesting that these compounds are promising candidates for polypharmacology approaches to AD. Additional proteins have been proposed as drug targets in this field. Tahtouh et al. suggested that the neuroprotective effects of compounds based on leucettines such as leucettine L41 (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), i.e., natural compounds derived from a marine sponge, are responsible for the inhibition of a set of proteins and lipid kinases involved in neurodegeneration.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Recently, a comprehensive review on multitarget therapies in AD was published by León et al.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> They presented diverse approaches targeting AchE in combination with different enzymes, ion channels, and receptors such as the aspartyl protease BACE-1, MAOs, calcium channels, and the <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate receptor and described noncholinergic based drug discovery efforts performed so far.</div><div class="NLM_p last">The application of polypharmacology in CNS and neurodegenerative diseases is challenging because of the complex mechanisms underlying these pathologies. Relevant targets such as GPCRs are difficult to address using multitarget activity approaches because of the cross-reactivity displayed by several of their ligands against different receptors.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Moreover, as mentioned above, other proteins besides GPCRs also represent promising CNS drug targets and are currently investigated in connection with GPCRs. Despite this complexity, polypharmacology approaches will surely be increasingly utilized for finding novel medicines in this field.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Rational Design of Multitarget Ligands</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62642" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62642" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Taking into consideration all aspects highlighted so far, the ability to rationally design drugs with a desired multitarget activity profile is becoming increasingly important.<a onclick="showRef(event, 'ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref69 ref70">(69, 70)</a> This task, which is challenging without doubt, involves considering structure–activity relationship profiles of molecules interacting with different biological targets and becomes most challenging when these targets are only distantly related or unrelated, i.e., when they belong to different protein families. At present this remains a critical point for the development of multitargeted drugs and explains why such activity profiles are generally sought within families of related proteins such as kinases and GPCRs.</div><div class="NLM_p">Activity landscapes are representations of the relation between structural similarity and biological activity of sets of active compounds.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> This approach can be extended from the analysis of the activity against a single target to multiple targets. Modeling of multitarget activity landscapes may provide useful insights into SAR of ligands active on proteins spanning different families.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> The exploration of such multitarget SARs is only a first step in the rationalization of multitarget profiles. However, multitarget (promiscuity) profiles of compounds can be systematically extracted from available compound activity data,<a onclick="showRef(event, 'ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref73 ref74">(73, 74)</a> their distribution across different targets and families can be assessed,<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> and relationship between promiscuity profiles and molecular similarity can be explored,<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> hence providing a knowledge base to aid in the design of compounds with desired multitarget activity.</div><div class="NLM_p">A comprehensive review focused on rationally designed multitarget ligands was published by Morphy and Rankovic.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> In this article the main strategies and applications in this field as reported in the literature between 1990 and 2004 are described. Over the past years, more methods have been proposed to rationalize the design of multitarget ligands. For example, Apsel et al.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> identified compounds that inhibit both tyrosine kinases and phosphatidylinositol-3-OH kinases. Proteins belonging to these kinase subfamilies are characterized by low overall sequence identity (e.g., 9% between SRC and PI3K p110γ isoform) but share a similar fold (two-lobed structure) and some conserved residue motifs in the ATP site. Both kinase subfamilies include relevant cancer drug targets. On the basis of iterative chemical synthesis, X-ray crystallography, and biochemical profiling, they discovered compounds with promising dual-target activity.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Structural features were also examined in protein/ligand complexes to rationalize the selectivity toward their targets. This work represents one of the first successful rational design attempts of multitarget ligands within the human kinome. More recently, Besnard et al.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> described an automated approach for the design of ligands with desirable polypharmacological profiles. Their method is based on the design of small focused libraries of analogues of an initial compound through automated machine learning of medicinal chemistry design strategies derived from the literature. Bayesian models were built to prioritize the generated compounds according to a set of multiple objectives, such as activity toward different targets or even ADME properties. Eight-hundred ligand–target predictions were tested experimentally, of which 75% were confirmed to be correct. In particular, starting from the approved drug donepezil, an acetylcholine esterase inhibitor used in the therapy of AD, they predicted and confirmed weak polypharmacological activity on dopamine receptors D<sub>4</sub> and D<sub>2</sub>. Importantly, since D<sub>2</sub> antagonism may be beneficial for AD therapy, the authors applied their algorithm to optimize the activity toward this target. In this way, they were able to generate compounds with optimized activity toward D<sub>2</sub>, enhanced blood–brain barrier permeability, and reduced activity toward the α<sub>1</sub>-adrenoceptor antitarget that can cause low blood pressure as a side effect.</div><div class="NLM_p">In another recent review, computational approaches focused on fragment-based methods have been proposed for the design of multitarget ligands.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> The use of fragments has the advantage of leaving room for optimization of hit compounds and associated increases in molecular weight. Ligand- and structure-based virtual screening continue to be proposed as attractive alternatives to more expensive high-throughput screening. In particular, the generation of libraries enriched with molecular structures focused on intended targets is thought to improve the likelihood of identifying multitarget compounds. In this context, an analysis of activity annotations deposited in public compound databases<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> identified compounds active against a single target, multiple targets belonging to the same protein family, and multiple targets belonging to different families (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> These findings highlighted that molecular scaffolds associated with different levels of target selectivity or promiscuity are found in known active compounds and that database annotations reporting promiscuous compounds are steadily growing over time. Such analyses can provide insights relevant for the rational design of multitarget compounds by exploiting information already available in public databases.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/medium/jm-2014-006463_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/medium/jm-2014-006463_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0004.jpeg" id="GRAPHIC-d3237e583-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Scaffold- and compound-based target networks. For ChEMBL<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> release 2 (available at the end of 2009) and release 14 (available in 2012), scaffold- and compound-based target networks are compared on the basis of <i>K</i><sub>i</sub> activity values (equilibrium constants) in (a) and (b), respectively, and on the basis of IC<sub>50</sub> measurements in (c) and (d), respectively. Nodes represent targets, and edges connect target pairs that share at least five scaffolds or compounds. Scaffolds that represent compounds active against multiple targets from the same family or different protein families are designated single-family (SF) and multifamily (MF) scaffolds, respectively. Intra- and interfamily target pairs are indicated by solid and dashed edges, respectively, and target families are listed and color-coded in (e). Network formation results from the presence of promiscuous bioactive compounds. The comparison of different ChEMBL releases illustrates the growth in promiscuous compounds. Furthermore, the comparison of <i>K</i><sub>i</sub> and IC<sub>50</sub> value-based networks reveals that the increase in compounds promiscuous across different target families predominantly results from IC<sub>50</sub>-based compound activity data. The figure was adapted from ref <a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">80</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0003.jpeg jm-2014-006463_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5006463&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A ligand-based approach named similarity ensemble approach (SEA) was introduced by Keiser et al. and successfully applied to identify proteins sharing related ligand sets and discover unknown off-target activities.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> This approach quantitatively evaluates chemical similarity of two sets of ligands by measuring the Tanimoto coefficient (Tc) of ligand pairs and by applying a statistical model reminiscent of the BLAST<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> algorithm to normalize similarity scores. Applying SEA, the authors were able to identify off-target activities for the drugs emetine and loperamide acting on α<sub>2</sub> adrenergic and neurokinin NK<sub>2</sub> receptors, respectively.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> This approach was also used for other off-target activity predictions,<a onclick="showRef(event, 'ref37 ref83'); return false;" href="javascript:void(0);" class="ref ref37 ref83">(37, 83)</a> for the discovery of new active molecules,<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> and for insightful chemoinformatics analyses.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Recently, Reker et al. put forward an approach, named self-organizing map-based prediction of drug equivalence relationships (SPiDER), designed to profile the targets of de novo designed molecules.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> SPiDER is based on self-organizing maps (SOM)<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> combined with a consensus scoring and a statistical analysis that evaluates prediction confidence. Two computationally designed HIV-1 protease inhibitors were predicted by SPiDER and experimentally confirmed to be active on three different GPCRs, namely, bradykinin B<sub>1</sub>, neurokinin 1, and vanilloid 1 receptors.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div><div class="NLM_p">Other computational structure-based protocols were proposed for the characterization of polypharmacology of antipsichotic drugs within bioaminergic GPCRs.<a onclick="showRef(event, 'ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref88 ref89">(88, 89)</a> In general, molecular docking into crystal structures or homology models of target proteins can provide a valuable strategy for screening libraries of potential ligands active against multiple receptors, despite the approximations inherent in this approach. For example, virtual screening<a onclick="showRef(event, 'ref90 ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref90 ref91 ref92">(90-92)</a> may be independently performed on two or more biological targets of interest, and multitarget hits may be identified from compounds located at the top of all ranked lists. Having favorable scores for all proteins, these compounds constitute suitable candidates for potent multitarget inhibition. The potential that resides in the automation and transferability of computational methods to different case studies involving diverse targets will be key in the future for the rational design of drugs with an a priori polypharmacological profile. The examples reported in this and previous sections represent a scenario in which rational polypharmacology approaches aiming at the design of multitarget drugs can benefit from the integration of diverse studies as schematically represented in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/medium/jm-2014-006463_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Different approaches relevant to the generation of multitarget drugs and their interplay are illustrated. The integration of complementary field of studies is thought to lead the way to rational polypharmacology approaches.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5006463&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Summary and Outlook</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66644" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66644" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Polypharmacology is emerging as a new paradigm in drug discovery. Approved drugs for which a beneficial polypharmacological profile was discovered only retrospectively provide strong support for the concepts of polypharmacology and multitarget compound design. The next challenges will be how to rationally design ligands with a desired polypharmacology profile and transform them into drug candidates. Molecules with optimal multitarget activities have the potential of improving efficacy and safety of drugs in the therapy of complex diseases. In this review we have highlighted that multitargeted drugs may represent a valuable complement or even alternative to therapeutic regimens based on drug combinations. We have also described relevant examples of polypharmacology-based therapeutic approaches in cancer and CNS diseases. In cancer a major example is represented by kinase inhibitors, while in CNS disorders such as depression and psychosis, cross-reactivity of GPCR ligands is the main source of polypharmacology. A general concern is that excessive promiscuity could lead to adverse reactions caused by interactions with antitargets. Hence, multitarget drug candidates should be designed by trying to optimize activity profiles toward the desired targets while minimizing the risk of antitarget activity. These requirements emphasize the need to explore multitarget SARs in the practice of medicinal chemistry, which is still far from being routine and will require the development of advanced SAR analysis tools to enable simultaneous SAR exploration and compound design directed at multiple targets. For multitarget approaches, the identification of the most suited combination of targets is challenging but extremely important. Screening of candidate drugs against panels of closely and/or distantly related targets, often referred to as compound profiling, is already performed on a routine basis in pharmaceutical research to identify the most promising and safe candidate compounds for given target(s) and eliminate compounds with antitarget liabilities. It is likely that compound profiling efforts will need to be further expanded and standardized to substantially aid in the design of compounds with multitarget activities. Moreover, screening directed toward a more extended characterization of the mechanisms of action of known drugs may have a large impact on the identification of optimal target combinations. Genetic and biochemical characterization of pathology mechanisms will also be of great importance for uncovering the most relevant target combinations. Moreover, screening and analyses of network activities might be increasingly directed toward exploring possibilities of repositioning drugs that modulate targets involved in different pathologies. This approach is likely to be further explored because reusing old drugs is economically convenient (yet more difficult to accomplish than often thought). A major challenge from a medicinal chemistry point of view is the ability to rationally design multitarget ligands, especially when the targets of interest are not phylogenetically or structurally related. Here, further methodological advancements will play a major role. To address this issue, dedicated efforts are made through integrated approaches involving medicinal chemistry, genetics, chemical biology, and computational chemistry. Promising computational approaches in this field include data mining and ligand-based analyses for the identification of target combinations, and virtual screening for the design of multitarget ligands. It is conceivable that in the near future rational polypharmacology will play an increasingly important role in drug discovery. The combination of different disciplines and expertise (experimental and computational) will likely be key to success.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm5006463" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47488" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47488" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giulio Rastelli</span> - <span class="hlFld-Affiliation affiliation">Life
Sciences Department, University of Modena
and Reggio Emilia, Via
Campi 183, 41125 Modena, Italy</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#35525c40595c5a1b475446415059595c75405b5c585a47501b5c41"><span class="__cf_email__" data-cfemail="93f4fae6fffafcbde1f2e0e7f6fffffad3e6fdfafefce1f6bdfae7">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Anighoro</span> - <span class="hlFld-Affiliation affiliation">Life
Sciences Department, University of Modena
and Reggio Emilia, Via
Campi 183, 41125 Modena, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jürgen Bajorath</span> - <span class="hlFld-Affiliation affiliation">Department
of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology
and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität, Dahlmannstrasse 2, D-53113 Bonn, Germany</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47742" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47742" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Andrew Anighoro</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5006463&amp;id=BIO-d3237e646-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Andrew Anighoro</b> is Postdoctoral Fellow at the Molecular Modeling and Drug Design laboratory (<a href="http://www.mmddlab.unimore.it" class="extLink">www.mmddlab.unimore.it</a>) of the University of Modena and Reggio Emilia, Italy. He received his Ph.D. in Science and Technologies for Health Products at the University of Modena and Reggio Emilia. During his Ph.D., he was Visiting Student at the University of Bonn, Germany, in the laboratory of Prof. Jürgen Bajorath. His research is focused on molecular modeling and structure- and ligand-based methods with a particular interest in multitarget drug design.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Jürgen Bajorath</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5006463&amp;id=BIO-d3237e654-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jürgen Bajorath</b> is Professor and Chair of Life Science Informatics at the University of Bonn, Germany. He is also an Affiliate Professor in the Department of Biological Structure at the University of Washington, Seattle, WA. His research interests include drug discovery, computer-aided medicinal chemistry and chemical biology, and chemoinformatics. For further details, see <a href="http://www.lifescienceinformatics.uni-bonn.de" class="extLink">http://www.lifescienceinformatics.uni-bonn.de</a>.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Giulio Rastelli</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5006463&amp;id=BIO-d3237e662-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Giulio Rastelli</b> is Professor of Medicinal Chemistry and Head of the Molecular Modeling and Drug Design laboratory (<a href="http://www.mmddlab.unimore.it" class="extLink">www.mmddlab.unimore.it</a>) of the University of Modena and Reggio Emilia, Italy. He received his Ph.D. in Medicinal Chemistry at the University of Modena and Reggio Emilia and has been Research Fellow at the University of California—San Francisco under the supervision of Prof. Daniel Santi and Peter Kollman. His research interests focus on the development and application of computational drug design methodologies to address problems that lie at the interface between chemistry, biology, and medicine. His lab recently developed BEAR, an innovative tool for virtual screening. He collaborates with academic and private institutions for the discovery and development of small-molecule inhibitors of relevant drug targets, with a special focus on cancer.</p></figure></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i13" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i13"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i14" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i14"> Abbreviations Used</h2><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">Hsp90</td><td class="NLM_def"><p class="first last">heat shock protein 90</p></td></tr><tr><td class="NLM_term">WHO</td><td class="NLM_def"><p class="first last">World Health Organization</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">multiple sclerosis</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">AE</td><td class="NLM_def"><p class="first last">adverse effect</p></td></tr><tr><td class="NLM_term">NCI</td><td class="NLM_def"><p class="first last">National Cancer Institute</p></td></tr><tr><td class="NLM_term">CTEP</td><td class="NLM_def"><p class="first last">Cancer Therapy Evaluation Program</p></td></tr><tr><td class="NLM_term">CA</td><td class="NLM_def"><p class="first last">carbonic anhydrase</p></td></tr><tr><td class="NLM_term">MBZ</td><td class="NLM_def"><p class="first last">mebendazole</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly(ADP-ribose) polymerase</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">PDE4</td><td class="NLM_def"><p class="first last">phosphodiesterase 4</p></td></tr><tr><td class="NLM_term">GSK-3</td><td class="NLM_def"><p class="first last">glycogen synthase kinase 3</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinson’s disease</p></td></tr><tr><td class="NLM_term">AChE</td><td class="NLM_def"><p class="first last">acetylcholine esterase</p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term">BuChE</td><td class="NLM_def"><p class="first last">butyrylcholinesterase</p></td></tr><tr><td class="NLM_term">SEA</td><td class="NLM_def"><p class="first last">similarity ensemble approach</p></td></tr><tr><td class="NLM_term">Tc</td><td class="NLM_def"><p class="first last">Tanimoto coefficient</p></td></tr><tr><td class="NLM_term">SPiDER</td><td class="NLM_def"><p class="first last">self-organizing map-based prediction of drug equivalence relationships</p></td></tr><tr><td class="NLM_term">SOM</td><td class="NLM_def"><p class="first last">self-organizing maps</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51140" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51140" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 92 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Network Pharmacology: The Next Paradigm in Drug Discovery</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">682</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnchembio.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=18936753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=682-690&author=A.+L.+Hopkins&title=Network+Pharmacology%3A+The+Next+Paradigm+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology: the next paradigm in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets.  However, many effective drugs act via modulation of multiple proteins rather than single targets.  Advances in systems biol. are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compds., compared with multi-target drugs, may exhibit lower than desired clin. efficacy.  This new appreciation of the role of polypharmacol. has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity.  Integrating network biol. and polypharmacol. holds the promise of expanding the current opportunity space for druggable targets.  However, the rational design of polypharmacol. faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties.  Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHy4FqkK-h7Vg90H21EOLACvtfcHk0liBV926srXypA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK&md5=03b8be3ddbcab7dc65afd17df7ee8395</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.118%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DNetwork%2520Pharmacology%253A%2520The%2520Next%2520Paradigm%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D682%26epage%3D690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Boran, A. D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyengar, R.</span><span> </span><span class="NLM_article-title">Systems Approaches to Polypharmacology and Drug Discovery</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=20443163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFCqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=297-309&author=A.+D.+W.+Boranauthor=R.+Iyengar&title=Systems+Approaches+to+Polypharmacology+and+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Systems approaches to polypharmacology and drug discovery</span></div><div class="casAuthors">Boran, Aislyn D. W.; Iyengar, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">297-309</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">2040-3437</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Systems biol. uses exptl. and computational approaches to characterize large sample populations systematically, process large datasets, examine and analyze regulatory networks, and model reactions to det. how components are joined to form functional systems.  Systems biol. technologies, data and knowledge are particularly useful in understanding disease processes and drug actions.  An important area of integration between systems biol. and drug discovery is the concept of polypharmacol.: the treatment of diseases by modulating more than one target.  Polypharmacol. for complex diseases is likely to involve multiple drugs acting on distinct targets that are part of a network regulating physiol. responses.  This review discusses the current state of the systems-level understanding of diseases and both the therapeutic and adverse mechanisms of drug actions.  Drug-target networks can be used to identify multiple targets and to det. suitable combinations of drug targets or drugs.  Thus, the discovery of new drug therapies for complex diseases may be greatly aided by systems biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7lrjWtBIXI7Vg90H21EOLACvtfcHk0liBV926srXypA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFCqtrk%253D&md5=b26a44ecd76a605816e08985ff8a576f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoran%26aufirst%3DA.%2BD.%2BW.%26aulast%3DIyengar%26aufirst%3DR.%26atitle%3DSystems%2520Approaches%2520to%2520Polypharmacology%2520and%2520Drug%2520Discovery%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2010%26volume%3D13%26spage%3D297%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Mestres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregori-Puigjané, E.</span><span> </span><span class="NLM_article-title">Conciliating Binding Efficiency and Polypharmacology</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">470</span><span class="NLM_x">–</span> <span class="NLM_lpage">474</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1016%2Fj.tips.2009.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=19717193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtV2rtb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=470-474&author=J.+Mestresauthor=E.+Gregori-Puigjan%C3%A9&title=Conciliating+Binding+Efficiency+and+Polypharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Conciliating binding efficiency and polypharmacology</span></div><div class="casAuthors">Mestres, Jordi; Gregori-Puigjane, Elisabet</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">470-474</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The assocn. between mol. size and risk of failure has promoted the use of binding efficiency as a prioritization metric in lead selection.  Even though by extension it is often referred to as "ligand efficiency", the concept was originally conceived to be strictly applicable to comparing the binding efficiencies of ligands for a single target.  With current trends in designing drugs to bind efficiently to multiple targets, a revision of the original binding efficiency definition is carried out.  To this aim, the dependency of binding efficiency on polypharmacol. is highlighted in a retrospective anal. of a set of antipsychotic drugs.  Statistical standardization of target binding efficiencies relative to basal values obtained from a large background of medicinal chem. compds. is proposed as a means to conciliate the concepts of binding efficiency and polypharmacol.  Finally, the interplay between binding efficiency and therapeutic efficacy for optimizing natural products, random hits, and fragments is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR83WbMBfphbVg90H21EOLACvtfcHk0liBV926srXypA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtV2rtb3L&md5=9ccaa31d1e43fc8867a7cf397d82d6d0</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2009.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2009.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DMestres%26aufirst%3DJ.%26aulast%3DGregori-Puigjan%25C3%25A9%26aufirst%3DE.%26atitle%3DConciliating%2520Binding%2520Efficiency%2520and%2520Polypharmacology%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D30%26spage%3D470%26epage%3D474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Peters, J.-U.</span><span> </span><span class="NLM_article-title">Polypharmacology—Foe or Friend?</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">8955</span><span class="NLM_x">–</span> <span class="NLM_lpage">8971</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.-U.+Peters&title=Polypharmacology%E2%80%94Foe+or+Friend%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26atitle%3DPolypharmacology%25E2%2580%2594Foe%2520or%2520Friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">Compound Promiscuity: What Can We Learn from Current Data?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">644</span><span class="NLM_x">–</span> <span class="NLM_lpage">650</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=644-650&author=Y.+Huauthor=J.+Bajorath&title=Compound+Promiscuity%3A+What+Can+We+Learn+from+Current+Data%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DCompound%2520Promiscuity%253A%2520What%2520Can%2520We%2520Learn%2520from%2520Current%2520Data%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D644%26epage%3D650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><a href="http://www.scopus.com" class="extLink">http://www.scopus.com</a> (accessed Dec<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.scopus.com+%28accessed+Dec+2013%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Jalencas, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestres, J.</span><span> </span><span class="NLM_article-title">On the Origins of Drug Polypharmacology</span> <span class="citation_source-journal">Med. Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1039%2Fc2md20242e" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=80-87&author=X.+Jalencasauthor=J.+Mestres&title=On+the+Origins+of+Drug+Polypharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1039%2Fc2md20242e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20242e%26sid%3Dliteratum%253Aachs%26aulast%3DJalencas%26aufirst%3DX.%26aulast%3DMestres%26aufirst%3DJ.%26atitle%3DOn%2520the%2520Origins%2520of%2520Drug%2520Polypharmacology%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2012%26volume%3D4%26spage%3D80%26epage%3D87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Lu, J.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-T.</span><span> </span><span class="NLM_article-title">Multi-Target Drugs: The Trend of Drug Research and Development</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e40262</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1371%2Fjournal.pone.0040262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=22768266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVaisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e40262&author=J.-J.+Luauthor=W.+Panauthor=Y.-J.+Huauthor=Y.-T.+Wang&title=Multi-Target+Drugs%3A+The+Trend+of+Drug+Research+and+Development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target drugs: the trend of drug research and development</span></div><div class="casAuthors">Lu, Jin-Jian; Pan, Wei; Hu, Yuan-Jia; Wang, Yi-Tao</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e40262</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Summarizing the status of drugs in the market and examg. the trend of drug research and development is important in drug discovery.  In this study, we compared the drug targets and the market sales of the new mol. entities approved by the U.S. Food and Drug Administration from Jan. 2000 to Dec. 2009.  Two networks, namely, the target-target and drug-drug networks, have been set up using the network anal. tools.  The multi-target drugs have much more potential, as shown by the network visualization and the market trends.  We discussed the possible reasons and proposed the rational strategies for drug research and development in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrapZATY1GnWbVg90H21EOLACvtfcHk0ljyHu409d-a-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVaisr8%253D&md5=79489aaf7a36ee9c30287621a7244a6a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0040262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0040262%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.-J.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DY.-J.%26aulast%3DWang%26aufirst%3DY.-T.%26atitle%3DMulti-Target%2520Drugs%253A%2520The%2520Trend%2520of%2520Drug%2520Research%2520and%2520Development%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De40262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Adams, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basuino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiest, O. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babbitt, P. C.</span><span> </span><span class="NLM_article-title">A Mapping of Drug Space from the Viewpoint of Small Molecule Metabolism</span> <span class="citation_source-journal">PLoS Comput. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1000474</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=e1000474&author=J.+C.+Adamsauthor=M.+J.+Keiserauthor=L.+Basuinoauthor=H.+F.+Chambersauthor=D.-S.+Leeauthor=O.+G.+Wiestauthor=P.+C.+Babbitt&title=A+Mapping+of+Drug+Space+from+the+Viewpoint+of+Small+Molecule+Metabolism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DJ.%2BC.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DBasuino%26aufirst%3DL.%26aulast%3DChambers%26aufirst%3DH.%2BF.%26aulast%3DLee%26aufirst%3DD.-S.%26aulast%3DWiest%26aufirst%3DO.%2BG.%26aulast%3DBabbitt%26aufirst%3DP.%2BC.%26atitle%3DA%2520Mapping%2520of%2520Drug%2520Space%2520from%2520the%2520Viewpoint%2520of%2520Small%2520Molecule%2520Metabolism%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3De1000474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Tian, L.; Zhang, S.</span><span> </span><span class="NLM_article-title">Mapping Drug–Target Interaction Networks</span>. Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2009; <span class="NLM_publisher-name">EMBC</span>: <span class="NLM_publisher-loc">Piscataway, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">2336</span><span class="NLM_x">–</span> <span class="NLM_lpage">2339</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Tian%2C+L.%3B+Zhang%2C+S.+Mapping+Drug%E2%80%93Target+Interaction+Networks.+Proceedings+of+the+Annual+International+Conference+of+the+IEEE+Engineering+in+Medicine+and+Biology+Society%2C+2009%3B+EMBC%3A+Piscataway%2C+NJ%2C+2009%3B+pp+2336%E2%80%932339."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DL.%26atitle%3DMapping%2520Drug%25E2%2580%2593Target%2520Interaction%2520Networks%26pub%3DEMBC%26date%3D2009%26spage%3D2336%26epage%3D2339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Simon, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peragovics, Á.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigh-Smeller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csukly, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tombor, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahoránszky-Kőhalmi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Végner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jelinek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hári, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hetényi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitter, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czobor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Málnási-Csizmadia, A.</span><span> </span><span class="NLM_article-title">Drug Effect Prediction by Polypharmacology-Based Interaction Profiling</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">145</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci2002022" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVyrs73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=134-145&author=Z.+Simonauthor=%C3%81.+Peragovicsauthor=M.+Vigh-Smellerauthor=G.+Csuklyauthor=L.+Tomborauthor=Z.+Yangauthor=G.+Zahor%C3%A1nszky-K%C5%91halmiauthor=L.+V%C3%A9gnerauthor=B.+Jelinekauthor=P.+H%C3%A1riauthor=C.+Het%C3%A9nyiauthor=I.+Bitterauthor=P.+Czoborauthor=A.+M%C3%A1ln%C3%A1si-Csizmadia&title=Drug+Effect+Prediction+by+Polypharmacology-Based+Interaction+Profiling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Effect Prediction by Polypharmacology-Based Interaction Profiling</span></div><div class="casAuthors">Simon, Zoltan; Peragovics, Agnes; Vigh-Smeller, Margit; Csukly, Gabor; Tombor, Laszlo; Yang, Zhenhui; Zahoranszky-Kohalmi, Gergely; Vegner, Laszlo; Jelinek, Balazs; Hari, Peter; Hetenyi, Csaba; Bitter, Istvan; Czobor, Pal; Malnasi-Csizmadia, Andras</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-145</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Most drugs exert their effects via multitarget interactions, as hypothesized by polypharmacol.  While these multitarget interactions are responsible for the clin. effect profiles of drugs, current methods have failed to uncover the complex relationships between them.  Here, we introduce an approach which is able to relate complex drug-protein interaction profiles with effect profiles.  Structural data and registered effect profiles of all small-mol. drugs were collected, and interactions to a series of non-target protein binding sites of each drug were calcd.  Statistical analyses confirmed a close relationship between the studied 177 major effect categories and interaction profiles of ca. 1200 FDA-approved small-mol. drugs.  On the basis of this relationship, the effect profiles of drugs were revealed in their entirety, and hitherto uncovered effects could be predicted in a systematic manner.  Our results show that the prediction power is independent of the compn. of the protein set used for interaction profile generation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH7-WOP-uBWbVg90H21EOLACvtfcHk0ljh1hJGVbXqlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVyrs73J&md5=50cb9593bcdc09f5cc8be563805a43bd</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fci2002022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci2002022%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DZ.%26aulast%3DPeragovics%26aufirst%3D%25C3%2581.%26aulast%3DVigh-Smeller%26aufirst%3DM.%26aulast%3DCsukly%26aufirst%3DG.%26aulast%3DTombor%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZahor%25C3%25A1nszky-K%25C5%2591halmi%26aufirst%3DG.%26aulast%3DV%25C3%25A9gner%26aufirst%3DL.%26aulast%3DJelinek%26aufirst%3DB.%26aulast%3DH%25C3%25A1ri%26aufirst%3DP.%26aulast%3DHet%25C3%25A9nyi%26aufirst%3DC.%26aulast%3DBitter%26aufirst%3DI.%26aulast%3DCzobor%26aufirst%3DP.%26aulast%3DM%25C3%25A1ln%25C3%25A1si-Csizmadia%26aufirst%3DA.%26atitle%3DDrug%2520Effect%2520Prediction%2520by%2520Polypharmacology-Based%2520Interaction%2520Profiling%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D134%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Yildirim, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cusick, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barabási, A.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidal, M.</span><span> </span><span class="NLM_article-title">Drug–Target Network</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1119</span><span class="NLM_x">–</span> <span class="NLM_lpage">1126</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=1119-1126&author=M.+A.+Yildirimauthor=K.-I.+Gohauthor=M.+E.+Cusickauthor=A.-L.+Barab%C3%A1siauthor=M.+Vidal&title=Drug%E2%80%93Target+Network"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYildirim%26aufirst%3DM.%2BA.%26aulast%3DGoh%26aufirst%3DK.-I.%26aulast%3DCusick%26aufirst%3DM.%2BE.%26aulast%3DBarab%25C3%25A1si%26aufirst%3DA.-L.%26aulast%3DVidal%26aufirst%3DM.%26atitle%3DDrug%25E2%2580%2593Target%2520Network%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D1119%26epage%3D1126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Reddy, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span> </span><span class="NLM_article-title">Polypharmacology: Drug Discovery for the Future</span> <span class="citation_source-journal">Expert Rev. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1586%2Fecp.12.74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=23272792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlei" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=41-47&author=A.+S.+Reddyauthor=S.+Zhang&title=Polypharmacology%3A+Drug+Discovery+for+the+Future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: drug discovery for the future</span></div><div class="casAuthors">Reddy, A. Srinivas; Zhang, Shuxing</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-47</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years, even with remarkable scientific advancements and a significant increase of global research and development spending, drugs are frequently withdrawn from markets.  This is primarily due to their side effects or toxicities.  Drug mols. often interact with multiple targets, coined as polypharmacol., and the unintended drug-target interactions could cause side effects.  Polypharmacol. remains one of the major challenges in drug development, and it opens novel avenues to rationally design the next generation of more effective, but less toxic, therapeutic agents.  This review outlines the latest progress and challenges in polypharmacol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh9arBzCHL27Vg90H21EOLACvtfcHk0lh6NQgtyQVtWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlei&md5=651b742d7e8254d8f4ef00f225dfa39e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1586%2Fecp.12.74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fecp.12.74%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DA.%2BS.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DPolypharmacology%253A%2520Drug%2520Discovery%2520for%2520the%2520Future%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D6%26spage%3D41%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Rask-Andersen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almén, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiöth, H. B.</span><span> </span><span class="NLM_article-title">Trends in the Exploitation of Novel Drug Targets</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">590</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnrd3478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=21804595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFKqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=579-590&author=M.+Rask-Andersenauthor=M.+S.+Alm%C3%A9nauthor=H.+B.+Schi%C3%B6th&title=Trends+in+the+Exploitation+of+Novel+Drug+Targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in the exploitation of novel drug targets</span></div><div class="casAuthors">Rask-Andersen, Mathias; Almen, Markus Saellman; Schioeth, Helgi B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">579-590</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The discovery and exploitation of new drug targets is a key focus for both the pharmaceutical industry and academic biomedical research.  To provide an insight into trends in the exploitation of new drug targets, we have analyzed the drugs that were approved by the US Food and Drug Administration during the past three decades and examd. the interactions of these drugs with therapeutic targets that are encoded by the human genome, using the DrugBank database and extensive manual curation.  We have identified 435 effect-mediating drug targets in the human genome, which are modulated by 989 unique drugs, through 2,242 drug-target interactions.  We also analyze trends in the introduction of drugs that modulate previously unexploited targets, and discuss the network pharmacol. of the drugs in our data set.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo19FXXFB-PsLVg90H21EOLACvtfcHk0lh6NQgtyQVtWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFKqsLc%253D&md5=9255431a28f2c07759b0f36975711f84</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrd3478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3478%26sid%3Dliteratum%253Aachs%26aulast%3DRask-Andersen%26aufirst%3DM.%26aulast%3DAlm%25C3%25A9n%26aufirst%3DM.%2BS.%26aulast%3DSchi%25C3%25B6th%26aufirst%3DH.%2BB.%26atitle%3DTrends%2520in%2520the%2520Exploitation%2520of%2520Novel%2520Drug%2520Targets%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D579%26epage%3D590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">Polypharmacology Directed Compound Data Mining: Identification of Promiscuous Chemotypes with Different Activity Profiles and Comparison to Approved Drugs</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2112</span><span class="NLM_x">–</span> <span class="NLM_lpage">2118</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci1003637" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWhtrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=2112-2118&author=Y.+Huauthor=J.+Bajorath&title=Polypharmacology+Directed+Compound+Data+Mining%3A+Identification+of+Promiscuous+Chemotypes+with+Different+Activity+Profiles+and+Comparison+to+Approved+Drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology directed compound data mining: identification of promiscuous chemotypes with different activity profiles and comparison to approved drugs</span></div><div class="casAuthors">Hu, Ye; Bajorath, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2112-2118</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Increasing evidence that many pharmaceutically relevant compds. elicit their effects through binding to multiple targets, so-called polypharmacol., is beginning to change conventional drug discovery and design strategies.  In light of this paradigm shift, we have mined publicly available compd. and bioactivity data for promiscuous chemotypes.  For this purpose, a hierarchy of active compds., at. property based scaffolds, and unique mol. topologies were generated, and activity annotations were analyzed using this framework.  Starting from ∼35 000 compds. active against human targets with at least 1 μM potency, 33 chemotypes with distinct topol. were identified that represented mols. active against at least 3 different target families.  Network representations were utilized to study scaffold-target family relationships and activity profiles of scaffolds corresponding to promiscuous chemotypes.  A subset of promiscuous chemotypes displayed a significant enrichment in drugs over bioactive compds.  A total of 190 drugs were identified that had on av. only 2 known target annotations but belonged to the 7 most promiscuous chemotypes that were active against 8-15 target families.  These drugs should be attractive candidates for polypharmacol. profiling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoeYreHJPURLVg90H21EOLACvtfcHk0ljSsaOv-KSAcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWhtrrM&md5=178b0ce8e4f4502ce79f8e59b5ed1a5c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fci1003637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci1003637%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DPolypharmacology%2520Directed%2520Compound%2520Data%2520Mining%253A%2520Identification%2520of%2520Promiscuous%2520Chemotypes%2520with%2520Different%2520Activity%2520Profiles%2520and%2520Comparison%2520to%2520Approved%2520Drugs%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26spage%3D2112%26epage%3D2118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">High-Resolution View of Compound Promiscuity</span> <span class="citation_source-journal">F1000Research</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">144</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.12688%2Ff1000research.2-144.v2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A280%3ADC%252BC2c3psVWrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=144&author=Y.+Huauthor=J.+Bajorath&title=High-Resolution+View+of+Compound+Promiscuity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">High-resolution view of compound promiscuity</span></div><div class="casAuthors">Hu Ye; Bajorath Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">F1000Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">144</span>
        ISSN:<span class="NLM_cas:issn">2046-1402</span>.
    </div><div class="casAbstract">Compound promiscuity is defined as the ability of a small molecule to specifically interact with multiple biological targets.  So-defined promiscuity is relevant for drug discovery because it provides the molecular basis of polypharmacology, which is increasingly implicated in the therapeutic efficacy of drugs.  Recent studies have analyzed different aspects of compound promiscuity on the basis of currently available activity data.  In this commentary, we present take-home messages from these studies augmented with new results to generate a detailed picture of compound promiscuity that might serve as a reference for further discussions and research activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRhg3urNXDByO2kE7krGOBfW6udTcc2eZQQpVWxlq25Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3psVWrug%253D%253D&md5=f96841e071505f8e25de1ef0766dc1a4</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.12688%2Ff1000research.2-144.v2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12688%252Ff1000research.2-144.v2%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DHigh-Resolution%2520View%2520of%2520Compound%2520Promiscuity%26jtitle%3DF1000Research%26date%3D2013%26volume%3D2%26spage%3D144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Altieri, D. C.</span><span> </span><span class="NLM_article-title">Mitochondrial Hsp90 Chaperones as Novel Molecular Targets in Prostate Cancer</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">487</span><span class="NLM_x">–</span> <span class="NLM_lpage">489</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.2217%2Ffon.10.26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=20373861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktlertL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=487-489&author=D.+C.+Altieri&title=Mitochondrial+Hsp90+Chaperones+as+Novel+Molecular+Targets+in+Prostate+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial Hsp90 chaperones as novel molecular targets in prostate cancer</span></div><div class="casAuthors">Altieri, Dario C.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">487-489</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  The mol. chaperone heat-shock protein-90 (Hsp90) is a well-known cancer nodal protein, orchestrating protein-folding quality control in multiple signaling pathways of cell proliferation, survival and adaptation.  Owing to its nodal properties, Hsp90 has been vigorously pursued as a target for network-oriented drug discovery, and several small mol. antagonists of its ATPase pocket are currently in advanced preclin. development or clin. evaluation.  Hsp90 and its related ATPase-directed chaperone, TNF receptor-assocd. protein-1 (TRAP-1), were found to exist in a novel subcellular pool compartmentalized in the mitochondria of tumor cells, but not in most normal tissues in vivo.  In prostate cancer, TRAP-1 turned out to be a sensitive and easily accessible biomarker of disease progression, abundantly expressed in prostatic intraepithelial neoplasia, all Gleason grades of cancer, and metastatic disease to lymph nodes and bones, but was undetectable in normal prostatic epithelium or benign prostatic hyperplasia.  Available evidence points to mitochondrial Hsp90 chaperones as novel and potentially attractive therapeutic targets in advanced prostate cancer, and identifies their subcellularly directed antagonists, i.e., Gamitrinibs, as a conceptually novel class of anticancer agents, worthy of further preclin. and clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJku2MZs523LVg90H21EOLACvtfcHk0lhhIUh9xJAOiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktlertL4%253D&md5=df39bd8e1482f87aa9802577e3c26048</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2217%2Ffon.10.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.10.26%26sid%3Dliteratum%253Aachs%26aulast%3DAltieri%26aufirst%3DD.%2BC.%26atitle%3DMitochondrial%2520Hsp90%2520Chaperones%2520as%2520Novel%2520Molecular%2520Targets%2520in%2520Prostate%2520Cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2010%26volume%3D6%26spage%3D487%26epage%3D489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Wright, J. J.</span><span> </span><span class="NLM_article-title">Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4094</span><span class="NLM_x">–</span> <span class="NLM_lpage">4104</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1158%2F1078-0432.CCR-09-2882" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=20682705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVajs7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=4094-4104&author=J.+J.+Wright&title=Combination+Therapy+of+Bortezomib+with+Novel+Targeted+Agents%3A+An+Emerging+Treatment+Strategy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy</span></div><div class="casAuthors">Wright, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4094-4104</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Clin. trials evaluating combinations of targeted agents with bortezomib, the first-in-class proteasome inhibitor, have been initiated, with the objective of enhancing its single agent activity in hematol. malignancies (myeloma, mantle cell lymphoma), as well as expanding its efficacy in solid tumors.  In most cases, preclin. studies have provided a supportive rationale for designing these doublet combination studies.  Novel, small mol.-targeted agents being investigated with bortezomib in clin. trials include protein deacetylase inhibitors, kinase inhibitors, farnesyltransferase inhibitors, heat-shock protein 90 inhibitors, pan-Bcl-2 family inhibitors, and other classes of targeted inhibitors.  Preliminary clin. data, available from a no. of ongoing trials, suggest that most of these combinations are well tolerated and some have promising clin. efficacy that will require subsequent confirmation.  Translational studies, conducted as part of the trials, may provide important insights into the putative mechanism of action delineated by preclin. studies of the combinations.  The emergence of novel proteasome inhibitors may also expand the opportunities for optimizing these combination therapies.  There is potential for an increasingly broad clin. trials program to investigate this therapeutic approach in a range of tumor types, as well as to consider addnl. agents in sequence or in combination.  Clin Cancer Res; 16(16); 4094-104.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq80JIFlg1k7bVg90H21EOLACvtfcHk0lhhIUh9xJAOiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVajs7zK&md5=70350d7044ef8f26fe4867d353d682b7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-2882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-2882%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26atitle%3DCombination%2520Therapy%2520of%2520Bortezomib%2520with%2520Novel%2520Targeted%2520Agents%253A%2520An%2520Emerging%2520Treatment%2520Strategy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D4094%26epage%3D4104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Sgobba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Structure-Based and in Silico Design of Hsp90 Inhibitors</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1399</span><span class="NLM_x">–</span> <span class="NLM_lpage">1409</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1399-1409&author=M.+Sgobbaauthor=G.+Rastelli&title=Structure-Based+and+in+Silico+Design+of+Hsp90+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSgobba%26aufirst%3DM.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DStructure-Based%2520and%2520in%2520Silico%2520Design%2520of%2520Hsp90%2520Inhibitors%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D1399%26epage%3D1409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruden, D. M.</span><span> </span><span class="NLM_article-title">Hsp90 Inhibitors and Drug Resistance in Cancer: The Potential Benefits of Combination Therapies of Hsp90 Inhibitors and Other Anti-Cancer Drugs</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">995</span><span class="NLM_x">–</span> <span class="NLM_lpage">1004</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2012&pages=995-1004&author=X.+Luauthor=L.+Xiaoauthor=L.+Wangauthor=D.+M.+Ruden&title=Hsp90+Inhibitors+and+Drug+Resistance+in+Cancer%3A+The+Potential+Benefits+of+Combination+Therapies+of+Hsp90+Inhibitors+and+Other+Anti-Cancer+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRuden%26aufirst%3DD.%2BM.%26atitle%3DHsp90%2520Inhibitors%2520and%2520Drug%2520Resistance%2520in%2520Cancer%253A%2520The%2520Potential%2520Benefits%2520of%2520Combination%2520Therapies%2520of%2520Hsp90%2520Inhibitors%2520and%2520Other%2520Anti-Cancer%2520Drugs%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D83%26spage%3D995%26epage%3D1004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopeck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linden, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandarlapaty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moynahan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannah, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudis, C.</span><span> </span><span class="NLM_article-title">HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5132</span><span class="NLM_x">–</span> <span class="NLM_lpage">5139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1158%2F1078-0432.CCR-11-0072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=21558407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFSksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=5132-5139&author=S.+Modiauthor=A.+Stopeckauthor=H.+Lindenauthor=D.+Solitauthor=S.+Chandarlapatyauthor=N.+Rosenauthor=G.+D%E2%80%99Andreaauthor=M.+Dicklerauthor=M.+E.+Moynahanauthor=S.+Sugarmanauthor=W.+Maauthor=S.+Patilauthor=L.+Nortonauthor=A.+L.+Hannahauthor=C.+Hudis&title=HSP90+Inhibition+Is+Effective+in+Breast+Cancer%3A+A+Phase+II+Trial+of+Tanespimycin+%2817-AAG%29+Plus+Trastuzumab+in+Patients+with+HER2-Positive+Metastatic+Breast+Cancer+Progressing+on+Trastuzumab"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab</span></div><div class="casAuthors">Modi, Shanu; Stopeck, Alison; Linden, Hannah; Solit, David; Chandarlapaty, Sarat; Rosen, Neal; D'Andrea, Gabriella; Dickler, Maura; Moynahan, Mary E.; Sugarman, Steven; Ma, Weining; Patil, Sujata; Norton, Larry; Hannah, Alison L.; Hudis, Clifford</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5132-5139</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: HSP90 is a chaperone protein required for the stability of a variety of client proteins. 17-Demethoxygeldanamycin (17-AAG) is a natural product that binds to HSP90 and inhibits its activity, thereby inducing the degrdn. of these clients.  In preclin. studies, HER2 is one of the most sensitive known client proteins of 17-AAG.  On the basis of these data and activity in a phase I study, we conducted a phase II study of 17-AAG (tanespimycin) with trastuzumab in advanced trastuzumab-refractory HER2-pos. breast cancer.  Exptl. Design: We enrolled patients with metastatic HER2+ breast cancer whose disease had previously progressed on trastuzumab.  All patients received weekly treatment with tanespimycin at 450 mg/m2 i.v. and trastuzumab at a conventional dose.  Therapy was continued until disease progression.  The primary endpoint was response rate by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.  RESULTS: Thirty-one patients were enrolled with a median age of 53 years and a median Karnofsky performance status (KPS) of 90%.  The most common toxicities, largely grade 1, were diarrhea, fatigue, nausea, and headache.  The overall response rate was 22%, the clin. benefit rate [complete response + partial response + stable disease] was 59%, the median progression-free survival was 6 mo (95% CI: 4-9), and the median overall survival was 17 mo (95% CI: 16-28).  CONCLUSIONS: This is the first phase II study to definitively show RECIST-defined responses for 17-AAG in solid tumors.  Tanespimycin plus trastuzumab has significant anticancer activity in patients with HER2-pos., metastatic breast cancer previously progressing on trastuzumab.  Further research exploring this therapeutic interaction and the activity of HSP90 inhibitors is clearly warranted.  Clin Cancer Res; 17(15); 5132-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFgVCzhN1fHLVg90H21EOLACvtfcHk0lgWWL9WElpEFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFSksbw%253D&md5=07d9e8e06caad7cd7abe03f9e9f7375a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0072%26sid%3Dliteratum%253Aachs%26aulast%3DModi%26aufirst%3DS.%26aulast%3DStopeck%26aufirst%3DA.%26aulast%3DLinden%26aufirst%3DH.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DG.%26aulast%3DDickler%26aufirst%3DM.%26aulast%3DMoynahan%26aufirst%3DM.%2BE.%26aulast%3DSugarman%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DPatil%26aufirst%3DS.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DHannah%26aufirst%3DA.%2BL.%26aulast%3DHudis%26aufirst%3DC.%26atitle%3DHSP90%2520Inhibition%2520Is%2520Effective%2520in%2520Breast%2520Cancer%253A%2520A%2520Phase%2520II%2520Trial%2520of%2520Tanespimycin%2520%252817-AAG%2529%2520Plus%2520Trastuzumab%2520in%2520Patients%2520with%2520HER2-Positive%2520Metastatic%2520Breast%2520Cancer%2520Progressing%2520on%2520Trastuzumab%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D5132%26epage%3D5139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Eastman, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidock, D. A.</span><span> </span><span class="NLM_article-title">Artemisinin-Based Combination Therapies: A Vital Tool in Efforts to Eliminate Malaria</span> <span class="citation_source-journal">Nat. Rev. Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">864</span><span class="NLM_x">–</span> <span class="NLM_lpage">874</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnrmicro2239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=19881520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCjtr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=864-874&author=R.+T.+Eastmanauthor=D.+A.+Fidock&title=Artemisinin-Based+Combination+Therapies%3A+A+Vital+Tool+in+Efforts+to+Eliminate+Malaria"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria</span></div><div class="casAuthors">Eastman, Richard T.; Fidock, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">864-874</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Plasmodium falciparum resistance to chloroquine and sulphadoxine-pyrimethamine has led to the recent adoption of artemisinin-based combination therapies (ACTs) as the first line of treatment against malaria.  ACTs comprise semisynthetic artemisinin derivs. paired with distinct chem. classes of longer acting drugs.  These artemisinins are exceptionally potent against the pathogenic asexual blood stages of Plasmodium parasites and also act on the transmissible sexual stages.  These combinations increase the rates of clin. and parasitol. cures and decrease the selection pressure for the emergence of antimalarial resistance.  This Review article discusses our current knowledge about the mode of action of ACTs, their pharmacol. properties and the proposed mechanisms of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXuOh192DpWbVg90H21EOLACvtfcHk0lgWWL9WElpEFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCjtr%252FJ&md5=36f98b991e7c0040d7db9fcbb369b84c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro2239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro2239%26sid%3Dliteratum%253Aachs%26aulast%3DEastman%26aufirst%3DR.%2BT.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26atitle%3DArtemisinin-Based%2520Combination%2520Therapies%253A%2520A%2520Vital%2520Tool%2520in%2520Efforts%2520to%2520Eliminate%2520Malaria%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2009%26volume%3D7%26spage%3D864%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Conway, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, J. A.</span><span> </span><span class="NLM_article-title">Combination Therapy in Multiple Sclerosis</span> <span class="citation_source-journal">Lancet Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1016%2FS1474-4422%2810%2970007-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=20170843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A280%3ADC%252BC3c7lsFahtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=299-308&author=D.+Conwayauthor=J.+A.+Cohen&title=Combination+Therapy+in+Multiple+Sclerosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy in multiple sclerosis</span></div><div class="casAuthors">Conway Devon; Cohen Jeffrey A</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Neurology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">299-308</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Multiple sclerosis (MS) is an autoimmune disease of the CNS.  It is the most common non-traumatic cause of neurological disability among young adults in western Europe and North America.  Existing MS therapies are partly effective in halting ongoing inflammatory tissue damage and clinical progression.  MS pathogenesis is complex and probably heterogeneous among patients, suggesting that combination therapy strategies that target a range of disease mechanisms might be more effective than medications used as monotherapy.  Potential regimens include the combination of interferons and glatiramer acetate with each other or with approved second-line drugs such as natalizumab and mitoxantrone.  Disease-modifying therapies have also been used in combination with drugs approved for other indications, such as corticosteroids, methotrexate, azathioprine, and cyclophosphamide.  Many preliminary studies have provided favourable results for various combination regimens.  However, several subsequent large, randomised, controlled trials have had negative or conflicting results.  Therefore, the usefulness of combination therapy in MS remains uncertain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-mj2O1SLeD3RxY89Cm6SyfW6udTcc2eZDly-7Aus3D7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7lsFahtA%253D%253D&md5=7f5769f0f5a2aaf1eb03cef5defaca60</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2810%2970007-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252810%252970007-7%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DD.%26aulast%3DCohen%26aufirst%3DJ.%2BA.%26atitle%3DCombination%2520Therapy%2520in%2520Multiple%2520Sclerosis%26jtitle%3DLancet%2520Neurol.%26date%3D2010%26volume%3D9%26spage%3D299%26epage%3D308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span>CTEP, Cancer Therapy Evaluation Program. <a href="http://ctep.cancer.gov" class="extLink">http://ctep.cancer.gov</a> (accessed Dec<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CTEP%2C+Cancer+Therapy+Evaluation+Program.+http%3A%2F%2Fctep.cancer.gov+%28accessed+Dec+2013%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorusso, P.</span><span> </span><span class="NLM_article-title">Analysis of Lung Cancer Patients Enrolled in CTEP (Cancer Therapy Evaluation Program)-Sponsored Phase I Trials</span> <span class="citation_source-journal">Clin. Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">218</span><span class="NLM_x">–</span> <span class="NLM_lpage">223</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1016%2Fj.cllc.2011.03.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=21726820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A280%3ADC%252BC3MnlsFemuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=218-223&author=S.+M.+Gadgeelauthor=P.+Ivyauthor=W.+Chenauthor=J.+Mauerauthor=D.+Smithauthor=P.+Lorusso&title=Analysis+of+Lung+Cancer+Patients+Enrolled+in+CTEP+%28Cancer+Therapy+Evaluation+Program%29-Sponsored+Phase+I+Trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trials</span></div><div class="casAuthors">Gadgeel Shirish M; Ivy Percy; Chen Wei; Mauer Joan; Smith Daryn; Lorusso Patricia</div><div class="citationInfo"><span class="NLM_cas:title">Clinical lung cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">218-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  A recent review of phase I trials suggests that participation in these trials can be associated with clinical benefit and the rate of drug-related deaths is low.  We conducted an analysis of the Cancer Therapy Evaluation Program (CTEP)-sponsored phase I trials to assess the outcomes of lung cancer patients enrolled in phase I trials.  MATERIALS AND METHODS:  Data from all CTEP-sponsored adult phase I trials conducted between 1997 and 2008 were analyzed.  An analysis of demographics, rates of toxicities, and clinical benefit rate among patients with non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), and other cancers was conducted.  RESULTS:  Of the 3560 patients enrolled in 136 phase I trials, 301 (8.5%) had NSCLC and 40 (1.1%) had SCLC.  The median age of lung cancer patients, at 60 years, was significantly higher than patients with other cancers.  The rest of the demographics were similar among the groups.  The rate of Grade 3-5 toxicities was higher among NSCLC patients (54% versus 46%).  The toxicity-related death rate was ≤ 1% among all groups.  The clinical benefit rate and median duration in study of approximately 2 months were similar among all groups of patients.  CONCLUSION:  An analysis of the CTEP-sponsored phase I trials shows that lung cancer patients enrolled in these trials have a similar incidence of toxicity-related deaths and a similar probability of clinical benefit as patients with other cancers.  These data suggest that patients with progressive lung cancer following approved therapies should be considered for phase I trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQm-N48QhUJkloaUqgkFHkfW6udTcc2ebt8uhv9ajkdLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnlsFemuw%253D%253D&md5=89e3772cff75712d2f8ffdc73f9ab474</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.cllc.2011.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cllc.2011.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DIvy%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DMauer%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DLorusso%26aufirst%3DP.%26atitle%3DAnalysis%2520of%2520Lung%2520Cancer%2520Patients%2520Enrolled%2520in%2520CTEP%2520%2528Cancer%2520Therapy%2520Evaluation%2520Program%2529-Sponsored%2520Phase%2520I%2520Trials%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2011%26volume%3D12%26spage%3D218%26epage%3D223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Luke, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubinstein, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. J.</span><span> </span><span class="NLM_article-title">Similar Efficacy for Phase I Trials in Comparison with DTIC for Advanced Malignant Melanoma: An Analysis of Melanoma Outcomes in CTEP-Sponsored Phase I Trials 1995–2011</span> <span class="citation_source-journal">Melanoma Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">152</span><span class="NLM_x">–</span> <span class="NLM_lpage">158</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1097%2FCMR.0b013e32835f73b2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=23411478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtlyhur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=152-158&author=J.+J.+Lukeauthor=L.+V.+Rubinsteinauthor=G.+L.+Smithauthor=S.+P.+Ivyauthor=P.+J.+Harris&title=Similar+Efficacy+for+Phase+I+Trials+in+Comparison+with+DTIC+for+Advanced+Malignant+Melanoma%3A+An+Analysis+of+Melanoma+Outcomes+in+CTEP-Sponsored+Phase+I+Trials+1995%E2%80%932011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011</span></div><div class="casAuthors">Luke, Jason J.; Rubinstein, Lawrence V.; Smith, Gary L.; Ivy, S. Percy; Harris, Pamela J.</div><div class="citationInfo"><span class="NLM_cas:title">Melanoma Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">152-158</span>CODEN:
                <span class="NLM_cas:coden">MREEEH</span>;
        ISSN:<span class="NLM_cas:issn">0960-8931</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">After ipilimumab, vemurafenib, and interleukin-2, std. of care chemotherapy for melanoma remains dacarbazine (response rate ∼9%).  Despite this, many physicians hesitate to refer patients to phase I protocols given a perceived lack of clin. benefit and potential for harm.  To better understand the validity of these perceptions, the experience of all patients with melanoma treated on phase I trials sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program (NCI-CTEP) from 1995 to 2011 were analyzed and compared with the pooled results of six contemporary phase III trials of dacarbazine.  A total of 937 patients with melanoma were treated in 148 CTEP phase I trials.  The majority were men with a median of two prior therapies (46% receiving prior dacarbazine).  Response and clin. benefit rates in these trials were not clin. different from those of dacarbazine (phase I: 6.3 and 26.8% vs. dacarbazine: 8.8 and 27.9%) although grades 3 and 4 toxicity was significantly higher (54 vs. 28%).  Efficacy and toxicity were generally consistent within phase I subgroups (targeted agents, immunotherapies, or chemotherapeutics) though targeted therapy was assocd. with a lower response rate, immunotherapy with lower clin. benefit rate, and chemotherapy with higher incidence of grade 4 toxicity.  Thus, the perception of limited efficacy of phase I trials for patients with melanoma was disproven, whereas the perception of toxicity was obsd.  However, this difference in toxicity may have been largely because of the nature of phase I vs. phase III trials (i.e. more heavily pretreated) and because of the phase I trials often being multiagent as opposed to dacarbazine alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPrB4efLzZmbVg90H21EOLACvtfcHk0ljTam23faT4pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtlyhur0%253D&md5=3a899d8bf69d2fea11427de2b604c134</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1097%2FCMR.0b013e32835f73b2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCMR.0b013e32835f73b2%26sid%3Dliteratum%253Aachs%26aulast%3DLuke%26aufirst%3DJ.%2BJ.%26aulast%3DRubinstein%26aufirst%3DL.%2BV.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DIvy%26aufirst%3DS.%2BP.%26aulast%3DHarris%26aufirst%3DP.%2BJ.%26atitle%3DSimilar%2520Efficacy%2520for%2520Phase%2520I%2520Trials%2520in%2520Comparison%2520with%2520DTIC%2520for%2520Advanced%2520Malignant%2520Melanoma%253A%2520An%2520Analysis%2520of%2520Melanoma%2520Outcomes%2520in%2520CTEP-Sponsored%2520Phase%2520I%2520Trials%25201995%25E2%2580%25932011%26jtitle%3DMelanoma%2520Res.%26date%3D2013%26volume%3D23%26spage%3D152%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Giacomini, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauss, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roden, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichelbaum, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayden, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, Y.</span><span> </span><span class="NLM_article-title">When Good Drugs Go Bad</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">446</span><span class="NLM_x">, </span> <span class="NLM_fpage">975</span><span class="NLM_x">–</span> <span class="NLM_lpage">977</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2F446975a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=17460642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFektL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=446&publication_year=2007&pages=975-977&author=K.+M.+Giacominiauthor=R.+M.+Kraussauthor=D.+M.+Rodenauthor=M.+Eichelbaumauthor=M.+R.+Haydenauthor=Y.+Nakamura&title=When+Good+Drugs+Go+Bad"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">When good drugs go bad</span></div><div class="casAuthors">Giacomini, Kathleen M.; Krauss, Ronald M.; Roden, Dan M.; Eichelbaum, Michel; Hayden, Michael R.; Nakamura, Yusuke</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">446</span>
        (<span class="NLM_cas:issue">7139</span>),
    <span class="NLM_cas:pages">975-977</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx3QRPuUhA4bVg90H21EOLACvtfcHk0ljTam23faT4pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFektL0%253D&md5=79a9929078be854ee44578fa3e2f9bb2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2F446975a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F446975a%26sid%3Dliteratum%253Aachs%26aulast%3DGiacomini%26aufirst%3DK.%2BM.%26aulast%3DKrauss%26aufirst%3DR.%2BM.%26aulast%3DRoden%26aufirst%3DD.%2BM.%26aulast%3DEichelbaum%26aufirst%3DM.%26aulast%3DHayden%26aufirst%3DM.%2BR.%26aulast%3DNakamura%26aufirst%3DY.%26atitle%3DWhen%2520Good%2520Drugs%2520Go%2520Bad%26jtitle%3DNature%26date%3D2007%26volume%3D446%26spage%3D975%26epage%3D977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Overall, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleifeld, O.</span><span> </span><span class="NLM_article-title">Tumour Microenvironment—Opinion: Validating Matrix Metalloproteinases as Drug Targets and Anti-Targets for Cancer Therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">239</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnrc1821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=16498445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhslelt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=227-239&author=C.+M.+Overallauthor=O.+Kleifeld&title=Tumour+Microenvironment%E2%80%94Opinion%3A+Validating+Matrix+Metalloproteinases+as+Drug+Targets+and+Anti-Targets+for+Cancer+Therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour microenvironment - Opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy</span></div><div class="casAuthors">Overall, Christopher M.; Kleifeld, Oded</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">227-239</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The matrix metalloproteinases (MMPs) mediate homeostasis of the extracellular environment.  They have multiple signaling activities that are commonly altered during tumorigenesis and that might serve as intervention points for anticancer drugs.  However, there are many criteria to consider in validating MMPs as drug targets and for the development of MMP inhibitors.  The inhibition of some MMPs could have pro-tumorigenic effects (making them anti-targets), counterbalancing the benefits of target inhibition.  These effects might partially account for the failure of MMP inhibitors in clin. trials.  What are the major challenges in MMP target validation and MMP-inhibitor-drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc3iBQEggRc7Vg90H21EOLACvtfcHk0ljTam23faT4pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhslelt70%253D&md5=3edfeca153a62c759443d0893a6212e2</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnrc1821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1821%26sid%3Dliteratum%253Aachs%26aulast%3DOverall%26aufirst%3DC.%2BM.%26aulast%3DKleifeld%26aufirst%3DO.%26atitle%3DTumour%2520Microenvironment%25E2%2580%2594Opinion%253A%2520Validating%2520Matrix%2520Metalloproteinases%2520as%2520Drug%2520Targets%2520and%2520Anti-Targets%2520for%2520Cancer%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D227%26epage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Aggarwal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondeti, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenna, R.</span><span> </span><span class="NLM_article-title">Insights towards Sulfonamide Drug Specificity in α-Carbonic Anhydrases</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1526</span><span class="NLM_x">–</span> <span class="NLM_lpage">1533</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=1526-1533&author=M.+Aggarwalauthor=B.+Kondetiauthor=R.+McKenna&title=Insights+towards+Sulfonamide+Drug+Specificity+in+%CE%B1-Carbonic+Anhydrases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DM.%26aulast%3DKondeti%26aufirst%3DB.%26aulast%3DMcKenna%26aufirst%3DR.%26atitle%3DInsights%2520towards%2520Sulfonamide%2520Drug%2520Specificity%2520in%2520%25CE%25B1-Carbonic%2520Anhydrases%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D1526%26epage%3D1533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Peters, J.-U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bissantz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillebrecht, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerebtzoff, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendels, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tillier, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migeon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guba, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span> </span><span class="NLM_article-title">Can We Discover Pharmacological Promiscuity Early in the Drug Discovery Process?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">335</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=325-335&author=J.-U.+Petersauthor=J.+Hertauthor=C.+Bissantzauthor=A.+Hillebrechtauthor=G.+Gerebtzoffauthor=S.+Bendelsauthor=F.+Tillierauthor=J.+Migeonauthor=H.+Fischerauthor=W.+Gubaauthor=M.+Kansy&title=Can+We+Discover+Pharmacological+Promiscuity+Early+in+the+Drug+Discovery+Process%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26aulast%3DHert%26aufirst%3DJ.%26aulast%3DBissantz%26aufirst%3DC.%26aulast%3DHillebrecht%26aufirst%3DA.%26aulast%3DGerebtzoff%26aufirst%3DG.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DTillier%26aufirst%3DF.%26aulast%3DMigeon%26aufirst%3DJ.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DGuba%26aufirst%3DW.%26aulast%3DKansy%26aufirst%3DM.%26atitle%3DCan%2520We%2520Discover%2520Pharmacological%2520Promiscuity%2520Early%2520in%2520the%2520Drug%2520Discovery%2520Process%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D325%26epage%3D335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Kuhn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al Banchaabouchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campillos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavin, A.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bork, P.</span><span> </span><span class="NLM_article-title">Systematic Identification of Proteins That Elicit Drug Side Effects</span> <span class="citation_source-journal">Mol. Syst. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">663</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=663&author=M.+Kuhnauthor=M.+Al+Banchaabouchiauthor=M.+Campillosauthor=L.+J.+Jensenauthor=C.+Grossauthor=A.-C.+Gavinauthor=P.+Bork&title=Systematic+Identification+of+Proteins+That+Elicit+Drug+Side+Effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKuhn%26aufirst%3DM.%26aulast%3DAl%2BBanchaabouchi%26aufirst%3DM.%26aulast%3DCampillos%26aufirst%3DM.%26aulast%3DJensen%26aufirst%3DL.%2BJ.%26aulast%3DGross%26aufirst%3DC.%26aulast%3DGavin%26aufirst%3DA.-C.%26aulast%3DBork%26aufirst%3DP.%26atitle%3DSystematic%2520Identification%2520of%2520Proteins%2520That%2520Elicit%2520Drug%2520Side%2520Effects%26jtitle%3DMol.%2520Syst.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3D663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Lounkine, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikhailov, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doak, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span> </span><span class="NLM_article-title">Large-Scale Prediction and Testing of Drug Activity on Side-Effect Targets</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">486</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnature11159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=22722194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFyrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=361-367&author=E.+Lounkineauthor=M.+J.+Keiserauthor=S.+Whitebreadauthor=D.+Mikhailovauthor=J.+Hamonauthor=J.+L.+Jenkinsauthor=P.+Lavanauthor=E.+Weberauthor=A.+K.+Doakauthor=S.+C%C3%B4t%C3%A9author=B.+K.+Shoichetauthor=L.+Urban&title=Large-Scale+Prediction+and+Testing+of+Drug+Activity+on+Side-Effect+Targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Large-scale prediction and testing of drug activity on side-effect targets</span></div><div class="casAuthors">Lounkine, Eugen; Keiser, Michael J.; Whitebread, Steven; Mikhailov, Dmitri; Hamon, Jacques; Jenkins, Jeremy L.; Lavan, Paul; Weber, Eckhard; Doak, Allison K.; Cote, Serge; Shoichet, Brian K.; Urban, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7403</span>),
    <span class="NLM_cas:pages">361-367</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Discovering the unintended off-targets' that predict adverse drug reactions is daunting by empirical methods alone.  Drugs can act on several protein targets, some of which can be unrelated by conventional mol. metrics, and hundreds of proteins have been implicated in side effects.  Here we use a computational strategy to predict the activity of 656 marketed drugs on 73 unintended side-effect' targets.  Approx. half of the predictions were confirmed, either from proprietary databases unknown to the method or by new exptl. assays.  Affinities for these new off-targets ranged from 1 nM to 30 μM.  To explore relevance, we developed an assocn. metric to prioritize those new off-targets that explained side effects better than any known target of a given drug, creating a drug-target-adverse drug reaction network.  Among these new assocns. was the prediction that the abdominal pain side effect of the synthetic estrogen chlorotrianisene was mediated through its newly discovered inhibition of the enzyme cyclooxygenase-1.  The clin. relevance of this inhibition was borne out in whole human blood platelet aggregation assays.  This approach may have wide application to de-risking toxicol. liabilities in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5sVjfn4mgLLVg90H21EOLACvtfcHk0lgOrTHq7qCRQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFyrtb0%253D&md5=9c133b839d9527818a27a5834e4dfe11</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnature11159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11159%26sid%3Dliteratum%253Aachs%26aulast%3DLounkine%26aufirst%3DE.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DMikhailov%26aufirst%3DD.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DLavan%26aufirst%3DP.%26aulast%3DWeber%26aufirst%3DE.%26aulast%3DDoak%26aufirst%3DA.%2BK.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DS.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DLarge-Scale%2520Prediction%2520and%2520Testing%2520of%2520Drug%2520Activity%2520on%2520Side-Effect%2520Targets%26jtitle%3DNature%26date%3D2012%26volume%3D486%26spage%3D361%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheiber, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzaoui, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span> </span><span class="NLM_article-title">Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off-Target Effects from Chemical Structure</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">861</span><span class="NLM_x">–</span> <span class="NLM_lpage">873</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1002%2Fcmdc.200700026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=17477341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntVShu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=861-873&author=A.+Benderauthor=J.+Scheiberauthor=M.+Glickauthor=J.+W.+Daviesauthor=K.+Azzaouiauthor=J.+Hamonauthor=L.+Urbanauthor=S.+Whitebreadauthor=J.+L.+Jenkins&title=Analysis+of+Pharmacology+Data+and+the+Prediction+of+Adverse+Drug+Reactions+and+Off-Target+Effects+from+Chemical+Structure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure</span></div><div class="casAuthors">Bender, Andreas; Scheiber, Josef; Glick, Meir; Davies, John W.; Azzaoui, Kamal; Hamon, Jacques; Urban, Laszlo; Whitebread, Steven; Jenkins, Jeremy L.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">861-873</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Preclin. Safety Pharmacol. (PSP) attempts to anticipate adverse drug reactions (ADRs) during early phases of drug discovery by testing compds. in simple, in vitro binding assays (i.e., preclin. profiling).  The selection of PSP targets is based largely on circumstantial evidence of their contribution to known clin. ADRs, inferred from findings in clin. trials, animal expts., and mol. studies going back more than 40 years.  In this work we explore PSP chem. space and its relevance for the prediction of adverse drug reactions.  Firstly, in silico (computational) Bayesian models for 70 PSP-related targets were built, which are able to detect 93% of the ligands binding at IC50≤ 10 μM at an overall correct classification rate of about 94 %.  Secondly, employing the World Drug Index (WDI), a model for adverse drug reactions was built directly based on normalized side-effect annotations in the WDI, which does not require any underlying functional knowledge.  This is, to our knowledge, the first attempt to predict adverse drug reactions across hundreds of categories from chem. structure alone.  On av. 90 % of the adverse drug reactions obsd. with known, clin. used compds. were detected, an overall correct classification rate of 92 %.  Drugs withdrawn from the market (Rapacuronium, Suprofen) were tested in the model and their predicted ADRs align well with known ADRs.  The anal. was repeated for acetylsalicylic acid and Benperidol which are still on the market.  Importantly, features of the models are interpretable and back-projectable to chem. structure, raising the possibility of rationally engineering out adverse effects.  By combining PSP and ADR models new hypotheses linking targets and adverse effects can be proposed and examples for the opioid μ and the muscarinic M2 receptors, as well as for cyclooxygenase-1 are presented.  It is hoped that the generation of predictive models for adverse drug reactions is able to help support early SAR to accelerate drug discovery and decrease late stage attrition in drug discovery projects.  In addn., models such as the ones presented here can be used for compd. profiling in all development stages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr28cgC-UGC3LVg90H21EOLACvtfcHk0lgOrTHq7qCRQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntVShu74%253D&md5=b04e52a6b745d233415b106e53e6e2c9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700026%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%26aulast%3DScheiber%26aufirst%3DJ.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DJ.%2BW.%26aulast%3DAzzaoui%26aufirst%3DK.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DUrban%26aufirst%3DL.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26atitle%3DAnalysis%2520of%2520Pharmacology%2520Data%2520and%2520the%2520Prediction%2520of%2520Adverse%2520Drug%2520Reactions%2520and%2520Off-Target%2520Effects%2520from%2520Chemical%2520Structure%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D861%26epage%3D873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Azzaoui, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacoby, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span> </span><span class="NLM_article-title">Modeling Promiscuity Based on in Vitro Safety Pharmacology Profiling Data</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">874</span><span class="NLM_x">–</span> <span class="NLM_lpage">880</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1002%2Fcmdc.200700036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=17492703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntVShu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=874-880&author=K.+Azzaouiauthor=J.+Hamonauthor=B.+Fallerauthor=S.+Whitebreadauthor=E.+Jacobyauthor=A.+Benderauthor=J.+L.+Jenkinsauthor=L.+Urban&title=Modeling+Promiscuity+Based+on+in+Vitro+Safety+Pharmacology+Profiling+Data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling promiscuity based on in vitro safety pharmacology profiling data</span></div><div class="casAuthors">Azzaoui, Kamal; Hamon, Jacques; Faller, Bernard; Whitebread, Steven; Jacoby, Edgar; Bender, Andreas; Jenkins, Jeremy L.; Urban, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">874-880</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">This study describes a method for mining and modeling binding data obtained from a large panel of targets (in vitro safety pharmacol.) to distinguish differences between promiscuous and selective compds.  Two naive Bayes models for promiscuity and selectivity were generated and validated on a test set as well as publicly available drug databases.  The model shows a higher score (lower promiscuity) for marketed drugs than for compds. in early development or compds. that failed during clin. development.  Such models can be used in triaging high-throughput screening data or for lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw2wR-U-z9YrVg90H21EOLACvtfcHk0ljsYKa6HL-86w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntVShu78%253D&md5=30c8923e136d16ffd0b1ecd62afb8ff3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700036%26sid%3Dliteratum%253Aachs%26aulast%3DAzzaoui%26aufirst%3DK.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFaller%26aufirst%3DB.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DJacoby%26aufirst%3DE.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DModeling%2520Promiscuity%2520Based%2520on%2520in%2520Vitro%2520Safety%2520Pharmacology%2520Profiling%2520Data%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D874%26epage%3D880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Lamers, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cysouw, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdouw, P. D.</span><span> </span><span class="NLM_article-title">Slow Calcium Channel Blockers and Calmodulin. Effect of Felodipine, Nifedipine, Prenylamine and Bepridil on Cardiac Sarcolemmal Calcium Pumping ATPase</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">3837</span><span class="NLM_x">–</span> <span class="NLM_lpage">3843</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1985&pages=3837-3843&author=J.+M.+Lamersauthor=K.+J.+Cysouwauthor=P.+D.+Verdouw&title=Slow+Calcium+Channel+Blockers+and+Calmodulin.+Effect+of+Felodipine%2C+Nifedipine%2C+Prenylamine+and+Bepridil+on+Cardiac+Sarcolemmal+Calcium+Pumping+ATPase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLamers%26aufirst%3DJ.%2BM.%26aulast%3DCysouw%26aufirst%3DK.%2BJ.%26aulast%3DVerdouw%26aufirst%3DP.%2BD.%26atitle%3DSlow%2520Calcium%2520Channel%2520Blockers%2520and%2520Calmodulin.%2520Effect%2520of%2520Felodipine%252C%2520Nifedipine%252C%2520Prenylamine%2520and%2520Bepridil%2520on%2520Cardiac%2520Sarcolemmal%2520Calcium%2520Pumping%2520ATPase%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1985%26volume%3D34%26spage%3D3837%26epage%3D3843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Chong, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, D. J.</span><span> </span><span class="NLM_article-title">New Uses for Old Drugs</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">448</span><span class="NLM_x">, </span> <span class="NLM_fpage">645</span><span class="NLM_x">–</span> <span class="NLM_lpage">646</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2F448645a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=17687303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD2sXos1ylu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=645-646&author=C.+R.+Chongauthor=D.+J.+Sullivan&title=New+Uses+for+Old+Drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">New uses for old drugs</span></div><div class="casAuthors">Chong, Curtis R.; Sullivan, David J., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7154</span>),
    <span class="NLM_cas:pages">645-646</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">It takes too long and costs too much to bring new drugs to market.  So let's beef up efforts to screen existing drugs for new uses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlEUwK7HNo67Vg90H21EOLACvtfcHk0ljsYKa6HL-86w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXos1ylu7o%253D&md5=9752ed45ce75d1ce1f48793a59d0bdc0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2F448645a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F448645a%26sid%3Dliteratum%253Aachs%26aulast%3DChong%26aufirst%3DC.%2BR.%26aulast%3DSullivan%26aufirst%3DD.%2BJ.%26atitle%3DNew%2520Uses%2520for%2520Old%2520Drugs%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D645%26epage%3D646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laggner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuijer, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matos, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whaley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, K. L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Predicting New Molecular Targets for Known Drugs</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnature08506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=19881490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlers7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=175-181&author=M.+J.+Keiserauthor=V.+Setolaauthor=J.+J.+Irwinauthor=C.+Laggnerauthor=A.+I.+Abbasauthor=S.+J.+Hufeisenauthor=N.+H.+Jensenauthor=M.+B.+Kuijerauthor=R.+C.+Matosauthor=T.+B.+Tranauthor=R.+Whaleyauthor=R.+A.+Glennonauthor=J.+Hertauthor=K.+L.+H.+Thomasauthor=D.+D.+Edwardsauthor=B.+K.+Shoichetauthor=B.+L.+Roth&title=Predicting+New+Molecular+Targets+for+Known+Drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting new molecular targets for known drugs</span></div><div class="casAuthors">Keiser, Michael J.; Setola, Vincent; Irwin, John J.; Laggner, Christian; Abbas, Atheir I.; Hufeisen, Sandra J.; Jensen, Niels H.; Kuijer, Michael B.; Matos, Roberto C.; Tran, Thuy B.; Whaley, Ryan; Glennon, Richard A.; Hert, Jerome; Thomas, Kelan L. H.; Edwards, Douglas D.; Shoichet, Brian K.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7270</span>),
    <span class="NLM_cas:pages">175-181</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although drugs are intended to be selective, at least some bind to several physiol. targets, explaining side effects and efficacy.  Because many drug-target combinations exist, it would be useful to explore possible interactions computationally.  Here we compared 3665 US Food and Drug Administration (FDA)-approved and investigational drugs against hundreds of targets, defining each target by its ligands.  Chem. similarities between drugs and ligand sets predicted thousands of unanticipated assocns.  Thirty were tested exptl., including the antagonism of the β1 receptor by the transporter inhibitor Prozac, the inhibition of the 5-hydroxytryptamine (5-HT) transporter by the ion channel drug Vadilex, and antagonism of the histamine H4 receptor by the enzyme inhibitor Rescriptor.  Overall, 23 new drug-target assocns. were confirmed, five of which were potent (<100 nM).  The physiol. relevance of one, the drug N,N-dimethyltryptamine (DMT) on serotonergic receptors, was confirmed in a knockout mouse.  The chem. similarity approach is systematic and comprehensive, and may suggest side-effects and new indications for many drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozd-8cCXUskrVg90H21EOLACvtfcHk0lgLCEtWiVv4FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlers7vO&md5=974e65f5d5b4dabde1a463c429215546</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnature08506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08506%26sid%3Dliteratum%253Aachs%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DLaggner%26aufirst%3DC.%26aulast%3DAbbas%26aufirst%3DA.%2BI.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DKuijer%26aufirst%3DM.%2BB.%26aulast%3DMatos%26aufirst%3DR.%2BC.%26aulast%3DTran%26aufirst%3DT.%2BB.%26aulast%3DWhaley%26aufirst%3DR.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DHert%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DK.%2BL.%2BH.%26aulast%3DEdwards%26aufirst%3DD.%2BD.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DPredicting%2520New%2520Molecular%2520Targets%2520for%2520Known%2520Drugs%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D175%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Boolell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gepi-Attee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muirhead, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naylor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterloh, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingell, C.</span><span> </span><span class="NLM_article-title">Sildenafil: An Orally Active Type 5 Cyclic GMP-Specific Phosphodiesterase Inhibitor for the Treatment of Penile Erectile Dysfunction</span> <span class="citation_source-journal">Int. J. Impotence Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">52</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=8858389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A280%3ADyaK2s%252FhtFekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1996&pages=47-52&author=M.+Boolellauthor=M.+J.+Allenauthor=S.+A.+Ballardauthor=S.+Gepi-Atteeauthor=G.+J.+Muirheadauthor=A.+M.+Naylorauthor=I.+H.+Osterlohauthor=C.+Gingell&title=Sildenafil%3A+An+Orally+Active+Type+5+Cyclic+GMP-Specific+Phosphodiesterase+Inhibitor+for+the+Treatment+of+Penile+Erectile+Dysfunction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction</span></div><div class="casAuthors">Boolell M; Allen M J; Ballard S A; Gepi-Attee S; Muirhead G J; Naylor A M; Osterloh I H; Gingell C</div><div class="citationInfo"><span class="NLM_cas:title">International journal of impotence research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">47-52</span>
        ISSN:<span class="NLM_cas:issn">0955-9930</span>.
    </div><div class="casAbstract">Sildenafil (Viagra, UK-92,480) is a novel oral agent under development for the treatment of penile erectile dysfunction.  Erection is dependent on nitric oxide and its second messenger, cyclic guanosine monophosphate (cGMP).  However, the relative importance of phosphodiesterase (PDE) isozymes is not clear.  We have identified both cGMP- and cyclic adenosine monophosphate-specific phosphodiesterases (PDEs) in human corpora cavernosa in vitro.  The main PDE activity in this tissue was due to PDE5, with PDE2 and 3 also identified.  Sildenafil is a selective inhibitor of PDE5 with a mean IC50 of 0.0039 microM.  In human volunteers, we have shown sildenafil to have suitable pharmacokinetic and pharmacodynamic properties (rapid absorption, relatively short half-life, no significant effect on heart rate and blood pressure) for an oral agent to be taken, as required, prior to sexual activity.  Moreover, in a clinical study of 12 patients with erectile dysfunction without an established organic cause, we have shown sildenafil to enhance the erectile response (duration and rigidity of erection) to visual sexual stimulation, thus highlighting the important role of PDE5 in human penile erection.  Sildenafil holds promise as a new effective oral treatment for penile erectile dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHiUn0Ryiem0bxh97K6Vt6fW6udTcc2eZ-OYmN4f92S7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s%252FhtFekuw%253D%253D&md5=35783bf8f6ff593b0a67e7e302392cd5</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoolell%26aufirst%3DM.%26aulast%3DAllen%26aufirst%3DM.%2BJ.%26aulast%3DBallard%26aufirst%3DS.%2BA.%26aulast%3DGepi-Attee%26aufirst%3DS.%26aulast%3DMuirhead%26aufirst%3DG.%2BJ.%26aulast%3DNaylor%26aufirst%3DA.%2BM.%26aulast%3DOsterloh%26aufirst%3DI.%2BH.%26aulast%3DGingell%26aufirst%3DC.%26atitle%3DSildenafil%253A%2520An%2520Orally%2520Active%2520Type%25205%2520Cyclic%2520GMP-Specific%2520Phosphodiesterase%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Penile%2520Erectile%2520Dysfunction%26jtitle%3DInt.%2520J.%2520Impotence%2520Res.%26date%3D1996%26volume%3D8%26spage%3D47%26epage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Silverman, W. A.</span><span> </span><span class="NLM_article-title">The Schizophrenic Career of a “Monster Drug”</span> <span class="citation_source-journal">Pediatrics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">404</span><span class="NLM_x">–</span> <span class="NLM_lpage">406</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2002&pages=404-406&author=W.+A.+Silverman&title=The+Schizophrenic+Career+of+a+%E2%80%9CMonster+Drug%E2%80%9D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSilverman%26aufirst%3DW.%2BA.%26atitle%3DThe%2520Schizophrenic%2520Career%2520of%2520a%2520%25E2%2580%259CMonster%2520Drug%25E2%2580%259D%26jtitle%3DPediatrics%26date%3D2002%26volume%3D110%26spage%3D404%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Cronstein, B. N.</span><span> </span><span class="NLM_article-title">Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1124%2Fpr.57.2.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=15914465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFejtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2005&pages=163-172&author=B.+N.+Cronstein&title=Low-Dose+Methotrexate%3A+A+Mainstay+in+the+Treatment+of+Rheumatoid+Arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Cronstein, Bruce N.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-172</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Methotrexate administered weekly in low doses is a mainstay in the therapy of rheumatoid arthritis.  Although originally developed as a folate antagonist for the treatment of cancer, its mechanism of action in the therapy of rheumatoid arthritis remains less clear.  Several mechanisms have been proposed including inhibition of T cell proliferation via its effects on purine and pyrimidine metab., inhibition of transmethylation reactions required for the prevention of T cell cytotoxicity, interference with glutathione metab. leading to alterations in recruitment of monocytes and other cells to the inflamed joint, and promotion of the release of the endogenous anti-inflammatory mediator adenosine.  These mechanisms of action and the role of methotrexate in the suppression of rheumatoid arthritis are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAeIg6zcVXbrVg90H21EOLACvtfcHk0lgLCEtWiVv4FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFejtLw%253D&md5=c6aae603ad4c25f2e2dc4296ecc540c2</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1124%2Fpr.57.2.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.57.2.3%26sid%3Dliteratum%253Aachs%26aulast%3DCronstein%26aufirst%3DB.%2BN.%26atitle%3DLow-Dose%2520Methotrexate%253A%2520A%2520Mainstay%2520in%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DPharmacol.%2520Rev.%26date%3D2005%26volume%3D57%26spage%3D163%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Nygren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fryknäs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agerup, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, R.</span><span> </span><span class="NLM_article-title">Repositioning of the Anthelmintic Drug Mebendazole for the Treatment for Colon Cancer</span> <span class="citation_source-journal">J. Cancer Res. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">139</span><span class="NLM_x">, </span> <span class="NLM_fpage">2133</span><span class="NLM_x">–</span> <span class="NLM_lpage">2140</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2013&pages=2133-2140&author=P.+Nygrenauthor=M.+Frykn%C3%A4sauthor=B.+Agerupauthor=R.+Larsson&title=Repositioning+of+the+Anthelmintic+Drug+Mebendazole+for+the+Treatment+for+Colon+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNygren%26aufirst%3DP.%26aulast%3DFrykn%25C3%25A4s%26aufirst%3DM.%26aulast%3DAgerup%26aufirst%3DB.%26aulast%3DLarsson%26aufirst%3DR.%26atitle%3DRepositioning%2520of%2520the%2520Anthelmintic%2520Drug%2520Mebendazole%2520for%2520the%2520Treatment%2520for%2520Colon%2520Cancer%26jtitle%3DJ.%2520Cancer%2520Res.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D139%26spage%3D2133%26epage%3D2140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Corbett, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, C.</span><span> </span><span class="NLM_article-title">Drug Repositioning: An Opportunity To Develop Novel Treatments for Alzheimer’s Disease</span> <span class="citation_source-journal">Pharmaceuticals (Basel, Switz.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1304</span><span class="NLM_x">–</span> <span class="NLM_lpage">1321</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.3390%2Fph6101304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A280%3ADC%252BC2c3ntVyqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=1304-1321&author=A.+Corbettauthor=G.+Williamsauthor=C.+Ballard&title=Drug+Repositioning%3A+An+Opportunity+To+Develop+Novel+Treatments+for+Alzheimer%E2%80%99s+Disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease</span></div><div class="casAuthors">Corbett Anne; Williams Gareth; Ballard Clive</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceuticals (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1304-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer's Disease (AD) is the most common cause of dementia, affecting approximately two thirds of the 35 million people worldwide with the condition.  Despite this, effective treatments are lacking, and there are no drugs that elicit disease modifying effects to improve outcome.  There is an urgent need to develop and evaluate more effective pharmacological treatments.  Drug repositioning offers an exciting opportunity to repurpose existing licensed treatments for use in AD, with the benefit of providing a far more rapid route to the clinic than through novel drug discovery approaches.  This review outlines the current most promising candidates for repositioning in AD, their supporting evidence and their progress through trials to date.  Furthermore, it begins to explore the potential of new transcriptomic and microarray techniques to consider the future of drug repositioning as a viable approach to drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS10Bk82pOZcJSWdIdmEou5fW6udTcc2eaQOYlshUVIH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3ntVyqsw%253D%253D&md5=45ddec28e1a9020c0f1f4f2e3bfd86ed</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.3390%2Fph6101304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph6101304%26sid%3Dliteratum%253Aachs%26aulast%3DCorbett%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DBallard%26aufirst%3DC.%26atitle%3DDrug%2520Repositioning%253A%2520An%2520Opportunity%2520To%2520Develop%2520Novel%2520Treatments%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DPharmaceuticals%2520%2528Basel%252C%2520Switz.%2529%26date%3D2013%26volume%3D6%26spage%3D1304%26epage%3D1321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Targeting the Cancer Kinome through Polypharmacology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+Cancer+Kinome+through+Polypharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0lgfbJz4Wb19fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520Cancer%2520Kinome%2520through%2520Polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D130%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting Cancer with Small Molecule Kinase Inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+Cancer+with+Small+Molecule+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0lgfbJz4Wb19fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520Cancer%2520with%2520Small%2520Molecule%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Blanc, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menet, C.</span><span> </span><span class="NLM_article-title">Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">731</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.2174%2F1871520611313050008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=23094911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslyku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=731-747&author=J.+Blancauthor=R.+Geneyauthor=C.+Menet&title=Type+II+Kinase+Inhibitors%3A+An+Opportunity+in+Cancer+for+Rational+Design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Type II kinase inhibitors: an opportunity in cancer for rational design</span></div><div class="casAuthors">Blanc, Javier; Geney, Raphael; Menet, Christel</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">731-747</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  With the advent of the Type II kinase inhibitor imatinib (Gleevec) for treatment against cancer, rational design of tailored mols. has brought a revolution in medicinal chem. for treating tumors caused by kinase malfunctioning.  Among different types of kinase inhibitors, the design of Type II inhibitors has been rationalized for maximizing the benefits and reducing drawbacks.  Here we highlight the development made in Type II inhibitors, discussing the advantages and disadvantages of these types of mols.  Furthermore, we present the strategies for designing druggable mols. that either selectively inhibit target kinases or overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7md6eYN1yg7Vg90H21EOLACvtfcHk0lgWM_kndBUtKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslyku78%253D&md5=30e72045115f723f2b868381898c2218</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.2174%2F1871520611313050008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520611313050008%26sid%3Dliteratum%253Aachs%26aulast%3DBlanc%26aufirst%3DJ.%26aulast%3DGeney%26aufirst%3DR.%26aulast%3DMenet%26aufirst%3DC.%26atitle%3DType%2520II%2520Kinase%2520Inhibitors%253A%2520An%2520Opportunity%2520in%2520Cancer%2520for%2520Rational%2520Design%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D731%26epage%3D747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Palmieri, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">αC Helix Displacement as a General Approach for Allosteric Modulation of Protein Kinases</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1016%2Fj.drudis.2012.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=23195331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVektrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=407-414&author=L.+Palmieriauthor=G.+Rastelli&title=%CE%B1C+Helix+Displacement+as+a+General+Approach+for+Allosteric+Modulation+of+Protein+Kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">αC helix displacement as a general approach for allosteric modulation of protein kinases</span></div><div class="casAuthors">Palmieri, Lorenzo; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">407-414</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Owing to their crucial role in the modulation of cell pathways, protein kinases are important targets for several human diseases, including but not limited to cancer.  The classic approach of targeting the ATP active site has recently come up against selectivity issues, which can be considerably reduced by following an allosteric modulation approach.  Being closely related to protein kinase inactivation, allosteric targeting via displacement of the conserved structural αC helix enables a direct and specific modulation mechanism.  A structure-based survey of the allosteric regulation of αC helix conformation in various kinase families is provided, highlighting key allosteric pockets and modulation mechanisms that appear to be more broadly conserved than was previously thought.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiEv57xKCTibVg90H21EOLACvtfcHk0lgWM_kndBUtKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVektrzE&md5=f2380fd543155c49602ca99b0c333ffe</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2012.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2012.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DPalmieri%26aufirst%3DL.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3D%25CE%25B1C%2520Helix%2520Displacement%2520as%2520a%2520General%2520Approach%2520for%2520Allosteric%2520Modulation%2520of%2520Protein%2520Kinases%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D407%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Di Desidero, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fioravanti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlandi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borrelli, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Man, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontanini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basolo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerbel, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danesi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bocci, G.</span><span> </span><span class="NLM_article-title">Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">E1465</span><span class="NLM_x">–</span> <span class="NLM_lpage">1473</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2013&pages=E1465-1473&author=T.+Di+Desideroauthor=A.+Fioravantiauthor=P.+Orlandiauthor=B.+Canuauthor=R.+Gianniniauthor=N.+Borrelliauthor=S.+Manauthor=P.+Xuauthor=G.+Fontaniniauthor=F.+Basoloauthor=R.+S.+Kerbelauthor=G.+Franciaauthor=R.+Danesiauthor=G.+Bocci&title=Antiproliferative+and+Proapoptotic+Activity+of+Sunitinib+on+Endothelial+and+Anaplastic+Thyroid+Cancer+Cells+via+Inhibition+of+Akt+and+ERK1%2F2+Phosphorylation+and+by+Down-Regulation+of+Cyclin-D1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BDesidero%26aufirst%3DT.%26aulast%3DFioravanti%26aufirst%3DA.%26aulast%3DOrlandi%26aufirst%3DP.%26aulast%3DCanu%26aufirst%3DB.%26aulast%3DGiannini%26aufirst%3DR.%26aulast%3DBorrelli%26aufirst%3DN.%26aulast%3DMan%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DFontanini%26aufirst%3DG.%26aulast%3DBasolo%26aufirst%3DF.%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26aulast%3DFrancia%26aufirst%3DG.%26aulast%3DDanesi%26aufirst%3DR.%26aulast%3DBocci%26aufirst%3DG.%26atitle%3DAntiproliferative%2520and%2520Proapoptotic%2520Activity%2520of%2520Sunitinib%2520on%2520Endothelial%2520and%2520Anaplastic%2520Thyroid%2520Cancer%2520Cells%2520via%2520Inhibition%2520of%2520Akt%2520and%2520ERK1%252F2%2520Phosphorylation%2520and%2520by%2520Down-Regulation%2520of%2520Cyclin-D1%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2013%26volume%3D98%26spage%3DE1465%26epage%3D1473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Dar, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cagan, R. L.</span><span> </span><span class="NLM_article-title">Chemical Genetic Discovery of Targets and Anti-Targets for Cancer Polypharmacology</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">486</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnature11127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=22678283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=80-84&author=A.+C.+Darauthor=T.+K.+Dasauthor=K.+M.+Shokatauthor=R.+L.+Cagan&title=Chemical+Genetic+Discovery+of+Targets+and+Anti-Targets+for+Cancer+Polypharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetic discovery of targets and anti-targets for cancer polypharmacology</span></div><div class="casAuthors">Dar, Arvin C.; Das, Tirtha K.; Shokat, Kevan M.; Cagan, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7401</span>),
    <span class="NLM_cas:pages">80-84</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The complexity of cancer has led to recent interest in polypharmacol. approaches for developing kinase-inhibitor drugs; however, optimal kinase-inhibition profiles remain difficult to predict.  Using a Ret-kinase-driven Drosophila model of multiple endocrine neoplasia type 2 and kinome-wide drug profiling, here the authors identify that AD57 rescues oncogenic Ret-induced lethality, whereas related Ret inhibitors imparted reduced efficacy and enhanced toxicity.  Drosophila genetics and compd. profiling defined three pathways accounting for the mechanistic basis of efficacy and dose-limiting toxicity.  Inhibition of Ret plus Raf, Src and S6K was required for optimal animal survival, whereas inhibition of the anti-target' Tor led to toxicity owing to release of neg. feedback.  Rational synthetic tailoring to eliminate Tor binding afforded AD80 and AD81, compds. featuring balanced pathway inhibition, improved efficacy and low toxicity in Drosophila and mammalian multiple endocrine neoplasia type 2 models.  Combining kinase-focused chem., kinome-wide profiling and Drosophila genetics provides a powerful systems pharmacol. approach towards developing compds. with a maximal therapeutic index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3OjBELXO9TbVg90H21EOLACvtfcHk0lgWM_kndBUtKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D&md5=4ed2f85f51453c1b38ee390a0a5f14db</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnature11127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11127%26sid%3Dliteratum%253Aachs%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DDas%26aufirst%3DT.%2BK.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DCagan%26aufirst%3DR.%2BL.%26atitle%3DChemical%2520Genetic%2520Discovery%2520of%2520Targets%2520and%2520Anti-Targets%2520for%2520Cancer%2520Polypharmacology%26jtitle%3DNature%26date%3D2012%26volume%3D486%26spage%3D80%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Xie, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evangelidis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourne, P. E.</span><span> </span><span class="NLM_article-title">Drug Discovery Using Chemical Systems Biology: Weak Inhibition of Multiple Kinases May Contribute to the Anti-Cancer Effect of Nelfinavir</span> <span class="citation_source-journal">PLoS Comput. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1002037</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1371%2Fjournal.pcbi.1002037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=21552547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsl2nsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=e1002037&author=L.+Xieauthor=T.+Evangelidisauthor=L.+Xieauthor=P.+E.+Bourne&title=Drug+Discovery+Using+Chemical+Systems+Biology%3A+Weak+Inhibition+of+Multiple+Kinases+May+Contribute+to+the+Anti-Cancer+Effect+of+Nelfinavir"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of Nelfinavir</span></div><div class="casAuthors">Xie, Li; Evangelidis, Thomas; Xie, Lei; Bourne, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e1002037</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Nelfinavir is a potent HIV-protease inhibitor with pleiotropic effects in cancer cells.  Exptl. studies connect its anti-cancer effects to the suppression of the Akt signaling pathway, but the actual mol. targets remain unknown.  Using a structural proteome-wide off-target pipeline, which integrates mol. dynamics simulation and MM/GBSA free energy calcns. with ligand binding site comparison and biol. network anal., we identified putative human off-targets of Nelfinavir and analyzed the impact on the assocd. biol. processes.  Our results suggest that Nelfinavir is able to inhibit multiple members of the protein kinase-like superfamily, which are involved in the regulation of cellular processes vital for carcinogenesis and metastasis.  The computational predictions are supported by kinase activity assays and are consistent with existing exptl. and clin. evidence.  This finding provides a mol. basis to explain the broad-spectrum anti-cancer effect of Nelfinavir and presents opportunities to optimize the drug as a targeted polypharmacol. agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGookAtcKasU9bVg90H21EOLACvtfcHk0ljMlCyvzG0XJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsl2nsrw%253D&md5=021c009e7d74cc1085577a5e11bfb23b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1002037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1002037%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DL.%26aulast%3DEvangelidis%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26atitle%3DDrug%2520Discovery%2520Using%2520Chemical%2520Systems%2520Biology%253A%2520Weak%2520Inhibition%2520of%2520Multiple%2520Kinases%2520May%2520Contribute%2520to%2520the%2520Anti-Cancer%2520Effect%2520of%2520Nelfinavir%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3De1002037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Hearn, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero-Canelón, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qamar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hands-Portman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadler, P. J.</span><span> </span><span class="NLM_article-title">Organometallic Iridium(III) Anticancer Complexes with New Mechanisms of Action: NCI-60 Screening, Mitochondrial Targeting, and Apoptosis</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1335</span><span class="NLM_x">–</span> <span class="NLM_lpage">1343</span></span><div class="citationLinks">[<a href="/doi/10.1021/cb400070a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1335-1343&author=J.+M.+Hearnauthor=I.+Romero-Canel%C3%B3nauthor=B.+Qamarauthor=Z.+Liuauthor=I.+Hands-Portmanauthor=P.+J.+Sadler&title=Organometallic+Iridium%28III%29+Anticancer+Complexes+with+New+Mechanisms+of+Action%3A+NCI-60+Screening%2C+Mitochondrial+Targeting%2C+and+Apoptosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fcb400070a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb400070a%26sid%3Dliteratum%253Aachs%26aulast%3DHearn%26aufirst%3DJ.%2BM.%26aulast%3DRomero-Canel%25C3%25B3n%26aufirst%3DI.%26aulast%3DQamar%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DHands-Portman%26aufirst%3DI.%26aulast%3DSadler%26aufirst%3DP.%2BJ.%26atitle%3DOrganometallic%2520Iridium%2528III%2529%2520Anticancer%2520Complexes%2520with%2520New%2520Mechanisms%2520of%2520Action%253A%2520NCI-60%2520Screening%252C%2520Mitochondrial%2520Targeting%252C%2520and%2520Apoptosis%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D1335%26epage%3D1343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Laufer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">New Frontiers in Kinases: Second Generation Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2167</span><span class="NLM_x">–</span> <span class="NLM_lpage">2168</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm500195x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjvVOgurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2167-2168&author=S.+Lauferauthor=J.+Bajorath&title=New+Frontiers+in+Kinases%3A+Second+Generation+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">New Frontiers in Kinases: Second Generation Inhibitors</span></div><div class="casAuthors">Laufer, Stefan; Bajorath, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2167-2168</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfZaVZXCypsLVg90H21EOLACvtfcHk0ljMlCyvzG0XJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjvVOgurk%253D&md5=df1c1e9d3ef2be7113785a979accb4f8</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm500195x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500195x%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DS.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DNew%2520Frontiers%2520in%2520Kinases%253A%2520Second%2520Generation%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2167%26epage%3D2168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Curtin, N.</span><span> </span><span class="NLM_article-title">PARP Inhibitors for Anticancer Therapy</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">82</span><span class="NLM_x">–</span> <span class="NLM_lpage">88</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1042%2FBST20130187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=24450632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOgsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=82-88&author=N.+Curtin&title=PARP+Inhibitors+for+Anticancer+Therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitors for anticancer therapy</span></div><div class="casAuthors">Curtin, Nicola</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">82-88</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  PARP-1 [poly(ADP-ribose) polymerase-1], which plays a key role in DNA repair, was discovered 50 years ago.  PARPi (PARP inhibitors), originally made to probe the function of the enzyme, inhibit DNA repair and increase the potency of anticancer cytotoxic agents.  PARPi of increasing potency were developed as chemo- and radio-sensitizers and first entered clin. trial in cancer patients in 2003.  However, it was the revelation in 2005 that they were synthetically lethal in cells with DNA repair defects, found almost exclusively in some tumors, that led to a major interest in this class of drug.  Several PARPi have entered clin. trials and show promising activity in breast, ovarian and other cancers assocd. with BRCA (breast cancer early-onset) mutations or other defects in homologous recombination DNA repair.  It is likely that at least one of these will be licensed soon.  The present review describes key events from the discovery to clin. application of PARPi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuwXKbeQike7Vg90H21EOLACvtfcHk0lhG2Je9wXXDrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOgsbY%253D&md5=53d50a336f0013c7ac2204ad8dca0e84</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1042%2FBST20130187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20130187%26sid%3Dliteratum%253Aachs%26aulast%3DCurtin%26aufirst%3DN.%26atitle%3DPARP%2520Inhibitors%2520for%2520Anticancer%2520Therapy%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2014%26volume%3D42%26spage%3D82%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Ekblad, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camaioni, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schüler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macchiarulo, A.</span><span> </span><span class="NLM_article-title">PARP Inhibitors: Polypharmacology versus Selective Inhibition</span> <span class="citation_source-journal">FEBS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">3563</span><span class="NLM_x">–</span> <span class="NLM_lpage">3575</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2013&pages=3563-3575&author=T.+Ekbladauthor=E.+Camaioniauthor=H.+Sch%C3%BClerauthor=A.+Macchiarulo&title=PARP+Inhibitors%3A+Polypharmacology+versus+Selective+Inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEkblad%26aufirst%3DT.%26aulast%3DCamaioni%26aufirst%3DE.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26aulast%3DMacchiarulo%26aufirst%3DA.%26atitle%3DPARP%2520Inhibitors%253A%2520Polypharmacology%2520versus%2520Selective%2520Inhibition%26jtitle%3DFEBS%2520J.%26date%3D2013%26volume%3D280%26spage%3D3563%26epage%3D3575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Echeverría, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernthaler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupuis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picard, D.</span><span> </span><span class="NLM_article-title">An Interaction Network Predicted from Public Data as a Discovery Tool: Application to the Hsp90 Molecular Chaperone Machine</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e26044</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e26044&author=P.+C.+Echeverr%C3%ADaauthor=A.+Bernthalerauthor=P.+Dupuisauthor=B.+Mayerauthor=D.+Picard&title=An+Interaction+Network+Predicted+from+Public+Data+as+a+Discovery+Tool%3A+Application+to+the+Hsp90+Molecular+Chaperone+Machine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEcheverr%25C3%25ADa%26aufirst%3DP.%2BC.%26aulast%3DBernthaler%26aufirst%3DA.%26aulast%3DDupuis%26aufirst%3DP.%26aulast%3DMayer%26aufirst%3DB.%26aulast%3DPicard%26aufirst%3DD.%26atitle%3DAn%2520Interaction%2520Network%2520Predicted%2520from%2520Public%2520Data%2520as%2520a%2520Discovery%2520Tool%253A%2520Application%2520to%2520the%2520Hsp90%2520Molecular%2520Chaperone%2520Machine%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De26044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Moulick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerchietti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomes DaGama, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldas-Lopes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beebe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perna, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatzi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zatorska, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taldone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith-Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alpaugh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillarsetty, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ku, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdjument-Bromage, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnick, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Affinity-Based Proteomics Reveal Cancer-Specific Networks Coordinated by Hsp90</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">818</span><span class="NLM_x">–</span> <span class="NLM_lpage">826</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnchembio.670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=21946277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1anurbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=818-826&author=K.+Moulickauthor=J.+H.+Ahnauthor=H.+Zongauthor=A.+Rodinaauthor=L.+Cerchiettiauthor=E.+M.+Gomes+DaGamaauthor=E.+Caldas-Lopesauthor=K.+Beebeauthor=F.+Pernaauthor=K.+Hatziauthor=L.+P.+Vuauthor=X.+Zhaoauthor=D.+Zatorskaauthor=T.+Taldoneauthor=P.+Smith-Jonesauthor=M.+Alpaughauthor=S.+S.+Grossauthor=N.+Pillarsettyauthor=T.+Kuauthor=J.+S.+Lewisauthor=S.+M.+Larsonauthor=R.+Levineauthor=H.+Erdjument-Bromageauthor=M.+L.+Guzmanauthor=S.+D.+Nimerauthor=A.+Melnickauthor=L.+Neckersauthor=G.+Chiosis&title=Affinity-Based+Proteomics+Reveal+Cancer-Specific+Networks+Coordinated+by+Hsp90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90</span></div><div class="casAuthors">Moulick, Kamalika; Ahn, James H.; Zong, Hongliang; Rodina, Anna; Cerchietti, Leandro; Gomes DaGama, Erica M.; Caldas-Lopes, Eloisi; Beebe, Kristin; Perna, Fabiana; Hatzi, Katerina; Vu, Ly P.; Zhao, Xinyang; Zatorska, Danuta; Taldone, Tony; Smith-Jones, Peter; Alpaugh, Mary; Gross, Steven S.; Pillarsetty, Nagavarakishore; Ku, Thomas; Lewis, Jason S.; Larson, Steven M.; Levine, Ross; Erdjument-Bromage, Hediye; Guzman, Monica L.; Nimer, Stephen D.; Melnick, Ari; Neckers, Len; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">818-826</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Most cancers were characterized by multiple mol. alterations, but identification of the key proteins involved in these signaling pathways is currently beyond reach.  The inhibitor PU-H71 preferentially targets tumor-enriched Hsp90 complexes and affinity captures Hsp90-dependent oncogenic client proteins.  The authors used PU-H71 affinity capture to design a proteomic approach that, when combined with bioinformatic pathway anal., identifies dysregulated signaling networks and key oncoproteins in chronic myeloid leukemia.  The identified interactome overlaps with the well-characterized altered proteome in this cancer, indicating that this method can provide global insights into the biol. of individual tumors, including primary patient specimens.  In addn., this approach can be used to identify previously uncharacterized oncoproteins and mechanisms, potentially leading to new targeted therapies.  Further the abundance of the PU-H71-enriched Hsp90 species, which is not dictated by Hsp90 expression alone, is predictive of the cell's sensitivity to Hsp90 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXTlQWF_MFU7Vg90H21EOLACvtfcHk0lhG2Je9wXXDrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1anurbN&md5=d62e663a2e054f3715a3a6e2d5e2c10e</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.670%26sid%3Dliteratum%253Aachs%26aulast%3DMoulick%26aufirst%3DK.%26aulast%3DAhn%26aufirst%3DJ.%2BH.%26aulast%3DZong%26aufirst%3DH.%26aulast%3DRodina%26aufirst%3DA.%26aulast%3DCerchietti%26aufirst%3DL.%26aulast%3DGomes%2BDaGama%26aufirst%3DE.%2BM.%26aulast%3DCaldas-Lopes%26aufirst%3DE.%26aulast%3DBeebe%26aufirst%3DK.%26aulast%3DPerna%26aufirst%3DF.%26aulast%3DHatzi%26aufirst%3DK.%26aulast%3DVu%26aufirst%3DL.%2BP.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DZatorska%26aufirst%3DD.%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DSmith-Jones%26aufirst%3DP.%26aulast%3DAlpaugh%26aufirst%3DM.%26aulast%3DGross%26aufirst%3DS.%2BS.%26aulast%3DPillarsetty%26aufirst%3DN.%26aulast%3DKu%26aufirst%3DT.%26aulast%3DLewis%26aufirst%3DJ.%2BS.%26aulast%3DLarson%26aufirst%3DS.%2BM.%26aulast%3DLevine%26aufirst%3DR.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DGuzman%26aufirst%3DM.%2BL.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DMelnick%26aufirst%3DA.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DAffinity-Based%2520Proteomics%2520Reveal%2520Cancer-Specific%2520Networks%2520Coordinated%2520by%2520Hsp90%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D818%26epage%3D826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Knox, A. J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawlak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golfis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flood, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fayne, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, D. G.</span><span> </span><span class="NLM_article-title">Integration of Ligand and Structure-Based Virtual Screening for the Identification of the First Dual Targeting Agent for Heat Shock Protein 90 (Hsp90) and Tubulin</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2177</span><span class="NLM_x">–</span> <span class="NLM_lpage">2180</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801569z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFGrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2177-2180&author=A.+J.+S.+Knoxauthor=T.+Priceauthor=M.+Pawlakauthor=G.+Golfisauthor=C.+T.+Floodauthor=D.+Fayneauthor=D.+C.+Williamsauthor=M.+J.+Meeganauthor=D.+G.+Lloyd&title=Integration+of+Ligand+and+Structure-Based+Virtual+Screening+for+the+Identification+of+the+First+Dual+Targeting+Agent+for+Heat+Shock+Protein+90+%28Hsp90%29+and+Tubulin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Integration of Ligand and Structure-Based Virtual Screening for the Identification of the First Dual Targeting Agent for Heat Shock Protein 90 (Hsp90) and Tubulin</span></div><div class="casAuthors">Knox, Andrew J. S.; Price, Trevor; Pawlak, Michal; Golfis, Georgia; Flood, Christopher T.; Fayne, Darren; Williams, D. Clive; Meegan, Mary J.; Lloyd, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2177-2180</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe the discovery of a novel indazole-based scaffold that represents the "first-in-class" dual Hsp90/tubulin binding compd.  Individual known ligands for both targets shared similar 3',4',5'-trimethoxyphenyl cores, and from this it was hypothesized that application of an integrated ligand and structure-based virtual screening (VS) workflow could yield a single scaffold with dual binding affinity.  Following validation of the VS protocol, we successfully identified a novel dual inhibitor, sourced from a com. screening collection of 160 000 compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRptEHjoTCsLVg90H21EOLACvtfcHk0lhX6ay0Tl_llw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFGrt70%253D&md5=c8268f36a0da627404be37696c5afe4b</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm801569z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801569z%26sid%3Dliteratum%253Aachs%26aulast%3DKnox%26aufirst%3DA.%2BJ.%2BS.%26aulast%3DPrice%26aufirst%3DT.%26aulast%3DPawlak%26aufirst%3DM.%26aulast%3DGolfis%26aufirst%3DG.%26aulast%3DFlood%26aufirst%3DC.%2BT.%26aulast%3DFayne%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%2BC.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26aulast%3DLloyd%26aufirst%3DD.%2BG.%26atitle%3DIntegration%2520of%2520Ligand%2520and%2520Structure-Based%2520Virtual%2520Screening%2520for%2520the%2520Identification%2520of%2520the%2520First%2520Dual%2520Targeting%2520Agent%2520for%2520Heat%2520Shock%2520Protein%252090%2520%2528Hsp90%2529%2520and%2520Tubulin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2177%26epage%3D2180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Owellen, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donigian, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartke, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhar, M. J.</span><span> </span><span class="NLM_article-title">The Binding of Vinblastine to Tubulin and to Particulate Fractions of Mammalian Brain</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1974</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">3180</span><span class="NLM_x">–</span> <span class="NLM_lpage">3186</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1974&pages=3180-3186&author=R.+J.+Owellenauthor=D.+W.+Donigianauthor=C.+A.+Hartkeauthor=R.+M.+Dickersonauthor=M.+J.+Kuhar&title=The+Binding+of+Vinblastine+to+Tubulin+and+to+Particulate+Fractions+of+Mammalian+Brain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOwellen%26aufirst%3DR.%2BJ.%26aulast%3DDonigian%26aufirst%3DD.%2BW.%26aulast%3DHartke%26aufirst%3DC.%2BA.%26aulast%3DDickerson%26aufirst%3DR.%2BM.%26aulast%3DKuhar%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520Binding%2520of%2520Vinblastine%2520to%2520Tubulin%2520and%2520to%2520Particulate%2520Fractions%2520of%2520Mammalian%2520Brain%26jtitle%3DCancer%2520Res.%26date%3D1974%26volume%3D34%26spage%3D3180%26epage%3D3186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, B.</span><span> </span><span class="NLM_article-title">Anti-Tumor Selectivity of a Novel Tubulin and HSP90 Dual-Targeting Inhibitor in Non-Small Cell Lung Cancer Models</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">351</span><span class="NLM_x">–</span> <span class="NLM_lpage">360</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2013&pages=351-360&author=Q.+Zhangauthor=S.+Zhaiauthor=L.+Liauthor=X.+Liauthor=H.+Zhouauthor=A.+Liuauthor=G.+Suauthor=Q.+Muauthor=Y.+Duauthor=B.+Yan&title=Anti-Tumor+Selectivity+of+a+Novel+Tubulin+and+HSP90+Dual-Targeting+Inhibitor+in+Non-Small+Cell+Lung+Cancer+Models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhai%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DG.%26aulast%3DMu%26aufirst%3DQ.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DB.%26atitle%3DAnti-Tumor%2520Selectivity%2520of%2520a%2520Novel%2520Tubulin%2520and%2520HSP90%2520Dual-Targeting%2520Inhibitor%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Models%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2013%26volume%3D86%26spage%3D351%26epage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Anighoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumpfe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heikamp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Targeting Hsp90 Interactome Using in Silico Polypharmacology Approaches</span> <span class="citation_source-journal">Chim. Ind.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=105-106&author=A.+Anighoroauthor=D.+Stumpfeauthor=K.+Heikampauthor=J.+Bajorathauthor=G.+Rastelli&title=Targeting+Hsp90+Interactome+Using+in+Silico+Polypharmacology+Approaches"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DStumpfe%26aufirst%3DD.%26aulast%3DHeikamp%26aufirst%3DK.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DTargeting%2520Hsp90%2520Interactome%2520Using%2520in%2520Silico%2520Polypharmacology%2520Approaches%26jtitle%3DChim.%2520Ind.%26date%3D2013%26volume%3D4%26spage%3D105%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Stevens, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katritch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abagyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wüthrich, K.</span><span> </span><span class="NLM_article-title">The GPCR Network: A Large-Scale Collaboration to Determine Human GPCR Structure and Function</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnrd3859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=23237917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVekurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=25-34&author=R.+C.+Stevensauthor=V.+Cherezovauthor=V.+Katritchauthor=R.+Abagyanauthor=P.+Kuhnauthor=H.+Rosenauthor=K.+W%C3%BCthrich&title=The+GPCR+Network%3A+A+Large-Scale+Collaboration+to+Determine+Human+GPCR+Structure+and+Function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The GPCR Network: a large-scale collaboration to determine human GPCR structure and function</span></div><div class="casAuthors">Stevens, Raymond C.; Cherezov, Vadim; Katritch, Vsevolod; Abagyan, Ruben; Kuhn, Peter; Rosen, Hugh; Wuethrich, Kurt</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-34</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) are targeted by ∼30-40% of marketed drugs, and their key roles in normal physiol. and in disease demonstrate that an understanding of their structure and function is valuable to researchers in both basic science and drug discovery.  However, until recently, detailed structural information on this protein family was limited by challenges in X-ray crystallog. anal. of such membrane proteins.  The GPCR Network was created in 2010 with the goal of structurally characterizing 15-25 representative human GPCRs within 5 years, based on an active outreach program addressing an interdisciplinary community of scientists interested in GPCR structure, chem. and biol.  Here, we provide an overview of how this collaborative effort has enabled the structural detn. and characterization of eight human GPCRs so far, and discuss some of the challenges that remain in gaining more detailed insights into structure-function relationships in this receptor superfamily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBDUU5HjYCg7Vg90H21EOLACvtfcHk0lhX6ay0Tl_llw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVekurzI&md5=8c303038034b529c6efd3492716fad19</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnrd3859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3859%26sid%3Dliteratum%253Aachs%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DAbagyan%26aufirst%3DR.%26aulast%3DKuhn%26aufirst%3DP.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DW%25C3%25BCthrich%26aufirst%3DK.%26atitle%3DThe%2520GPCR%2520Network%253A%2520A%2520Large-Scale%2520Collaboration%2520to%2520Determine%2520Human%2520GPCR%2520Structure%2520and%2520Function%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D25%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span> </span><span class="NLM_article-title">Structure-Based Drug Screening for G-Protein-Coupled Receptors</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=268-272&author=B.+K.+Shoichetauthor=B.+K.+Kobilka&title=Structure-Based+Drug+Screening+for+G-Protein-Coupled+Receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DStructure-Based%2520Drug%2520Screening%2520for%2520G-Protein-Coupled%2520Receptors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2012%26volume%3D33%26spage%3D268%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheffler, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroeze, W. K.</span><span> </span><span class="NLM_article-title">Magic Shotguns versus Magic Bullets: Selectively Non-Selective Drugs for Mood Disorders and Schizophrenia</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnrd1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=15060530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=353-359&author=B.+L.+Rothauthor=D.+J.+Shefflerauthor=W.+K.+Kroeze&title=Magic+Shotguns+versus+Magic+Bullets%3A+Selectively+Non-Selective+Drugs+for+Mood+Disorders+and+Schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span></div><div class="casAuthors">Roth, Bryan L.; Sheffler, Douglas J.; Kroeze, Wesley K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most common central nervous system disorders - such as depression, bipolar disorder, and schizophrenia - seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies.  Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single mol. targets (i.e., 'magic bullets') have, not surprisingly, been largely unsuccessful.  Here the authors propose that designing selectively non-selective drugs (i.e., 'magic shotguns') that interact with several mol. targets will lead to new and more effective medications for a variety of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSsuUXzmbirVg90H21EOLACvtfcHk0lj_f5zG-mfBBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D&md5=77196583acccca65457fec7a67218463</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnrd1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1346%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DMagic%2520Shotguns%2520versus%2520Magic%2520Bullets%253A%2520Selectively%2520Non-Selective%2520Drugs%2520for%2520Mood%2520Disorders%2520and%2520Schizophrenia%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D353%26epage%3D359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Lipina, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palomo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roder, J. C.</span><span> </span><span class="NLM_article-title">Dual Inhibitor of PDE7 and GSK-3-VP1.15 Acts as Antipsychotic and Cognitive Enhancer in C57BL/6J Mice</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">214</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=205-214&author=T.+V.+Lipinaauthor=V.+Palomoauthor=C.+Gilauthor=A.+Martinezauthor=J.+C.+Roder&title=Dual+Inhibitor+of+PDE7+and+GSK-3-VP1.15+Acts+as+Antipsychotic+and+Cognitive+Enhancer+in+C57BL%2F6J+Mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLipina%26aufirst%3DT.%2BV.%26aulast%3DPalomo%26aufirst%3DV.%26aulast%3DGil%26aufirst%3DC.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DRoder%26aufirst%3DJ.%2BC.%26atitle%3DDual%2520Inhibitor%2520of%2520PDE7%2520and%2520GSK-3-VP1.15%2520Acts%2520as%2520Antipsychotic%2520and%2520Cognitive%2520Enhancer%2520in%2520C57BL%252F6J%2520Mice%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D64%26spage%3D205%26epage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Lipina, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roder, J. C.</span><span> </span><span class="NLM_article-title">Synergistic Interactions between PDE4B and GSK-3: DISC1 Mutant Mice</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1252</span><span class="NLM_x">–</span> <span class="NLM_lpage">1262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2012&pages=1252-1262&author=T.+V.+Lipinaauthor=M.+Wangauthor=F.+Liuauthor=J.+C.+Roder&title=Synergistic+Interactions+between+PDE4B+and+GSK-3%3A+DISC1+Mutant+Mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLipina%26aufirst%3DT.%2BV.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DRoder%26aufirst%3DJ.%2BC.%26atitle%3DSynergistic%2520Interactions%2520between%2520PDE4B%2520and%2520GSK-3%253A%2520DISC1%2520Mutant%2520Mice%26jtitle%3DNeuropharmacology%26date%3D2012%26volume%3D62%26spage%3D1252%26epage%3D1262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Youdim, M. B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buccafusco, J. J.</span><span> </span><span class="NLM_article-title">Multi-Functional Drugs for Various CNS Targets in the Treatment of Neurodegenerative Disorders</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1016%2Fj.tips.2004.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=15629202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktV2m" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=27-35&author=M.+B.+H.+Youdimauthor=J.+J.+Buccafusco&title=Multi-Functional+Drugs+for+Various+CNS+Targets+in+the+Treatment+of+Neurodegenerative+Disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders</span></div><div class="casAuthors">Youdim, Moussa B. H.; Buccafusco, Jerry J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-35</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Individuals with neurodegenerative diseases such as Parkinson's disease or Alzheimer's disease are benefiting from drugs developed to act on a single mol. target.  However, current pharmacol. approaches are limited in their ability to modify significantly the course of the disease, and offer incomplete and transient benefit to patients.  New therapeutic strategies comprise drug candidates designed specifically to act on multiple neural and biochem. targets for the treatment of cognition impairment, motor dysfunction, depression and neurodegeneration.  Examples include the development of single mol. entities that combine 2 or more of the following properties: (i) cholinesterase inhibition; (ii) activation or inhibition of specific subtypes of acetylcholine receptors or α-adrenoceptors; (iii) anti-inflammatory activity; (iv) monoamine oxidase inhibition; (v) catechol-O-Me transferase inhibition; (vi) nitric oxide prodn.; (vii) neuroprotection; (viii) anti-apoptotic activity; and (ix) activation of mitochondrial-dependent cell-survival genes and proteins.  These bi- or multi-functional compds. might provide greater symptomatic efficacy, and better utility as potential neuroprotective disease-modifying drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreBPSKLWPfGLVg90H21EOLACvtfcHk0lj_f5zG-mfBBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktV2m&md5=0f2bd02614627d98b7e17a7a49905d1a</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2004.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2004.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26aulast%3DBuccafusco%26aufirst%3DJ.%2BJ.%26atitle%3DMulti-Functional%2520Drugs%2520for%2520Various%2520CNS%2520Targets%2520in%2520the%2520Treatment%2520of%2520Neurodegenerative%2520Disorders%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2005%26volume%3D26%26spage%3D27%26epage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Bolea, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juárez-Jiménez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de los Ríos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chioua, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pouplana, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luque, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unzeta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marco-Contelles, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samadi, A.</span><span> </span><span class="NLM_article-title">Synthesis, Biological Evaluation, and Molecular Modeling of Donepezil and <i>N</i>-[(5-(Benzyloxy)-1-methyl-1<i>H</i>-indol-2-yl)methyl]-<i>N</i>-methylprop-2-yn-1-amine Hybrids as New Multipotent Cholinesterase/Monoamine Oxidase Inhibitors for the Treatment of Alzheimer’s Disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8251</span><span class="NLM_x">–</span> <span class="NLM_lpage">8270</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200853t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8251-8270&author=I.+Boleaauthor=J.+Ju%C3%A1rez-Jim%C3%A9nezauthor=C.+de+los+R%C3%ADosauthor=M.+Chiouaauthor=R.+Pouplanaauthor=F.+J.+Luqueauthor=M.+Unzetaauthor=J.+Marco-Contellesauthor=A.+Samadi&title=Synthesis%2C+Biological+Evaluation%2C+and+Molecular+Modeling+of+Donepezil+and+N-%5B%285-%28Benzyloxy%29-1-methyl-1H-indol-2-yl%29methyl%5D-N-methylprop-2-yn-1-amine+Hybrids+as+New+Multipotent+Cholinesterase%2FMonoamine+Oxidase+Inhibitors+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjm200853t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200853t%26sid%3Dliteratum%253Aachs%26aulast%3DBolea%26aufirst%3DI.%26aulast%3DJu%25C3%25A1rez-Jim%25C3%25A9nez%26aufirst%3DJ.%26aulast%3Dde%2Blos%2BR%25C3%25ADos%26aufirst%3DC.%26aulast%3DChioua%26aufirst%3DM.%26aulast%3DPouplana%26aufirst%3DR.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DUnzeta%26aufirst%3DM.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DSamadi%26aufirst%3DA.%26atitle%3DSynthesis%252C%2520Biological%2520Evaluation%252C%2520and%2520Molecular%2520Modeling%2520of%2520Donepezil%2520and%2520N-%255B%25285-%2528Benzyloxy%2529-1-methyl-1H-indol-2-yl%2529methyl%255D-N-methylprop-2-yn-1-amine%2520Hybrids%2520as%2520New%2520Multipotent%2520Cholinesterase%252FMonoamine%2520Oxidase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8251%26epage%3D8270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Tahtouh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkins, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soundararajan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durieu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cochet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delhommel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oberholzer, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreaux, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bazureau, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span> </span><span class="NLM_article-title">Selectivity, Cocrystal Structures, and Neuroprotective Properties of Leucettines, a Family of Protein Kinase Inhibitors Derived from the Marine Sponge Alkaloid Leucettamine B</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">9312</span><span class="NLM_x">–</span> <span class="NLM_lpage">9330</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301034u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9312-9330&author=T.+Tahtouhauthor=J.+M.+Elkinsauthor=P.+Filippakopoulosauthor=M.+Soundararajanauthor=G.+Burgyauthor=E.+Durieuauthor=C.+Cochetauthor=R.+S.+Schmidauthor=D.+C.+Loauthor=F.+Delhommelauthor=A.+E.+Oberholzerauthor=L.+H.+Pearlauthor=F.+Carreauxauthor=J.-P.+Bazureauauthor=S.+Knappauthor=L.+Meijer&title=Selectivity%2C+Cocrystal+Structures%2C+and+Neuroprotective+Properties+of+Leucettines%2C+a+Family+of+Protein+Kinase+Inhibitors+Derived+from+the+Marine+Sponge+Alkaloid+Leucettamine+B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fjm301034u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301034u%26sid%3Dliteratum%253Aachs%26aulast%3DTahtouh%26aufirst%3DT.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DSoundararajan%26aufirst%3DM.%26aulast%3DBurgy%26aufirst%3DG.%26aulast%3DDurieu%26aufirst%3DE.%26aulast%3DCochet%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DR.%2BS.%26aulast%3DLo%26aufirst%3DD.%2BC.%26aulast%3DDelhommel%26aufirst%3DF.%26aulast%3DOberholzer%26aufirst%3DA.%2BE.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DCarreaux%26aufirst%3DF.%26aulast%3DBazureau%26aufirst%3DJ.-P.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DSelectivity%252C%2520Cocrystal%2520Structures%252C%2520and%2520Neuroprotective%2520Properties%2520of%2520Leucettines%252C%2520a%2520Family%2520of%2520Protein%2520Kinase%2520Inhibitors%2520Derived%2520from%2520the%2520Marine%2520Sponge%2520Alkaloid%2520Leucettamine%2520B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9312%26epage%3D9330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">León, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marco-Contelles, J.</span><span> </span><span class="NLM_article-title">Recent Advances in the Multitarget-Directed Ligands Approach for the Treatment of Alzheimer’s Disease</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">139</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1002%2Fmed.20248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=21793014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCktrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=139-189&author=R.+Le%C3%B3nauthor=A.+G.+Garciaauthor=J.+Marco-Contelles&title=Recent+Advances+in+the+Multitarget-Directed+Ligands+Approach+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Leon, Rafael; Garcia, Antonio G.; Marco-Contelles, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">139-189</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  With 27 million cases worldwide documented in 2006, Alzheimer's disease (AD) constitutes an overwhelming health, social, economic, and political problem to nations.  Unless a new medicine capable to delay disease progression is found, the no. of cases will reach 107 million in 2050.  So far, the therapeutic paradigm one-compd.-one-target has failed.  This could be due to the multiple pathogenic mechanisms involved in AD including amyloid β (Aβ) aggregation to form plaques, τ hyperphosphorylation to disrupt microtubule to form neurofibrillary tangles, calcium imbalance, enhanced oxidative stress, impaired mitochondrial function, apoptotic neuronal death, and deterioration of synaptic transmission, particularly at cholinergic neurons.  Approx. 100 compds. are presently been investigated directed to single targets, namely inhibitors of β and γ secretase, vaccines or antibodies that clear Aβ, metal chelators to inhibit Aβ aggregation, blockers of glycogen synthase kinase 3β, enhancers of mitochondrial function, antioxidants, modulators of calcium-permeable channels such as voltage-dependent calcium channels, N-methyl-D-aspartate receptors for glutamate, or enhancers of cholinergic neurotransmission such as inhibitors of acetylcholinesterase or butyrylcholinesterase.  In view of this complex pathogenic mechanisms, and the successful treatment of chronic diseases such as HIV or cancer, with multiple drugs having complementary mechanisms of action, the concern is growing that AD could better be treated with a single compd. targeting two or more of the pathogenic mechanisms leading to neuronal death.  This review summarizes the current therapeutic strategies based on the paradigm one-compd.-various targets to treat AD.  A treatment that delays disease onset and/or progression by 5 years could halve the no. of people requiring institutionalization and/or dying from AD.  © 2011 Wiley Periodicals, Inc.  Med Res Rev.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8YQ_Czzj5brVg90H21EOLACvtfcHk0lhwRiy_0JYsCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCktrvL&md5=b08806a8a4ca71c35a3594338c881e74</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1002%2Fmed.20248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20248%26sid%3Dliteratum%253Aachs%26aulast%3DLe%25C3%25B3n%26aufirst%3DR.%26aulast%3DGarcia%26aufirst%3DA.%2BG.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Multitarget-Directed%2520Ligands%2520Approach%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2013%26volume%3D33%26spage%3D139%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overington, J. P.</span><span> </span><span class="NLM_article-title">Can. We Rationally Design Promiscuous Drugs?</span> <span class="citation_source-journal">Curr. Opin. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1016%2Fj.sbi.2006.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=16442279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=127-136&author=A.+L.+Hopkinsauthor=J.+S.+Masonauthor=J.+P.+Overington&title=Can.+We+Rationally+Design+Promiscuous+Drugs%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Can we rationally design promiscuous drugs?</span></div><div class="casAuthors">Hopkins, Andrew L.; Mason, Jonathan S.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-136</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Structure-based drug design is now used widely in modern medicinal chem.  The application of structural biol. to medicinal chem. has heralded the 'rational drug design' vision of discovering exquisitely selective ligands.  However, recent advances in post-genomic biol. are indicating that polypharmacol. may be a necessary trait for the efficacy of many drugs, therefore questioning the 'one drug, one target' assumption of current rational drug design.  By combining advances in chemoinformatics and structural biol., it might be possible to rationally design the next generation of promiscuous drugs with polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQWdh60x9AHrVg90H21EOLACvtfcHk0lhwRiy_0JYsCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D&md5=8f9e95a41976b8e3ac790f2fff2c406f</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2006.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2006.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DCan.%2520We%2520Rationally%2520Design%2520Promiscuous%2520Drugs%253F%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2006%26volume%3D16%26spage%3D127%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Morphy, J. R.; Harris, C. J.</span> <span class="citation_source-book">Designing Multi-Target Drugs</span>; <span class="NLM_publisher-name">Royal Society of Chemistry</span>: <span class="NLM_publisher-loc">Cambridge, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1039%2F9781849734912" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.+R.+Morphy&author=C.+J.+Harris&title=Designing+Multi-Target+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1039%2F9781849734912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1039%252F9781849734912%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26btitle%3DDesigning%2520Multi-Target%2520Drugs%26pub%3DRoyal%2520Society%2520of%2520Chemistry%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Bajorath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltason, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wawer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lajiness, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Drie, J. H.</span><span> </span><span class="NLM_article-title">Navigating Structure–Activity Landscapes</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">698</span><span class="NLM_x">–</span> <span class="NLM_lpage">705</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=698-705&author=J.+Bajorathauthor=L.+Peltasonauthor=M.+Wawerauthor=R.+Guhaauthor=M.+S.+Lajinessauthor=J.+H.+Van+Drie&title=Navigating+Structure%E2%80%93Activity+Landscapes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DPeltason%26aufirst%3DL.%26aulast%3DWawer%26aufirst%3DM.%26aulast%3DGuha%26aufirst%3DR.%26aulast%3DLajiness%26aufirst%3DM.%2BS.%26aulast%3DVan%2BDrie%26aufirst%3DJ.%2BH.%26atitle%3DNavigating%2520Structure%25E2%2580%2593Activity%2520Landscapes%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D698%26epage%3D705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Dimova, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wawer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wassermann, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">Design of Multitarget Activity Landscapes That Capture Hierarchical Activity Cliff Distributions</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">258</span><span class="NLM_x">–</span> <span class="NLM_lpage">266</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci100477m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFKmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=258-266&author=D.+Dimovaauthor=M.+Wawerauthor=A.+M.+Wassermannauthor=J.+Bajorath&title=Design+of+Multitarget+Activity+Landscapes+That+Capture+Hierarchical+Activity+Cliff+Distributions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Design of multitarget activity landscapes that capture hierarchical activity cliff distributions</span></div><div class="casAuthors">Dimova, Dilyana; Wawer, Mathias; Wassermann, Anne Mai; Bajorath, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">258-266</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An activity landscape model of a compd. data set can be rationalized as a graphical representation that integrates mol. similarity and potency relationships.  Activity landscape representations of different design are utilized to aid in the anal. of structure-activity relationships and the selection of informative compds.  Activity landscape models reported thus far focus on a single target (i.e., a single biol. activity) or at most two targets, giving rise to selectivity landscapes.  For compds. active against more than two targets, landscapes representing multi-target activities are difficult to conceptualize and have not yet been reported.  Herein, a first activity landscape design that integrates compd. potency relationships across multiple targets in a formally consistent manner is presented.  These multi-target activity landscapes are based on a general activity cliff classification scheme and are visualized in graph representations, where activity cliffs are represented as edges.  Furthermore, the contributions of individual compds. to structure-activity relationship discontinuity across multiple targets are monitored.  The methodol. has been applied to derive multi-target activity landscapes for compd. data sets active against different target families.  The resulting landscapes identify single-, dual-, and triple-target activity cliffs and reveal the presence of hierarchical cliff distributions.  From these multi-target activity landscapes, compds. forming complex activity cliffs can be readily selected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriKlLr6TJI67Vg90H21EOLACvtfcHk0lh80Rg7_xVhZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFKmt7o%253D&md5=487996ca26f9c0f999b94ce801ac5710</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fci100477m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci100477m%26sid%3Dliteratum%253Aachs%26aulast%3DDimova%26aufirst%3DD.%26aulast%3DWawer%26aufirst%3DM.%26aulast%3DWassermann%26aufirst%3DA.%2BM.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DDesign%2520of%2520Multitarget%2520Activity%2520Landscapes%2520That%2520Capture%2520Hierarchical%2520Activity%2520Cliff%2520Distributions%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D258%26epage%3D266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">Promiscuity Profiles of Bioactive Compounds: Potency Range and Difference Distributions and the Relation to Target Numbers and Families</span> <span class="citation_source-journal">Med. Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1196</span><span class="NLM_x">–</span> <span class="NLM_lpage">1201</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1039%2Fc3md00105a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1196-1201&author=Y.+Huauthor=J.+Bajorath&title=Promiscuity+Profiles+of+Bioactive+Compounds%3A+Potency+Range+and+Difference+Distributions+and+the+Relation+to+Target+Numbers+and+Families"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1039%2Fc3md00105a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3md00105a%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DPromiscuity%2520Profiles%2520of%2520Bioactive%2520Compounds%253A%2520Potency%2520Range%2520and%2520Difference%2520Distributions%2520and%2520the%2520Relation%2520to%2520Target%2520Numbers%2520and%2520Families%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2013%26volume%3D4%26spage%3D1196%26epage%3D1201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">Activity Profile Relationships between Structurally Similar Promiscuous Compounds</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">393</span><span class="NLM_x">–</span> <span class="NLM_lpage">398</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2013&pages=393-398&author=Y.+Huauthor=J.+Bajorath&title=Activity+Profile+Relationships+between+Structurally+Similar+Promiscuous+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DActivity%2520Profile%2520Relationships%2520between%2520Structurally%2520Similar%2520Promiscuous%2520Compounds%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D69%26spage%3D393%26epage%3D398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Designed Multiple Ligands. An Emerging Drug Discovery Paradigm</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6523</span><span class="NLM_x">–</span> <span class="NLM_lpage">6543</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+Multiple+Ligands.+An+Emerging+Drug+Discovery+Paradigm"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lh80Rg7_xVhZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520Multiple%2520Ligands.%2520An%2520Emerging%2520Drug%2520Discovery%2520Paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Apsel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazif, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aizenstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span> </span><span class="NLM_article-title">Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">699</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnchembio.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=18849971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=691-699&author=B.+Apselauthor=J.+A.+Blairauthor=B.+Gonzalezauthor=T.+M.+Nazifauthor=M.+E.+Feldmanauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=R.+L.+Williamsauthor=K.+M.+Shokatauthor=Z.+A.+Knight&title=Targeted+Polypharmacology%3A+Discovery+of+Dual+Inhibitors+of+Tyrosine+and+Phosphoinositide+Kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</span></div><div class="casAuthors">Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">691-699</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles.  It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of targets that are structurally divergent.  Here we report the systematic discovery of mols. that potently inhibit both tyrosine kinases and phosphatidylinositol-3-OH kinases, two protein families that are among the most intensely pursued cancer drug targets.  Through iterative chem. synthesis, X-ray crystallog. and kinome-level biochem. profiling, we identified compds. that inhibit a spectrum of new target combinations in these two families.  Crystal structures revealed that the dual selectivity of these mols. is controlled by a hydrophobic pocket conserved in both enzyme classes and accessible through a rotatable bond in the drug skeleton.  We show that compd. I blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kinases and phosphatidylinositol-3-OH kinases.  These mols. demonstrate the feasibility of accessing a chem. space that intersects two families of oncogenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xlegha5YF7Vg90H21EOLACvtfcHk0lgc0NG-EnFUVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF&md5=4da10a973f6895f92a644ca82ca5cdcd</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.117%26sid%3Dliteratum%253Aachs%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DNazif%26aufirst%3DT.%2BM.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26atitle%3DTargeted%2520Polypharmacology%253A%2520Discovery%2520of%2520Dual%2520Inhibitors%2520of%2520Tyrosine%2520and%2520Phosphoinositide%2520Kinases%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D691%26epage%3D699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Besnard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruda, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abecassis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguiz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norval, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simeons, F. R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stojanovski, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidah, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Constam, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bickerton, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Automated Design of Ligands to Polypharmacological Profiles</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">492</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnature11691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=23235874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=215-220&author=J.+Besnardauthor=G.+F.+Rudaauthor=V.+Setolaauthor=K.+Abecassisauthor=R.+M.+Rodriguizauthor=X.-P.+Huangauthor=S.+Norvalauthor=M.+F.+Sassanoauthor=A.+I.+Shinauthor=L.+A.+Websterauthor=F.+R.+C.+Simeonsauthor=L.+Stojanovskiauthor=A.+Pratauthor=N.+G.+Seidahauthor=D.+B.+Constamauthor=G.+R.+Bickertonauthor=K.+D.+Readauthor=W.+C.+Wetselauthor=I.+H.+Gilbertauthor=B.+L.+Rothauthor=A.+L.+Hopkins&title=Automated+Design+of+Ligands+to+Polypharmacological+Profiles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Automated design of ligands to polypharmacological profiles</span></div><div class="casAuthors">Besnard, Jeremy; Ruda, Gian Filippo; Setola, Vincent; Abecassis, Keren; Rodriguiz, Ramona M.; Huang, Xi-Ping; Norval, Suzanne; Sassano, Maria F.; Shin, Antony I.; Webster, Lauren A.; Simeons, Frederick R. C.; Stojanovski, Laste; Prat, Annik; Seidah, Nabil G.; Constam, Daniel B.; Bickerton, G. Richard; Read, Kevin D.; Wetsel, William C.; Gilbert, Ian H.; Roth, Bryan L.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7428</span>),
    <span class="NLM_cas:pages">215-220</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy and safety of a drug is detd. by its activity profile across many proteins in the proteome.  However, designing drugs with a specific multi-target profile is both complex and difficult.  Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery.  Here is described a new approach for the automated design of ligands against profiles of multiple drug targets.  The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug donepezil (I) into brain-penetrable ligands with either specific polypharmacol. or exquisite selectivity profiles for G-protein-coupled receptors.  Overall, 800 ligand-target predictions of prospectively designed ligands were tested exptl., of which 75% were confirmed to be correct.  Target engagement in vivo is also demonstrated.  The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNu5bwrBD3tbVg90H21EOLACvtfcHk0lgc0NG-EnFUVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN&md5=ace6cced250cf968d327b482a5bf1798</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1038%2Fnature11691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11691%26sid%3Dliteratum%253Aachs%26aulast%3DBesnard%26aufirst%3DJ.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DAbecassis%26aufirst%3DK.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DShin%26aufirst%3DA.%2BI.%26aulast%3DWebster%26aufirst%3DL.%2BA.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DSeidah%26aufirst%3DN.%2BG.%26aulast%3DConstam%26aufirst%3DD.%2BB.%26aulast%3DBickerton%26aufirst%3DG.%2BR.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DAutomated%2520Design%2520of%2520Ligands%2520to%2520Polypharmacological%2520Profiles%26jtitle%3DNature%26date%3D2012%26volume%3D492%26spage%3D215%26epage%3D220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Bottegoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favia, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recanatini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span> </span><span class="NLM_article-title">The Role of Fragment-Based and Computational Methods in Polypharmacology</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1016%2Fj.drudis.2011.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=21864710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC38Xns12gtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=23-34&author=G.+Bottegoniauthor=A.+D.+Faviaauthor=M.+Recanatiniauthor=A.+Cavalli&title=The+Role+of+Fragment-Based+and+Computational+Methods+in+Polypharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">The role of fragment-based and computational methods in polypharmacology</span></div><div class="casAuthors">Bottegoni, Giovanni; Favia, Angelo D.; Recanatini, Maurizio; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">23-34</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Polypharmacol.-based strategies are gaining increased attention as a novel approach to obtaining potentially innovative medicines for multifactorial diseases.  However, some within the pharmaceutical community have resisted these strategies because they can be resource-hungry in the early stages of the drug discovery process.  Here, we report on fragment-based and computational methods that might accelerate and optimize the discovery of multitarget drugs.  In particular, we illustrate that fragment-based approaches can be particularly suited for polypharmacol., owing to the inherent promiscuous nature of fragments.  In parallel, we explain how computer-assisted protocols can provide invaluable insights into how to unveil compds. theor. able to bind to more than one protein.  Furthermore, several pragmatic aspects related to the use of these approaches are covered, thus offering the reader practical insights on multitarget-oriented drug discovery projects.  We report on fragment-based and computational approaches as possible ways to accelerate and optimize the discovery of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqX_beZ_hY17Vg90H21EOLACvtfcHk0lgc0NG-EnFUVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xns12gtw%253D%253D&md5=c774326a467a2b8fef62c6e1224c2a78</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DFavia%26aufirst%3DA.%2BD.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DThe%2520Role%2520of%2520Fragment-Based%2520and%2520Computational%2520Methods%2520in%2520Polypharmacology%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D23%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Gaulton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellis, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bento, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Light, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGlinchey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalovich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Lazikani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overington, J. P.</span><span> </span><span class="NLM_article-title">ChEMBL: A Large-Scale Bioactivity Database for Drug Discovery</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">D1100</span><span class="NLM_x">–</span> <span class="NLM_lpage">D1107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1093%2Fnar%2Fgkr777" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=21948594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs12htbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=D1100-D1107&author=A.+Gaultonauthor=L.+J.+Bellisauthor=A.+P.+Bentoauthor=J.+Chambersauthor=M.+Daviesauthor=A.+Herseyauthor=Y.+Lightauthor=S.+McGlincheyauthor=D.+Michalovichauthor=B.+Al-Lazikaniauthor=J.+P.+Overington&title=ChEMBL%3A+A+Large-Scale+Bioactivity+Database+for+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">ChEMBL: a large-scale bioactivity database for drug discovery</span></div><div class="casAuthors">Gaulton, Anna; Bellis, Louisa J.; Bento, A. Patricia; Chambers, Jon; Davies, Mark; Hersey, Anne; Light, Yvonne; McGlinchey, Shaun; Michalovich, David; Al-Lazikani, Bissan; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D1100-D1107</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">ChEMBL is an Open Data database contg. binding, functional and ADMET information for a large no. of drug-like bioactive compds.  These data are manually abstracted from the primary published literature on a regular basis, then further curated and standardized to maximize their quality and utility across a wide range of chem. biol. and drug-discovery research problems.  Currently, the database contains 5.4 million bioactivity measurements for more than 1 million compds. and 5200 protein targets.  Access is available through a web-based interface, data downloads and web services at: https://www.ebi.ac.uk/chembldb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9e9jRENTtubVg90H21EOLACvtfcHk0ligokLSrq_jBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs12htbjN&md5=aedf7793e1ca54b6a4fa272ea3ef7d0e</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkr777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkr777%26sid%3Dliteratum%253Aachs%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DBellis%26aufirst%3DL.%2BJ.%26aulast%3DBento%26aufirst%3DA.%2BP.%26aulast%3DChambers%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DM.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DLight%26aufirst%3DY.%26aulast%3DMcGlinchey%26aufirst%3DS.%26aulast%3DMichalovich%26aufirst%3DD.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DChEMBL%253A%2520A%2520Large-Scale%2520Bioactivity%2520Database%2520for%2520Drug%2520Discovery%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2012%26volume%3D40%26spage%3DD1100%26epage%3DD1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">Systematic Identification of Scaffolds Representing Compounds Active against Individual Targets and Single or Multiple Target Families</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">312</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci300616s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=312-326&author=Y.+Huauthor=J.+Bajorath&title=Systematic+Identification+of+Scaffolds+Representing+Compounds+Active+against+Individual+Targets+and+Single+or+Multiple+Target+Families"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic Identification of Scaffolds Representing Compounds Active against Individual Targets and Single or Multiple Target Families</span></div><div class="casAuthors">Hu, Ye; Bajorath, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">312-326</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Given the enormous growth of compd. activity data we currently observe, we have revisited the previously introduced concepts of privileged substructures and community-selective scaffolds and systematically searched for mol. scaffolds representing compds. active against single targets, multiple targets belonging to the same target family, or targets belonging to different families.  The influence of different types of activity measurements on scaffold assignments has been detd.  Furthermore, scaffold assignments have also been carried out after applying a potency threshold to exclude weakly active compds. from the comparison and address the issue of mol. selectivity.  In both instances, the results were very similar indicating that single-target and single-family scaffolds display target- and family-selective tendencies, resp.  Unexpectedly large nos. of 630 unique single-target, 489 single-family, and 336 multi-family scaffolds have been identified in public domain compd. data that represented relatively large nos. of compds.  Other important findings are that most of the growth in high-confidence compd. activity data has been due to the evaluation of new compds., rather than addnl. measurements for previously tested compds. or analog series for previously explored scaffolds.  The majority of scaffolds have remained in the same category over time.  Activity measurement type-dependent sets of single-target, single-family, and multi-family scaffolds are also provided as an up-to-date scaffold knowledge base.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlBrLCyCzg3bVg90H21EOLACvtfcHk0ligokLSrq_jBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCnsbs%253D&md5=cef563cb1046bad1070ff8b62f8bd552</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fci300616s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci300616s%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DSystematic%2520Identification%2520of%2520Scaffolds%2520Representing%2520Compounds%2520Active%2520against%2520Individual%2520Targets%2520and%2520Single%2520or%2520Multiple%2520Target%2520Families%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D312%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armbruster, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernsberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">Relating Protein Pharmacology by Ligand Chemistry</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnbt1284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=17287757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=197-206&author=M.+J.+Keiserauthor=B.+L.+Rothauthor=B.+N.+Armbrusterauthor=P.+Ernsbergerauthor=J.+J.+Irwinauthor=B.+K.+Shoichet&title=Relating+Protein+Pharmacology+by+Ligand+Chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Relating protein pharmacology by ligand chemistry</span></div><div class="casAuthors">Keiser, Michael J.; Roth, Bryan L.; Armbruster, Blaine N.; Ernsberger, Paul; Irwin, John J.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-206</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The identification of protein function based on biol. information is an area of intense research.  Here the authors consider a complementary technique that quant. groups and relates proteins based on the chem. similarity of their ligands.  The authors began with 65,000 ligands annotated into sets for hundreds of drug targets.  The similarity score between each set was calcd. using ligand topol.  A statistical model was developed to rank the significance of the resulting similarity scores, which are expressed as a min. spanning tree to map the sets together.  Although these maps are connected solely by chem. similarity, biol. sensible clusters nevertheless emerged.  Links among unexpected targets also emerged, among them that methadone, emetine and loperamide (Imodium) may antagonize muscarinic M3, α2 adrenergic and neurokinin NK2 receptors, resp.  These predictions were subsequently confirmed exptl.  Relating receptors by ligand chem. organizes biol. to reveal unexpected relationships that may be assayed using the ligands themselves.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNKEMguhmluLVg90H21EOLACvtfcHk0ligokLSrq_jBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOrsLo%253D&md5=1b7373d52563fca5fe1e893d85f70573</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fnbt1284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1284%26sid%3Dliteratum%253Aachs%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DArmbruster%26aufirst%3DB.%2BN.%26aulast%3DErnsberger%26aufirst%3DP.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DRelating%2520Protein%2520Pharmacology%2520by%2520Ligand%2520Chemistry%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D197%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Altschul, S. F.</span><span> </span><span class="NLM_article-title">Evaluating the Statistical Significance of Multiple Distinct Local Alignments</span>. In  <span class="citation_source-book">Theoretical and Computational Methods in Genome Research</span>; <span class="NLM_contrib-group">Suhai, S.</span>, Ed.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1997</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1007%2F978-1-4615-5903-0_1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&pages=1-14&author=S.+F.+Altschulauthor=S.+Suhai&title=Theoretical+and+Computational+Methods+in+Genome+Research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1007%2F978-1-4615-5903-0_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4615-5903-0_1%26sid%3Dliteratum%253Aachs%26aulast%3DAltschul%26aufirst%3DS.%2BF.%26atitle%3DEvaluating%2520the%2520Statistical%2520Significance%2520of%2520Multiple%2520Distinct%2520Local%2520Alignments%26btitle%3DTheoretical%2520and%2520Computational%2520Methods%2520in%2520Genome%2520Research%26aulast%3DSuhai%26aufirst%3DS.%26pub%3DSpringer%26date%3D1997%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">DeGraw, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochocki, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Distefano, M. D.</span><span> </span><span class="NLM_article-title">Prediction and Evaluation of Protein Farnesyltransferase Inhibition by Commercial Drugs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2464</span><span class="NLM_x">–</span> <span class="NLM_lpage">2471</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901613f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2464-2471&author=A.+J.+DeGrawauthor=M.+J.+Keiserauthor=J.+D.+Ochockiauthor=B.+K.+Shoichetauthor=M.+D.+Distefano&title=Prediction+and+Evaluation+of+Protein+Farnesyltransferase+Inhibition+by+Commercial+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Fjm901613f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901613f%26sid%3Dliteratum%253Aachs%26aulast%3DDeGraw%26aufirst%3DA.%2BJ.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DOchocki%26aufirst%3DJ.%2BD.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DDistefano%26aufirst%3DM.%2BD.%26atitle%3DPrediction%2520and%2520Evaluation%2520of%2520Protein%2520Farnesyltransferase%2520Inhibition%2520by%2520Commercial%2520Drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2464%26epage%3D2471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Carlsson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span> </span><span class="NLM_article-title">Structure-Based Discovery of A2A Adenosine Receptor Ligands</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3748</span><span class="NLM_x">–</span> <span class="NLM_lpage">3755</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100240h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFaqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3748-3755&author=J.+Carlssonauthor=L.+Yooauthor=Z.-G.+Gaoauthor=J.+J.+Irwinauthor=B.+K.+Shoichetauthor=K.+A.+Jacobson&title=Structure-Based+Discovery+of+A2A+Adenosine+Receptor+Ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Discovery of A2A Adenosine Receptor Ligands</span></div><div class="casAuthors">Carlsson, Jens; Yoo, Lena; Gao, Zhan-Guo; Irwin, John J.; Shoichet, Brian K.; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3748-3755</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent detn. of X-ray structures of pharmacol. relevant GPCRs has made these targets accessible to structure-based ligand discovery.  Here we explore whether novel chemotypes may be discovered for the A2A adenosine receptor, based on complementarity to its recently detd. structure.  The A2A adenosine receptor signals in the periphery and the CNS, with agonists explored as anti-inflammatory drugs and antagonists explored for neurodegenerative diseases.  We used mol. docking to screen a 1.4 million compd. database against the X-ray structure computationally and tested 20 high-ranking, previously unknown mols. exptl.  Of these 35% showed substantial activity with affinities between 200 nM and 9 μM.  For the most potent of these new inhibitors, over 50-fold specificity was obsd. for the A2A vs. the related A1 and A3 subtypes.  These high hit rates and affinities at least partly reflect the bias of com. libraries toward GPCR-like chemotypes, an issue that we attempt to investigate quant.  Despite this bias, many of the most potent new ligands were novel, dissimilar from known ligands, providing new lead structures for modulation of this medically important target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzvS6-9T9bd7Vg90H21EOLACvtfcHk0ljetUJsZRU5dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFaqsL8%253D&md5=c36c941d52d2cec06387d79c4c423d46</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Fjm100240h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100240h%26sid%3Dliteratum%253Aachs%26aulast%3DCarlsson%26aufirst%3DJ.%26aulast%3DYoo%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DZ.-G.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DStructure-Based%2520Discovery%2520of%2520A2A%2520Adenosine%2520Receptor%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3748%26epage%3D3755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Hert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oprea, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">Quantifying the Relationships among Drug Classes</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">755</span><span class="NLM_x">–</span> <span class="NLM_lpage">765</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci8000259" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjt1WqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=755-765&author=J.+Hertauthor=M.+J.+Keiserauthor=J.+J.+Irwinauthor=T.+I.+Opreaauthor=B.+K.+Shoichet&title=Quantifying+the+Relationships+among+Drug+Classes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Quantifying the Relationships among Drug Classes</span></div><div class="casAuthors">Hert, Jerome; Keiser, Michael J.; Irwin, John J.; Oprea, Tudor I.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">755-765</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The similarity of drug targets is typically measured using sequence or structural information.  Here, we consider chemo-centric approaches that measure target similarity on the basis of their ligands, asking how chemoinformatics similarities differ from those derived bioinformatically, how stable the ligand networks are to changes in chemoinformatics metrics, and which network is the most reliable for prediction of pharmacol.  We calcd. the similarities between hundreds of drug targets and their ligands and mapped the relationship between them in a formal network.  Bioinformatics networks were based on the BLAST similarity between sequences, while chemoinformatics networks were based on the ligand-set similarities calcd. with either the Similarity Ensemble Approach (SEA) or a method derived from Bayesian statistics.  By multiple criteria, bioinformatics and chemoinformatics networks differed substantially, and only occasionally did a high sequence similarity correspond to a high ligand-set similarity.  In contrast, the chemoinformatics networks were stable to the method used to calc. the ligand-set similarities and to the chem. representation of the ligands.  Also, the chemoinformatics networks were more natural and more organized, by network theory, than their bioinformatics counterparts: ligand-based networks were found to be small-world and broad-scale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqREaEettV4KbVg90H21EOLACvtfcHk0ljetUJsZRU5dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjt1WqsrY%253D&md5=628dde363e13134238c9de5dc27acd7e</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fci8000259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci8000259%26sid%3Dliteratum%253Aachs%26aulast%3DHert%26aufirst%3DJ.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DQuantifying%2520the%2520Relationships%2520among%2520Drug%2520Classes%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2008%26volume%3D48%26spage%3D755%26epage%3D765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Reker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, G.</span><span> </span><span class="NLM_article-title">Identifying the Macromolecular Targets of de Novo-Designed Chemical Entities through Self-Organizing Map Consensus</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">4067</span><span class="NLM_x">–</span> <span class="NLM_lpage">4072</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1073%2Fpnas.1320001111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=24591595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtl2msbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=4067-4072&author=D.+Rekerauthor=T.+Rodriguesauthor=P.+Schneiderauthor=G.+Schneider&title=Identifying+the+Macromolecular+Targets+of+de+Novo-Designed+Chemical+Entities+through+Self-Organizing+Map+Consensus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus</span></div><div class="casAuthors">Reker, Daniel; Rodrigues, Tiago; Schneider, Petra; Schneider, Gisbert</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4067-4072</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">De novo mol. design and in silico prediction of polypharmacol. profiles are emerging research topics that will profoundly affect the future of drug discovery and chem. biol.  The goal is to identify the macromol. targets of new chem. agents.  Although several computational tools for predicting such targets are publicly available, none of these methods was explicitly designed to predict target engagement by de novo-designed mols.  Here the authors present the development and practical application of a unique technique, self-organizing map-based prediction of drug equivalence relationships (SPiDER), that merges the concepts of self-organizing maps, consensus scoring, and statistical anal. to successfully identify targets for both known drugs and computer-generated mol. scaffolds.  The authors discovered a potential off-target liability of fenofibrate-related compds., and in a comprehensive prospective application, the authors identified a multitarget-modulating profile of de novo designed mols.  These results demonstrate that SPiDER may be used to identify innovative compds. in chem. biol. and in the early stages of drug discovery, and help investigate the potential side effects of drugs and their repurposing options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD_gPUwcpea7Vg90H21EOLACvtfcHk0ljetUJsZRU5dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtl2msbg%253D&md5=5322c8755c4aeee029288015d8a55d69</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1320001111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1320001111%26sid%3Dliteratum%253Aachs%26aulast%3DReker%26aufirst%3DD.%26aulast%3DRodrigues%26aufirst%3DT.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DIdentifying%2520the%2520Macromolecular%2520Targets%2520of%2520de%2520Novo-Designed%2520Chemical%2520Entities%2520through%2520Self-Organizing%2520Map%2520Consensus%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26spage%3D4067%26epage%3D4072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Kohonen, T.</span> <span class="citation_source-book">Self-Organizing Maps</span>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1007%2F978-3-642-56927-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=T.+Kohonen&title=Self-Organizing+Maps"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-56927-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-642-56927-2%26sid%3Dliteratum%253Aachs%26aulast%3DKohonen%26aufirst%3DT.%26btitle%3DSelf-Organizing%2520Maps%26pub%3DSpringer%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Anighoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Enrichment Factor Analyses on G-Protein Coupled Receptors with Known Crystal Structure</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">743</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci4000745" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvFWitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=739-743&author=A.+Anighoroauthor=G.+Rastelli&title=Enrichment+Factor+Analyses+on+G-Protein+Coupled+Receptors+with+Known+Crystal+Structure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Enrichment Factor Analyses on G-Protein Coupled Receptors with Known Crystal Structure</span></div><div class="casAuthors">Anighoro, Andrew; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">739-743</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-protein coupled receptors (GPCRs) are highly relevant drug targets.  Four GPCRs with known crystal structure were analyzed with docking (AutoDock4) and postdocking (MM-PBSA) in order to evaluate the ability to recognize known antagonists from a larger database of mol. decoys and to predict correct binding modes.  Moreover, implications on multitarget drug screening are put forward.  The results suggest that these methods may be of interest to the growing field of GPCR structure-based virtual screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGpJ6O40Y6MrVg90H21EOLACvtfcHk0ljn0tqGM7y_tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvFWitb0%253D&md5=b99ed5c128225b5f7ffd8d4334d5a87d</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fci4000745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci4000745%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DEnrichment%2520Factor%2520Analyses%2520on%2520G-Protein%2520Coupled%2520Receptors%2520with%2520Known%2520Crystal%2520Structure%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D739%26epage%3D743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Selvam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tikhonova, I. G.</span><span> </span><span class="NLM_article-title">Addressing Selective Polypharmacology of Antipsychotic Drugs Targeting the Bioaminergic Receptors through Receptor Dynamic Conformational Ensembles</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1761</span><span class="NLM_x">–</span> <span class="NLM_lpage">1774</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci400282q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVGhtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=1761-1774&author=B.+Selvamauthor=S.+L.+Porterauthor=I.+G.+Tikhonova&title=Addressing+Selective+Polypharmacology+of+Antipsychotic+Drugs+Targeting+the+Bioaminergic+Receptors+through+Receptor+Dynamic+Conformational+Ensembles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Addressing Selective Polypharmacology of Antipsychotic Drugs Targeting the Bioaminergic Receptors through Receptor Dynamic Conformational Ensembles</span></div><div class="casAuthors">Selvam, Balaji; Porter, Simon L.; Tikhonova, Irina G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1761-1774</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective polypharmacol., where a drug acts on multiple rather than a single mol. target involved in a disease, emerges to develop a structure-based system biol. approach to design drugs selectively targeting a disease-active protein network.  We focus on the bioaminergic receptors that belong to the group of G-protein-coupled receptors (GPCRs) and represent targets for therapeutic agents against schizophrenia and depression.  Among them, it has been shown that the serotonin (5-HT2A and 5-HT6) and dopamine (D2 and D3) receptors induce a cognition-enhancing effect (group 1), while the histamine (H1) and serotonin (5-HT2C) receptors lead to metabolic side effects and the 5-HT2B serotonin receptor causes pulmonary hypertension (group 2).  Thus, the problem arises to develop an approach that allows identifying drugs targeting only the disease-active receptors, i.e. group 1.  The recent release of several crystal structures of the bioaminergic receptors, involving the D3 and H1 receptors, provides the possibility to model the structures of all receptors and initiate a study of the structural and dynamic context of selective polypharmacol.  In this work, we use mol. dynamics simulations to generate a conformational space of the receptors and subsequently characterize its binding properties applying mol. probe mapping.  All-against-all comparison of the generated probe maps of the selected diverse conformations of all receptors with the Tanimoto similarity coeff. (Tc) enable the sepn. of the receptors of group 1 from group 2.  The pharmacophore built based on the Tc-selected receptor conformations, using the multiple probe maps discovers structural features that can be used to design mols. selective toward the receptors of group 1.  The importance of several predicted residues to ligand selectivity is supported by the available mutagenesis and ligand structure-activity relationship studies.  In addn., the Tc-selected conformations of the receptors for group 1 show good performance in isolation of known ligands from a random decoy.  Our computational structure-based protocol to tackle selective polypharmacol. of antipsychotic drugs could be applied for other diseases involving multiple drug targets, such as oncol. and infectious disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFhv00UaxiCLVg90H21EOLACvtfcHk0ljn0tqGM7y_tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVGhtbk%253D&md5=84bfd85ac645c0212f3cc0dbed9601af</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fci400282q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci400282q%26sid%3Dliteratum%253Aachs%26aulast%3DSelvam%26aufirst%3DB.%26aulast%3DPorter%26aufirst%3DS.%2BL.%26aulast%3DTikhonova%26aufirst%3DI.%2BG.%26atitle%3DAddressing%2520Selective%2520Polypharmacology%2520of%2520Antipsychotic%2520Drugs%2520Targeting%2520the%2520Bioaminergic%2520Receptors%2520through%2520Receptor%2520Dynamic%2520Conformational%2520Ensembles%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D1761%26epage%3D1774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Ripphausen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nisius, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltason, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">Quo Vadis, Virtual Screening? A Comprehensive Survey of Prospective Applications</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8461</span><span class="NLM_x">–</span> <span class="NLM_lpage">8467</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101020z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1GqtrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8461-8467&author=P.+Ripphausenauthor=B.+Nisiusauthor=L.+Peltasonauthor=J.+Bajorath&title=Quo+Vadis%2C+Virtual+Screening%3F+A+Comprehensive+Survey+of+Prospective+Applications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Quo Vadis, Virtual Screening? A Comprehensive Survey of Prospective Applications</span></div><div class="casAuthors">Ripphausen, Peter; Nisius, Britta; Peltason, Lisa; Bajorath, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8461-8467</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Our anal. has revealed that the majority of prospective virtual screening (VS) studies have thus far been reported in only a small no. of journals.  In addn., we have found that docking investigations clearly dominate the prospective VS field at present.  We see an increasing no. of successful VS studies that are based on docking into homol. models, and the potency of such identified hits is on av. higher than for hits identified by docking into X-ray structures, although model-based docking calcns. are more approx. in nature.  In this context, it is interesting to note that NMR structures have thus far only rarely been used in practical VS applications.  Currently there are three times more structure-based virtual screening (SBVS) than ligand-based virtual screening (LBVS) applications available, but LBVS methods identify hits that are on av. more potent.  In particular, nearly all of the still limited no. of LBVS investigations that combine 2D and 3D components yield potent hits.  Furthermore, kinases, G-protein-coupled receptors (GPCRs), and proteases are the most popular VS targets.  For kinases and GPCRs, potent submicromolar VS hits are frequently obtained, in contrast to proteases, where the majority of reported hits are only weakly potent.  However, protein kinases and proteases only represent ∼36 % of all enzymes targeted by VS, and more than 50 % of these enzymes do not belong to the five major families.  Taken together, the results of our anal. have provided us with a rather detailed view of the prospective VS landscape and there have certainly been a few surprises.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHMK13XT0tD7Vg90H21EOLACvtfcHk0lhVzRKWd_X2HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1GqtrnK&md5=c20f82a1869c0ea176b177bc74ad92a4</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Fjm101020z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101020z%26sid%3Dliteratum%253Aachs%26aulast%3DRipphausen%26aufirst%3DP.%26aulast%3DNisius%26aufirst%3DB.%26aulast%3DPeltason%26aufirst%3DL.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DQuo%2520Vadis%252C%2520Virtual%2520Screening%253F%2520A%2520Comprehensive%2520Survey%2520of%2520Prospective%2520Applications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8461%26epage%3D8467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Emerging Topics in Structure-Based Virtual Screening</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1458</span><span class="NLM_x">–</span> <span class="NLM_lpage">1463</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2013&pages=1458-1463&author=G.+Rastelli&title=Emerging+Topics+in+Structure-Based+Virtual+Screening"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DEmerging%2520Topics%2520in%2520Structure-Based%2520Virtual%2520Screening%26jtitle%3DPharm.%2520Res.%26date%3D2013%26volume%3D30%26spage%3D1458%26epage%3D1463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Rastelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degliesposti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Rio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sgobba, M.</span><span> </span><span class="NLM_article-title">Binding Estimation after Refinement, a New Automated Procedure for the Refinement and Rescoring of Docked Ligands in Virtual Screening</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1111%2Fj.1747-0285.2009.00780.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=19207463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjt1WhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2009&pages=283-286&author=G.+Rastelliauthor=G.+Degliespostiauthor=A.+Del+Rioauthor=M.+Sgobba&title=Binding+Estimation+after+Refinement%2C+a+New+Automated+Procedure+for+the+Refinement+and+Rescoring+of+Docked+Ligands+in+Virtual+Screening"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Binding estimation after refinement, a new automated procedure for the refinement and rescoring of docked ligands in virtual screening</span></div><div class="casAuthors">Rastelli, Giulio; Degliesposti, Gianluca; Del Rio, Alberto; Sgobba, Miriam</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">283-286</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Binding estn. after refinement (BEAR) is a novel automated computational procedure suitable for correcting and overcoming limitations of docking procedures such as poor scoring function and the generation of unreasonable ligand conformations.  BEAR makes use of mol. dynamics simulation followed by MM-PBSA and MM-GBSA binding free energy ests. as tools to refine and rescore the structures obtained from docking virtual screenings.  As binding estn. after refinement relies on mol. dynamics, the entire procedure can be tailored to the needs of the end-user in terms of computational time and the desired accuracy of the results.  In a validation test, binding estn. after refinement and rescoring resulted in a significant enrichment of known ligands among top scoring compds. compared with the original docking results.  Binding estn. after refinement has direct and straightforward application in virtual screening for correcting both false-pos. and false-neg. hits, and should facilitate more reliable selection of biol. active mols. from compd. databases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_CIA8Wshju7Vg90H21EOLACvtfcHk0lhVzRKWd_X2HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjt1WhtL8%253D&md5=8a113fb4e3ae908b3d70eb97a4c964f5</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2009.00780.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2009.00780.x%26sid%3Dliteratum%253Aachs%26aulast%3DRastelli%26aufirst%3DG.%26aulast%3DDegliesposti%26aufirst%3DG.%26aulast%3DDel%2BRio%26aufirst%3DA.%26aulast%3DSgobba%26aufirst%3DM.%26atitle%3DBinding%2520Estimation%2520after%2520Refinement%252C%2520a%2520New%2520Automated%2520Procedure%2520for%2520the%2520Refinement%2520and%2520Rescoring%2520of%2520Docked%2520Ligands%2520in%2520Virtual%2520Screening%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2009%26volume%3D73%26spage%3D283%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 475 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Ahmed Abdelhameed, Mei Feng, April C. Joice, Emilia M. Zywot, Yiru Jin, Chris La Rosa, Xiaoping Liao, Heidi L. Meeds, Yena Kim, Junan Li, Craig A. McElroy, Michael Zhuo Wang, <span class="NLM_string-name hlFld-ContribAuthor">Karl A. Werbovetz</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Antileishmanial Evaluation of Arylimidamide–Azole Hybrids Containing a Phenoxyalkyl Linker. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2021,</strong> <em>7 </em>
                                    (7)
                                     , 1901-1922. <a href="https://doi.org/10.1021/acsinfecdis.0c00855" title="DOI URL">https://doi.org/10.1021/acsinfecdis.0c00855</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.0c00855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.0c00855%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DSynthesis%252Band%252BAntileishmanial%252BEvaluation%252Bof%252BArylimidamide%2525E2%252580%252593Azole%252BHybrids%252BContaining%252Ba%252BPhenoxyalkyl%252BLinker%26aulast%3DAbdelhameed%26aufirst%3DAhmed%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D05122020%26date%3D04022021%26volume%3D7%26issue%3D7%26spage%3D1901%26epage%3D1922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Su-Lei Zhang, Wen-Wen Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Bi-Jie Li</span>. </span><span class="cited-content_cbyCitation_article-title">Ir-Catalyzed Regio- and Enantioselective Hydroalkynylation of Trisubstituted Alkene to Access All-Carbon Quaternary Stereocenters. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (25)
                                     , 9639-9647. <a href="https://doi.org/10.1021/jacs.1c04493" title="DOI URL">https://doi.org/10.1021/jacs.1c04493</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.1c04493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.1c04493%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DIr-Catalyzed%252BRegio-%252Band%252BEnantioselective%252BHydroalkynylation%252Bof%252BTrisubstituted%252BAlkene%252Bto%252BAccess%252BAll-Carbon%252BQuaternary%252BStereocenters%26aulast%3DZhang%26aufirst%3DSu-Lei%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D29042021%26date%3D21062021%26volume%3D143%26issue%3D25%26spage%3D9639%26epage%3D9647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wen Shuai, Guan Wang, Yiwen Zhang, Faqian Bu, Sicheng Zhang, Duane D. Miller, Wei Li, Liang Ouyang, <span class="NLM_string-name hlFld-ContribAuthor">Yuxi Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 7963-7990. <a href="https://doi.org/10.1021/acs.jmedchem.1c00100" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00100%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BProgress%252Bon%252BTubulin%252BInhibitors%252Bwith%252BDual%252BTargeting%252BCapabilities%252Bfor%252BCancer%252BTherapy%26aulast%3DShuai%26aufirst%3DWen%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D19012021%26date%3D08062021%26volume%3D64%26issue%3D12%26spage%3D7963%26epage%3D7990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaopeng Peng, Jingxuan Chen, Ling Li, Zhiqiang Sun, Jin Liu, Yichang Ren, Junli Huang, <span class="NLM_string-name hlFld-ContribAuthor">Jianjun Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8447-8473. <a href="https://doi.org/10.1021/acs.jmedchem.1c00413" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00413%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEfficient%252BSynthesis%252Band%252BBioevaluation%252Bof%252BNovel%252BDual%252BTubulin%25252FHistone%252BDeacetylase%252B3%252BInhibitors%252Bas%252BPotential%252BAnticancer%252BAgents%26aulast%3DPeng%26aufirst%3DXiaopeng%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08032021%26date%3D07062021%26volume%3D64%26issue%3D12%26spage%3D8447%26epage%3D8473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Stefanie Hagenow, Anna Affini, Elsa Y. Pioli, Sonja Hinz, Yan Zhao, Gregory Porras, Vigneshwaran Namasivayam, Christa E. Müller, Jian-Sheng Lin, Erwan Bezard, <span class="NLM_string-name hlFld-ContribAuthor">Holger Stark</span>. </span><span class="cited-content_cbyCitation_article-title">Adenosine A2AR/A1R Antagonists Enabling Additional H3R Antagonism for the Treatment of Parkinson’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8246-8262. <a href="https://doi.org/10.1021/acs.jmedchem.0c00914" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00914</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00914%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAdenosine%252BA2AR%25252FA1R%252BAntagonists%252BEnabling%252BAdditional%252BH3R%252BAntagonism%252Bfor%252Bthe%252BTreatment%252Bof%252BParkinson%2525E2%252580%252599s%252BDisease%26aulast%3DHagenow%26aufirst%3DStefanie%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D25012021%26date%3D09062021%26volume%3D64%26issue%3D12%26spage%3D8246%26epage%3D8262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mengzhu Zheng, Junfeng Huo, Xiaoxia Gu, Yali Wang, Canrong Wu, Qingzhe Zhang, Wang Wang, Yang Liu, Yu Liu, Xuechen Zhou, Lixia Chen, Yirong Zhou, <span class="NLM_string-name hlFld-ContribAuthor">Hua Li</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7839-7852. <a href="https://doi.org/10.1021/acs.jmedchem.1c00649" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00649</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00649%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252BDesign%252Band%252BSynthesis%252Bof%252BNovel%252BDual%252BPROTACs%252Bfor%252BSimultaneous%252BDegradation%252Bof%252BEGFR%252Band%252BPARP%26aulast%3DZheng%26aufirst%3DMengzhu%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D09042021%26date%3D26052021%26volume%3D64%26issue%3D11%26spage%3D7839%26epage%3D7852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gao Tu, Tingting Fu, Fengyuan Yang, Jingyi Yang, Zhao Zhang, Xiaojun Yao, Weiwei Xue, <span class="NLM_string-name hlFld-ContribAuthor">Feng Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Understanding the Polypharmacological Profiles of Triple Reuptake Inhibitors by Molecular Simulation. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2021,</strong> <em>12 </em>
                                    (11)
                                     , 2013-2026. <a href="https://doi.org/10.1021/acschemneuro.1c00127" title="DOI URL">https://doi.org/10.1021/acschemneuro.1c00127</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.1c00127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.1c00127%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DUnderstanding%252Bthe%252BPolypharmacological%252BProfiles%252Bof%252BTriple%252BReuptake%252BInhibitors%252Bby%252BMolecular%252BSimulation%26aulast%3DTu%26aufirst%3DGao%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08032021%26date%3D07052021%26date%3D12052021%26volume%3D12%26issue%3D11%26spage%3D2013%26epage%3D2026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kalpana Tilekar, Jessica D. Hess, Neha Upadhyay, Alessandra Lo Bianco, Markus Schweipert, Antonio Laghezza, Fulvio Loiodice, Franz-Josef Meyer-Almes, Renato J. Aguilera, Antonio Lavecchia, <span class="NLM_string-name hlFld-ContribAuthor">Ramaa C S</span>. </span><span class="cited-content_cbyCitation_article-title">Thiazolidinedione “Magic Bullets” Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their In Vitro and In Vivo Antitumor Effects. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (10)
                                     , 6949-6971. <a href="https://doi.org/10.1021/acs.jmedchem.1c00491" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00491%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThiazolidinedione%252B%2525E2%252580%25259CMagic%252BBullets%2525E2%252580%25259D%252BSimultaneously%252BTargeting%252BPPAR%2525CE%2525B3%252Band%252BHDACs%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BInvestigations%252Bof%252Btheir%252BIn%252BVitro%252Band%252BIn%252BVivo%252BAntitumor%252BEffects%26aulast%3DTilekar%26aufirst%3DKalpana%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D18032021%26date%3D18052021%26volume%3D64%26issue%3D10%26spage%3D6949%26epage%3D6971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Norberto Sánchez-Cruz, <span class="NLM_string-name hlFld-ContribAuthor">José L. Medina-Franco</span>. </span><span class="cited-content_cbyCitation_article-title">Epigenetic Target Profiler: A Web Server to Predict Epigenetic Targets of Small Molecules. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2021,</strong> <em>61 </em>
                                    (4)
                                     , 1550-1554. <a href="https://doi.org/10.1021/acs.jcim.1c00045" title="DOI URL">https://doi.org/10.1021/acs.jcim.1c00045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.1c00045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.1c00045%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DEpigenetic%252BTarget%252BProfiler%25253A%252BA%252BWeb%252BServer%252Bto%252BPredict%252BEpigenetic%252BTargets%252Bof%252BSmall%252BMolecules%26aulast%3DS%25C3%25A1nchez-Cruz%26aufirst%3DNorberto%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D13012021%26date%3D17032021%26volume%3D61%26issue%3D4%26spage%3D1550%26epage%3D1554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Moritz Helmstädter, Jurema Schmidt, Astrid Kaiser, Lilia Weizel, Ewgenij Proschak, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Merk</span>. </span><span class="cited-content_cbyCitation_article-title">Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice. </span><span class="cited-content_cbyCitation_journal-name">ACS Pharmacology & Translational Science</span><span> <strong>2021,</strong> <em>4 </em>
                                    (2)
                                     , 966-979. <a href="https://doi.org/10.1021/acsptsci.1c00041" title="DOI URL">https://doi.org/10.1021/acsptsci.1c00041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsptsci.1c00041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsptsci.1c00041%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Pharmacology%2520%2526%2520Translational%2520Science%26atitle%3DDifferential%252BTherapeutic%252BEffects%252Bof%252BFXR%252BActivation%25252C%252BsEH%252BInhibition%25252C%252Band%252BDual%252BFXR%25252FsEH%252BModulation%252Bin%252BNASH%252Bin%252BDiet-Induced%252BObese%252BMice%26aulast%3DHelmst%25C3%25A4dter%26aufirst%3DMoritz%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D28012021%26date%3D29032021%26volume%3D4%26issue%3D2%26spage%3D966%26epage%3D979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Giuseppe Felice Mangiatordi, Francesca Intranuovo, Pietro Delre, Francesca Serena Abatematteo, Carmen Abate, Mauro Niso, Teresa Maria Creanza, Nicola Ancona, Angela Stefanachi, <span class="NLM_string-name hlFld-ContribAuthor">Marialessandra Contino</span>. </span><span class="cited-content_cbyCitation_article-title">Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14448-14469. <a href="https://doi.org/10.1021/acs.jmedchem.0c01357" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01357</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01357%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCannabinoid%252BReceptor%252BSubtype%252B2%252B%252528CB2R%252529%252Bin%252Ba%252BMultitarget%252BApproach%25253A%252BPerspective%252Bof%252Ban%252BInnovative%252BStrategy%252Bin%252BCancer%252Band%252BNeurodegeneration%26aulast%3DMangiatordi%26aufirst%3DGiuseppe%2BFelice%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03082020%26date%3D23102020%26volume%3D63%26issue%3D23%26spage%3D14448%26epage%3D14469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Christian Feldmann, Dimitar Yonchev, Dagmar Stumpfe, <span class="NLM_string-name hlFld-ContribAuthor">Jürgen Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic Data Analysis and Diagnostic Machine Learning Reveal Differences between Compounds with Single- and Multitarget Activity. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2020,</strong> <em>17 </em>
                                    (12)
                                     , 4652-4666. <a href="https://doi.org/10.1021/acs.molpharmaceut.0c00901" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.0c00901</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.0c00901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.0c00901%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DSystematic%252BData%252BAnalysis%252Band%252BDiagnostic%252BMachine%252BLearning%252BReveal%252BDifferences%252Bbetween%252BCompounds%252Bwith%252BSingle-%252Band%252BMultitarget%252BActivity%26aulast%3DFeldmann%26aufirst%3DChristian%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04092020%26date%3D23102020%26date%3D02102020%26date%3D05112020%26volume%3D17%26issue%3D12%26spage%3D4652%26epage%3D4666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tao Liang, Yi Zhou, Reham M. Elhassan, Xuben Hou, Xinying Yang, <span class="NLM_string-name hlFld-ContribAuthor">Hao Fang</span>. </span><span class="cited-content_cbyCitation_article-title">HDAC–Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 12083-12099. <a href="https://doi.org/10.1021/acs.jmedchem.0c01454" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01454</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01454%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHDAC%2525E2%252580%252593Bax%252BMultiple%252BLigands%252BEnhance%252BBax-Dependent%252BApoptosis%252Bin%252BHeLa%252BCells%26aulast%3DLiang%26aufirst%3DTao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D21082020%26date%3D06102020%26volume%3D63%26issue%3D20%26spage%3D12083%26epage%3D12099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mingzhe Shen, Maozi Chen, Tianjian Liang, Siyi Wang, Ying Xue, Richard Bertz, Xiang-Qun Xie, <span class="NLM_string-name hlFld-ContribAuthor">Zhiwei Feng</span>. </span><span class="cited-content_cbyCitation_article-title">Pain Chemogenomics Knowledgebase (Pain-CKB) for Systems Pharmacology Target Mapping and Physiologically Based Pharmacokinetic Modeling Investigation of Opioid Drug–Drug Interactions. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2020,</strong> <em>11 </em>
                                    (20)
                                     , 3245-3258. <a href="https://doi.org/10.1021/acschemneuro.0c00372" title="DOI URL">https://doi.org/10.1021/acschemneuro.0c00372</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.0c00372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.0c00372%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DPain%252BChemogenomics%252BKnowledgebase%252B%252528Pain-CKB%252529%252Bfor%252BSystems%252BPharmacology%252BTarget%252BMapping%252Band%252BPhysiologically%252BBased%252BPharmacokinetic%252BModeling%252BInvestigation%252Bof%252BOpioid%252BDrug%2525E2%252580%252593Drug%252BInteractions%26aulast%3DShen%26aufirst%3DMingzhe%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15062020%26date%3D23092020%26date%3D07102020%26date%3D23092020%26volume%3D11%26issue%3D20%26spage%3D3245%26epage%3D3258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kaikai Lv, Weicong Chen, Danqi Chen, Jie Mou, Huijie Zhang, Tiantian Fan, Yanlian Li, Danyan Cao, Xin Wang, Lin Chen, Jingkang Shen, Dongsheng Pei, <span class="NLM_string-name hlFld-ContribAuthor">Bing Xiong</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Design and Evaluation of 6-(Pyrimidin-2-ylamino)-3,4-dihydroquinoxalin-2(1H)-ones as Polypharmacological Inhibitors of BET and Kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 9787-9802. <a href="https://doi.org/10.1021/acs.jmedchem.0c00962" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00962</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00962%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252BDesign%252Band%252BEvaluation%252Bof%252B6-%252528Pyrimidin-2-ylamino%252529-3%25252C4-dihydroquinoxalin-2%2525281H%252529-ones%252Bas%252BPolypharmacological%252BInhibitors%252Bof%252BBET%252Band%252BKinases%26aulast%3DLv%26aufirst%3DKaikai%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D05062020%26date%3D26082020%26date%3D11082020%26volume%3D63%26issue%3D17%26spage%3D9787%26epage%3D9802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zengrui Wu, Yayuan Peng, Zhuohang Yu, Weihua Li, Guixia Liu, <span class="NLM_string-name hlFld-ContribAuthor">Yun Tang</span>. </span><span class="cited-content_cbyCitation_article-title">NetInfer: A Web Server for Prediction of Targets and Therapeutic and Adverse Effects via Network-Based Inference Methods. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (8)
                                     , 3687-3691. <a href="https://doi.org/10.1021/acs.jcim.0c00291" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c00291</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c00291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c00291%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DNetInfer%25253A%252BA%252BWeb%252BServer%252Bfor%252BPrediction%252Bof%252BTargets%252Band%252BTherapeutic%252Band%252BAdverse%252BEffects%252Bvia%252BNetwork-Based%252BInference%252BMethods%26aulast%3DWu%26aufirst%3DZengrui%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D24032020%26date%3D04082020%26date%3D20072020%26volume%3D60%26issue%3D8%26spage%3D3687%26epage%3D3691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jinsol Yang, Sohee Kwon, Sang-Hun Bae, Kyoung Mii Park, Changsik Yoon, Ji-Hyun Lee, <span class="NLM_string-name hlFld-ContribAuthor">Chaok Seok</span>. </span><span class="cited-content_cbyCitation_article-title">GalaxySagittarius: Structure- and Similarity-Based Prediction of Protein Targets for Druglike Compounds. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (6)
                                     , 3246-3254. <a href="https://doi.org/10.1021/acs.jcim.0c00104" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c00104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c00104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c00104%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DGalaxySagittarius%25253A%252BStructure-%252Band%252BSimilarity-Based%252BPrediction%252Bof%252BProtein%252BTargets%252Bfor%252BDruglike%252BCompounds%26aulast%3DYang%26aufirst%3DJinsol%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28012020%26date%3D22052020%26date%3D13052020%26volume%3D60%26issue%3D6%26spage%3D3246%26epage%3D3254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Guiyan Han, Na Liu, Chenglan Li, Jie Tu, Zhuang Li, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (10)
                                     , 5341-5359. <a href="https://doi.org/10.1021/acs.jmedchem.0c00102" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00102</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00102%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BFungal%252BLanosterol%252B14%2525CE%2525B1-Demethylase%252B%252528CYP51%252529%25252FHistone%252BDeacetylase%252BDual%252BInhibitors%252Bto%252BTreat%252BAzole-Resistant%252BCandidiasis%26aulast%3DHan%26aufirst%3DGuiyan%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04022020%26date%3D09052020%26date%3D29042020%26volume%3D63%26issue%3D10%26spage%3D5341%26epage%3D5359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Luca Pinzi, Rosaria Benedetti, Lucia Altucci, <span class="NLM_string-name hlFld-ContribAuthor">Giulio Rastelli</span>. </span><span class="cited-content_cbyCitation_article-title">Design of Dual Inhibitors of Histone Deacetylase 6 and Heat Shock Protein 90. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (20)
                                     , 11473-11480. <a href="https://doi.org/10.1021/acsomega.0c00559" title="DOI URL">https://doi.org/10.1021/acsomega.0c00559</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c00559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c00559%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DDesign%252Bof%252BDual%252BInhibitors%252Bof%252BHistone%252BDeacetylase%252B6%252Band%252BHeat%252BShock%252BProtein%252B90%26aulast%3DPinzi%26aufirst%3DLuca%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07022020%26date%3D24032020%26date%3D11052020%26volume%3D5%26issue%3D20%26spage%3D11473%26epage%3D11480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yi Zhou, Xiaoting Liu, Junxin Xue, Lulu Liu, Tao Liang, Wen Li, Xinying Yang, Xuben Hou, <span class="NLM_string-name hlFld-ContribAuthor">Hao Fang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 4701-4715. <a href="https://doi.org/10.1021/acs.jmedchem.9b02161" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02161</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02161%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPeptide%252BBoronate%252BDerivatives%252Bas%252BHistone%252BDeacetylase%252Band%252BProteasome%252BDual%252BInhibitors%252Bfor%252BOvercoming%252BBortezomib%252BResistance%252Bof%252BMultiple%252BMyeloma%26aulast%3DZhou%26aufirst%3DYi%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D24122019%26date%3D23042020%26date%3D08042020%26volume%3D63%26issue%3D9%26spage%3D4701%26epage%3D4715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ashish Thakur, Gregory J. Tawa, Mark J. Henderson, Carina Danchik, Suiyang Liu, Pranav Shah, Amy Q. Wang, Garrett Dunn, Md Kabir, Elias C. Padilha, Xin Xu, Anton Simeonov, Surender Kharbanda, Richard Stone, <span class="NLM_string-name hlFld-ContribAuthor">Gurmit Grewal</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4256-4292. <a href="https://doi.org/10.1021/acs.jmedchem.0c00193" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00193%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BQuinazolin-4-one-Based%252BHydroxamic%252BAcids%252Bas%252BDual%252BPI3K%25252FHDAC%252BInhibitors%26aulast%3DThakur%26aufirst%3DAshish%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03022020%26date%3D08042020%26date%3D26032020%26volume%3D63%26issue%3D8%26spage%3D4256%26epage%3D4292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Žiga Skok, Nace Zidar, Danijel Kikelj, <span class="NLM_string-name hlFld-ContribAuthor">Janez Ilaš</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (3)
                                     , 884-904. <a href="https://doi.org/10.1021/acs.jmedchem.9b00726" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00726</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00726%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252BInhibitors%252Bof%252BHuman%252BDNA%252BTopoisomerase%252BII%252Band%252BOther%252BCancer-Related%252BTargets%26aulast%3DSkok%26aufirst%3D%25C5%25BDiga%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D03052019%26date%3D21102019%26date%3D08102019%26volume%3D63%26issue%3D3%26spage%3D884%26epage%3D904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Luca Pinzi, <span class="NLM_string-name hlFld-ContribAuthor">Giulio Rastelli</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Target Associations for Polypharmacology from Analysis of Crystallographic Ligands of the Protein Data Bank. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (1)
                                     , 372-390. <a href="https://doi.org/10.1021/acs.jcim.9b00821" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00821</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00821%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DIdentification%252Bof%252BTarget%252BAssociations%252Bfor%252BPolypharmacology%252Bfrom%252BAnalysis%252Bof%252BCrystallographic%252BLigands%252Bof%252Bthe%252BProtein%252BData%252BBank%26aulast%3DPinzi%26aufirst%3DLuca%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D20092019%26date%3D19122019%26date%3D04122019%26volume%3D60%26issue%3D1%26spage%3D372%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tomoya Sameshima, Tomoya Yukawa, Yoshihiko Hirozane, Masato Yoshikawa, Taisuke Katoh, Hideto Hara, Takatoshi Yogo, Ikuo Miyahisa, Teruaki Okuda, Makoto Miyamoto, <span class="NLM_string-name hlFld-ContribAuthor">Russell Naven</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Scale Panel Comprising Diverse Gene Family Targets To Evaluate Compound Promiscuity. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2020,</strong> <em>33 </em>
                                    (1)
                                     , 154-161. <a href="https://doi.org/10.1021/acs.chemrestox.9b00128" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.9b00128</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.9b00128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.9b00128%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DSmall-Scale%252BPanel%252BComprising%252BDiverse%252BGene%252BFamily%252BTargets%252BTo%252BEvaluate%252BCompound%252BPromiscuity%26aulast%3DSameshima%26aufirst%3DTomoya%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D25032019%26date%3D06092019%26date%3D28082019%26volume%3D33%26issue%3D1%26spage%3D154%26epage%3D161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Junwei Wang, Hui Li, Guangchao He, Zhaoxing Chu, Kewen Peng, Yiran Ge, Qihua Zhu, <span class="NLM_string-name hlFld-ContribAuthor">Yungen Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (1)
                                     , 122-139. <a href="https://doi.org/10.1021/acs.jmedchem.9b00622" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00622</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00622%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BDual%252BPoly%252528ADP-ribose%252529polymerase%252Band%252BPhosphoinositide%252B3-Kinase%252BInhibitors%252Bas%252Ba%252BPromising%252BStrategy%252Bfor%252BCancer%252BTherapy%26aulast%3DWang%26aufirst%3DJunwei%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D11042019%26date%3D27122019%26date%3D17122019%26volume%3D63%26issue%3D1%26spage%3D122%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Brittany S. Morgan, Bilva G. Sanaba, Anita Donlic, Diane B. Karloff, Jordan E. Forte, Yuqi Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Amanda E. Hargrove</span>. </span><span class="cited-content_cbyCitation_article-title">R-BIND: An Interactive Database for Exploring and Developing RNA-Targeted Chemical Probes. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2019,</strong> <em>14 </em>
                                    (12)
                                     , 2691-2700. <a href="https://doi.org/10.1021/acschembio.9b00631" title="DOI URL">https://doi.org/10.1021/acschembio.9b00631</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.9b00631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.9b00631%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DR-BIND%25253A%252BAn%252BInteractive%252BDatabase%252Bfor%252BExploring%252Band%252BDeveloping%252BRNA-Targeted%252BChemical%252BProbes%26aulast%3DMorgan%26aufirst%3DBrittany%2BS.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03082019%26date%3D07102019%26date%3D29102019%26date%3D07102019%26volume%3D14%26issue%3D12%26spage%3D2691%26epage%3D2700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Junting Zhou, Xueyang Jiang, Siyu He, Hongli Jiang, Feng Feng, Wenyuan Liu, Wei Qu, <span class="NLM_string-name hlFld-ContribAuthor">Haopeng Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 8881-8914. <a href="https://doi.org/10.1021/acs.jmedchem.9b00017" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00017%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252BDesign%252Bof%252BMultitarget-Directed%252BLigands%25253A%252BStrategies%252Band%252BEmerging%252BParadigms%26aulast%3DZhou%26aufirst%3DJunting%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D04012019%26date%3D28052019%26date%3D13052019%26volume%3D62%26issue%3D20%26spage%3D8881%26epage%3D8914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James Schuler, <span class="NLM_string-name hlFld-ContribAuthor">Ram Samudrala</span>. </span><span class="cited-content_cbyCitation_article-title">Fingerprinting CANDO: Increased Accuracy with Structure- and Ligand-Based Shotgun Drug Repurposing. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (17)
                                     , 17393-17403. <a href="https://doi.org/10.1021/acsomega.9b02160" title="DOI URL">https://doi.org/10.1021/acsomega.9b02160</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b02160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b02160%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DFingerprinting%252BCANDO%25253A%252BIncreased%252BAccuracy%252Bwith%252BStructure-%252Band%252BLigand-Based%252BShotgun%252BDrug%252BRepurposing%26aulast%3DSchuler%26aufirst%3DJames%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D12072019%26date%3D30082019%26date%3D09102019%26volume%3D4%26issue%3D17%26spage%3D17393%26epage%3D17403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xin Yang, Yifei Wang, Ryan Byrne, Gisbert Schneider, <span class="NLM_string-name hlFld-ContribAuthor">Shengyong Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2019,</strong> <em>119 </em>
                                    (18)
                                     , 10520-10594. <a href="https://doi.org/10.1021/acs.chemrev.8b00728" title="DOI URL">https://doi.org/10.1021/acs.chemrev.8b00728</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.8b00728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.8b00728%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DConcepts%252Bof%252BArtificial%252BIntelligence%252Bfor%252BComputer-Assisted%252BDrug%252BDiscovery%26aulast%3DYang%26aufirst%3DXin%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D29112018%26date%3D11072019%26volume%3D119%26issue%3D18%26spage%3D10520%26epage%3D10594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Vincent Grattan, Andrew R. Vaino, Zachary Prensky, <span class="NLM_string-name hlFld-ContribAuthor">Mark S. Hixon</span>. </span><span class="cited-content_cbyCitation_article-title">Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (9)
                                     , 14151-14154. <a href="https://doi.org/10.1021/acsomega.9b02144" title="DOI URL">https://doi.org/10.1021/acsomega.9b02144</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b02144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b02144%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DAntipsychotic%252BBenzamides%252BAmisulpride%252Band%252BLB-102%252BDisplay%252BPolypharmacy%252Bas%252BRacemates%25252C%252BS%252BEnantiomers%252BEngage%252BReceptors%252BD2%252Band%252BD3%25252C%252Bwhile%252BR%252BEnantiomers%252BEngage%252B5-HT7%26aulast%3DGrattan%26aufirst%3DVincent%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D11072019%26date%3D02082019%26date%3D15082019%26volume%3D4%26issue%3D9%26spage%3D14151%26epage%3D14154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kehui Zhang, Fangfang Lai, Songwen Lin, Ming Ji, Jingbo Zhang, Yan Zhang, Jing Jin, Rong Fu, Deyu Wu, Hua Tian, Nina Xue, Li Sheng, Xiaowen Zou, Yan Li, Xiaoguang Chen, <span class="NLM_string-name hlFld-ContribAuthor">Heng Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (15)
                                     , 6992-7014. <a href="https://doi.org/10.1021/acs.jmedchem.9b00390" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00390</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00390%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252B4-Methyl%252BQuinazoline%252BDerivatives%252Bas%252BAnticancer%252BAgents%252BSimultaneously%252BTargeting%252BPhosphoinositide%252B3-Kinases%252Band%252BHistone%252BDeacetylases%26aulast%3DZhang%26aufirst%3DKehui%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03032019%26date%3D29052019%26date%3D22052019%26volume%3D62%26issue%3D15%26spage%3D6992%26epage%3D7014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dominique Sydow, Lindsey Burggraaff, Angelika Szengel, Herman W. T. van Vlijmen, Adriaan P. IJzerman, Gerard J. P. van Westen, <span class="NLM_string-name hlFld-ContribAuthor">Andrea Volkamer</span>. </span><span class="cited-content_cbyCitation_article-title">Advances and Challenges in Computational Target Prediction. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (5)
                                     , 1728-1742. <a href="https://doi.org/10.1021/acs.jcim.8b00832" title="DOI URL">https://doi.org/10.1021/acs.jcim.8b00832</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.8b00832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.8b00832%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DAdvances%252Band%252BChallenges%252Bin%252BComputational%252BTarget%252BPrediction%26aulast%3DSydow%26aufirst%3DDominique%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D21112018%26date%3D28022019%26volume%3D59%26issue%3D5%26spage%3D1728%26epage%3D1742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hana Kostrhunova, Juraj Zajac, Vojtech Novohradsky, Jana Kasparkova, Jaroslav Malina, Janice R. Aldrich-Wright, Emanuele Petruzzella, Roman Sirota, Dan Gibson, <span class="NLM_string-name hlFld-ContribAuthor">Viktor Brabec</span>. </span><span class="cited-content_cbyCitation_article-title">A Subset of New Platinum Antitumor Agents Kills Cells by a Multimodal Mechanism of Action Also Involving Changes in the Organization of the Microtubule Cytoskeleton. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (10)
                                     , 5176-5190. <a href="https://doi.org/10.1021/acs.jmedchem.9b00489" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00489</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00489%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BSubset%252Bof%252BNew%252BPlatinum%252BAntitumor%252BAgents%252BKills%252BCells%252Bby%252Ba%252BMultimodal%252BMechanism%252Bof%252BAction%252BAlso%252BInvolving%252BChanges%252Bin%252Bthe%252BOrganization%252Bof%252Bthe%252BMicrotubule%252BCytoskeleton%26aulast%3DKostrhunova%26aufirst%3DHana%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D20032019%26date%3D09052019%26date%3D28042019%26volume%3D62%26issue%3D10%26spage%3D5176%26epage%3D5190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sandra Arancibia, Matías Marambio, Jorge M Campusano, <span class="NLM_string-name hlFld-ContribAuthor">Angélica Fierro</span>. </span><span class="cited-content_cbyCitation_article-title">Modeling of the Binding of Octopamine and Dopamine in Insect Monoamine Transporters Reveals Structural and Electrostatic Differences. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2019,</strong> <em>10 </em>
                                    (5)
                                     , 2310-2317. <a href="https://doi.org/10.1021/acschemneuro.8b00631" title="DOI URL">https://doi.org/10.1021/acschemneuro.8b00631</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.8b00631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.8b00631%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DModeling%252Bof%252Bthe%252BBinding%252Bof%252BOctopamine%252Band%252BDopamine%252Bin%252BInsect%252BMonoamine%252BTransporters%252BReveals%252BStructural%252Band%252BElectrostatic%252BDifferences%26aulast%3DArancibia%26aufirst%3DSandra%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D14112018%26date%3D03012019%26date%3D15012019%26date%3D03012019%26volume%3D10%26issue%3D5%26spage%3D2310%26epage%3D2317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Thomas Blaschke, Filip Miljković, <span class="NLM_string-name hlFld-ContribAuthor">Jürgen Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Prediction of Different Classes of Promiscuous and Nonpromiscuous Compounds Using Machine Learning and Nearest Neighbor Analysis. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (4)
                                     , 6883-6890. <a href="https://doi.org/10.1021/acsomega.9b00492" title="DOI URL">https://doi.org/10.1021/acsomega.9b00492</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b00492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b00492%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DPrediction%252Bof%252BDifferent%252BClasses%252Bof%252BPromiscuous%252Band%252BNonpromiscuous%252BCompounds%252BUsing%252BMachine%252BLearning%252Band%252BNearest%252BNeighbor%252BAnalysis%26aulast%3DBlaschke%26aufirst%3DThomas%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D21022019%26date%3D04042019%26volume%3D4%26issue%3D4%26spage%3D6883%26epage%3D6890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xuewu Liang, Jie Zang, Xiaoyang Li, Shuai Tang, Min Huang, Meiyu Geng, C. James Chou, Chunpu Li, Yichun Cao, Wenfang Xu, Hong Liu, <span class="NLM_string-name hlFld-ContribAuthor">Yingjie Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (8)
                                     , 3898-3923. <a href="https://doi.org/10.1021/acs.jmedchem.8b01597" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01597</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01597%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BJanus%252BKinase%252B%252528JAK%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BDual%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BHematological%252BMalignancies%26aulast%3DLiang%26aufirst%3DXuewu%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D14102018%26date%3D03042019%26date%3D22032019%26volume%3D62%26issue%3D8%26spage%3D3898%26epage%3D3923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Syed Muhammad Usama, Bosheng Zhao, <span class="NLM_string-name hlFld-ContribAuthor">Kevin Burgess</span>. </span><span class="cited-content_cbyCitation_article-title">A Near-IR Fluorescent Dasatinib Derivative That Localizes in Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2019,</strong> <em>30 </em>
                                    (4)
                                     , 1175-1181. <a href="https://doi.org/10.1021/acs.bioconjchem.9b00118" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.9b00118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.9b00118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.9b00118%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DA%252BNear-IR%252BFluorescent%252BDasatinib%252BDerivative%252BThat%252BLocalizes%252Bin%252BCancer%252BCells%26aulast%3DUsama%26aufirst%3DSyed%2BMuhammad%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D12022019%26date%3D19032019%26date%3D01042019%26volume%3D30%26issue%3D4%26spage%3D1175%26epage%3D1181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Conrad Stork, Ya Chen, Martin Šícho, <span class="NLM_string-name hlFld-ContribAuthor">Johannes Kirchmair</span>. </span><span class="cited-content_cbyCitation_article-title">Hit Dexter 2.0: Machine-Learning Models for the Prediction of Frequent Hitters. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (3)
                                     , 1030-1043. <a href="https://doi.org/10.1021/acs.jcim.8b00677" title="DOI URL">https://doi.org/10.1021/acs.jcim.8b00677</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.8b00677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.8b00677%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DHit%252BDexter%252B2.0%25253A%252BMachine-Learning%252BModels%252Bfor%252Bthe%252BPrediction%252Bof%252BFrequent%252BHitters%26aulast%3DStork%26aufirst%3DConrad%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D01102018%26date%3D25012019%26date%3D09012019%26volume%3D59%26issue%3D3%26spage%3D1030%26epage%3D1043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Maria Laura Bolognesi</span>. </span><span class="cited-content_cbyCitation_article-title">Harnessing Polypharmacology with Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (3)
                                     , 273-275. <a href="https://doi.org/10.1021/acsmedchemlett.9b00039" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00039%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DHarnessing%252BPolypharmacology%252Bwith%252BMedicinal%252BChemistry%26aulast%3DBolognesi%26aufirst%3DMaria%2BLaura%26date%3D2019%26date%3D2019%26date%3D15022019%26volume%3D10%26issue%3D3%26spage%3D273%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Erik Gilberg, <span class="NLM_string-name hlFld-ContribAuthor">Jürgen Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Progress in Structure-Based Evaluation of Compound Promiscuity. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (2)
                                     , 2758-2765. <a href="https://doi.org/10.1021/acsomega.8b03639" title="DOI URL">https://doi.org/10.1021/acsomega.8b03639</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b03639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b03639%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DRecent%252BProgress%252Bin%252BStructure-Based%252BEvaluation%252Bof%252BCompound%252BPromiscuity%26aulast%3DGilberg%26aufirst%3DErik%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D27122018%26date%3D29012019%26volume%3D4%26issue%3D2%26spage%3D2758%26epage%3D2765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Erik Gilberg, Michael Gütschow, <span class="NLM_string-name hlFld-ContribAuthor">Jürgen Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Promiscuous Ligands from Experimentally Determined Structures, Binding Conformations, and Protein Family-Dependent Interaction Hotspots. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (1)
                                     , 1729-1737. <a href="https://doi.org/10.1021/acsomega.8b03481" title="DOI URL">https://doi.org/10.1021/acsomega.8b03481</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b03481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b03481%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DPromiscuous%252BLigands%252Bfrom%252BExperimentally%252BDetermined%252BStructures%25252C%252BBinding%252BConformations%25252C%252Band%252BProtein%252BFamily-Dependent%252BInteraction%252BHotspots%26aulast%3DGilberg%26aufirst%3DErik%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D12122018%26date%3D10012019%26volume%3D4%26issue%3D1%26spage%3D1729%26epage%3D1737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ewgenij Proschak, Holger Stark, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Merk</span>. </span><span class="cited-content_cbyCitation_article-title">Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (2)
                                     , 420-444. <a href="https://doi.org/10.1021/acs.jmedchem.8b00760" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00760</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPolypharmacology%252Bby%252BDesign%25253A%252BA%252BMedicinal%252BChemist%2525E2%252580%252599s%252BPerspective%252Bon%252BMultitargeting%252BCompounds%26aulast%3DProschak%26aufirst%3DEwgenij%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D11052018%26date%3D03082018%26date%3D23072018%26volume%3D62%26issue%3D2%26spage%3D420%26epage%3D444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sonali
S. Bharate, Serge Mignani, <span class="NLM_string-name hlFld-ContribAuthor">Ram A. Vishwakarma</span>. </span><span class="cited-content_cbyCitation_article-title">Why Are the Majority of Active Compounds in the CNS Domain Natural Products? A Critical Analysis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (23)
                                     , 10345-10374. <a href="https://doi.org/10.1021/acs.jmedchem.7b01922" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01922</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01922%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhy%252BAre%252Bthe%252BMajority%252Bof%252BActive%252BCompounds%252Bin%252Bthe%252BCNS%252BDomain%252BNatural%252BProducts%25253F%252BA%252BCritical%252BAnalysis%26aulast%3DBharate%26aufirst%3DSonali%2BS.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D30122017%26date%3D20072018%26date%3D10072018%26volume%3D61%26issue%3D23%26spage%3D10345%26epage%3D10374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joshua Meyers, Nicola E. A. Chessum, Salyha Ali, N. Yi Mok, Birgit Wilding, A. Elisa Pasqua, Martin Rowlands, Michael J. Tucker, Lindsay E. Evans, Carl S. Rye, Lisa O’Fee, Yann-Vaï Le Bihan, Rosemary Burke, Michael Carter, Paul Workman, Julian Blagg, Nathan Brown, Rob L. M. van Montfort, Keith Jones, <span class="NLM_string-name hlFld-ContribAuthor">Matthew D. Cheeseman</span>. </span><span class="cited-content_cbyCitation_article-title">Privileged Structures and Polypharmacology within and between Protein Families. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (12)
                                     , 1199-1204. <a href="https://doi.org/10.1021/acsmedchemlett.8b00364" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00364</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00364%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPrivileged%252BStructures%252Band%252BPolypharmacology%252Bwithin%252Band%252Bbetween%252BProtein%252BFamilies%26aulast%3DMeyers%26aufirst%3DJoshua%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09082018%26date%3D16112018%26date%3D26112018%26date%3D16112018%26volume%3D9%26issue%3D12%26spage%3D1199%26epage%3D1204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sanil Bhatia, Viktoria Krieger, Michael Groll, Jeremy D. Osko, Nina Reßing, Heinz Ahlert, Arndt Borkhardt, Thomas Kurz, David W. Christianson, Julia Hauer, <span class="NLM_string-name hlFld-ContribAuthor">Finn K. Hansen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of the First-in-Class Dual Histone Deacetylase–Proteasome Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (22)
                                     , 10299-10309. <a href="https://doi.org/10.1021/acs.jmedchem.8b01487" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01487</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01487%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthe%252BFirst-in-Class%252BDual%252BHistone%252BDeacetylase%2525E2%252580%252593Proteasome%252BInhibitor%26aulast%3DBhatia%26aufirst%3DSanil%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D24092018%26date%3D08112018%26date%3D26102018%26volume%3D61%26issue%3D22%26spage%3D10299%26epage%3D10309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Matthew
K. Matlock, Tyler B. Hughes, Jayme L. Dahlin, <span class="NLM_string-name hlFld-ContribAuthor">S. Joshua Swamidass</span>. </span><span class="cited-content_cbyCitation_article-title">Modeling Small-Molecule Reactivity Identifies Promiscuous Bioactive Compounds. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2018,</strong> <em>58 </em>
                                    (8)
                                     , 1483-1500. <a href="https://doi.org/10.1021/acs.jcim.8b00104" title="DOI URL">https://doi.org/10.1021/acs.jcim.8b00104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.8b00104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.8b00104%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DModeling%252BSmall-Molecule%252BReactivity%252BIdentifies%252BPromiscuous%252BBioactive%252BCompounds%26aulast%3DMatlock%26aufirst%3DMatthew%2BK.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D21022018%26date%3D23072018%26date%3D10072018%26volume%3D58%26issue%3D8%26spage%3D1483%26epage%3D1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shipeng He, Guoqiang Dong, Shanchao Wu, Kun Fang, Zhenyuan Miao, Wei Wang, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (16)
                                     , 7245-7260. <a href="https://doi.org/10.1021/acs.jmedchem.8b00664" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00664</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00664%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecules%252BSimultaneously%252BInhibiting%252Bp53-Murine%252BDouble%252BMinute%252B2%252B%252528MDM2%252529%252BInteraction%252Band%252BHistone%252BDeacetylases%252B%252528HDACs%252529%25253A%252BDiscovery%252Bof%252BNovel%252BMultitargeting%252BAntitumor%252BAgents%26aulast%3DHe%26aufirst%3DShipeng%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D26042018%26date%3D09082018%26date%3D25072018%26volume%3D61%26issue%3D16%26spage%3D7245%26epage%3D7260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Koilpitchai Sivamuthuraman, <span class="NLM_string-name hlFld-ContribAuthor">Venkitasamy Kesavan</span>. </span><span class="cited-content_cbyCitation_article-title">Stereodivergent Synthesis of 3-Aminooxindole Derivatives Containing Vicinal Tetrasubstituted Stereocenters via the Mannich Reaction. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (16)
                                     , 8936-8952. <a href="https://doi.org/10.1021/acs.joc.8b01020" title="DOI URL">https://doi.org/10.1021/acs.joc.8b01020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b01020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b01020%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DStereodivergent%252BSynthesis%252Bof%252B3-Aminooxindole%252BDerivatives%252BContaining%252BVicinal%252BTetrasubstituted%252BStereocenters%252Bvia%252Bthe%252BMannich%252BReaction%26aulast%3DSivamuthuraman%26aufirst%3DKoilpitchai%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D05052018%26date%3D23072018%26date%3D02072018%26volume%3D83%26issue%3D16%26spage%3D8936%26epage%3D8952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Diana Lamaa, Hsin-Ping Lin, Lena Zig, Cyril Bauvais, Guillaume Bollot, Jérôme Bignon, Helene Levaique, Olivier Pamlard, Joelle Dubois, Mehdi Ouaissi, Martin Souce, Athena Kasselouri, François Saller, Delphine Borgel, Chantal Jayat-Vignoles, Hazar Al-Mouhammad, Jean Feuillard, Karim Benihoud, Mouad Alami, <span class="NLM_string-name hlFld-ContribAuthor">Abdallah Hamze</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6574-6591. <a href="https://doi.org/10.1021/acs.jmedchem.8b00050" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00050%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BTubulin%252Band%252BHistone%252BDeacetylase%252BInhibitor%252BBased%252Bon%252Biso-Combretastatin%252BA-4%26aulast%3DLamaa%26aufirst%3DDiana%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D12012018%26date%3D26072018%26date%3D13072018%26volume%3D61%26issue%3D15%26spage%3D6574%26epage%3D6591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dahlia
R. Weiss, Joel Karpiak, Xi-Ping Huang, Maria F. Sassano, Jiankun Lyu, Bryan L. Roth, <span class="NLM_string-name hlFld-ContribAuthor">Brian K. Shoichet</span>. </span><span class="cited-content_cbyCitation_article-title">Selectivity Challenges in Docking Screens for GPCR Targets and Antitargets. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6830-6845. <a href="https://doi.org/10.1021/acs.jmedchem.8b00718" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00718</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00718%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSelectivity%252BChallenges%252Bin%252BDocking%252BScreens%252Bfor%252BGPCR%252BTargets%252Band%252BAntitargets%26aulast%3DWeiss%26aufirst%3DDahlia%2BR.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D04052018%26date%3D24072018%26date%3D10072018%26volume%3D61%26issue%3D15%26spage%3D6830%26epage%3D6845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yang Sun, David K. Heidary, Zhihui Zhang, Christopher I. Richards, <span class="NLM_string-name hlFld-ContribAuthor">Edith C. Glazer</span>. </span><span class="cited-content_cbyCitation_article-title">Bacterial Cytological Profiling Reveals the Mechanism of Action of Anticancer Metal Complexes. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2018,</strong> <em>15 </em>
                                    (8)
                                     , 3404-3416. <a href="https://doi.org/10.1021/acs.molpharmaceut.8b00407" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.8b00407</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.8b00407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.8b00407%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DBacterial%252BCytological%252BProfiling%252BReveals%252Bthe%252BMechanism%252Bof%252BAction%252Bof%252BAnticancer%252BMetal%252BComplexes%26aulast%3DSun%26aufirst%3DYang%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D18042018%26date%3D04062018%26date%3D29052018%26date%3D30062018%26date%3D04062018%26volume%3D15%26issue%3D8%26spage%3D3404%26epage%3D3416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yahui Huang, Guoqiang Dong, Huanqiu Li, Na Liu, Wannian Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (14)
                                     , 6056-6074. <a href="https://doi.org/10.1021/acs.jmedchem.8b00393" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00393</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00393%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BJanus%252BKinase%252B2%252B%252528JAK2%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BDual%252BInhibitors%252Bas%252Ba%252BNovel%252BStrategy%252Bfor%252Bthe%252BCombinational%252BTreatment%252Bof%252BLeukemia%252Band%252BInvasive%252BFungal%252BInfections%26aulast%3DHuang%26aufirst%3DYahui%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D10032018%26date%3D14072018%26date%3D25062018%26volume%3D61%26issue%3D14%26spage%3D6056%26epage%3D6074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mariama Jaiteh, Alexey Zeifman, Marcus Saarinen, Per Svenningsson, Jose Bréa, Maria Isabel Loza, <span class="NLM_string-name hlFld-ContribAuthor">Jens Carlsson</span>. </span><span class="cited-content_cbyCitation_article-title">Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinson’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (12)
                                     , 5269-5278. <a href="https://doi.org/10.1021/acs.jmedchem.8b00204" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00204</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00204%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDocking%252BScreens%252Bfor%252BDual%252BInhibitors%252Bof%252BDisparate%252BDrug%252BTargets%252Bfor%252BParkinson%2525E2%252580%252599s%252BDisease%26aulast%3DJaiteh%26aufirst%3DMariama%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D06022018%26date%3D15062018%26date%3D24052018%26volume%3D61%26issue%3D12%26spage%3D5269%26epage%3D5278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jie Zang, Xuewu Liang, Yongxue Huang, Yuping Jia, Xiaoyang Li, Wenfang Xu, C. James Chou, <span class="NLM_string-name hlFld-ContribAuthor">Yingjie Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (12)
                                     , 5304-5322. <a href="https://doi.org/10.1021/acs.jmedchem.8b00384" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00384</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00384%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BPazopanib-Based%252BHDAC%252Band%252BVEGFR%252BDual%252BInhibitors%252BTargeting%252BCancer%252BEpigenetics%252Band%252BAngiogenesis%252BSimultaneously%26aulast%3DZang%26aufirst%3DJie%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09032018%26date%3D07062018%26date%3D22052018%26volume%3D61%26issue%3D12%26spage%3D5304%26epage%3D5322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Cecilia Lindgren, Mohit Tyagi, Johan Viljanen, Johannes Toms, Changrong Ge, Naru Zhang, Rikard Holmdahl, Jan Kihlberg, <span class="NLM_string-name hlFld-ContribAuthor">Anna Linusson</span>. </span><span class="cited-content_cbyCitation_article-title">Dynamics Determine Signaling in a Multicomponent System Associated with Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (11)
                                     , 4774-4790. <a href="https://doi.org/10.1021/acs.jmedchem.7b01880" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01880</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01880%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDynamics%252BDetermine%252BSignaling%252Bin%252Ba%252BMulticomponent%252BSystem%252BAssociated%252Bwith%252BRheumatoid%252BArthritis%26aulast%3DLindgren%26aufirst%3DCecilia%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D02012018%26date%3D24052018%26date%3D04052018%26volume%3D61%26issue%3D11%26spage%3D4774%26epage%3D4790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kun Fang, Guoqiang Dong, Yu Li, Shipeng He, Ying Wu, Shanchao Wu, Wei Wang, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (4)
                                     , 312-317. <a href="https://doi.org/10.1021/acsmedchemlett.7b00487" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00487</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00487%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BNovel%252BIndoleamine%252B2%25252C3-Dioxygenase%252B1%252B%252528IDO1%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BDual%252BInhibitors%26aulast%3DFang%26aufirst%3DKun%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D26112017%26date%3D26032018%26date%3D02042018%26date%3D26032018%26volume%3D9%26issue%3D4%26spage%3D312%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Erik  Gilberg</span>, <span class="hlFld-ContribAuthor ">Dagmar  Stumpfe</span>, and <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>  . </span><span class="cited-content_cbyCitation_article-title">X-ray-Structure-Based Identification of Compounds with Activity against Targets from Different Families and Generation of Templates for Multitarget Ligand Design. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2018,</strong> <em>3 </em>
                                    (1)
                                     , 106-111. <a href="https://doi.org/10.1021/acsomega.7b01849" title="DOI URL">https://doi.org/10.1021/acsomega.7b01849</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.7b01849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.7b01849%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DX-ray-Structure-Based%252BIdentification%252Bof%252BCompounds%252Bwith%252BActivity%252Bagainst%252BTargets%252Bfrom%252BDifferent%252BFamilies%252Band%252BGeneration%252Bof%252BTemplates%252Bfor%252BMultitarget%252BLigand%252BDesign%26aulast%3DGilberg%26aufirst%3DErik%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D24112017%26date%3D18122017%26date%3D31012018%26volume%3D3%26issue%3D1%26spage%3D106%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Devawati  Dutta</span>, <span class="hlFld-ContribAuthor ">Ranjita  Das</span>, <span class="hlFld-ContribAuthor ">Chhabinath  Mandal</span>, and <span class="hlFld-ContribAuthor ">Chitra  Mandal</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Based Kinase Profiling To Understand the Polypharmacological Behavior of Therapeutic Molecules. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2018,</strong> <em>58 </em>
                                    (1)
                                     , 68-89. <a href="https://doi.org/10.1021/acs.jcim.7b00227" title="DOI URL">https://doi.org/10.1021/acs.jcim.7b00227</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.7b00227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.7b00227%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DStructure-Based%252BKinase%252BProfiling%252BTo%252BUnderstand%252Bthe%252BPolypharmacological%252BBehavior%252Bof%252BTherapeutic%252BMolecules%26aulast%3DDutta%26aufirst%3DDevawati%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D24042017%26date%3D15122017%26date%3D22012018%26volume%3D58%26issue%3D1%26spage%3D68%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Chen</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Dong</span>, <span class="hlFld-ContribAuthor ">Ying  Wu</span>, <span class="hlFld-ContribAuthor ">Wannian  Zhang</span>, <span class="hlFld-ContribAuthor ">Chaoyu  Miao</span>, and <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>  . </span><span class="cited-content_cbyCitation_article-title">Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (1)
                                     , 34-38. <a href="https://doi.org/10.1021/acsmedchemlett.7b00414" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00414</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00414%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDual%252BNAMPT%25252FHDAC%252BInhibitors%252Bas%252Ba%252BNew%252BStrategy%252Bfor%252BMultitargeting%252BAntitumor%252BDrug%252BDiscovery%26aulast%3DChen%26aufirst%3DWei%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D10102017%26date%3D14122017%26date%3D19122017%26date%3D11012018%26date%3D14122017%26volume%3D9%26issue%3D1%26spage%3D34%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lianbin  Yao</span>, <span class="hlFld-ContribAuthor ">Nurulhuda  Mustafa</span>, <span class="hlFld-ContribAuthor ">Eng Chong  Tan</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Prachi  Singh</span>, <span class="hlFld-ContribAuthor ">Minh-Dao  Duong-Thi</span>, <span class="hlFld-ContribAuthor ">Jeannie X. T.  Lee</span>, <span class="hlFld-ContribAuthor ">Pondy Murugappan  Ramanujulu</span>, <span class="hlFld-ContribAuthor ">Wee Joo  Chng</span>, <span class="hlFld-ContribAuthor ">Jeffrey J. Y.  Yen</span>, <span class="hlFld-ContribAuthor ">Sten  Ohlson</span>, and <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (20)
                                     , 8336-8357. <a href="https://doi.org/10.1021/acs.jmedchem.7b00678" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00678</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BLigand%252BEfficient%252BDual%252BInhibitors%252Bof%252BJanus%252BKinase%252B%252528JAK%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BBased%252Bon%252BRuxolitinib%252Band%252BVorinostat%26aulast%3DYao%26aufirst%3DLianbin%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D11052017%26date%3D10102017%26date%3D26102017%26date%3D27092017%26volume%3D60%26issue%3D20%26spage%3D8336%26epage%3D8357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guoqiang  Dong</span>, <span class="hlFld-ContribAuthor ">Wei  Chen</span>, <span class="hlFld-ContribAuthor ">Xia  Wang</span>, <span class="hlFld-ContribAuthor ">Xinglin  Yang</span>, <span class="hlFld-ContribAuthor ">Tianying  Xu</span>, <span class="hlFld-ContribAuthor ">Pei  Wang</span>, <span class="hlFld-ContribAuthor ">Wannian  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  Rao</span>, <span class="hlFld-ContribAuthor ">Chaoyu  Miao</span>, and <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>  . </span><span class="cited-content_cbyCitation_article-title">Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (19)
                                     , 7965-7983. <a href="https://doi.org/10.1021/acs.jmedchem.7b00467" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00467</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00467%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BInhibitors%252BSimultaneously%252BTargeting%252BCancer%252BMetabolism%252Band%252BEpigenetics%25253A%252BDiscovery%252Bof%252BNovel%252BNicotinamide%252BPhosphoribosyltransferase%252B%252528NAMPT%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BDual%252BInhibitors%26aulast%3DDong%26aufirst%3DGuoqiang%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D27032017%26date%3D21092017%26date%3D12102017%26date%3D08092017%26volume%3D60%26issue%3D19%26spage%3D7965%26epage%3D7983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Floriana  Morgillo</span>, <span class="hlFld-ContribAuthor ">Giorgio  Amendola</span>, <span class="hlFld-ContribAuthor ">Carminia Maria  Della Corte</span>, <span class="hlFld-ContribAuthor ">Chiara  Giacomelli</span>, <span class="hlFld-ContribAuthor ">Lorenzo  Botta</span>, <span class="hlFld-ContribAuthor ">Salvatore  Di Maro</span>, <span class="hlFld-ContribAuthor ">Anna  Messere</span>, <span class="hlFld-ContribAuthor ">Vincenza  Ciaramella</span>, <span class="hlFld-ContribAuthor ">Sabrina  Taliani</span>, <span class="hlFld-ContribAuthor ">Luciana  Marinelli</span>, <span class="hlFld-ContribAuthor ">Maria Letizia  Trincavelli</span>, <span class="hlFld-ContribAuthor ">Claudia  Martini</span>, <span class="hlFld-ContribAuthor ">Ettore  Novellino</span>, <span class="hlFld-ContribAuthor ">Fortunato  Ciardiello</span>, and <span class="hlFld-ContribAuthor ">Sandro  Cosconati</span>  . </span><span class="cited-content_cbyCitation_article-title">Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (17)
                                     , 7447-7458. <a href="https://doi.org/10.1021/acs.jmedchem.7b00794" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00794</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00794%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252BMET%252Band%252BSMO%252BNegative%252BModulators%252BOvercome%252BResistance%252Bto%252BEGFR%252BInhibitors%252Bin%252BHuman%252BNonsmall%252BCell%252BLung%252BCancer%26aulast%3DMorgillo%26aufirst%3DFloriana%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D31052017%26date%3D22082017%26date%3D14092017%26date%3D08082017%26volume%3D60%26issue%3D17%26spage%3D7447%26epage%3D7458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinha  Yu</span>, <span class="hlFld-ContribAuthor ">Seyeon  Ahn</span>, <span class="hlFld-ContribAuthor ">Hee Jin  Kim</span>, <span class="hlFld-ContribAuthor ">Moonyoung  Lee</span>, <span class="hlFld-ContribAuthor ">Sungjin  Ahn</span>, <span class="hlFld-ContribAuthor ">Jungmin  Kim</span>, <span class="hlFld-ContribAuthor ">Sun Hee  Jin</span>, <span class="hlFld-ContribAuthor ">Eunyoung  Lee</span>, <span class="hlFld-ContribAuthor ">Gyudong  Kim</span>, <span class="hlFld-ContribAuthor ">Jae Hoon  Cheong</span>, <span class="hlFld-ContribAuthor ">Kenneth A.  Jacobson</span>, <span class="hlFld-ContribAuthor ">Lak Shin  Jeong</span>, and <span class="hlFld-ContribAuthor ">Minsoo  Noh</span>  . </span><span class="cited-content_cbyCitation_article-title">Polypharmacology of N6-(3-Iodobenzyl)adenosine-5′-N-methyluronamide (IB-MECA) and Related A3 Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) γ Partial Agonist and PPARδ Antagonist Activity Suggests Their Antidiabetic Potential. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (17)
                                     , 7459-7475. <a href="https://doi.org/10.1021/acs.jmedchem.7b00805" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00805</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00805%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPolypharmacology%252Bof%252BN6-%2525283-Iodobenzyl%252529adenosine-5%2525E2%252580%2525B2-N-methyluronamide%252B%252528IB-MECA%252529%252Band%252BRelated%252BA3%252BAdenosine%252BReceptor%252BLigands%25253A%252BPeroxisome%252BProliferator%252BActivated%252BReceptor%252B%252528PPAR%252529%252B%2525CE%2525B3%252BPartial%252BAgonist%252Band%252BPPAR%2525CE%2525B4%252BAntagonist%252BActivity%252BSuggests%252BTheir%252BAntidiabetic%252BPotential%26aulast%3DYu%26aufirst%3DJinha%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D09062017%26date%3D28082017%26date%3D14092017%26date%3D11082017%26volume%3D60%26issue%3D17%26spage%3D7459%26epage%3D7475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adam  Bucki</span>, <span class="hlFld-ContribAuthor ">Monika  Marcinkowska</span>, <span class="hlFld-ContribAuthor ">Joanna  Śniecikowska</span>, <span class="hlFld-ContribAuthor ">Krzysztof  Więckowski</span>, <span class="hlFld-ContribAuthor ">Maciej  Pawłowski</span>, <span class="hlFld-ContribAuthor ">Monika  Głuch-Lutwin</span>, <span class="hlFld-ContribAuthor ">Anna  Gryboś</span>, <span class="hlFld-ContribAuthor ">Agata  Siwek</span>, <span class="hlFld-ContribAuthor ">Karolina  Pytka</span>, <span class="hlFld-ContribAuthor ">Magdalena  Jastrzębska-Więsek</span>, <span class="hlFld-ContribAuthor ">Anna  Partyka</span>, <span class="hlFld-ContribAuthor ">Anna  Wesołowska</span>, <span class="hlFld-ContribAuthor ">Paweł  Mierzejewski</span>, and <span class="hlFld-ContribAuthor ">Marcin  Kołaczkowski</span>  . </span><span class="cited-content_cbyCitation_article-title">Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (17)
                                     , 7483-7501. <a href="https://doi.org/10.1021/acs.jmedchem.7b00839" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00839</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00839%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252B3-%2525281%25252C2%25252C3%25252C6-Tetrahydropyridin-4-yl%252529-1H-indole-Based%252BMultifunctional%252BLigands%252Bwith%252BAntipsychotic-Like%25252C%252BMood-Modulating%25252C%252Band%252BProcognitive%252BActivity%26aulast%3DBucki%26aufirst%3DAdam%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D12062017%26date%3D18082017%26date%3D14092017%26date%3D01082017%26volume%3D60%26issue%3D17%26spage%3D7483%26epage%3D7501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anne-Sophie  Cornec</span>, <span class="hlFld-ContribAuthor ">Ludovica  Monti</span>, <span class="hlFld-ContribAuthor ">Jane  Kovalevich</span>, <span class="hlFld-ContribAuthor ">Vishruti  Makani</span>, <span class="hlFld-ContribAuthor ">Michael J.  James</span>, <span class="hlFld-ContribAuthor ">Krishna G.  Vijayendran</span>, <span class="hlFld-ContribAuthor ">Killian  Oukoloff</span>, <span class="hlFld-ContribAuthor ">Yuemang  Yao</span>, <span class="hlFld-ContribAuthor ">Virginia M.-Y.  Lee</span>, <span class="hlFld-ContribAuthor ">John Q.  Trojanowski</span>, <span class="hlFld-ContribAuthor ">Amos B.  Smith, III</span>, <span class="hlFld-ContribAuthor ">Kurt R.  Brunden</span>, and <span class="hlFld-ContribAuthor ">Carlo  Ballatore</span>  . </span><span class="cited-content_cbyCitation_article-title">Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer’s and Other Neurodegenerative Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (12)
                                     , 5120-5145. <a href="https://doi.org/10.1021/acs.jmedchem.7b00475" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00475</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00475%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMultitargeted%252BImidazoles%25253A%252BPotential%252BTherapeutic%252BLeads%252Bfor%252BAlzheimer%2525E2%252580%252599s%252Band%252BOther%252BNeurodegenerative%252BDiseases%26aulast%3DCornec%26aufirst%3DAnne-Sophie%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D27032017%26date%3D08062017%26date%3D22062017%26date%3D22052017%26volume%3D60%26issue%3D12%26spage%3D5120%26epage%3D5145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Georgios  Drakakis</span>, <span class="hlFld-ContribAuthor ">Keith A.  Wafford</span>, <span class="hlFld-ContribAuthor ">Suzanne C.  Brewerton</span>, <span class="hlFld-ContribAuthor ">Michael J.  Bodkin</span>, <span class="hlFld-ContribAuthor ">David A.  Evans</span>, and <span class="hlFld-ContribAuthor ">Andreas  Bender</span>  . </span><span class="cited-content_cbyCitation_article-title">Polypharmacological in Silico Bioactivity Profiling and Experimental Validation Uncovers Sedative-Hypnotic Effects of Approved and Experimental Drugs in Rat. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2017,</strong> <em>12 </em>
                                    (6)
                                     , 1593-1602. <a href="https://doi.org/10.1021/acschembio.7b00209" title="DOI URL">https://doi.org/10.1021/acschembio.7b00209</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.7b00209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.7b00209%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DPolypharmacological%252Bin%252BSilico%252BBioactivity%252BProfiling%252Band%252BExperimental%252BValidation%252BUncovers%252BSedative-Hypnotic%252BEffects%252Bof%252BApproved%252Band%252BExperimental%252BDrugs%252Bin%252BRat%26aulast%3DDrakakis%26aufirst%3DGeorgios%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D08032017%26date%3D17042017%26date%3D01052017%26date%3D16062017%26date%3D17042017%26volume%3D12%26issue%3D6%26spage%3D1593%26epage%3D1602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David  Schaller</span>, <span class="hlFld-ContribAuthor ">Stefanie  Hagenow</span>, <span class="hlFld-ContribAuthor ">Gina  Alpert</span>, <span class="hlFld-ContribAuthor ">Alexandra  Naß</span>, <span class="hlFld-ContribAuthor ">Robert  Schulz</span>, <span class="hlFld-ContribAuthor ">Marcel  Bermudez</span>, <span class="hlFld-ContribAuthor ">Holger  Stark</span>, and <span class="hlFld-ContribAuthor ">Gerhard  Wolber</span>  . </span><span class="cited-content_cbyCitation_article-title">Systematic Data Mining Reveals Synergistic H3R/MCHR1 Ligands. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (6)
                                     , 648-653. <a href="https://doi.org/10.1021/acsmedchemlett.7b00118" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00118%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSystematic%252BData%252BMining%252BReveals%252BSynergistic%252BH3R%25252FMCHR1%252BLigands%26aulast%3DSchaller%26aufirst%3DDavid%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D18032017%26date%3D04052017%26date%3D08052017%26date%3D08062017%26date%3D04052017%26volume%3D8%26issue%3D6%26spage%3D648%26epage%3D653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Riccardo  Petrelli</span>, <span class="hlFld-ContribAuthor ">Mirko  Scortichini</span>, <span class="hlFld-ContribAuthor ">Sonja  Kachler</span>, <span class="hlFld-ContribAuthor ">Serena  Boccella</span>, <span class="hlFld-ContribAuthor ">Carmen  Cerchia</span>, <span class="hlFld-ContribAuthor ">Ilaria  Torquati</span>, <span class="hlFld-ContribAuthor ">Fabio  Del Bello</span>, <span class="hlFld-ContribAuthor ">Daniela  Salvemini</span>, <span class="hlFld-ContribAuthor ">Ettore  Novellino</span>, <span class="hlFld-ContribAuthor ">Livio  Luongo</span>, <span class="hlFld-ContribAuthor ">Sabatino  Maione</span>, <span class="hlFld-ContribAuthor ">Kenneth A.  Jacobson</span>, <span class="hlFld-ContribAuthor ">Antonio  Lavecchia</span>, <span class="hlFld-ContribAuthor ">Karl-Norbert  Klotz</span>, and <span class="hlFld-ContribAuthor ">Loredana  Cappellacci</span>  . </span><span class="cited-content_cbyCitation_article-title">Exploring the Role of N6-Substituents in Potent Dual Acting 5′-C-Ethyltetrazolyladenosine Derivatives: Synthesis, Binding, Functional Assays, and Antinociceptive Effects in Mice. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (10)
                                     , 4327-4341. <a href="https://doi.org/10.1021/acs.jmedchem.7b00291" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00291</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00291%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExploring%252Bthe%252BRole%252Bof%252BN6-Substituents%252Bin%252BPotent%252BDual%252BActing%252B5%2525E2%252580%2525B2-C-Ethyltetrazolyladenosine%252BDerivatives%25253A%252BSynthesis%25252C%252BBinding%25252C%252BFunctional%252BAssays%25252C%252Band%252BAntinociceptive%252BEffects%252Bin%252BMice%26aulast%3DPetrelli%26aufirst%3DRiccardo%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D22022017%26date%3D05052017%26date%3D25052017%26date%3D27042017%26volume%3D60%26issue%3D10%26spage%3D4327%26epage%3D4341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Erica  Salvati</span>, <span class="hlFld-ContribAuthor ">Lorenzo  Botta</span>, <span class="hlFld-ContribAuthor ">Jussara  Amato</span>, <span class="hlFld-ContribAuthor ">Francesco Saverio  Di Leva</span>, <span class="hlFld-ContribAuthor ">Pasquale  Zizza</span>, <span class="hlFld-ContribAuthor ">Antimo  Gioiello</span>, <span class="hlFld-ContribAuthor ">Bruno  Pagano</span>, <span class="hlFld-ContribAuthor ">Grazia  Graziani</span>, <span class="hlFld-ContribAuthor ">Madalena  Tarsounas</span>, <span class="hlFld-ContribAuthor ">Antonio  Randazzo</span>, <span class="hlFld-ContribAuthor ">Ettore  Novellino</span>, <span class="hlFld-ContribAuthor ">Annamaria  Biroccio</span>, and <span class="hlFld-ContribAuthor ">Sandro  Cosconati</span>  . </span><span class="cited-content_cbyCitation_article-title">Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (9)
                                     , 3626-3635. <a href="https://doi.org/10.1021/acs.jmedchem.6b01563" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01563</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01563%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLead%252BDiscovery%252Bof%252BDual%252BG-Quadruplex%252BStabilizers%252Band%252BPoly%252528ADP-ribose%252529%252BPolymerases%252B%252528PARPs%252529%252BInhibitors%25253A%252BA%252BNew%252BAvenue%252Bin%252BAnticancer%252BTreatment%26aulast%3DSalvati%26aufirst%3DErica%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D21102016%26date%3D01052017%26date%3D11052017%26date%3D26042017%26volume%3D60%26issue%3D9%26spage%3D3626%26epage%3D3635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon  Krautwald</span> and <span class="hlFld-ContribAuthor ">Erick M.  Carreira</span>  . </span><span class="cited-content_cbyCitation_article-title">Stereodivergence in Asymmetric Catalysis. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2017,</strong> <em>139 </em>
                                    (16)
                                     , 5627-5639. <a href="https://doi.org/10.1021/jacs.6b13340" title="DOI URL">https://doi.org/10.1021/jacs.6b13340</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.6b13340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.6b13340%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DStereodivergence%252Bin%252BAsymmetric%252BCatalysis%26aulast%3DKrautwald%26aufirst%3DSimon%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D29122016%26date%3D12042017%26date%3D26042017%26date%3D06042017%26volume%3D139%26issue%3D16%26spage%3D5627%26epage%3D5639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Inès  Rasolohery</span>, <span class="hlFld-ContribAuthor ">Gautier  Moroy</span>, and <span class="hlFld-ContribAuthor ">Frédéric  Guyon</span>  . </span><span class="cited-content_cbyCitation_article-title">PatchSearch: A Fast Computational Method for Off-Target Detection. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (4)
                                     , 769-777. <a href="https://doi.org/10.1021/acs.jcim.6b00529" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00529</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00529%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DPatchSearch%25253A%252BA%252BFast%252BComputational%252BMethod%252Bfor%252BOff-Target%252BDetection%26aulast%3DRasolohery%26aufirst%3DIn%25C3%25A8s%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D05092016%26date%3D24032017%26date%3D24042017%26date%3D10032017%26volume%3D57%26issue%3D4%26spage%3D769%26epage%3D777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weilin  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianfeng  Pei</span>, and <span class="hlFld-ContribAuthor ">Luhua  Lai</span>  . </span><span class="cited-content_cbyCitation_article-title">Computational Multitarget Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (3)
                                     , 403-412. <a href="https://doi.org/10.1021/acs.jcim.6b00491" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00491%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DComputational%252BMultitarget%252BDrug%252BDesign%26aulast%3DZhang%26aufirst%3DWeilin%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D19082016%26date%3D23022017%26date%3D27032017%26date%3D06022017%26volume%3D57%26issue%3D3%26spage%3D403%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sabrina  Tassini</span>, <span class="hlFld-ContribAuthor ">Liang  Sun</span>, <span class="hlFld-ContribAuthor ">Kristina  Lanko</span>, <span class="hlFld-ContribAuthor ">Emmanuele  Crespan</span>, <span class="hlFld-ContribAuthor ">Emily  Langron</span>, <span class="hlFld-ContribAuthor ">Federico  Falchi</span>, <span class="hlFld-ContribAuthor ">Miroslava  Kissova</span>, <span class="hlFld-ContribAuthor ">Jorge I.  Armijos-Rivera</span>, <span class="hlFld-ContribAuthor ">Leen  Delang</span>, <span class="hlFld-ContribAuthor ">Carmen  Mirabelli</span>, <span class="hlFld-ContribAuthor ">Johan  Neyts</span>, <span class="hlFld-ContribAuthor ">Marco  Pieroni</span>, <span class="hlFld-ContribAuthor ">Andrea  Cavalli</span>, <span class="hlFld-ContribAuthor ">Gabriele  Costantino</span>, <span class="hlFld-ContribAuthor ">Giovanni  Maga</span>, <span class="hlFld-ContribAuthor ">Paola  Vergani</span>, <span class="hlFld-ContribAuthor ">Pieter  Leyssen</span>, and <span class="hlFld-ContribAuthor ">Marco  Radi</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (4)
                                     , 1400-1416. <a href="https://doi.org/10.1021/acs.jmedchem.6b01521" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01521</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01521%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BMultitarget%252BAgents%252BActive%252Bas%252BBroad-Spectrum%252BAntivirals%252Band%252BCorrectors%252Bof%252BCystic%252BFibrosis%252BTransmembrane%252BConductance%252BRegulator%252Bfor%252BAssociated%252BPulmonary%252BDiseases%26aulast%3DTassini%26aufirst%3DSabrina%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D18102016%26date%3D10022017%26date%3D23022017%26date%3D25012017%26volume%3D60%26issue%3D4%26spage%3D1400%26epage%3D1416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew D.  Cheeseman</span>, <span class="hlFld-ContribAuthor ">Nicola E. A.  Chessum</span>, <span class="hlFld-ContribAuthor ">Carl S.  Rye</span>, <span class="hlFld-ContribAuthor ">A. Elisa  Pasqua</span>, <span class="hlFld-ContribAuthor ">Michael J.  Tucker</span>, <span class="hlFld-ContribAuthor ">Birgit  Wilding</span>, <span class="hlFld-ContribAuthor ">Lindsay E.  Evans</span>, <span class="hlFld-ContribAuthor ">Susan  Lepri</span>, <span class="hlFld-ContribAuthor ">Meirion  Richards</span>, <span class="hlFld-ContribAuthor ">Swee Y.  Sharp</span>, <span class="hlFld-ContribAuthor ">Salyha  Ali</span>, <span class="hlFld-ContribAuthor ">Martin  Rowlands</span>, <span class="hlFld-ContribAuthor ">Lisa  O’Fee</span>, <span class="hlFld-ContribAuthor ">Asadh  Miah</span>, <span class="hlFld-ContribAuthor ">Angela  Hayes</span>, <span class="hlFld-ContribAuthor ">Alan T.  Henley</span>, <span class="hlFld-ContribAuthor ">Marissa  Powers</span>, <span class="hlFld-ContribAuthor ">Robert  te Poele</span>, <span class="hlFld-ContribAuthor ">Emmanuel  De Billy</span>, <span class="hlFld-ContribAuthor ">Loredana  Pellegrino</span>, <span class="hlFld-ContribAuthor ">Florence  Raynaud</span>, <span class="hlFld-ContribAuthor ">Rosemary  Burke</span>, <span class="hlFld-ContribAuthor ">Rob L. M.  van Montfort</span>, <span class="hlFld-ContribAuthor ">Suzanne A.  Eccles</span>, <span class="hlFld-ContribAuthor ">Paul  Workman</span>, and <span class="hlFld-ContribAuthor ">Keith  Jones</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (1)
                                     , 180-201. <a href="https://doi.org/10.1021/acs.jmedchem.6b01055" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01055%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BChemical%252BProbe%252BBisamide%252B%252528CCT251236%252529%25253A%252BAn%252BOrally%252BBioavailable%252BEfficacious%252BPirin%252BLigand%252Bfrom%252Ba%252BHeat%252BShock%252BTranscription%252BFactor%252B1%252B%252528HSF1%252529%252BPhenotypic%252BScreen%26aulast%3DCheeseman%26aufirst%3DMatthew%2BD.%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D15072016%26date%3D22122016%26date%3D12012017%26date%3D23112016%26volume%3D60%26issue%3D1%26spage%3D180%26epage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luca  Carlino</span> and <span class="hlFld-ContribAuthor ">Giulio  Rastelli</span>  . </span><span class="cited-content_cbyCitation_article-title">Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (20)
                                     , 9305-9320. <a href="https://doi.org/10.1021/acs.jmedchem.6b00438" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00438</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00438%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252BKinase-Bromodomain%252BInhibitors%252Bin%252BAnticancer%252BDrug%252BDiscovery%25253A%252BA%252BStructural%252Band%252BPharmacological%252BPerspective%26aulast%3DCarlino%26aufirst%3DLuca%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D24032016%26date%3D07092016%26date%3D27102016%26date%3D25082016%26volume%3D59%26issue%3D20%26spage%3D9305%26epage%3D9320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul  Czodrowski</span> and <span class="hlFld-ContribAuthor ">Wolf-Guido  Bolick</span>  . </span><span class="cited-content_cbyCitation_article-title">OCEAN: Optimized Cross rEActivity estimatioN. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (10)
                                     , 2013-2023. <a href="https://doi.org/10.1021/acs.jcim.6b00067" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00067%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DOCEAN%25253A%252BOptimized%252BCross%252BrEActivity%252BestimatioN%26aulast%3DCzodrowski%26aufirst%3DPaul%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D11022016%26date%3D26092016%26date%3D24102016%26volume%3D56%26issue%3D10%26spage%3D2013%26epage%3D2023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michel  Frédérich</span>, <span class="hlFld-ContribAuthor ">Bernard  Pirotte</span>, <span class="hlFld-ContribAuthor ">Marianne  Fillet</span>, and <span class="hlFld-ContribAuthor ">Pascal  de Tullio</span>  . </span><span class="cited-content_cbyCitation_article-title">Metabolomics as a Challenging Approach for Medicinal Chemistry and Personalized Medicine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (19)
                                     , 8649-8666. <a href="https://doi.org/10.1021/acs.jmedchem.5b01335" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01335</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01335%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMetabolomics%252Bas%252Ba%252BChallenging%252BApproach%252Bfor%252BMedicinal%252BChemistry%252Band%252BPersonalized%252BMedicine%26aulast%3DFr%25C3%25A9d%25C3%25A9rich%26aufirst%3DMichel%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D28082015%26date%3D27062016%26date%3D13102016%26date%3D13062016%26volume%3D59%26issue%3D19%26spage%3D8649%26epage%3D8666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eugene Guorong  Yang</span>, <span class="hlFld-ContribAuthor ">Nurulhuda  Mustafa</span>, <span class="hlFld-ContribAuthor ">Eng Chong  Tan</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Pondy Murugappan  Ramanujulu</span>, <span class="hlFld-ContribAuthor ">Wee Joo  Chng</span>, <span class="hlFld-ContribAuthor ">Jeffrey J. Y.  Yen</span>, and <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (18)
                                     , 8233-8262. <a href="https://doi.org/10.1021/acs.jmedchem.6b00157" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00157</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BJanus%252BKinase%252B2%252B%252528JAK2%252529%252Band%252BHistone%252BDeacetlyase%252B%252528HDAC%252529%252BBispecific%252BInhibitors%252BBased%252Bon%252BPacritinib%252Band%252BEvidence%252Bof%252BDual%252BPathway%252BInhibition%252Bin%252BHematological%252BCell%252BLines%26aulast%3DYang%26aufirst%3DEugene%2BGuorong%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D03022016%26date%3D08092016%26date%3D22092016%26date%3D19082016%26volume%3D59%26issue%3D18%26spage%3D8233%26epage%3D8262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dagmar  Stumpfe</span>, <span class="hlFld-ContribAuthor ">Dilyana  Dimova</span>, and <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>  . </span><span class="cited-content_cbyCitation_article-title">Computational Method for the Systematic Identification of Analog Series and Key Compounds Representing Series and Their Biological Activity Profiles. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (16)
                                     , 7667-7676. <a href="https://doi.org/10.1021/acs.jmedchem.6b00906" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00906</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00906%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DComputational%252BMethod%252Bfor%252Bthe%252BSystematic%252BIdentification%252Bof%252BAnalog%252BSeries%252Band%252BKey%252BCompounds%252BRepresenting%252BSeries%252Band%252BTheir%252BBiological%252BActivity%252BProfiles%26aulast%3DStumpfe%26aufirst%3DDagmar%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D16062016%26date%3D08082016%26date%3D25082016%26volume%3D59%26issue%3D16%26spage%3D7667%26epage%3D7676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhibin  Liang</span>, <span class="hlFld-ContribAuthor ">Bei  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei Wen  Su</span>, <span class="hlFld-ContribAuthor ">Philip G.  Williams</span>, and <span class="hlFld-ContribAuthor ">Qing X.  Li</span>  . </span><span class="cited-content_cbyCitation_article-title">C-Glycosylflavones Alleviate Tau Phosphorylation and Amyloid Neurotoxicity through GSK3β Inhibition. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2016,</strong> <em>7 </em>
                                    (7)
                                     , 912-923. <a href="https://doi.org/10.1021/acschemneuro.6b00059" title="DOI URL">https://doi.org/10.1021/acschemneuro.6b00059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.6b00059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.6b00059%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DC-Glycosylflavones%252BAlleviate%252BTau%252BPhosphorylation%252Band%252BAmyloid%252BNeurotoxicity%252Bthrough%252BGSK3%2525CE%2525B2%252BInhibition%26aulast%3DLiang%26aufirst%3DZhibin%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D25022016%26date%3D23052016%26date%3D03062016%26date%3D20072016%26date%3D23052016%26volume%3D7%26issue%3D7%26spage%3D912%26epage%3D923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bruce E.  Maryanoff</span>  . </span><span class="cited-content_cbyCitation_article-title">Phenotypic Assessment and the Discovery of Topiramate. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (7)
                                     , 662-665. <a href="https://doi.org/10.1021/acsmedchemlett.6b00176" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00176</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00176%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPhenotypic%252BAssessment%252Band%252Bthe%252BDiscovery%252Bof%252BTopiramate%26aulast%3DMaryanoff%26aufirst%3DBruce%2BE.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D27042016%26date%3D13062016%26date%3D01072016%26date%3D14072016%26date%3D13062016%26volume%3D7%26issue%3D7%26spage%3D662%26epage%3D665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xia  Wang</span>, <span class="hlFld-ContribAuthor ">Chenxu  Pan</span>, <span class="hlFld-ContribAuthor ">Jiayu  Gong</span>, <span class="hlFld-ContribAuthor ">Xiaofeng  Liu</span>, and <span class="hlFld-ContribAuthor ">Honglin  Li</span>  . </span><span class="cited-content_cbyCitation_article-title">Enhancing the Enrichment of Pharmacophore-Based Target Prediction for the Polypharmacological Profiles of Drugs. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (6)
                                     , 1175-1183. <a href="https://doi.org/10.1021/acs.jcim.5b00690" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00690</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00690%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DEnhancing%252Bthe%252BEnrichment%252Bof%252BPharmacophore-Based%252BTarget%252BPrediction%252Bfor%252Bthe%252BPolypharmacological%252BProfiles%252Bof%252BDrugs%26aulast%3DWang%26aufirst%3DXia%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D17112015%26date%3D31052016%26date%3D27062016%26date%3D17052016%26volume%3D56%26issue%3D6%26spage%3D1175%26epage%3D1183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andreas  Thomann</span>, <span class="hlFld-ContribAuthor ">Antonio G. G.  de Mello Martins</span>, <span class="hlFld-ContribAuthor ">Christian  Brengel</span>, <span class="hlFld-ContribAuthor ">Martin  Empting</span>, and <span class="hlFld-ContribAuthor ">Rolf W.  Hartmann</span>  . </span><span class="cited-content_cbyCitation_article-title">Application of Dual Inhibition Concept within Looped Autoregulatory Systems toward Antivirulence Agents against Pseudomonas aeruginosa Infections. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2016,</strong> <em>11 </em>
                                    (5)
                                     , 1279-1286. <a href="https://doi.org/10.1021/acschembio.6b00117" title="DOI URL">https://doi.org/10.1021/acschembio.6b00117</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.6b00117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.6b00117%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DApplication%252Bof%252BDual%252BInhibition%252BConcept%252Bwithin%252BLooped%252BAutoregulatory%252BSystems%252Btoward%252BAntivirulence%252BAgents%252Bagainst%252BPseudomonas%252Baeruginosa%252BInfections%26aulast%3DThomann%26aufirst%3DAndreas%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D05022016%26date%3D16022016%26date%3D01032016%26date%3D20052016%26date%3D16022016%26volume%3D11%26issue%3D5%26spage%3D1279%26epage%3D1286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Petra  Schneider</span> and <span class="hlFld-ContribAuthor ">Gisbert  Schneider</span>  . </span><span class="cited-content_cbyCitation_article-title">De Novo Design at the Edge of Chaos. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (9)
                                     , 4077-4086. <a href="https://doi.org/10.1021/acs.jmedchem.5b01849" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01849</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01849%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDe%252BNovo%252BDesign%252Bat%252Bthe%252BEdge%252Bof%252BChaos%26aulast%3DSchneider%26aufirst%3DPetra%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D30112015%26date%3D16022016%26date%3D12052016%26volume%3D59%26issue%3D9%26spage%3D4077%26epage%3D4086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew N.  McCarroll</span>, <span class="hlFld-ContribAuthor ">Leo  Gendelev</span>, <span class="hlFld-ContribAuthor ">Michael J.  Keiser</span>, and <span class="hlFld-ContribAuthor ">David  Kokel</span>  . </span><span class="cited-content_cbyCitation_article-title">Leveraging Large-scale Behavioral Profiling in Zebrafish to Explore Neuroactive Polypharmacology. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2016,</strong> <em>11 </em>
                                    (4)
                                     , 842-849. <a href="https://doi.org/10.1021/acschembio.5b00800" title="DOI URL">https://doi.org/10.1021/acschembio.5b00800</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.5b00800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.5b00800%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DLeveraging%252BLarge-scale%252BBehavioral%252BProfiling%252Bin%252BZebrafish%252Bto%252BExplore%252BNeuroactive%252BPolypharmacology%26aulast%3DMcCarroll%26aufirst%3DMatthew%2BN.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D02102015%26date%3D04022016%26date%3D17022016%26date%3D15042016%26date%3D04022016%26volume%3D11%26issue%3D4%26spage%3D842%26epage%3D849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joonhyeok  Choi</span>, <span class="hlFld-ContribAuthor ">Kwang-Eun  Choi</span>, <span class="hlFld-ContribAuthor ">Sung Jean  Park</span>, <span class="hlFld-ContribAuthor ">Sun Yeou  Kim</span>, and <span class="hlFld-ContribAuthor ">Jun-Goo  Jee</span>  . </span><span class="cited-content_cbyCitation_article-title">Ensemble-Based Virtual Screening Led to the Discovery of New Classes of Potent Tyrosinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (2)
                                     , 354-367. <a href="https://doi.org/10.1021/acs.jcim.5b00484" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00484</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00484%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DEnsemble-Based%252BVirtual%252BScreening%252BLed%252Bto%252Bthe%252BDiscovery%252Bof%252BNew%252BClasses%252Bof%252BPotent%252BTyrosinase%252BInhibitors%26aulast%3DChoi%26aufirst%3DJoonhyeok%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D05082015%26date%3D20012016%26date%3D22022016%26date%3D11012016%26volume%3D56%26issue%3D2%26spage%3D354%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shibing  Tang</span>, <span class="hlFld-ContribAuthor ">Min  Xie</span>, <span class="hlFld-ContribAuthor ">Nan  Cao</span>, and <span class="hlFld-ContribAuthor ">Sheng  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">Patient-Specific Induced Pluripotent Stem Cells for Disease Modeling and Phenotypic Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (1)
                                     , 2-15. <a href="https://doi.org/10.1021/acs.jmedchem.5b00789" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00789</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00789%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPatient-Specific%252BInduced%252BPluripotent%252BStem%252BCells%252Bfor%252BDisease%252BModeling%252Band%252BPhenotypic%252BDrug%252BDiscovery%26aulast%3DTang%26aufirst%3DShibing%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D22052015%26date%3D04092015%26date%3D14012016%26date%3D31082015%26volume%3D59%26issue%3D1%26spage%3D2%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Ye    Hu </span><span class="hlFld-ContribAuthor "> Jürgen    Bajorath </span>. </span><span class="cited-content_cbyCitation_article-title">Exploring Molecular Promiscuity from a Ligand and Target Perspective. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 19-34. <a href="https://doi.org/10.1021/bk-2016-1222.ch003" title="DOI URL">https://doi.org/10.1021/bk-2016-1222.ch003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2016-1222.ch003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2016-1222.ch003%26sid%3Dliteratum%253Aachs%26atitle%3DExploring%252BMolecular%252BPromiscuity%252Bfrom%252Ba%252BLigand%252Band%252BTarget%252BPerspective%26aulast%3DHu%26aufirst%3DYe%26date%3D2016%26date%3D2016%26spage%3D19%26epage%3D34%26atitle%3DFrontiers%252Bin%252BMolecular%252BDesign%252Band%252BChemical%252BInformation%252BScience%252B-%252BHerman%252BSkolnik%252BAward%252BSymposium%252B2015%25253A%252BJ%2525C3%2525BCrgen%252BBajorath%26aulast%3DBienstock%26aufirst%3DRachelle%2BJ.%26date%3D2016%26date%3D2016%26volume%3D1222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Gerald    Maggiora </span><span class="hlFld-ContribAuthor "> Vijay    Gokhale </span>. </span><span class="cited-content_cbyCitation_article-title">Non-Specificity of Drug-Target Interactions – Consequences for Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 91-142. <a href="https://doi.org/10.1021/bk-2016-1222.ch007" title="DOI URL">https://doi.org/10.1021/bk-2016-1222.ch007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2016-1222.ch007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2016-1222.ch007%26sid%3Dliteratum%253Aachs%26atitle%3DNon-Specificity%252Bof%252BDrug-Target%252BInteractions%252B%2525E2%252580%252593%252BConsequences%252Bfor%252BDrug%252BDiscovery%26aulast%3DMaggiora%26aufirst%3DGerald%26date%3D2016%26date%3D2016%26spage%3D91%26epage%3D142%26atitle%3DFrontiers%252Bin%252BMolecular%252BDesign%252Band%252BChemical%252BInformation%252BScience%252B-%252BHerman%252BSkolnik%252BAward%252BSymposium%252B2015%25253A%252BJ%2525C3%2525BCrgen%252BBajorath%26aulast%3DBienstock%26aufirst%3DRachelle%2BJ.%26date%3D2016%26date%3D2016%26volume%3D1222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lien  Nguyen</span>, <span class="hlFld-ContribAuthor ">Long M.  Luu</span>, <span class="hlFld-ContribAuthor ">Shaohong  Peng</span>, <span class="hlFld-ContribAuthor ">Julio F.  Serrano</span>, <span class="hlFld-ContribAuthor ">H. Y. Edwin  Chan</span>, and <span class="hlFld-ContribAuthor ">Steven C.  Zimmerman</span>  . </span><span class="cited-content_cbyCitation_article-title">Rationally Designed Small Molecules That Target Both the DNA and RNA Causing Myotonic Dystrophy Type 1. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2015,</strong> <em>137 </em>
                                    (44)
                                     , 14180-14189. <a href="https://doi.org/10.1021/jacs.5b09266" title="DOI URL">https://doi.org/10.1021/jacs.5b09266</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.5b09266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.5b09266%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DRationally%252BDesigned%252BSmall%252BMolecules%252BThat%252BTarget%252BBoth%252Bthe%252BDNA%252Band%252BRNA%252BCausing%252BMyotonic%252BDystrophy%252BType%252B1%26aulast%3DNguyen%26aufirst%3DLien%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D05092015%26date%3D03112015%26date%3D11112015%26date%3D16102015%26volume%3D137%26issue%3D44%26spage%3D14180%26epage%3D14189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weijun  Xu</span>, <span class="hlFld-ContribAuthor ">Junxian  Lim</span>, <span class="hlFld-ContribAuthor ">Chai-Yeen  Goh</span>, <span class="hlFld-ContribAuthor ">Jacky Y.  Suen</span>, <span class="hlFld-ContribAuthor ">Yuhong  Jiang</span>, <span class="hlFld-ContribAuthor ">Mei-Kwan  Yau</span>, <span class="hlFld-ContribAuthor ">Kai-Chen  Wu</span>, <span class="hlFld-ContribAuthor ">Ligong  Liu</span>, and <span class="hlFld-ContribAuthor ">David P.  Fairlie</span>  . </span><span class="cited-content_cbyCitation_article-title">Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2015,</strong> <em>55 </em>
                                    (10)
                                     , 2079-2084. <a href="https://doi.org/10.1021/acs.jcim.5b00500" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00500</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00500%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DRepurposing%252BRegistered%252BDrugs%252Bas%252BAntagonists%252Bfor%252BProtease-Activated%252BReceptor%252B2%26aulast%3DXu%26aufirst%3DWeijun%26date%3D2015%26date%3D2015%26date%3D07102015%26date%3D12102015%26date%3D26102015%26date%3D07102015%26volume%3D55%26issue%3D10%26spage%3D2079%26epage%3D2084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ricard  Garcia-Serna</span>, <span class="hlFld-ContribAuthor ">David  Vidal</span>, <span class="hlFld-ContribAuthor ">Nikita  Remez</span>, and <span class="hlFld-ContribAuthor ">Jordi  Mestres</span>  . </span><span class="cited-content_cbyCitation_article-title">Large-Scale Predictive Drug Safety: From Structural Alerts to Biological Mechanisms. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2015,</strong> <em>28 </em>
                                    (10)
                                     , 1875-1887. <a href="https://doi.org/10.1021/acs.chemrestox.5b00260" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.5b00260</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.5b00260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.5b00260%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DLarge-Scale%252BPredictive%252BDrug%252BSafety%25253A%252BFrom%252BStructural%252BAlerts%252Bto%252BBiological%252BMechanisms%26aulast%3DGarcia-Serna%26aufirst%3DRicard%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D19062015%26date%3D21092015%26date%3D19102015%26date%3D11092015%26volume%3D28%26issue%3D10%26spage%3D1875%26epage%3D1887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahendra  Awale</span> and <span class="hlFld-ContribAuthor ">Jean-Louis  Reymond</span>  . </span><span class="cited-content_cbyCitation_article-title">Similarity Mapplet: Interactive Visualization of the Directory of Useful Decoys and ChEMBL in High Dimensional Chemical Spaces. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2015,</strong> <em>55 </em>
                                    (8)
                                     , 1509-1516. <a href="https://doi.org/10.1021/acs.jcim.5b00182" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00182</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00182%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DSimilarity%252BMapplet%25253A%252BInteractive%252BVisualization%252Bof%252Bthe%252BDirectory%252Bof%252BUseful%252BDecoys%252Band%252BChEMBL%252Bin%252BHigh%252BDimensional%252BChemical%252BSpaces%26aulast%3DAwale%26aufirst%3DMahendra%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D02042015%26date%3D05082015%26date%3D24082015%26date%3D24072015%26volume%3D55%26issue%3D8%26spage%3D1509%26epage%3D1516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paolo  Vincetti</span>, <span class="hlFld-ContribAuthor ">Fabiana  Caporuscio</span>, <span class="hlFld-ContribAuthor ">Suzanne  Kaptein</span>, <span class="hlFld-ContribAuthor ">Antimo  Gioiello</span>, <span class="hlFld-ContribAuthor ">Valentina  Mancino</span>, <span class="hlFld-ContribAuthor ">Youichi  Suzuki</span>, <span class="hlFld-ContribAuthor ">Naoki  Yamamoto</span>, <span class="hlFld-ContribAuthor ">Emmanuele  Crespan</span>, <span class="hlFld-ContribAuthor ">Andrea  Lossani</span>, <span class="hlFld-ContribAuthor ">Giovanni  Maga</span>, <span class="hlFld-ContribAuthor ">Giulio  Rastelli</span>, <span class="hlFld-ContribAuthor ">Daniele  Castagnolo</span>, <span class="hlFld-ContribAuthor ">Johan  Neyts</span>, <span class="hlFld-ContribAuthor ">Pieter  Leyssen</span>, <span class="hlFld-ContribAuthor ">Gabriele  Costantino</span>, and <span class="hlFld-ContribAuthor ">Marco  Radi</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (12)
                                     , 4964-4975. <a href="https://doi.org/10.1021/acs.jmedchem.5b00108" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00108</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00108%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BMultitarget%252BAntivirals%252BActing%252Bon%252BBoth%252Bthe%252BDengue%252BVirus%252BNS5-NS3%252BInteraction%252Band%252Bthe%252BHost%252BSrc%25252FFyn%252BKinases%26aulast%3DVincetti%26aufirst%3DPaolo%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D16012015%26date%3D15062015%26date%3D25062015%26date%3D03062015%26volume%3D58%26issue%3D12%26spage%3D4964%26epage%3D4975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tom-Marten  Kilian</span>, <span class="hlFld-ContribAuthor ">Nora  Klöting</span>, <span class="hlFld-ContribAuthor ">Ralf  Bergmann</span>, <span class="hlFld-ContribAuthor ">Sylvia  Els-Heindl</span>, <span class="hlFld-ContribAuthor ">Stefanie  Babilon</span>, <span class="hlFld-ContribAuthor ">Mathieu  Clément-Ziza</span>, <span class="hlFld-ContribAuthor ">Yixin  Zhang</span>, <span class="hlFld-ContribAuthor ">Annette G.  Beck-Sickinger</span>, and <span class="hlFld-ContribAuthor ">Constance  Chollet</span>  . </span><span class="cited-content_cbyCitation_article-title">Rational Design of Dual Peptides Targeting Ghrelin and Y2 Receptors to Regulate Food Intake and Body Weight. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (10)
                                     , 4180-4193. <a href="https://doi.org/10.1021/jm501702q" title="DOI URL">https://doi.org/10.1021/jm501702q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501702q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501702q%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252BDesign%252Bof%252BDual%252BPeptides%252BTargeting%252BGhrelin%252Band%252BY2%252BReceptors%252Bto%252BRegulate%252BFood%252BIntake%252Band%252BBody%252BWeight%26aulast%3DKilian%26aufirst%3DTom-Marten%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D03112014%26date%3D07052015%26date%3D28052015%26date%3D23042015%26volume%3D58%26issue%3D10%26spage%3D4180%26epage%3D4193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sudharshan  Madapa</span> and <span class="hlFld-ContribAuthor ">Wayne W.  Harding</span>  . </span><span class="cited-content_cbyCitation_article-title">Semisynthetic Studies on and Biological Evaluation of N-Methyllaurotetanine Analogues as Ligands for 5-HT Receptors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2015,</strong> <em>78 </em>
                                    (4)
                                     , 722-729. <a href="https://doi.org/10.1021/np500893h" title="DOI URL">https://doi.org/10.1021/np500893h</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/np500893h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fnp500893h%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DSemisynthetic%252BStudies%252Bon%252Band%252BBiological%252BEvaluation%252Bof%252BN-Methyllaurotetanine%252BAnalogues%252Bas%252BLigands%252Bfor%252B5-HT%252BReceptors%26aulast%3DMadapa%26aufirst%3DSudharshan%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D10112014%26date%3D19022015%26date%3D24042015%26volume%3D78%26issue%3D4%26spage%3D722%26epage%3D729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew  Anighoro</span>, <span class="hlFld-ContribAuthor ">Dagmar  Stumpfe</span>, <span class="hlFld-ContribAuthor ">Kathrin  Heikamp</span>, <span class="hlFld-ContribAuthor ">Kristin  Beebe</span>, <span class="hlFld-ContribAuthor ">Leonard M.  Neckers</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>, and <span class="hlFld-ContribAuthor ">Giulio  Rastelli</span>  . </span><span class="cited-content_cbyCitation_article-title">Computational Polypharmacology Analysis of the Heat Shock Protein 90 Interactome. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2015,</strong> <em>55 </em>
                                    (3)
                                     , 676-686. <a href="https://doi.org/10.1021/ci5006959" title="DOI URL">https://doi.org/10.1021/ci5006959</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci5006959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci5006959%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DComputational%252BPolypharmacology%252BAnalysis%252Bof%252Bthe%252BHeat%252BShock%252BProtein%252B90%252BInteractome%26aulast%3DAnighoro%26aufirst%3DAndrew%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D21112014%26date%3D23022015%26date%3D23032015%26date%3D16022015%26volume%3D55%26issue%3D3%26spage%3D676%26epage%3D686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paula  Morales</span>, <span class="hlFld-ContribAuthor ">Sandra  Blasco-Benito</span>, <span class="hlFld-ContribAuthor ">Clara  Andradas</span>, <span class="hlFld-ContribAuthor ">María  Gómez-Cañas</span>, <span class="hlFld-ContribAuthor ">Juana María  Flores</span>, <span class="hlFld-ContribAuthor ">Pilar  Goya</span>, <span class="hlFld-ContribAuthor ">Javier  Fernández-Ruiz</span>, <span class="hlFld-ContribAuthor ">Cristina  Sánchez</span>, and <span class="hlFld-ContribAuthor ">Nadine  Jagerovic</span>  . </span><span class="cited-content_cbyCitation_article-title">Selective, Nontoxic CB2 Cannabinoid o-Quinone with in Vivo Activity against Triple-Negative Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (5)
                                     , 2256-2264. <a href="https://doi.org/10.1021/acs.jmedchem.5b00078" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00078%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSelective%25252C%252BNontoxic%252BCB2%252BCannabinoid%252Bo-Quinone%252Bwith%252Bin%252BVivo%252BActivity%252Bagainst%252BTriple-Negative%252BBreast%252BCancer%26aulast%3DMorales%26aufirst%3DPaula%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D14102014%26date%3D20022015%26date%3D12032015%26date%3D11022015%26volume%3D58%26issue%3D5%26spage%3D2256%26epage%3D2264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shipeng  He</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Dong</span>, <span class="hlFld-ContribAuthor ">Zhibin  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Chen</span>, <span class="hlFld-ContribAuthor ">Yahui  Huang</span>, <span class="hlFld-ContribAuthor ">Zhengang  Li</span>, <span class="hlFld-ContribAuthor ">Yan  Jiang</span>, <span class="hlFld-ContribAuthor ">Na  Liu</span>, <span class="hlFld-ContribAuthor ">Jianzhong  Yao</span>, <span class="hlFld-ContribAuthor ">Zhenyuan  Miao</span>, <span class="hlFld-ContribAuthor ">Wannian  Zhang</span>, and <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (3)
                                     , 239-243. <a href="https://doi.org/10.1021/ml500327q" title="DOI URL">https://doi.org/10.1021/ml500327q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml500327q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml500327q%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BNovel%252BMultiacting%252BTopoisomerase%252BI%25252FII%252Band%252BHistone%252BDeacetylase%252BInhibitors%26aulast%3DHe%26aufirst%3DShipeng%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D05082014%26date%3D14012015%26date%3D20012015%26date%3D12032015%26date%3D14012015%26volume%3D6%26issue%3D3%26spage%3D239%26epage%3D243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oscar M.  Bautista-Aguilera</span>, <span class="hlFld-ContribAuthor ">Abdelouahid  Samadi</span>, <span class="hlFld-ContribAuthor ">Mourad  Chioua</span>, <span class="hlFld-ContribAuthor ">Katarina  Nikolic</span>, <span class="hlFld-ContribAuthor ">Slavica  Filipic</span>, <span class="hlFld-ContribAuthor ">Danica  Agbaba</span>, <span class="hlFld-ContribAuthor ">Elena  Soriano</span>, <span class="hlFld-ContribAuthor ">Lucía  de Andrés</span>, <span class="hlFld-ContribAuthor ">María Isabel  Rodríguez-Franco</span>, <span class="hlFld-ContribAuthor ">Stefano  Alcaro</span>, <span class="hlFld-ContribAuthor ">Rona R.  Ramsay</span>, <span class="hlFld-ContribAuthor ">Francesco  Ortuso</span>, <span class="hlFld-ContribAuthor ">Matilde  Yañez</span>, and <span class="hlFld-ContribAuthor ">José  Marco-Contelles</span>  . </span><span class="cited-content_cbyCitation_article-title">N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a New Cholinesterase and Monoamine Oxidase Dual Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (24)
                                     , 10455-10463. <a href="https://doi.org/10.1021/jm501501a" title="DOI URL">https://doi.org/10.1021/jm501501a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501501a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501501a%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DN-Methyl-N-%252528%2525281-methyl-5-%2525283-%2525281-%2525282-methylbenzyl%252529piperidin-4-yl%252529propoxy%252529-1H-indol-2-yl%252529methyl%252529prop-2-yn-1-amine%25252C%252Ba%252BNew%252BCholinesterase%252Band%252BMonoamine%252BOxidase%252BDual%252BInhibitor%26aulast%3DBautista-Aguilera%26aufirst%3DOscar%2BM.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D18092014%26date%3D08122014%26date%3D26122014%26date%3D24112014%26volume%3D57%26issue%3D24%26spage%3D10455%26epage%3D10463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm5006463&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Fjm5006463%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-19%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text&amp;citedByCount=475&amp;pagesCount=5&amp;pageNumber=2" title="Load more citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load more citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/medium/jm-2014-006463_0006.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5006463&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/medium/jm-2014-006463_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Scaffolds and promiscuity profiles. Shown is a set of topologically equivalent scaffolds including dipenylmethane, one of the most promiscuous scaffolds found in bioactive compounds, and their promiscuity profiles. Nodes represent scaffolds, and an edge connects two scaffolds if they are active against the same target(s). Edge labels report the number of shared targets (and node labels scaffold IDs). The structure of each scaffold is annotated with its promiscuity profile consisting of “target family: number of relevant targets” expressions. For example, the scaffold at the bottom has the activity profile “1:1; 2:3; 10:7”, which means that this scaffold is present in compounds that are active against one target in target family 1, three targets in family 2, and seven targets in family 10. The figure was adapted from ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">15</a>. Scaffolds and target families are numbered according to the original publication.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5006463&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/medium/jm-2014-006463_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of representative drugs and pharmaceutically relevant compounds discussed in the text.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5006463&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/medium/jm-2014-006463_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/medium/jm-2014-006463_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0004.jpeg" id="rightTab-GRAPHIC-d3237e583-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Scaffold- and compound-based target networks. For ChEMBL<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> release 2 (available at the end of 2009) and release 14 (available in 2012), scaffold- and compound-based target networks are compared on the basis of <i>K</i><sub>i</sub> activity values (equilibrium constants) in (a) and (b), respectively, and on the basis of IC<sub>50</sub> measurements in (c) and (d), respectively. Nodes represent targets, and edges connect target pairs that share at least five scaffolds or compounds. Scaffolds that represent compounds active against multiple targets from the same family or different protein families are designated single-family (SF) and multifamily (MF) scaffolds, respectively. Intra- and interfamily target pairs are indicated by solid and dashed edges, respectively, and target families are listed and color-coded in (e). Network formation results from the presence of promiscuous bioactive compounds. The comparison of different ChEMBL releases illustrates the growth in promiscuous compounds. Furthermore, the comparison of <i>K</i><sub>i</sub> and IC<sub>50</sub> value-based networks reveals that the increase in compounds promiscuous across different target families predominantly results from IC<sub>50</sub>-based compound activity data. The figure was adapted from ref <a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">80</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0003.jpeg jm-2014-006463_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5006463&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/medium/jm-2014-006463_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Different approaches relevant to the generation of multitarget drugs and their interplay are illustrated. The integration of complementary field of studies is thought to lead the way to rational polypharmacology approaches.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-19/jm5006463/20141006/images/large/jm-2014-006463_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5006463&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i15">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53138" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53138" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 92 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Network Pharmacology: The Next Paradigm in Drug Discovery</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">682</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnchembio.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=18936753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=682-690&author=A.+L.+Hopkins&title=Network+Pharmacology%3A+The+Next+Paradigm+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology: the next paradigm in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets.  However, many effective drugs act via modulation of multiple proteins rather than single targets.  Advances in systems biol. are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compds., compared with multi-target drugs, may exhibit lower than desired clin. efficacy.  This new appreciation of the role of polypharmacol. has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity.  Integrating network biol. and polypharmacol. holds the promise of expanding the current opportunity space for druggable targets.  However, the rational design of polypharmacol. faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties.  Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHy4FqkK-h7Vg90H21EOLACvtfcHk0lhbRjps0Sr_Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK&md5=03b8be3ddbcab7dc65afd17df7ee8395</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.118%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DNetwork%2520Pharmacology%253A%2520The%2520Next%2520Paradigm%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D682%26epage%3D690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Boran, A. D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyengar, R.</span><span> </span><span class="NLM_article-title">Systems Approaches to Polypharmacology and Drug Discovery</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=20443163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFCqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=297-309&author=A.+D.+W.+Boranauthor=R.+Iyengar&title=Systems+Approaches+to+Polypharmacology+and+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Systems approaches to polypharmacology and drug discovery</span></div><div class="casAuthors">Boran, Aislyn D. W.; Iyengar, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">297-309</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">2040-3437</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Systems biol. uses exptl. and computational approaches to characterize large sample populations systematically, process large datasets, examine and analyze regulatory networks, and model reactions to det. how components are joined to form functional systems.  Systems biol. technologies, data and knowledge are particularly useful in understanding disease processes and drug actions.  An important area of integration between systems biol. and drug discovery is the concept of polypharmacol.: the treatment of diseases by modulating more than one target.  Polypharmacol. for complex diseases is likely to involve multiple drugs acting on distinct targets that are part of a network regulating physiol. responses.  This review discusses the current state of the systems-level understanding of diseases and both the therapeutic and adverse mechanisms of drug actions.  Drug-target networks can be used to identify multiple targets and to det. suitable combinations of drug targets or drugs.  Thus, the discovery of new drug therapies for complex diseases may be greatly aided by systems biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7lrjWtBIXI7Vg90H21EOLACvtfcHk0lgLE7EupeJ4Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFCqtrk%253D&md5=b26a44ecd76a605816e08985ff8a576f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoran%26aufirst%3DA.%2BD.%2BW.%26aulast%3DIyengar%26aufirst%3DR.%26atitle%3DSystems%2520Approaches%2520to%2520Polypharmacology%2520and%2520Drug%2520Discovery%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2010%26volume%3D13%26spage%3D297%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Mestres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregori-Puigjané, E.</span><span> </span><span class="NLM_article-title">Conciliating Binding Efficiency and Polypharmacology</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">470</span><span class="NLM_x">–</span> <span class="NLM_lpage">474</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1016%2Fj.tips.2009.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=19717193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtV2rtb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=470-474&author=J.+Mestresauthor=E.+Gregori-Puigjan%C3%A9&title=Conciliating+Binding+Efficiency+and+Polypharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Conciliating binding efficiency and polypharmacology</span></div><div class="casAuthors">Mestres, Jordi; Gregori-Puigjane, Elisabet</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">470-474</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The assocn. between mol. size and risk of failure has promoted the use of binding efficiency as a prioritization metric in lead selection.  Even though by extension it is often referred to as "ligand efficiency", the concept was originally conceived to be strictly applicable to comparing the binding efficiencies of ligands for a single target.  With current trends in designing drugs to bind efficiently to multiple targets, a revision of the original binding efficiency definition is carried out.  To this aim, the dependency of binding efficiency on polypharmacol. is highlighted in a retrospective anal. of a set of antipsychotic drugs.  Statistical standardization of target binding efficiencies relative to basal values obtained from a large background of medicinal chem. compds. is proposed as a means to conciliate the concepts of binding efficiency and polypharmacol.  Finally, the interplay between binding efficiency and therapeutic efficacy for optimizing natural products, random hits, and fragments is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR83WbMBfphbVg90H21EOLACvtfcHk0lgLE7EupeJ4Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtV2rtb3L&md5=9ccaa31d1e43fc8867a7cf397d82d6d0</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2009.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2009.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DMestres%26aufirst%3DJ.%26aulast%3DGregori-Puigjan%25C3%25A9%26aufirst%3DE.%26atitle%3DConciliating%2520Binding%2520Efficiency%2520and%2520Polypharmacology%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D30%26spage%3D470%26epage%3D474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Peters, J.-U.</span><span> </span><span class="NLM_article-title">Polypharmacology—Foe or Friend?</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">8955</span><span class="NLM_x">–</span> <span class="NLM_lpage">8971</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.-U.+Peters&title=Polypharmacology%E2%80%94Foe+or+Friend%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26atitle%3DPolypharmacology%25E2%2580%2594Foe%2520or%2520Friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">Compound Promiscuity: What Can We Learn from Current Data?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">644</span><span class="NLM_x">–</span> <span class="NLM_lpage">650</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=644-650&author=Y.+Huauthor=J.+Bajorath&title=Compound+Promiscuity%3A+What+Can+We+Learn+from+Current+Data%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DCompound%2520Promiscuity%253A%2520What%2520Can%2520We%2520Learn%2520from%2520Current%2520Data%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D644%26epage%3D650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><a href="http://www.scopus.com" class="extLink">http://www.scopus.com</a> (accessed Dec<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.scopus.com+%28accessed+Dec+2013%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Jalencas, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestres, J.</span><span> </span><span class="NLM_article-title">On the Origins of Drug Polypharmacology</span> <span class="citation_source-journal">Med. Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1039%2Fc2md20242e" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=80-87&author=X.+Jalencasauthor=J.+Mestres&title=On+the+Origins+of+Drug+Polypharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1039%2Fc2md20242e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20242e%26sid%3Dliteratum%253Aachs%26aulast%3DJalencas%26aufirst%3DX.%26aulast%3DMestres%26aufirst%3DJ.%26atitle%3DOn%2520the%2520Origins%2520of%2520Drug%2520Polypharmacology%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2012%26volume%3D4%26spage%3D80%26epage%3D87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Lu, J.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-T.</span><span> </span><span class="NLM_article-title">Multi-Target Drugs: The Trend of Drug Research and Development</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e40262</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1371%2Fjournal.pone.0040262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=22768266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVaisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e40262&author=J.-J.+Luauthor=W.+Panauthor=Y.-J.+Huauthor=Y.-T.+Wang&title=Multi-Target+Drugs%3A+The+Trend+of+Drug+Research+and+Development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target drugs: the trend of drug research and development</span></div><div class="casAuthors">Lu, Jin-Jian; Pan, Wei; Hu, Yuan-Jia; Wang, Yi-Tao</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e40262</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Summarizing the status of drugs in the market and examg. the trend of drug research and development is important in drug discovery.  In this study, we compared the drug targets and the market sales of the new mol. entities approved by the U.S. Food and Drug Administration from Jan. 2000 to Dec. 2009.  Two networks, namely, the target-target and drug-drug networks, have been set up using the network anal. tools.  The multi-target drugs have much more potential, as shown by the network visualization and the market trends.  We discussed the possible reasons and proposed the rational strategies for drug research and development in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrapZATY1GnWbVg90H21EOLACvtfcHk0lhZ0QfQMJJf8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVaisr8%253D&md5=79489aaf7a36ee9c30287621a7244a6a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0040262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0040262%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.-J.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DY.-J.%26aulast%3DWang%26aufirst%3DY.-T.%26atitle%3DMulti-Target%2520Drugs%253A%2520The%2520Trend%2520of%2520Drug%2520Research%2520and%2520Development%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De40262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Adams, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basuino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiest, O. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babbitt, P. C.</span><span> </span><span class="NLM_article-title">A Mapping of Drug Space from the Viewpoint of Small Molecule Metabolism</span> <span class="citation_source-journal">PLoS Comput. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1000474</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=e1000474&author=J.+C.+Adamsauthor=M.+J.+Keiserauthor=L.+Basuinoauthor=H.+F.+Chambersauthor=D.-S.+Leeauthor=O.+G.+Wiestauthor=P.+C.+Babbitt&title=A+Mapping+of+Drug+Space+from+the+Viewpoint+of+Small+Molecule+Metabolism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DJ.%2BC.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DBasuino%26aufirst%3DL.%26aulast%3DChambers%26aufirst%3DH.%2BF.%26aulast%3DLee%26aufirst%3DD.-S.%26aulast%3DWiest%26aufirst%3DO.%2BG.%26aulast%3DBabbitt%26aufirst%3DP.%2BC.%26atitle%3DA%2520Mapping%2520of%2520Drug%2520Space%2520from%2520the%2520Viewpoint%2520of%2520Small%2520Molecule%2520Metabolism%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3De1000474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Tian, L.; Zhang, S.</span><span> </span><span class="NLM_article-title">Mapping Drug–Target Interaction Networks</span>. Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2009; <span class="NLM_publisher-name">EMBC</span>: <span class="NLM_publisher-loc">Piscataway, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">2336</span><span class="NLM_x">–</span> <span class="NLM_lpage">2339</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Tian%2C+L.%3B+Zhang%2C+S.+Mapping+Drug%E2%80%93Target+Interaction+Networks.+Proceedings+of+the+Annual+International+Conference+of+the+IEEE+Engineering+in+Medicine+and+Biology+Society%2C+2009%3B+EMBC%3A+Piscataway%2C+NJ%2C+2009%3B+pp+2336%E2%80%932339."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DL.%26atitle%3DMapping%2520Drug%25E2%2580%2593Target%2520Interaction%2520Networks%26pub%3DEMBC%26date%3D2009%26spage%3D2336%26epage%3D2339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Simon, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peragovics, Á.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigh-Smeller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csukly, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tombor, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahoránszky-Kőhalmi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Végner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jelinek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hári, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hetényi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitter, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czobor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Málnási-Csizmadia, A.</span><span> </span><span class="NLM_article-title">Drug Effect Prediction by Polypharmacology-Based Interaction Profiling</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">145</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci2002022" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVyrs73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=134-145&author=Z.+Simonauthor=%C3%81.+Peragovicsauthor=M.+Vigh-Smellerauthor=G.+Csuklyauthor=L.+Tomborauthor=Z.+Yangauthor=G.+Zahor%C3%A1nszky-K%C5%91halmiauthor=L.+V%C3%A9gnerauthor=B.+Jelinekauthor=P.+H%C3%A1riauthor=C.+Het%C3%A9nyiauthor=I.+Bitterauthor=P.+Czoborauthor=A.+M%C3%A1ln%C3%A1si-Csizmadia&title=Drug+Effect+Prediction+by+Polypharmacology-Based+Interaction+Profiling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Effect Prediction by Polypharmacology-Based Interaction Profiling</span></div><div class="casAuthors">Simon, Zoltan; Peragovics, Agnes; Vigh-Smeller, Margit; Csukly, Gabor; Tombor, Laszlo; Yang, Zhenhui; Zahoranszky-Kohalmi, Gergely; Vegner, Laszlo; Jelinek, Balazs; Hari, Peter; Hetenyi, Csaba; Bitter, Istvan; Czobor, Pal; Malnasi-Csizmadia, Andras</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-145</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Most drugs exert their effects via multitarget interactions, as hypothesized by polypharmacol.  While these multitarget interactions are responsible for the clin. effect profiles of drugs, current methods have failed to uncover the complex relationships between them.  Here, we introduce an approach which is able to relate complex drug-protein interaction profiles with effect profiles.  Structural data and registered effect profiles of all small-mol. drugs were collected, and interactions to a series of non-target protein binding sites of each drug were calcd.  Statistical analyses confirmed a close relationship between the studied 177 major effect categories and interaction profiles of ca. 1200 FDA-approved small-mol. drugs.  On the basis of this relationship, the effect profiles of drugs were revealed in their entirety, and hitherto uncovered effects could be predicted in a systematic manner.  Our results show that the prediction power is independent of the compn. of the protein set used for interaction profile generation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH7-WOP-uBWbVg90H21EOLACvtfcHk0lhZ0QfQMJJf8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVyrs73J&md5=50cb9593bcdc09f5cc8be563805a43bd</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fci2002022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci2002022%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DZ.%26aulast%3DPeragovics%26aufirst%3D%25C3%2581.%26aulast%3DVigh-Smeller%26aufirst%3DM.%26aulast%3DCsukly%26aufirst%3DG.%26aulast%3DTombor%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZahor%25C3%25A1nszky-K%25C5%2591halmi%26aufirst%3DG.%26aulast%3DV%25C3%25A9gner%26aufirst%3DL.%26aulast%3DJelinek%26aufirst%3DB.%26aulast%3DH%25C3%25A1ri%26aufirst%3DP.%26aulast%3DHet%25C3%25A9nyi%26aufirst%3DC.%26aulast%3DBitter%26aufirst%3DI.%26aulast%3DCzobor%26aufirst%3DP.%26aulast%3DM%25C3%25A1ln%25C3%25A1si-Csizmadia%26aufirst%3DA.%26atitle%3DDrug%2520Effect%2520Prediction%2520by%2520Polypharmacology-Based%2520Interaction%2520Profiling%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D134%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Yildirim, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cusick, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barabási, A.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidal, M.</span><span> </span><span class="NLM_article-title">Drug–Target Network</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1119</span><span class="NLM_x">–</span> <span class="NLM_lpage">1126</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=1119-1126&author=M.+A.+Yildirimauthor=K.-I.+Gohauthor=M.+E.+Cusickauthor=A.-L.+Barab%C3%A1siauthor=M.+Vidal&title=Drug%E2%80%93Target+Network"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYildirim%26aufirst%3DM.%2BA.%26aulast%3DGoh%26aufirst%3DK.-I.%26aulast%3DCusick%26aufirst%3DM.%2BE.%26aulast%3DBarab%25C3%25A1si%26aufirst%3DA.-L.%26aulast%3DVidal%26aufirst%3DM.%26atitle%3DDrug%25E2%2580%2593Target%2520Network%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D1119%26epage%3D1126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Reddy, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span> </span><span class="NLM_article-title">Polypharmacology: Drug Discovery for the Future</span> <span class="citation_source-journal">Expert Rev. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1586%2Fecp.12.74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=23272792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlei" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=41-47&author=A.+S.+Reddyauthor=S.+Zhang&title=Polypharmacology%3A+Drug+Discovery+for+the+Future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: drug discovery for the future</span></div><div class="casAuthors">Reddy, A. Srinivas; Zhang, Shuxing</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-47</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years, even with remarkable scientific advancements and a significant increase of global research and development spending, drugs are frequently withdrawn from markets.  This is primarily due to their side effects or toxicities.  Drug mols. often interact with multiple targets, coined as polypharmacol., and the unintended drug-target interactions could cause side effects.  Polypharmacol. remains one of the major challenges in drug development, and it opens novel avenues to rationally design the next generation of more effective, but less toxic, therapeutic agents.  This review outlines the latest progress and challenges in polypharmacol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh9arBzCHL27Vg90H21EOLACvtfcHk0lhcxbQpU4-r1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlei&md5=651b742d7e8254d8f4ef00f225dfa39e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1586%2Fecp.12.74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fecp.12.74%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DA.%2BS.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DPolypharmacology%253A%2520Drug%2520Discovery%2520for%2520the%2520Future%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D6%26spage%3D41%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Rask-Andersen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almén, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiöth, H. B.</span><span> </span><span class="NLM_article-title">Trends in the Exploitation of Novel Drug Targets</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">590</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnrd3478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=21804595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFKqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=579-590&author=M.+Rask-Andersenauthor=M.+S.+Alm%C3%A9nauthor=H.+B.+Schi%C3%B6th&title=Trends+in+the+Exploitation+of+Novel+Drug+Targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in the exploitation of novel drug targets</span></div><div class="casAuthors">Rask-Andersen, Mathias; Almen, Markus Saellman; Schioeth, Helgi B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">579-590</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The discovery and exploitation of new drug targets is a key focus for both the pharmaceutical industry and academic biomedical research.  To provide an insight into trends in the exploitation of new drug targets, we have analyzed the drugs that were approved by the US Food and Drug Administration during the past three decades and examd. the interactions of these drugs with therapeutic targets that are encoded by the human genome, using the DrugBank database and extensive manual curation.  We have identified 435 effect-mediating drug targets in the human genome, which are modulated by 989 unique drugs, through 2,242 drug-target interactions.  We also analyze trends in the introduction of drugs that modulate previously unexploited targets, and discuss the network pharmacol. of the drugs in our data set.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo19FXXFB-PsLVg90H21EOLACvtfcHk0lhcxbQpU4-r1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFKqsLc%253D&md5=9255431a28f2c07759b0f36975711f84</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrd3478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3478%26sid%3Dliteratum%253Aachs%26aulast%3DRask-Andersen%26aufirst%3DM.%26aulast%3DAlm%25C3%25A9n%26aufirst%3DM.%2BS.%26aulast%3DSchi%25C3%25B6th%26aufirst%3DH.%2BB.%26atitle%3DTrends%2520in%2520the%2520Exploitation%2520of%2520Novel%2520Drug%2520Targets%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D579%26epage%3D590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">Polypharmacology Directed Compound Data Mining: Identification of Promiscuous Chemotypes with Different Activity Profiles and Comparison to Approved Drugs</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2112</span><span class="NLM_x">–</span> <span class="NLM_lpage">2118</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci1003637" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWhtrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=2112-2118&author=Y.+Huauthor=J.+Bajorath&title=Polypharmacology+Directed+Compound+Data+Mining%3A+Identification+of+Promiscuous+Chemotypes+with+Different+Activity+Profiles+and+Comparison+to+Approved+Drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology directed compound data mining: identification of promiscuous chemotypes with different activity profiles and comparison to approved drugs</span></div><div class="casAuthors">Hu, Ye; Bajorath, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2112-2118</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Increasing evidence that many pharmaceutically relevant compds. elicit their effects through binding to multiple targets, so-called polypharmacol., is beginning to change conventional drug discovery and design strategies.  In light of this paradigm shift, we have mined publicly available compd. and bioactivity data for promiscuous chemotypes.  For this purpose, a hierarchy of active compds., at. property based scaffolds, and unique mol. topologies were generated, and activity annotations were analyzed using this framework.  Starting from ∼35 000 compds. active against human targets with at least 1 μM potency, 33 chemotypes with distinct topol. were identified that represented mols. active against at least 3 different target families.  Network representations were utilized to study scaffold-target family relationships and activity profiles of scaffolds corresponding to promiscuous chemotypes.  A subset of promiscuous chemotypes displayed a significant enrichment in drugs over bioactive compds.  A total of 190 drugs were identified that had on av. only 2 known target annotations but belonged to the 7 most promiscuous chemotypes that were active against 8-15 target families.  These drugs should be attractive candidates for polypharmacol. profiling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoeYreHJPURLVg90H21EOLACvtfcHk0liPr6F3vFMFXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWhtrrM&md5=178b0ce8e4f4502ce79f8e59b5ed1a5c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fci1003637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci1003637%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DPolypharmacology%2520Directed%2520Compound%2520Data%2520Mining%253A%2520Identification%2520of%2520Promiscuous%2520Chemotypes%2520with%2520Different%2520Activity%2520Profiles%2520and%2520Comparison%2520to%2520Approved%2520Drugs%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26spage%3D2112%26epage%3D2118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">High-Resolution View of Compound Promiscuity</span> <span class="citation_source-journal">F1000Research</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">144</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.12688%2Ff1000research.2-144.v2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A280%3ADC%252BC2c3psVWrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=144&author=Y.+Huauthor=J.+Bajorath&title=High-Resolution+View+of+Compound+Promiscuity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">High-resolution view of compound promiscuity</span></div><div class="casAuthors">Hu Ye; Bajorath Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">F1000Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">144</span>
        ISSN:<span class="NLM_cas:issn">2046-1402</span>.
    </div><div class="casAbstract">Compound promiscuity is defined as the ability of a small molecule to specifically interact with multiple biological targets.  So-defined promiscuity is relevant for drug discovery because it provides the molecular basis of polypharmacology, which is increasingly implicated in the therapeutic efficacy of drugs.  Recent studies have analyzed different aspects of compound promiscuity on the basis of currently available activity data.  In this commentary, we present take-home messages from these studies augmented with new results to generate a detailed picture of compound promiscuity that might serve as a reference for further discussions and research activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRhg3urNXDByO2kE7krGOBfW6udTcc2ebJ_IF1wvCKHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3psVWrug%253D%253D&md5=f96841e071505f8e25de1ef0766dc1a4</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.12688%2Ff1000research.2-144.v2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12688%252Ff1000research.2-144.v2%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DHigh-Resolution%2520View%2520of%2520Compound%2520Promiscuity%26jtitle%3DF1000Research%26date%3D2013%26volume%3D2%26spage%3D144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Altieri, D. C.</span><span> </span><span class="NLM_article-title">Mitochondrial Hsp90 Chaperones as Novel Molecular Targets in Prostate Cancer</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">487</span><span class="NLM_x">–</span> <span class="NLM_lpage">489</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.2217%2Ffon.10.26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=20373861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktlertL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=487-489&author=D.+C.+Altieri&title=Mitochondrial+Hsp90+Chaperones+as+Novel+Molecular+Targets+in+Prostate+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial Hsp90 chaperones as novel molecular targets in prostate cancer</span></div><div class="casAuthors">Altieri, Dario C.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">487-489</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  The mol. chaperone heat-shock protein-90 (Hsp90) is a well-known cancer nodal protein, orchestrating protein-folding quality control in multiple signaling pathways of cell proliferation, survival and adaptation.  Owing to its nodal properties, Hsp90 has been vigorously pursued as a target for network-oriented drug discovery, and several small mol. antagonists of its ATPase pocket are currently in advanced preclin. development or clin. evaluation.  Hsp90 and its related ATPase-directed chaperone, TNF receptor-assocd. protein-1 (TRAP-1), were found to exist in a novel subcellular pool compartmentalized in the mitochondria of tumor cells, but not in most normal tissues in vivo.  In prostate cancer, TRAP-1 turned out to be a sensitive and easily accessible biomarker of disease progression, abundantly expressed in prostatic intraepithelial neoplasia, all Gleason grades of cancer, and metastatic disease to lymph nodes and bones, but was undetectable in normal prostatic epithelium or benign prostatic hyperplasia.  Available evidence points to mitochondrial Hsp90 chaperones as novel and potentially attractive therapeutic targets in advanced prostate cancer, and identifies their subcellularly directed antagonists, i.e., Gamitrinibs, as a conceptually novel class of anticancer agents, worthy of further preclin. and clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJku2MZs523LVg90H21EOLACvtfcHk0ljyxtEW0l4hKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktlertL4%253D&md5=df39bd8e1482f87aa9802577e3c26048</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2217%2Ffon.10.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.10.26%26sid%3Dliteratum%253Aachs%26aulast%3DAltieri%26aufirst%3DD.%2BC.%26atitle%3DMitochondrial%2520Hsp90%2520Chaperones%2520as%2520Novel%2520Molecular%2520Targets%2520in%2520Prostate%2520Cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2010%26volume%3D6%26spage%3D487%26epage%3D489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Wright, J. J.</span><span> </span><span class="NLM_article-title">Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4094</span><span class="NLM_x">–</span> <span class="NLM_lpage">4104</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1158%2F1078-0432.CCR-09-2882" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=20682705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVajs7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=4094-4104&author=J.+J.+Wright&title=Combination+Therapy+of+Bortezomib+with+Novel+Targeted+Agents%3A+An+Emerging+Treatment+Strategy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy</span></div><div class="casAuthors">Wright, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4094-4104</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Clin. trials evaluating combinations of targeted agents with bortezomib, the first-in-class proteasome inhibitor, have been initiated, with the objective of enhancing its single agent activity in hematol. malignancies (myeloma, mantle cell lymphoma), as well as expanding its efficacy in solid tumors.  In most cases, preclin. studies have provided a supportive rationale for designing these doublet combination studies.  Novel, small mol.-targeted agents being investigated with bortezomib in clin. trials include protein deacetylase inhibitors, kinase inhibitors, farnesyltransferase inhibitors, heat-shock protein 90 inhibitors, pan-Bcl-2 family inhibitors, and other classes of targeted inhibitors.  Preliminary clin. data, available from a no. of ongoing trials, suggest that most of these combinations are well tolerated and some have promising clin. efficacy that will require subsequent confirmation.  Translational studies, conducted as part of the trials, may provide important insights into the putative mechanism of action delineated by preclin. studies of the combinations.  The emergence of novel proteasome inhibitors may also expand the opportunities for optimizing these combination therapies.  There is potential for an increasingly broad clin. trials program to investigate this therapeutic approach in a range of tumor types, as well as to consider addnl. agents in sequence or in combination.  Clin Cancer Res; 16(16); 4094-104.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq80JIFlg1k7bVg90H21EOLACvtfcHk0ljyxtEW0l4hKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVajs7zK&md5=70350d7044ef8f26fe4867d353d682b7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-2882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-2882%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26atitle%3DCombination%2520Therapy%2520of%2520Bortezomib%2520with%2520Novel%2520Targeted%2520Agents%253A%2520An%2520Emerging%2520Treatment%2520Strategy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D4094%26epage%3D4104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Sgobba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Structure-Based and in Silico Design of Hsp90 Inhibitors</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1399</span><span class="NLM_x">–</span> <span class="NLM_lpage">1409</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1399-1409&author=M.+Sgobbaauthor=G.+Rastelli&title=Structure-Based+and+in+Silico+Design+of+Hsp90+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSgobba%26aufirst%3DM.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DStructure-Based%2520and%2520in%2520Silico%2520Design%2520of%2520Hsp90%2520Inhibitors%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D1399%26epage%3D1409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruden, D. M.</span><span> </span><span class="NLM_article-title">Hsp90 Inhibitors and Drug Resistance in Cancer: The Potential Benefits of Combination Therapies of Hsp90 Inhibitors and Other Anti-Cancer Drugs</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">995</span><span class="NLM_x">–</span> <span class="NLM_lpage">1004</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2012&pages=995-1004&author=X.+Luauthor=L.+Xiaoauthor=L.+Wangauthor=D.+M.+Ruden&title=Hsp90+Inhibitors+and+Drug+Resistance+in+Cancer%3A+The+Potential+Benefits+of+Combination+Therapies+of+Hsp90+Inhibitors+and+Other+Anti-Cancer+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRuden%26aufirst%3DD.%2BM.%26atitle%3DHsp90%2520Inhibitors%2520and%2520Drug%2520Resistance%2520in%2520Cancer%253A%2520The%2520Potential%2520Benefits%2520of%2520Combination%2520Therapies%2520of%2520Hsp90%2520Inhibitors%2520and%2520Other%2520Anti-Cancer%2520Drugs%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D83%26spage%3D995%26epage%3D1004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopeck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linden, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandarlapaty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moynahan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannah, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudis, C.</span><span> </span><span class="NLM_article-title">HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5132</span><span class="NLM_x">–</span> <span class="NLM_lpage">5139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1158%2F1078-0432.CCR-11-0072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=21558407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFSksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=5132-5139&author=S.+Modiauthor=A.+Stopeckauthor=H.+Lindenauthor=D.+Solitauthor=S.+Chandarlapatyauthor=N.+Rosenauthor=G.+D%E2%80%99Andreaauthor=M.+Dicklerauthor=M.+E.+Moynahanauthor=S.+Sugarmanauthor=W.+Maauthor=S.+Patilauthor=L.+Nortonauthor=A.+L.+Hannahauthor=C.+Hudis&title=HSP90+Inhibition+Is+Effective+in+Breast+Cancer%3A+A+Phase+II+Trial+of+Tanespimycin+%2817-AAG%29+Plus+Trastuzumab+in+Patients+with+HER2-Positive+Metastatic+Breast+Cancer+Progressing+on+Trastuzumab"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab</span></div><div class="casAuthors">Modi, Shanu; Stopeck, Alison; Linden, Hannah; Solit, David; Chandarlapaty, Sarat; Rosen, Neal; D'Andrea, Gabriella; Dickler, Maura; Moynahan, Mary E.; Sugarman, Steven; Ma, Weining; Patil, Sujata; Norton, Larry; Hannah, Alison L.; Hudis, Clifford</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5132-5139</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: HSP90 is a chaperone protein required for the stability of a variety of client proteins. 17-Demethoxygeldanamycin (17-AAG) is a natural product that binds to HSP90 and inhibits its activity, thereby inducing the degrdn. of these clients.  In preclin. studies, HER2 is one of the most sensitive known client proteins of 17-AAG.  On the basis of these data and activity in a phase I study, we conducted a phase II study of 17-AAG (tanespimycin) with trastuzumab in advanced trastuzumab-refractory HER2-pos. breast cancer.  Exptl. Design: We enrolled patients with metastatic HER2+ breast cancer whose disease had previously progressed on trastuzumab.  All patients received weekly treatment with tanespimycin at 450 mg/m2 i.v. and trastuzumab at a conventional dose.  Therapy was continued until disease progression.  The primary endpoint was response rate by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.  RESULTS: Thirty-one patients were enrolled with a median age of 53 years and a median Karnofsky performance status (KPS) of 90%.  The most common toxicities, largely grade 1, were diarrhea, fatigue, nausea, and headache.  The overall response rate was 22%, the clin. benefit rate [complete response + partial response + stable disease] was 59%, the median progression-free survival was 6 mo (95% CI: 4-9), and the median overall survival was 17 mo (95% CI: 16-28).  CONCLUSIONS: This is the first phase II study to definitively show RECIST-defined responses for 17-AAG in solid tumors.  Tanespimycin plus trastuzumab has significant anticancer activity in patients with HER2-pos., metastatic breast cancer previously progressing on trastuzumab.  Further research exploring this therapeutic interaction and the activity of HSP90 inhibitors is clearly warranted.  Clin Cancer Res; 17(15); 5132-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFgVCzhN1fHLVg90H21EOLACvtfcHk0lggdINTqLY13Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFSksbw%253D&md5=07d9e8e06caad7cd7abe03f9e9f7375a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0072%26sid%3Dliteratum%253Aachs%26aulast%3DModi%26aufirst%3DS.%26aulast%3DStopeck%26aufirst%3DA.%26aulast%3DLinden%26aufirst%3DH.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DG.%26aulast%3DDickler%26aufirst%3DM.%26aulast%3DMoynahan%26aufirst%3DM.%2BE.%26aulast%3DSugarman%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DPatil%26aufirst%3DS.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DHannah%26aufirst%3DA.%2BL.%26aulast%3DHudis%26aufirst%3DC.%26atitle%3DHSP90%2520Inhibition%2520Is%2520Effective%2520in%2520Breast%2520Cancer%253A%2520A%2520Phase%2520II%2520Trial%2520of%2520Tanespimycin%2520%252817-AAG%2529%2520Plus%2520Trastuzumab%2520in%2520Patients%2520with%2520HER2-Positive%2520Metastatic%2520Breast%2520Cancer%2520Progressing%2520on%2520Trastuzumab%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D5132%26epage%3D5139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Eastman, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidock, D. A.</span><span> </span><span class="NLM_article-title">Artemisinin-Based Combination Therapies: A Vital Tool in Efforts to Eliminate Malaria</span> <span class="citation_source-journal">Nat. Rev. Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">864</span><span class="NLM_x">–</span> <span class="NLM_lpage">874</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnrmicro2239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=19881520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCjtr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=864-874&author=R.+T.+Eastmanauthor=D.+A.+Fidock&title=Artemisinin-Based+Combination+Therapies%3A+A+Vital+Tool+in+Efforts+to+Eliminate+Malaria"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria</span></div><div class="casAuthors">Eastman, Richard T.; Fidock, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">864-874</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Plasmodium falciparum resistance to chloroquine and sulphadoxine-pyrimethamine has led to the recent adoption of artemisinin-based combination therapies (ACTs) as the first line of treatment against malaria.  ACTs comprise semisynthetic artemisinin derivs. paired with distinct chem. classes of longer acting drugs.  These artemisinins are exceptionally potent against the pathogenic asexual blood stages of Plasmodium parasites and also act on the transmissible sexual stages.  These combinations increase the rates of clin. and parasitol. cures and decrease the selection pressure for the emergence of antimalarial resistance.  This Review article discusses our current knowledge about the mode of action of ACTs, their pharmacol. properties and the proposed mechanisms of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXuOh192DpWbVg90H21EOLACvtfcHk0lggdINTqLY13Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCjtr%252FJ&md5=36f98b991e7c0040d7db9fcbb369b84c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro2239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro2239%26sid%3Dliteratum%253Aachs%26aulast%3DEastman%26aufirst%3DR.%2BT.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26atitle%3DArtemisinin-Based%2520Combination%2520Therapies%253A%2520A%2520Vital%2520Tool%2520in%2520Efforts%2520to%2520Eliminate%2520Malaria%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2009%26volume%3D7%26spage%3D864%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Conway, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, J. A.</span><span> </span><span class="NLM_article-title">Combination Therapy in Multiple Sclerosis</span> <span class="citation_source-journal">Lancet Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1016%2FS1474-4422%2810%2970007-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=20170843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A280%3ADC%252BC3c7lsFahtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=299-308&author=D.+Conwayauthor=J.+A.+Cohen&title=Combination+Therapy+in+Multiple+Sclerosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy in multiple sclerosis</span></div><div class="casAuthors">Conway Devon; Cohen Jeffrey A</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Neurology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">299-308</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Multiple sclerosis (MS) is an autoimmune disease of the CNS.  It is the most common non-traumatic cause of neurological disability among young adults in western Europe and North America.  Existing MS therapies are partly effective in halting ongoing inflammatory tissue damage and clinical progression.  MS pathogenesis is complex and probably heterogeneous among patients, suggesting that combination therapy strategies that target a range of disease mechanisms might be more effective than medications used as monotherapy.  Potential regimens include the combination of interferons and glatiramer acetate with each other or with approved second-line drugs such as natalizumab and mitoxantrone.  Disease-modifying therapies have also been used in combination with drugs approved for other indications, such as corticosteroids, methotrexate, azathioprine, and cyclophosphamide.  Many preliminary studies have provided favourable results for various combination regimens.  However, several subsequent large, randomised, controlled trials have had negative or conflicting results.  Therefore, the usefulness of combination therapy in MS remains uncertain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-mj2O1SLeD3RxY89Cm6SyfW6udTcc2eYPKnkqlq0Dibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7lsFahtA%253D%253D&md5=7f5769f0f5a2aaf1eb03cef5defaca60</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2810%2970007-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252810%252970007-7%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DD.%26aulast%3DCohen%26aufirst%3DJ.%2BA.%26atitle%3DCombination%2520Therapy%2520in%2520Multiple%2520Sclerosis%26jtitle%3DLancet%2520Neurol.%26date%3D2010%26volume%3D9%26spage%3D299%26epage%3D308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span>CTEP, Cancer Therapy Evaluation Program. <a href="http://ctep.cancer.gov" class="extLink">http://ctep.cancer.gov</a> (accessed Dec<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CTEP%2C+Cancer+Therapy+Evaluation+Program.+http%3A%2F%2Fctep.cancer.gov+%28accessed+Dec+2013%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorusso, P.</span><span> </span><span class="NLM_article-title">Analysis of Lung Cancer Patients Enrolled in CTEP (Cancer Therapy Evaluation Program)-Sponsored Phase I Trials</span> <span class="citation_source-journal">Clin. Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">218</span><span class="NLM_x">–</span> <span class="NLM_lpage">223</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1016%2Fj.cllc.2011.03.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=21726820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A280%3ADC%252BC3MnlsFemuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=218-223&author=S.+M.+Gadgeelauthor=P.+Ivyauthor=W.+Chenauthor=J.+Mauerauthor=D.+Smithauthor=P.+Lorusso&title=Analysis+of+Lung+Cancer+Patients+Enrolled+in+CTEP+%28Cancer+Therapy+Evaluation+Program%29-Sponsored+Phase+I+Trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trials</span></div><div class="casAuthors">Gadgeel Shirish M; Ivy Percy; Chen Wei; Mauer Joan; Smith Daryn; Lorusso Patricia</div><div class="citationInfo"><span class="NLM_cas:title">Clinical lung cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">218-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  A recent review of phase I trials suggests that participation in these trials can be associated with clinical benefit and the rate of drug-related deaths is low.  We conducted an analysis of the Cancer Therapy Evaluation Program (CTEP)-sponsored phase I trials to assess the outcomes of lung cancer patients enrolled in phase I trials.  MATERIALS AND METHODS:  Data from all CTEP-sponsored adult phase I trials conducted between 1997 and 2008 were analyzed.  An analysis of demographics, rates of toxicities, and clinical benefit rate among patients with non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), and other cancers was conducted.  RESULTS:  Of the 3560 patients enrolled in 136 phase I trials, 301 (8.5%) had NSCLC and 40 (1.1%) had SCLC.  The median age of lung cancer patients, at 60 years, was significantly higher than patients with other cancers.  The rest of the demographics were similar among the groups.  The rate of Grade 3-5 toxicities was higher among NSCLC patients (54% versus 46%).  The toxicity-related death rate was ≤ 1% among all groups.  The clinical benefit rate and median duration in study of approximately 2 months were similar among all groups of patients.  CONCLUSION:  An analysis of the CTEP-sponsored phase I trials shows that lung cancer patients enrolled in these trials have a similar incidence of toxicity-related deaths and a similar probability of clinical benefit as patients with other cancers.  These data suggest that patients with progressive lung cancer following approved therapies should be considered for phase I trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQm-N48QhUJkloaUqgkFHkfW6udTcc2eYPKnkqlq0Dibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnlsFemuw%253D%253D&md5=89e3772cff75712d2f8ffdc73f9ab474</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.cllc.2011.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cllc.2011.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DIvy%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DMauer%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DLorusso%26aufirst%3DP.%26atitle%3DAnalysis%2520of%2520Lung%2520Cancer%2520Patients%2520Enrolled%2520in%2520CTEP%2520%2528Cancer%2520Therapy%2520Evaluation%2520Program%2529-Sponsored%2520Phase%2520I%2520Trials%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2011%26volume%3D12%26spage%3D218%26epage%3D223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Luke, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubinstein, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. J.</span><span> </span><span class="NLM_article-title">Similar Efficacy for Phase I Trials in Comparison with DTIC for Advanced Malignant Melanoma: An Analysis of Melanoma Outcomes in CTEP-Sponsored Phase I Trials 1995–2011</span> <span class="citation_source-journal">Melanoma Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">152</span><span class="NLM_x">–</span> <span class="NLM_lpage">158</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1097%2FCMR.0b013e32835f73b2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=23411478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtlyhur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=152-158&author=J.+J.+Lukeauthor=L.+V.+Rubinsteinauthor=G.+L.+Smithauthor=S.+P.+Ivyauthor=P.+J.+Harris&title=Similar+Efficacy+for+Phase+I+Trials+in+Comparison+with+DTIC+for+Advanced+Malignant+Melanoma%3A+An+Analysis+of+Melanoma+Outcomes+in+CTEP-Sponsored+Phase+I+Trials+1995%E2%80%932011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011</span></div><div class="casAuthors">Luke, Jason J.; Rubinstein, Lawrence V.; Smith, Gary L.; Ivy, S. Percy; Harris, Pamela J.</div><div class="citationInfo"><span class="NLM_cas:title">Melanoma Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">152-158</span>CODEN:
                <span class="NLM_cas:coden">MREEEH</span>;
        ISSN:<span class="NLM_cas:issn">0960-8931</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">After ipilimumab, vemurafenib, and interleukin-2, std. of care chemotherapy for melanoma remains dacarbazine (response rate ∼9%).  Despite this, many physicians hesitate to refer patients to phase I protocols given a perceived lack of clin. benefit and potential for harm.  To better understand the validity of these perceptions, the experience of all patients with melanoma treated on phase I trials sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program (NCI-CTEP) from 1995 to 2011 were analyzed and compared with the pooled results of six contemporary phase III trials of dacarbazine.  A total of 937 patients with melanoma were treated in 148 CTEP phase I trials.  The majority were men with a median of two prior therapies (46% receiving prior dacarbazine).  Response and clin. benefit rates in these trials were not clin. different from those of dacarbazine (phase I: 6.3 and 26.8% vs. dacarbazine: 8.8 and 27.9%) although grades 3 and 4 toxicity was significantly higher (54 vs. 28%).  Efficacy and toxicity were generally consistent within phase I subgroups (targeted agents, immunotherapies, or chemotherapeutics) though targeted therapy was assocd. with a lower response rate, immunotherapy with lower clin. benefit rate, and chemotherapy with higher incidence of grade 4 toxicity.  Thus, the perception of limited efficacy of phase I trials for patients with melanoma was disproven, whereas the perception of toxicity was obsd.  However, this difference in toxicity may have been largely because of the nature of phase I vs. phase III trials (i.e. more heavily pretreated) and because of the phase I trials often being multiagent as opposed to dacarbazine alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPrB4efLzZmbVg90H21EOLACvtfcHk0lgxiv6dK6NdUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtlyhur0%253D&md5=3a899d8bf69d2fea11427de2b604c134</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1097%2FCMR.0b013e32835f73b2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCMR.0b013e32835f73b2%26sid%3Dliteratum%253Aachs%26aulast%3DLuke%26aufirst%3DJ.%2BJ.%26aulast%3DRubinstein%26aufirst%3DL.%2BV.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DIvy%26aufirst%3DS.%2BP.%26aulast%3DHarris%26aufirst%3DP.%2BJ.%26atitle%3DSimilar%2520Efficacy%2520for%2520Phase%2520I%2520Trials%2520in%2520Comparison%2520with%2520DTIC%2520for%2520Advanced%2520Malignant%2520Melanoma%253A%2520An%2520Analysis%2520of%2520Melanoma%2520Outcomes%2520in%2520CTEP-Sponsored%2520Phase%2520I%2520Trials%25201995%25E2%2580%25932011%26jtitle%3DMelanoma%2520Res.%26date%3D2013%26volume%3D23%26spage%3D152%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Giacomini, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauss, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roden, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichelbaum, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayden, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, Y.</span><span> </span><span class="NLM_article-title">When Good Drugs Go Bad</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">446</span><span class="NLM_x">, </span> <span class="NLM_fpage">975</span><span class="NLM_x">–</span> <span class="NLM_lpage">977</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2F446975a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=17460642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFektL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=446&publication_year=2007&pages=975-977&author=K.+M.+Giacominiauthor=R.+M.+Kraussauthor=D.+M.+Rodenauthor=M.+Eichelbaumauthor=M.+R.+Haydenauthor=Y.+Nakamura&title=When+Good+Drugs+Go+Bad"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">When good drugs go bad</span></div><div class="casAuthors">Giacomini, Kathleen M.; Krauss, Ronald M.; Roden, Dan M.; Eichelbaum, Michel; Hayden, Michael R.; Nakamura, Yusuke</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">446</span>
        (<span class="NLM_cas:issue">7139</span>),
    <span class="NLM_cas:pages">975-977</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx3QRPuUhA4bVg90H21EOLACvtfcHk0lgxiv6dK6NdUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFektL0%253D&md5=79a9929078be854ee44578fa3e2f9bb2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2F446975a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F446975a%26sid%3Dliteratum%253Aachs%26aulast%3DGiacomini%26aufirst%3DK.%2BM.%26aulast%3DKrauss%26aufirst%3DR.%2BM.%26aulast%3DRoden%26aufirst%3DD.%2BM.%26aulast%3DEichelbaum%26aufirst%3DM.%26aulast%3DHayden%26aufirst%3DM.%2BR.%26aulast%3DNakamura%26aufirst%3DY.%26atitle%3DWhen%2520Good%2520Drugs%2520Go%2520Bad%26jtitle%3DNature%26date%3D2007%26volume%3D446%26spage%3D975%26epage%3D977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Overall, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleifeld, O.</span><span> </span><span class="NLM_article-title">Tumour Microenvironment—Opinion: Validating Matrix Metalloproteinases as Drug Targets and Anti-Targets for Cancer Therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">239</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnrc1821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=16498445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhslelt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=227-239&author=C.+M.+Overallauthor=O.+Kleifeld&title=Tumour+Microenvironment%E2%80%94Opinion%3A+Validating+Matrix+Metalloproteinases+as+Drug+Targets+and+Anti-Targets+for+Cancer+Therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour microenvironment - Opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy</span></div><div class="casAuthors">Overall, Christopher M.; Kleifeld, Oded</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">227-239</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The matrix metalloproteinases (MMPs) mediate homeostasis of the extracellular environment.  They have multiple signaling activities that are commonly altered during tumorigenesis and that might serve as intervention points for anticancer drugs.  However, there are many criteria to consider in validating MMPs as drug targets and for the development of MMP inhibitors.  The inhibition of some MMPs could have pro-tumorigenic effects (making them anti-targets), counterbalancing the benefits of target inhibition.  These effects might partially account for the failure of MMP inhibitors in clin. trials.  What are the major challenges in MMP target validation and MMP-inhibitor-drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc3iBQEggRc7Vg90H21EOLACvtfcHk0ljeXR2NnsJQHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhslelt70%253D&md5=3edfeca153a62c759443d0893a6212e2</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnrc1821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1821%26sid%3Dliteratum%253Aachs%26aulast%3DOverall%26aufirst%3DC.%2BM.%26aulast%3DKleifeld%26aufirst%3DO.%26atitle%3DTumour%2520Microenvironment%25E2%2580%2594Opinion%253A%2520Validating%2520Matrix%2520Metalloproteinases%2520as%2520Drug%2520Targets%2520and%2520Anti-Targets%2520for%2520Cancer%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D227%26epage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Aggarwal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondeti, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenna, R.</span><span> </span><span class="NLM_article-title">Insights towards Sulfonamide Drug Specificity in α-Carbonic Anhydrases</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1526</span><span class="NLM_x">–</span> <span class="NLM_lpage">1533</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=1526-1533&author=M.+Aggarwalauthor=B.+Kondetiauthor=R.+McKenna&title=Insights+towards+Sulfonamide+Drug+Specificity+in+%CE%B1-Carbonic+Anhydrases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DM.%26aulast%3DKondeti%26aufirst%3DB.%26aulast%3DMcKenna%26aufirst%3DR.%26atitle%3DInsights%2520towards%2520Sulfonamide%2520Drug%2520Specificity%2520in%2520%25CE%25B1-Carbonic%2520Anhydrases%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D1526%26epage%3D1533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Peters, J.-U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bissantz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillebrecht, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerebtzoff, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendels, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tillier, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migeon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guba, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span> </span><span class="NLM_article-title">Can We Discover Pharmacological Promiscuity Early in the Drug Discovery Process?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">335</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=325-335&author=J.-U.+Petersauthor=J.+Hertauthor=C.+Bissantzauthor=A.+Hillebrechtauthor=G.+Gerebtzoffauthor=S.+Bendelsauthor=F.+Tillierauthor=J.+Migeonauthor=H.+Fischerauthor=W.+Gubaauthor=M.+Kansy&title=Can+We+Discover+Pharmacological+Promiscuity+Early+in+the+Drug+Discovery+Process%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26aulast%3DHert%26aufirst%3DJ.%26aulast%3DBissantz%26aufirst%3DC.%26aulast%3DHillebrecht%26aufirst%3DA.%26aulast%3DGerebtzoff%26aufirst%3DG.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DTillier%26aufirst%3DF.%26aulast%3DMigeon%26aufirst%3DJ.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DGuba%26aufirst%3DW.%26aulast%3DKansy%26aufirst%3DM.%26atitle%3DCan%2520We%2520Discover%2520Pharmacological%2520Promiscuity%2520Early%2520in%2520the%2520Drug%2520Discovery%2520Process%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D325%26epage%3D335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Kuhn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al Banchaabouchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campillos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavin, A.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bork, P.</span><span> </span><span class="NLM_article-title">Systematic Identification of Proteins That Elicit Drug Side Effects</span> <span class="citation_source-journal">Mol. Syst. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">663</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=663&author=M.+Kuhnauthor=M.+Al+Banchaabouchiauthor=M.+Campillosauthor=L.+J.+Jensenauthor=C.+Grossauthor=A.-C.+Gavinauthor=P.+Bork&title=Systematic+Identification+of+Proteins+That+Elicit+Drug+Side+Effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKuhn%26aufirst%3DM.%26aulast%3DAl%2BBanchaabouchi%26aufirst%3DM.%26aulast%3DCampillos%26aufirst%3DM.%26aulast%3DJensen%26aufirst%3DL.%2BJ.%26aulast%3DGross%26aufirst%3DC.%26aulast%3DGavin%26aufirst%3DA.-C.%26aulast%3DBork%26aufirst%3DP.%26atitle%3DSystematic%2520Identification%2520of%2520Proteins%2520That%2520Elicit%2520Drug%2520Side%2520Effects%26jtitle%3DMol.%2520Syst.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3D663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Lounkine, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikhailov, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doak, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span> </span><span class="NLM_article-title">Large-Scale Prediction and Testing of Drug Activity on Side-Effect Targets</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">486</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnature11159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=22722194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFyrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=361-367&author=E.+Lounkineauthor=M.+J.+Keiserauthor=S.+Whitebreadauthor=D.+Mikhailovauthor=J.+Hamonauthor=J.+L.+Jenkinsauthor=P.+Lavanauthor=E.+Weberauthor=A.+K.+Doakauthor=S.+C%C3%B4t%C3%A9author=B.+K.+Shoichetauthor=L.+Urban&title=Large-Scale+Prediction+and+Testing+of+Drug+Activity+on+Side-Effect+Targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Large-scale prediction and testing of drug activity on side-effect targets</span></div><div class="casAuthors">Lounkine, Eugen; Keiser, Michael J.; Whitebread, Steven; Mikhailov, Dmitri; Hamon, Jacques; Jenkins, Jeremy L.; Lavan, Paul; Weber, Eckhard; Doak, Allison K.; Cote, Serge; Shoichet, Brian K.; Urban, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7403</span>),
    <span class="NLM_cas:pages">361-367</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Discovering the unintended off-targets' that predict adverse drug reactions is daunting by empirical methods alone.  Drugs can act on several protein targets, some of which can be unrelated by conventional mol. metrics, and hundreds of proteins have been implicated in side effects.  Here we use a computational strategy to predict the activity of 656 marketed drugs on 73 unintended side-effect' targets.  Approx. half of the predictions were confirmed, either from proprietary databases unknown to the method or by new exptl. assays.  Affinities for these new off-targets ranged from 1 nM to 30 μM.  To explore relevance, we developed an assocn. metric to prioritize those new off-targets that explained side effects better than any known target of a given drug, creating a drug-target-adverse drug reaction network.  Among these new assocns. was the prediction that the abdominal pain side effect of the synthetic estrogen chlorotrianisene was mediated through its newly discovered inhibition of the enzyme cyclooxygenase-1.  The clin. relevance of this inhibition was borne out in whole human blood platelet aggregation assays.  This approach may have wide application to de-risking toxicol. liabilities in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5sVjfn4mgLLVg90H21EOLACvtfcHk0lib5JVYBxuGEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFyrtb0%253D&md5=9c133b839d9527818a27a5834e4dfe11</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnature11159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11159%26sid%3Dliteratum%253Aachs%26aulast%3DLounkine%26aufirst%3DE.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DMikhailov%26aufirst%3DD.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DLavan%26aufirst%3DP.%26aulast%3DWeber%26aufirst%3DE.%26aulast%3DDoak%26aufirst%3DA.%2BK.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DS.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DLarge-Scale%2520Prediction%2520and%2520Testing%2520of%2520Drug%2520Activity%2520on%2520Side-Effect%2520Targets%26jtitle%3DNature%26date%3D2012%26volume%3D486%26spage%3D361%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheiber, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzaoui, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span> </span><span class="NLM_article-title">Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off-Target Effects from Chemical Structure</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">861</span><span class="NLM_x">–</span> <span class="NLM_lpage">873</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1002%2Fcmdc.200700026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=17477341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntVShu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=861-873&author=A.+Benderauthor=J.+Scheiberauthor=M.+Glickauthor=J.+W.+Daviesauthor=K.+Azzaouiauthor=J.+Hamonauthor=L.+Urbanauthor=S.+Whitebreadauthor=J.+L.+Jenkins&title=Analysis+of+Pharmacology+Data+and+the+Prediction+of+Adverse+Drug+Reactions+and+Off-Target+Effects+from+Chemical+Structure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure</span></div><div class="casAuthors">Bender, Andreas; Scheiber, Josef; Glick, Meir; Davies, John W.; Azzaoui, Kamal; Hamon, Jacques; Urban, Laszlo; Whitebread, Steven; Jenkins, Jeremy L.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">861-873</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Preclin. Safety Pharmacol. (PSP) attempts to anticipate adverse drug reactions (ADRs) during early phases of drug discovery by testing compds. in simple, in vitro binding assays (i.e., preclin. profiling).  The selection of PSP targets is based largely on circumstantial evidence of their contribution to known clin. ADRs, inferred from findings in clin. trials, animal expts., and mol. studies going back more than 40 years.  In this work we explore PSP chem. space and its relevance for the prediction of adverse drug reactions.  Firstly, in silico (computational) Bayesian models for 70 PSP-related targets were built, which are able to detect 93% of the ligands binding at IC50≤ 10 μM at an overall correct classification rate of about 94 %.  Secondly, employing the World Drug Index (WDI), a model for adverse drug reactions was built directly based on normalized side-effect annotations in the WDI, which does not require any underlying functional knowledge.  This is, to our knowledge, the first attempt to predict adverse drug reactions across hundreds of categories from chem. structure alone.  On av. 90 % of the adverse drug reactions obsd. with known, clin. used compds. were detected, an overall correct classification rate of 92 %.  Drugs withdrawn from the market (Rapacuronium, Suprofen) were tested in the model and their predicted ADRs align well with known ADRs.  The anal. was repeated for acetylsalicylic acid and Benperidol which are still on the market.  Importantly, features of the models are interpretable and back-projectable to chem. structure, raising the possibility of rationally engineering out adverse effects.  By combining PSP and ADR models new hypotheses linking targets and adverse effects can be proposed and examples for the opioid μ and the muscarinic M2 receptors, as well as for cyclooxygenase-1 are presented.  It is hoped that the generation of predictive models for adverse drug reactions is able to help support early SAR to accelerate drug discovery and decrease late stage attrition in drug discovery projects.  In addn., models such as the ones presented here can be used for compd. profiling in all development stages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr28cgC-UGC3LVg90H21EOLACvtfcHk0lib5JVYBxuGEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntVShu74%253D&md5=b04e52a6b745d233415b106e53e6e2c9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700026%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%26aulast%3DScheiber%26aufirst%3DJ.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DJ.%2BW.%26aulast%3DAzzaoui%26aufirst%3DK.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DUrban%26aufirst%3DL.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26atitle%3DAnalysis%2520of%2520Pharmacology%2520Data%2520and%2520the%2520Prediction%2520of%2520Adverse%2520Drug%2520Reactions%2520and%2520Off-Target%2520Effects%2520from%2520Chemical%2520Structure%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D861%26epage%3D873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Azzaoui, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacoby, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span> </span><span class="NLM_article-title">Modeling Promiscuity Based on in Vitro Safety Pharmacology Profiling Data</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">874</span><span class="NLM_x">–</span> <span class="NLM_lpage">880</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1002%2Fcmdc.200700036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=17492703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntVShu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=874-880&author=K.+Azzaouiauthor=J.+Hamonauthor=B.+Fallerauthor=S.+Whitebreadauthor=E.+Jacobyauthor=A.+Benderauthor=J.+L.+Jenkinsauthor=L.+Urban&title=Modeling+Promiscuity+Based+on+in+Vitro+Safety+Pharmacology+Profiling+Data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling promiscuity based on in vitro safety pharmacology profiling data</span></div><div class="casAuthors">Azzaoui, Kamal; Hamon, Jacques; Faller, Bernard; Whitebread, Steven; Jacoby, Edgar; Bender, Andreas; Jenkins, Jeremy L.; Urban, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">874-880</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">This study describes a method for mining and modeling binding data obtained from a large panel of targets (in vitro safety pharmacol.) to distinguish differences between promiscuous and selective compds.  Two naive Bayes models for promiscuity and selectivity were generated and validated on a test set as well as publicly available drug databases.  The model shows a higher score (lower promiscuity) for marketed drugs than for compds. in early development or compds. that failed during clin. development.  Such models can be used in triaging high-throughput screening data or for lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw2wR-U-z9YrVg90H21EOLACvtfcHk0lhVaY5xc0_0Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntVShu78%253D&md5=30c8923e136d16ffd0b1ecd62afb8ff3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700036%26sid%3Dliteratum%253Aachs%26aulast%3DAzzaoui%26aufirst%3DK.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFaller%26aufirst%3DB.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DJacoby%26aufirst%3DE.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DModeling%2520Promiscuity%2520Based%2520on%2520in%2520Vitro%2520Safety%2520Pharmacology%2520Profiling%2520Data%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D874%26epage%3D880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Lamers, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cysouw, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdouw, P. D.</span><span> </span><span class="NLM_article-title">Slow Calcium Channel Blockers and Calmodulin. Effect of Felodipine, Nifedipine, Prenylamine and Bepridil on Cardiac Sarcolemmal Calcium Pumping ATPase</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">3837</span><span class="NLM_x">–</span> <span class="NLM_lpage">3843</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1985&pages=3837-3843&author=J.+M.+Lamersauthor=K.+J.+Cysouwauthor=P.+D.+Verdouw&title=Slow+Calcium+Channel+Blockers+and+Calmodulin.+Effect+of+Felodipine%2C+Nifedipine%2C+Prenylamine+and+Bepridil+on+Cardiac+Sarcolemmal+Calcium+Pumping+ATPase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLamers%26aufirst%3DJ.%2BM.%26aulast%3DCysouw%26aufirst%3DK.%2BJ.%26aulast%3DVerdouw%26aufirst%3DP.%2BD.%26atitle%3DSlow%2520Calcium%2520Channel%2520Blockers%2520and%2520Calmodulin.%2520Effect%2520of%2520Felodipine%252C%2520Nifedipine%252C%2520Prenylamine%2520and%2520Bepridil%2520on%2520Cardiac%2520Sarcolemmal%2520Calcium%2520Pumping%2520ATPase%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1985%26volume%3D34%26spage%3D3837%26epage%3D3843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Chong, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, D. J.</span><span> </span><span class="NLM_article-title">New Uses for Old Drugs</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">448</span><span class="NLM_x">, </span> <span class="NLM_fpage">645</span><span class="NLM_x">–</span> <span class="NLM_lpage">646</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2F448645a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=17687303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD2sXos1ylu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=645-646&author=C.+R.+Chongauthor=D.+J.+Sullivan&title=New+Uses+for+Old+Drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">New uses for old drugs</span></div><div class="casAuthors">Chong, Curtis R.; Sullivan, David J., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7154</span>),
    <span class="NLM_cas:pages">645-646</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">It takes too long and costs too much to bring new drugs to market.  So let's beef up efforts to screen existing drugs for new uses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlEUwK7HNo67Vg90H21EOLACvtfcHk0lhVaY5xc0_0Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXos1ylu7o%253D&md5=9752ed45ce75d1ce1f48793a59d0bdc0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2F448645a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F448645a%26sid%3Dliteratum%253Aachs%26aulast%3DChong%26aufirst%3DC.%2BR.%26aulast%3DSullivan%26aufirst%3DD.%2BJ.%26atitle%3DNew%2520Uses%2520for%2520Old%2520Drugs%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D645%26epage%3D646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laggner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuijer, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matos, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whaley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, K. L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Predicting New Molecular Targets for Known Drugs</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnature08506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=19881490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlers7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=175-181&author=M.+J.+Keiserauthor=V.+Setolaauthor=J.+J.+Irwinauthor=C.+Laggnerauthor=A.+I.+Abbasauthor=S.+J.+Hufeisenauthor=N.+H.+Jensenauthor=M.+B.+Kuijerauthor=R.+C.+Matosauthor=T.+B.+Tranauthor=R.+Whaleyauthor=R.+A.+Glennonauthor=J.+Hertauthor=K.+L.+H.+Thomasauthor=D.+D.+Edwardsauthor=B.+K.+Shoichetauthor=B.+L.+Roth&title=Predicting+New+Molecular+Targets+for+Known+Drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting new molecular targets for known drugs</span></div><div class="casAuthors">Keiser, Michael J.; Setola, Vincent; Irwin, John J.; Laggner, Christian; Abbas, Atheir I.; Hufeisen, Sandra J.; Jensen, Niels H.; Kuijer, Michael B.; Matos, Roberto C.; Tran, Thuy B.; Whaley, Ryan; Glennon, Richard A.; Hert, Jerome; Thomas, Kelan L. H.; Edwards, Douglas D.; Shoichet, Brian K.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7270</span>),
    <span class="NLM_cas:pages">175-181</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although drugs are intended to be selective, at least some bind to several physiol. targets, explaining side effects and efficacy.  Because many drug-target combinations exist, it would be useful to explore possible interactions computationally.  Here we compared 3665 US Food and Drug Administration (FDA)-approved and investigational drugs against hundreds of targets, defining each target by its ligands.  Chem. similarities between drugs and ligand sets predicted thousands of unanticipated assocns.  Thirty were tested exptl., including the antagonism of the β1 receptor by the transporter inhibitor Prozac, the inhibition of the 5-hydroxytryptamine (5-HT) transporter by the ion channel drug Vadilex, and antagonism of the histamine H4 receptor by the enzyme inhibitor Rescriptor.  Overall, 23 new drug-target assocns. were confirmed, five of which were potent (<100 nM).  The physiol. relevance of one, the drug N,N-dimethyltryptamine (DMT) on serotonergic receptors, was confirmed in a knockout mouse.  The chem. similarity approach is systematic and comprehensive, and may suggest side-effects and new indications for many drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozd-8cCXUskrVg90H21EOLACvtfcHk0lix0hW7RE90KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlers7vO&md5=974e65f5d5b4dabde1a463c429215546</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnature08506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08506%26sid%3Dliteratum%253Aachs%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DLaggner%26aufirst%3DC.%26aulast%3DAbbas%26aufirst%3DA.%2BI.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DKuijer%26aufirst%3DM.%2BB.%26aulast%3DMatos%26aufirst%3DR.%2BC.%26aulast%3DTran%26aufirst%3DT.%2BB.%26aulast%3DWhaley%26aufirst%3DR.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DHert%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DK.%2BL.%2BH.%26aulast%3DEdwards%26aufirst%3DD.%2BD.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DPredicting%2520New%2520Molecular%2520Targets%2520for%2520Known%2520Drugs%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D175%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Boolell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gepi-Attee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muirhead, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naylor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterloh, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingell, C.</span><span> </span><span class="NLM_article-title">Sildenafil: An Orally Active Type 5 Cyclic GMP-Specific Phosphodiesterase Inhibitor for the Treatment of Penile Erectile Dysfunction</span> <span class="citation_source-journal">Int. J. Impotence Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">52</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=8858389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A280%3ADyaK2s%252FhtFekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1996&pages=47-52&author=M.+Boolellauthor=M.+J.+Allenauthor=S.+A.+Ballardauthor=S.+Gepi-Atteeauthor=G.+J.+Muirheadauthor=A.+M.+Naylorauthor=I.+H.+Osterlohauthor=C.+Gingell&title=Sildenafil%3A+An+Orally+Active+Type+5+Cyclic+GMP-Specific+Phosphodiesterase+Inhibitor+for+the+Treatment+of+Penile+Erectile+Dysfunction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction</span></div><div class="casAuthors">Boolell M; Allen M J; Ballard S A; Gepi-Attee S; Muirhead G J; Naylor A M; Osterloh I H; Gingell C</div><div class="citationInfo"><span class="NLM_cas:title">International journal of impotence research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">47-52</span>
        ISSN:<span class="NLM_cas:issn">0955-9930</span>.
    </div><div class="casAbstract">Sildenafil (Viagra, UK-92,480) is a novel oral agent under development for the treatment of penile erectile dysfunction.  Erection is dependent on nitric oxide and its second messenger, cyclic guanosine monophosphate (cGMP).  However, the relative importance of phosphodiesterase (PDE) isozymes is not clear.  We have identified both cGMP- and cyclic adenosine monophosphate-specific phosphodiesterases (PDEs) in human corpora cavernosa in vitro.  The main PDE activity in this tissue was due to PDE5, with PDE2 and 3 also identified.  Sildenafil is a selective inhibitor of PDE5 with a mean IC50 of 0.0039 microM.  In human volunteers, we have shown sildenafil to have suitable pharmacokinetic and pharmacodynamic properties (rapid absorption, relatively short half-life, no significant effect on heart rate and blood pressure) for an oral agent to be taken, as required, prior to sexual activity.  Moreover, in a clinical study of 12 patients with erectile dysfunction without an established organic cause, we have shown sildenafil to enhance the erectile response (duration and rigidity of erection) to visual sexual stimulation, thus highlighting the important role of PDE5 in human penile erection.  Sildenafil holds promise as a new effective oral treatment for penile erectile dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHiUn0Ryiem0bxh97K6Vt6fW6udTcc2ea1Q9NQXWmCCLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s%252FhtFekuw%253D%253D&md5=35783bf8f6ff593b0a67e7e302392cd5</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoolell%26aufirst%3DM.%26aulast%3DAllen%26aufirst%3DM.%2BJ.%26aulast%3DBallard%26aufirst%3DS.%2BA.%26aulast%3DGepi-Attee%26aufirst%3DS.%26aulast%3DMuirhead%26aufirst%3DG.%2BJ.%26aulast%3DNaylor%26aufirst%3DA.%2BM.%26aulast%3DOsterloh%26aufirst%3DI.%2BH.%26aulast%3DGingell%26aufirst%3DC.%26atitle%3DSildenafil%253A%2520An%2520Orally%2520Active%2520Type%25205%2520Cyclic%2520GMP-Specific%2520Phosphodiesterase%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Penile%2520Erectile%2520Dysfunction%26jtitle%3DInt.%2520J.%2520Impotence%2520Res.%26date%3D1996%26volume%3D8%26spage%3D47%26epage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Silverman, W. A.</span><span> </span><span class="NLM_article-title">The Schizophrenic Career of a “Monster Drug”</span> <span class="citation_source-journal">Pediatrics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">404</span><span class="NLM_x">–</span> <span class="NLM_lpage">406</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2002&pages=404-406&author=W.+A.+Silverman&title=The+Schizophrenic+Career+of+a+%E2%80%9CMonster+Drug%E2%80%9D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSilverman%26aufirst%3DW.%2BA.%26atitle%3DThe%2520Schizophrenic%2520Career%2520of%2520a%2520%25E2%2580%259CMonster%2520Drug%25E2%2580%259D%26jtitle%3DPediatrics%26date%3D2002%26volume%3D110%26spage%3D404%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Cronstein, B. N.</span><span> </span><span class="NLM_article-title">Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1124%2Fpr.57.2.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=15914465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFejtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2005&pages=163-172&author=B.+N.+Cronstein&title=Low-Dose+Methotrexate%3A+A+Mainstay+in+the+Treatment+of+Rheumatoid+Arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Cronstein, Bruce N.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-172</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Methotrexate administered weekly in low doses is a mainstay in the therapy of rheumatoid arthritis.  Although originally developed as a folate antagonist for the treatment of cancer, its mechanism of action in the therapy of rheumatoid arthritis remains less clear.  Several mechanisms have been proposed including inhibition of T cell proliferation via its effects on purine and pyrimidine metab., inhibition of transmethylation reactions required for the prevention of T cell cytotoxicity, interference with glutathione metab. leading to alterations in recruitment of monocytes and other cells to the inflamed joint, and promotion of the release of the endogenous anti-inflammatory mediator adenosine.  These mechanisms of action and the role of methotrexate in the suppression of rheumatoid arthritis are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAeIg6zcVXbrVg90H21EOLACvtfcHk0lgE8kUcFmUjkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFejtLw%253D&md5=c6aae603ad4c25f2e2dc4296ecc540c2</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1124%2Fpr.57.2.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.57.2.3%26sid%3Dliteratum%253Aachs%26aulast%3DCronstein%26aufirst%3DB.%2BN.%26atitle%3DLow-Dose%2520Methotrexate%253A%2520A%2520Mainstay%2520in%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DPharmacol.%2520Rev.%26date%3D2005%26volume%3D57%26spage%3D163%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Nygren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fryknäs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agerup, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, R.</span><span> </span><span class="NLM_article-title">Repositioning of the Anthelmintic Drug Mebendazole for the Treatment for Colon Cancer</span> <span class="citation_source-journal">J. Cancer Res. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">139</span><span class="NLM_x">, </span> <span class="NLM_fpage">2133</span><span class="NLM_x">–</span> <span class="NLM_lpage">2140</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2013&pages=2133-2140&author=P.+Nygrenauthor=M.+Frykn%C3%A4sauthor=B.+Agerupauthor=R.+Larsson&title=Repositioning+of+the+Anthelmintic+Drug+Mebendazole+for+the+Treatment+for+Colon+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNygren%26aufirst%3DP.%26aulast%3DFrykn%25C3%25A4s%26aufirst%3DM.%26aulast%3DAgerup%26aufirst%3DB.%26aulast%3DLarsson%26aufirst%3DR.%26atitle%3DRepositioning%2520of%2520the%2520Anthelmintic%2520Drug%2520Mebendazole%2520for%2520the%2520Treatment%2520for%2520Colon%2520Cancer%26jtitle%3DJ.%2520Cancer%2520Res.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D139%26spage%3D2133%26epage%3D2140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Corbett, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, C.</span><span> </span><span class="NLM_article-title">Drug Repositioning: An Opportunity To Develop Novel Treatments for Alzheimer’s Disease</span> <span class="citation_source-journal">Pharmaceuticals (Basel, Switz.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1304</span><span class="NLM_x">–</span> <span class="NLM_lpage">1321</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.3390%2Fph6101304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A280%3ADC%252BC2c3ntVyqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=1304-1321&author=A.+Corbettauthor=G.+Williamsauthor=C.+Ballard&title=Drug+Repositioning%3A+An+Opportunity+To+Develop+Novel+Treatments+for+Alzheimer%E2%80%99s+Disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease</span></div><div class="casAuthors">Corbett Anne; Williams Gareth; Ballard Clive</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceuticals (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1304-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer's Disease (AD) is the most common cause of dementia, affecting approximately two thirds of the 35 million people worldwide with the condition.  Despite this, effective treatments are lacking, and there are no drugs that elicit disease modifying effects to improve outcome.  There is an urgent need to develop and evaluate more effective pharmacological treatments.  Drug repositioning offers an exciting opportunity to repurpose existing licensed treatments for use in AD, with the benefit of providing a far more rapid route to the clinic than through novel drug discovery approaches.  This review outlines the current most promising candidates for repositioning in AD, their supporting evidence and their progress through trials to date.  Furthermore, it begins to explore the potential of new transcriptomic and microarray techniques to consider the future of drug repositioning as a viable approach to drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS10Bk82pOZcJSWdIdmEou5fW6udTcc2eYDHUKoE3PLH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3ntVyqsw%253D%253D&md5=45ddec28e1a9020c0f1f4f2e3bfd86ed</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.3390%2Fph6101304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph6101304%26sid%3Dliteratum%253Aachs%26aulast%3DCorbett%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DBallard%26aufirst%3DC.%26atitle%3DDrug%2520Repositioning%253A%2520An%2520Opportunity%2520To%2520Develop%2520Novel%2520Treatments%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DPharmaceuticals%2520%2528Basel%252C%2520Switz.%2529%26date%3D2013%26volume%3D6%26spage%3D1304%26epage%3D1321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Targeting the Cancer Kinome through Polypharmacology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+Cancer+Kinome+through+Polypharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0lgD-dhGVTwM0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520Cancer%2520Kinome%2520through%2520Polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D130%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting Cancer with Small Molecule Kinase Inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+Cancer+with+Small+Molecule+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0lgD-dhGVTwM0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520Cancer%2520with%2520Small%2520Molecule%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Blanc, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menet, C.</span><span> </span><span class="NLM_article-title">Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">731</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.2174%2F1871520611313050008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=23094911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslyku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=731-747&author=J.+Blancauthor=R.+Geneyauthor=C.+Menet&title=Type+II+Kinase+Inhibitors%3A+An+Opportunity+in+Cancer+for+Rational+Design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Type II kinase inhibitors: an opportunity in cancer for rational design</span></div><div class="casAuthors">Blanc, Javier; Geney, Raphael; Menet, Christel</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">731-747</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  With the advent of the Type II kinase inhibitor imatinib (Gleevec) for treatment against cancer, rational design of tailored mols. has brought a revolution in medicinal chem. for treating tumors caused by kinase malfunctioning.  Among different types of kinase inhibitors, the design of Type II inhibitors has been rationalized for maximizing the benefits and reducing drawbacks.  Here we highlight the development made in Type II inhibitors, discussing the advantages and disadvantages of these types of mols.  Furthermore, we present the strategies for designing druggable mols. that either selectively inhibit target kinases or overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7md6eYN1yg7Vg90H21EOLACvtfcHk0liAIh2_d_9-0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslyku78%253D&md5=30e72045115f723f2b868381898c2218</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.2174%2F1871520611313050008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520611313050008%26sid%3Dliteratum%253Aachs%26aulast%3DBlanc%26aufirst%3DJ.%26aulast%3DGeney%26aufirst%3DR.%26aulast%3DMenet%26aufirst%3DC.%26atitle%3DType%2520II%2520Kinase%2520Inhibitors%253A%2520An%2520Opportunity%2520in%2520Cancer%2520for%2520Rational%2520Design%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D731%26epage%3D747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Palmieri, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">αC Helix Displacement as a General Approach for Allosteric Modulation of Protein Kinases</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1016%2Fj.drudis.2012.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=23195331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVektrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=407-414&author=L.+Palmieriauthor=G.+Rastelli&title=%CE%B1C+Helix+Displacement+as+a+General+Approach+for+Allosteric+Modulation+of+Protein+Kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">αC helix displacement as a general approach for allosteric modulation of protein kinases</span></div><div class="casAuthors">Palmieri, Lorenzo; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">407-414</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Owing to their crucial role in the modulation of cell pathways, protein kinases are important targets for several human diseases, including but not limited to cancer.  The classic approach of targeting the ATP active site has recently come up against selectivity issues, which can be considerably reduced by following an allosteric modulation approach.  Being closely related to protein kinase inactivation, allosteric targeting via displacement of the conserved structural αC helix enables a direct and specific modulation mechanism.  A structure-based survey of the allosteric regulation of αC helix conformation in various kinase families is provided, highlighting key allosteric pockets and modulation mechanisms that appear to be more broadly conserved than was previously thought.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiEv57xKCTibVg90H21EOLACvtfcHk0liAIh2_d_9-0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVektrzE&md5=f2380fd543155c49602ca99b0c333ffe</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2012.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2012.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DPalmieri%26aufirst%3DL.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3D%25CE%25B1C%2520Helix%2520Displacement%2520as%2520a%2520General%2520Approach%2520for%2520Allosteric%2520Modulation%2520of%2520Protein%2520Kinases%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D407%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Di Desidero, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fioravanti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlandi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borrelli, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Man, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontanini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basolo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerbel, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danesi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bocci, G.</span><span> </span><span class="NLM_article-title">Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">E1465</span><span class="NLM_x">–</span> <span class="NLM_lpage">1473</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2013&pages=E1465-1473&author=T.+Di+Desideroauthor=A.+Fioravantiauthor=P.+Orlandiauthor=B.+Canuauthor=R.+Gianniniauthor=N.+Borrelliauthor=S.+Manauthor=P.+Xuauthor=G.+Fontaniniauthor=F.+Basoloauthor=R.+S.+Kerbelauthor=G.+Franciaauthor=R.+Danesiauthor=G.+Bocci&title=Antiproliferative+and+Proapoptotic+Activity+of+Sunitinib+on+Endothelial+and+Anaplastic+Thyroid+Cancer+Cells+via+Inhibition+of+Akt+and+ERK1%2F2+Phosphorylation+and+by+Down-Regulation+of+Cyclin-D1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BDesidero%26aufirst%3DT.%26aulast%3DFioravanti%26aufirst%3DA.%26aulast%3DOrlandi%26aufirst%3DP.%26aulast%3DCanu%26aufirst%3DB.%26aulast%3DGiannini%26aufirst%3DR.%26aulast%3DBorrelli%26aufirst%3DN.%26aulast%3DMan%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DFontanini%26aufirst%3DG.%26aulast%3DBasolo%26aufirst%3DF.%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26aulast%3DFrancia%26aufirst%3DG.%26aulast%3DDanesi%26aufirst%3DR.%26aulast%3DBocci%26aufirst%3DG.%26atitle%3DAntiproliferative%2520and%2520Proapoptotic%2520Activity%2520of%2520Sunitinib%2520on%2520Endothelial%2520and%2520Anaplastic%2520Thyroid%2520Cancer%2520Cells%2520via%2520Inhibition%2520of%2520Akt%2520and%2520ERK1%252F2%2520Phosphorylation%2520and%2520by%2520Down-Regulation%2520of%2520Cyclin-D1%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2013%26volume%3D98%26spage%3DE1465%26epage%3D1473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Dar, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cagan, R. L.</span><span> </span><span class="NLM_article-title">Chemical Genetic Discovery of Targets and Anti-Targets for Cancer Polypharmacology</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">486</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnature11127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=22678283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=80-84&author=A.+C.+Darauthor=T.+K.+Dasauthor=K.+M.+Shokatauthor=R.+L.+Cagan&title=Chemical+Genetic+Discovery+of+Targets+and+Anti-Targets+for+Cancer+Polypharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetic discovery of targets and anti-targets for cancer polypharmacology</span></div><div class="casAuthors">Dar, Arvin C.; Das, Tirtha K.; Shokat, Kevan M.; Cagan, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7401</span>),
    <span class="NLM_cas:pages">80-84</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The complexity of cancer has led to recent interest in polypharmacol. approaches for developing kinase-inhibitor drugs; however, optimal kinase-inhibition profiles remain difficult to predict.  Using a Ret-kinase-driven Drosophila model of multiple endocrine neoplasia type 2 and kinome-wide drug profiling, here the authors identify that AD57 rescues oncogenic Ret-induced lethality, whereas related Ret inhibitors imparted reduced efficacy and enhanced toxicity.  Drosophila genetics and compd. profiling defined three pathways accounting for the mechanistic basis of efficacy and dose-limiting toxicity.  Inhibition of Ret plus Raf, Src and S6K was required for optimal animal survival, whereas inhibition of the anti-target' Tor led to toxicity owing to release of neg. feedback.  Rational synthetic tailoring to eliminate Tor binding afforded AD80 and AD81, compds. featuring balanced pathway inhibition, improved efficacy and low toxicity in Drosophila and mammalian multiple endocrine neoplasia type 2 models.  Combining kinase-focused chem., kinome-wide profiling and Drosophila genetics provides a powerful systems pharmacol. approach towards developing compds. with a maximal therapeutic index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3OjBELXO9TbVg90H21EOLACvtfcHk0lgQQTvhXgIfIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D&md5=4ed2f85f51453c1b38ee390a0a5f14db</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnature11127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11127%26sid%3Dliteratum%253Aachs%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DDas%26aufirst%3DT.%2BK.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DCagan%26aufirst%3DR.%2BL.%26atitle%3DChemical%2520Genetic%2520Discovery%2520of%2520Targets%2520and%2520Anti-Targets%2520for%2520Cancer%2520Polypharmacology%26jtitle%3DNature%26date%3D2012%26volume%3D486%26spage%3D80%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Xie, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evangelidis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourne, P. E.</span><span> </span><span class="NLM_article-title">Drug Discovery Using Chemical Systems Biology: Weak Inhibition of Multiple Kinases May Contribute to the Anti-Cancer Effect of Nelfinavir</span> <span class="citation_source-journal">PLoS Comput. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1002037</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1371%2Fjournal.pcbi.1002037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=21552547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsl2nsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=e1002037&author=L.+Xieauthor=T.+Evangelidisauthor=L.+Xieauthor=P.+E.+Bourne&title=Drug+Discovery+Using+Chemical+Systems+Biology%3A+Weak+Inhibition+of+Multiple+Kinases+May+Contribute+to+the+Anti-Cancer+Effect+of+Nelfinavir"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of Nelfinavir</span></div><div class="casAuthors">Xie, Li; Evangelidis, Thomas; Xie, Lei; Bourne, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e1002037</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Nelfinavir is a potent HIV-protease inhibitor with pleiotropic effects in cancer cells.  Exptl. studies connect its anti-cancer effects to the suppression of the Akt signaling pathway, but the actual mol. targets remain unknown.  Using a structural proteome-wide off-target pipeline, which integrates mol. dynamics simulation and MM/GBSA free energy calcns. with ligand binding site comparison and biol. network anal., we identified putative human off-targets of Nelfinavir and analyzed the impact on the assocd. biol. processes.  Our results suggest that Nelfinavir is able to inhibit multiple members of the protein kinase-like superfamily, which are involved in the regulation of cellular processes vital for carcinogenesis and metastasis.  The computational predictions are supported by kinase activity assays and are consistent with existing exptl. and clin. evidence.  This finding provides a mol. basis to explain the broad-spectrum anti-cancer effect of Nelfinavir and presents opportunities to optimize the drug as a targeted polypharmacol. agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGookAtcKasU9bVg90H21EOLACvtfcHk0lgQQTvhXgIfIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsl2nsrw%253D&md5=021c009e7d74cc1085577a5e11bfb23b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1002037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1002037%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DL.%26aulast%3DEvangelidis%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26atitle%3DDrug%2520Discovery%2520Using%2520Chemical%2520Systems%2520Biology%253A%2520Weak%2520Inhibition%2520of%2520Multiple%2520Kinases%2520May%2520Contribute%2520to%2520the%2520Anti-Cancer%2520Effect%2520of%2520Nelfinavir%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3De1002037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Hearn, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero-Canelón, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qamar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hands-Portman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadler, P. J.</span><span> </span><span class="NLM_article-title">Organometallic Iridium(III) Anticancer Complexes with New Mechanisms of Action: NCI-60 Screening, Mitochondrial Targeting, and Apoptosis</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1335</span><span class="NLM_x">–</span> <span class="NLM_lpage">1343</span></span><div class="citationLinks">[<a href="/doi/10.1021/cb400070a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1335-1343&author=J.+M.+Hearnauthor=I.+Romero-Canel%C3%B3nauthor=B.+Qamarauthor=Z.+Liuauthor=I.+Hands-Portmanauthor=P.+J.+Sadler&title=Organometallic+Iridium%28III%29+Anticancer+Complexes+with+New+Mechanisms+of+Action%3A+NCI-60+Screening%2C+Mitochondrial+Targeting%2C+and+Apoptosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fcb400070a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb400070a%26sid%3Dliteratum%253Aachs%26aulast%3DHearn%26aufirst%3DJ.%2BM.%26aulast%3DRomero-Canel%25C3%25B3n%26aufirst%3DI.%26aulast%3DQamar%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DHands-Portman%26aufirst%3DI.%26aulast%3DSadler%26aufirst%3DP.%2BJ.%26atitle%3DOrganometallic%2520Iridium%2528III%2529%2520Anticancer%2520Complexes%2520with%2520New%2520Mechanisms%2520of%2520Action%253A%2520NCI-60%2520Screening%252C%2520Mitochondrial%2520Targeting%252C%2520and%2520Apoptosis%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D1335%26epage%3D1343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Laufer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">New Frontiers in Kinases: Second Generation Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2167</span><span class="NLM_x">–</span> <span class="NLM_lpage">2168</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm500195x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjvVOgurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2167-2168&author=S.+Lauferauthor=J.+Bajorath&title=New+Frontiers+in+Kinases%3A+Second+Generation+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">New Frontiers in Kinases: Second Generation Inhibitors</span></div><div class="casAuthors">Laufer, Stefan; Bajorath, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2167-2168</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfZaVZXCypsLVg90H21EOLACvtfcHk0lido2R1_WFjWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjvVOgurk%253D&md5=df1c1e9d3ef2be7113785a979accb4f8</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm500195x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500195x%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DS.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DNew%2520Frontiers%2520in%2520Kinases%253A%2520Second%2520Generation%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2167%26epage%3D2168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Curtin, N.</span><span> </span><span class="NLM_article-title">PARP Inhibitors for Anticancer Therapy</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">82</span><span class="NLM_x">–</span> <span class="NLM_lpage">88</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1042%2FBST20130187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=24450632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOgsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=82-88&author=N.+Curtin&title=PARP+Inhibitors+for+Anticancer+Therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitors for anticancer therapy</span></div><div class="casAuthors">Curtin, Nicola</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">82-88</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  PARP-1 [poly(ADP-ribose) polymerase-1], which plays a key role in DNA repair, was discovered 50 years ago.  PARPi (PARP inhibitors), originally made to probe the function of the enzyme, inhibit DNA repair and increase the potency of anticancer cytotoxic agents.  PARPi of increasing potency were developed as chemo- and radio-sensitizers and first entered clin. trial in cancer patients in 2003.  However, it was the revelation in 2005 that they were synthetically lethal in cells with DNA repair defects, found almost exclusively in some tumors, that led to a major interest in this class of drug.  Several PARPi have entered clin. trials and show promising activity in breast, ovarian and other cancers assocd. with BRCA (breast cancer early-onset) mutations or other defects in homologous recombination DNA repair.  It is likely that at least one of these will be licensed soon.  The present review describes key events from the discovery to clin. application of PARPi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuwXKbeQike7Vg90H21EOLACvtfcHk0lido2R1_WFjWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOgsbY%253D&md5=53d50a336f0013c7ac2204ad8dca0e84</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1042%2FBST20130187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20130187%26sid%3Dliteratum%253Aachs%26aulast%3DCurtin%26aufirst%3DN.%26atitle%3DPARP%2520Inhibitors%2520for%2520Anticancer%2520Therapy%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2014%26volume%3D42%26spage%3D82%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Ekblad, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camaioni, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schüler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macchiarulo, A.</span><span> </span><span class="NLM_article-title">PARP Inhibitors: Polypharmacology versus Selective Inhibition</span> <span class="citation_source-journal">FEBS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">3563</span><span class="NLM_x">–</span> <span class="NLM_lpage">3575</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2013&pages=3563-3575&author=T.+Ekbladauthor=E.+Camaioniauthor=H.+Sch%C3%BClerauthor=A.+Macchiarulo&title=PARP+Inhibitors%3A+Polypharmacology+versus+Selective+Inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEkblad%26aufirst%3DT.%26aulast%3DCamaioni%26aufirst%3DE.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26aulast%3DMacchiarulo%26aufirst%3DA.%26atitle%3DPARP%2520Inhibitors%253A%2520Polypharmacology%2520versus%2520Selective%2520Inhibition%26jtitle%3DFEBS%2520J.%26date%3D2013%26volume%3D280%26spage%3D3563%26epage%3D3575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Echeverría, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernthaler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupuis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picard, D.</span><span> </span><span class="NLM_article-title">An Interaction Network Predicted from Public Data as a Discovery Tool: Application to the Hsp90 Molecular Chaperone Machine</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e26044</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e26044&author=P.+C.+Echeverr%C3%ADaauthor=A.+Bernthalerauthor=P.+Dupuisauthor=B.+Mayerauthor=D.+Picard&title=An+Interaction+Network+Predicted+from+Public+Data+as+a+Discovery+Tool%3A+Application+to+the+Hsp90+Molecular+Chaperone+Machine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEcheverr%25C3%25ADa%26aufirst%3DP.%2BC.%26aulast%3DBernthaler%26aufirst%3DA.%26aulast%3DDupuis%26aufirst%3DP.%26aulast%3DMayer%26aufirst%3DB.%26aulast%3DPicard%26aufirst%3DD.%26atitle%3DAn%2520Interaction%2520Network%2520Predicted%2520from%2520Public%2520Data%2520as%2520a%2520Discovery%2520Tool%253A%2520Application%2520to%2520the%2520Hsp90%2520Molecular%2520Chaperone%2520Machine%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De26044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Moulick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerchietti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomes DaGama, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldas-Lopes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beebe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perna, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatzi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zatorska, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taldone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith-Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alpaugh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillarsetty, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ku, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdjument-Bromage, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnick, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Affinity-Based Proteomics Reveal Cancer-Specific Networks Coordinated by Hsp90</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">818</span><span class="NLM_x">–</span> <span class="NLM_lpage">826</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnchembio.670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=21946277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1anurbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=818-826&author=K.+Moulickauthor=J.+H.+Ahnauthor=H.+Zongauthor=A.+Rodinaauthor=L.+Cerchiettiauthor=E.+M.+Gomes+DaGamaauthor=E.+Caldas-Lopesauthor=K.+Beebeauthor=F.+Pernaauthor=K.+Hatziauthor=L.+P.+Vuauthor=X.+Zhaoauthor=D.+Zatorskaauthor=T.+Taldoneauthor=P.+Smith-Jonesauthor=M.+Alpaughauthor=S.+S.+Grossauthor=N.+Pillarsettyauthor=T.+Kuauthor=J.+S.+Lewisauthor=S.+M.+Larsonauthor=R.+Levineauthor=H.+Erdjument-Bromageauthor=M.+L.+Guzmanauthor=S.+D.+Nimerauthor=A.+Melnickauthor=L.+Neckersauthor=G.+Chiosis&title=Affinity-Based+Proteomics+Reveal+Cancer-Specific+Networks+Coordinated+by+Hsp90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90</span></div><div class="casAuthors">Moulick, Kamalika; Ahn, James H.; Zong, Hongliang; Rodina, Anna; Cerchietti, Leandro; Gomes DaGama, Erica M.; Caldas-Lopes, Eloisi; Beebe, Kristin; Perna, Fabiana; Hatzi, Katerina; Vu, Ly P.; Zhao, Xinyang; Zatorska, Danuta; Taldone, Tony; Smith-Jones, Peter; Alpaugh, Mary; Gross, Steven S.; Pillarsetty, Nagavarakishore; Ku, Thomas; Lewis, Jason S.; Larson, Steven M.; Levine, Ross; Erdjument-Bromage, Hediye; Guzman, Monica L.; Nimer, Stephen D.; Melnick, Ari; Neckers, Len; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">818-826</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Most cancers were characterized by multiple mol. alterations, but identification of the key proteins involved in these signaling pathways is currently beyond reach.  The inhibitor PU-H71 preferentially targets tumor-enriched Hsp90 complexes and affinity captures Hsp90-dependent oncogenic client proteins.  The authors used PU-H71 affinity capture to design a proteomic approach that, when combined with bioinformatic pathway anal., identifies dysregulated signaling networks and key oncoproteins in chronic myeloid leukemia.  The identified interactome overlaps with the well-characterized altered proteome in this cancer, indicating that this method can provide global insights into the biol. of individual tumors, including primary patient specimens.  In addn., this approach can be used to identify previously uncharacterized oncoproteins and mechanisms, potentially leading to new targeted therapies.  Further the abundance of the PU-H71-enriched Hsp90 species, which is not dictated by Hsp90 expression alone, is predictive of the cell's sensitivity to Hsp90 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXTlQWF_MFU7Vg90H21EOLACvtfcHk0li8VuA9HyvAhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1anurbN&md5=d62e663a2e054f3715a3a6e2d5e2c10e</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.670%26sid%3Dliteratum%253Aachs%26aulast%3DMoulick%26aufirst%3DK.%26aulast%3DAhn%26aufirst%3DJ.%2BH.%26aulast%3DZong%26aufirst%3DH.%26aulast%3DRodina%26aufirst%3DA.%26aulast%3DCerchietti%26aufirst%3DL.%26aulast%3DGomes%2BDaGama%26aufirst%3DE.%2BM.%26aulast%3DCaldas-Lopes%26aufirst%3DE.%26aulast%3DBeebe%26aufirst%3DK.%26aulast%3DPerna%26aufirst%3DF.%26aulast%3DHatzi%26aufirst%3DK.%26aulast%3DVu%26aufirst%3DL.%2BP.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DZatorska%26aufirst%3DD.%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DSmith-Jones%26aufirst%3DP.%26aulast%3DAlpaugh%26aufirst%3DM.%26aulast%3DGross%26aufirst%3DS.%2BS.%26aulast%3DPillarsetty%26aufirst%3DN.%26aulast%3DKu%26aufirst%3DT.%26aulast%3DLewis%26aufirst%3DJ.%2BS.%26aulast%3DLarson%26aufirst%3DS.%2BM.%26aulast%3DLevine%26aufirst%3DR.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DGuzman%26aufirst%3DM.%2BL.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DMelnick%26aufirst%3DA.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DAffinity-Based%2520Proteomics%2520Reveal%2520Cancer-Specific%2520Networks%2520Coordinated%2520by%2520Hsp90%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D818%26epage%3D826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Knox, A. J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawlak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golfis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flood, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fayne, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, D. G.</span><span> </span><span class="NLM_article-title">Integration of Ligand and Structure-Based Virtual Screening for the Identification of the First Dual Targeting Agent for Heat Shock Protein 90 (Hsp90) and Tubulin</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2177</span><span class="NLM_x">–</span> <span class="NLM_lpage">2180</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801569z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFGrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2177-2180&author=A.+J.+S.+Knoxauthor=T.+Priceauthor=M.+Pawlakauthor=G.+Golfisauthor=C.+T.+Floodauthor=D.+Fayneauthor=D.+C.+Williamsauthor=M.+J.+Meeganauthor=D.+G.+Lloyd&title=Integration+of+Ligand+and+Structure-Based+Virtual+Screening+for+the+Identification+of+the+First+Dual+Targeting+Agent+for+Heat+Shock+Protein+90+%28Hsp90%29+and+Tubulin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Integration of Ligand and Structure-Based Virtual Screening for the Identification of the First Dual Targeting Agent for Heat Shock Protein 90 (Hsp90) and Tubulin</span></div><div class="casAuthors">Knox, Andrew J. S.; Price, Trevor; Pawlak, Michal; Golfis, Georgia; Flood, Christopher T.; Fayne, Darren; Williams, D. Clive; Meegan, Mary J.; Lloyd, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2177-2180</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe the discovery of a novel indazole-based scaffold that represents the "first-in-class" dual Hsp90/tubulin binding compd.  Individual known ligands for both targets shared similar 3',4',5'-trimethoxyphenyl cores, and from this it was hypothesized that application of an integrated ligand and structure-based virtual screening (VS) workflow could yield a single scaffold with dual binding affinity.  Following validation of the VS protocol, we successfully identified a novel dual inhibitor, sourced from a com. screening collection of 160 000 compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRptEHjoTCsLVg90H21EOLACvtfcHk0lg18u_wNrg94A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFGrt70%253D&md5=c8268f36a0da627404be37696c5afe4b</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm801569z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801569z%26sid%3Dliteratum%253Aachs%26aulast%3DKnox%26aufirst%3DA.%2BJ.%2BS.%26aulast%3DPrice%26aufirst%3DT.%26aulast%3DPawlak%26aufirst%3DM.%26aulast%3DGolfis%26aufirst%3DG.%26aulast%3DFlood%26aufirst%3DC.%2BT.%26aulast%3DFayne%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%2BC.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26aulast%3DLloyd%26aufirst%3DD.%2BG.%26atitle%3DIntegration%2520of%2520Ligand%2520and%2520Structure-Based%2520Virtual%2520Screening%2520for%2520the%2520Identification%2520of%2520the%2520First%2520Dual%2520Targeting%2520Agent%2520for%2520Heat%2520Shock%2520Protein%252090%2520%2528Hsp90%2529%2520and%2520Tubulin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2177%26epage%3D2180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Owellen, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donigian, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartke, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhar, M. J.</span><span> </span><span class="NLM_article-title">The Binding of Vinblastine to Tubulin and to Particulate Fractions of Mammalian Brain</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1974</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">3180</span><span class="NLM_x">–</span> <span class="NLM_lpage">3186</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1974&pages=3180-3186&author=R.+J.+Owellenauthor=D.+W.+Donigianauthor=C.+A.+Hartkeauthor=R.+M.+Dickersonauthor=M.+J.+Kuhar&title=The+Binding+of+Vinblastine+to+Tubulin+and+to+Particulate+Fractions+of+Mammalian+Brain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOwellen%26aufirst%3DR.%2BJ.%26aulast%3DDonigian%26aufirst%3DD.%2BW.%26aulast%3DHartke%26aufirst%3DC.%2BA.%26aulast%3DDickerson%26aufirst%3DR.%2BM.%26aulast%3DKuhar%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520Binding%2520of%2520Vinblastine%2520to%2520Tubulin%2520and%2520to%2520Particulate%2520Fractions%2520of%2520Mammalian%2520Brain%26jtitle%3DCancer%2520Res.%26date%3D1974%26volume%3D34%26spage%3D3180%26epage%3D3186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, B.</span><span> </span><span class="NLM_article-title">Anti-Tumor Selectivity of a Novel Tubulin and HSP90 Dual-Targeting Inhibitor in Non-Small Cell Lung Cancer Models</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">351</span><span class="NLM_x">–</span> <span class="NLM_lpage">360</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2013&pages=351-360&author=Q.+Zhangauthor=S.+Zhaiauthor=L.+Liauthor=X.+Liauthor=H.+Zhouauthor=A.+Liuauthor=G.+Suauthor=Q.+Muauthor=Y.+Duauthor=B.+Yan&title=Anti-Tumor+Selectivity+of+a+Novel+Tubulin+and+HSP90+Dual-Targeting+Inhibitor+in+Non-Small+Cell+Lung+Cancer+Models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhai%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DG.%26aulast%3DMu%26aufirst%3DQ.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DB.%26atitle%3DAnti-Tumor%2520Selectivity%2520of%2520a%2520Novel%2520Tubulin%2520and%2520HSP90%2520Dual-Targeting%2520Inhibitor%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Models%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2013%26volume%3D86%26spage%3D351%26epage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Anighoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumpfe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heikamp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Targeting Hsp90 Interactome Using in Silico Polypharmacology Approaches</span> <span class="citation_source-journal">Chim. Ind.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=105-106&author=A.+Anighoroauthor=D.+Stumpfeauthor=K.+Heikampauthor=J.+Bajorathauthor=G.+Rastelli&title=Targeting+Hsp90+Interactome+Using+in+Silico+Polypharmacology+Approaches"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DStumpfe%26aufirst%3DD.%26aulast%3DHeikamp%26aufirst%3DK.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DTargeting%2520Hsp90%2520Interactome%2520Using%2520in%2520Silico%2520Polypharmacology%2520Approaches%26jtitle%3DChim.%2520Ind.%26date%3D2013%26volume%3D4%26spage%3D105%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Stevens, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katritch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abagyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wüthrich, K.</span><span> </span><span class="NLM_article-title">The GPCR Network: A Large-Scale Collaboration to Determine Human GPCR Structure and Function</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnrd3859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=23237917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVekurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=25-34&author=R.+C.+Stevensauthor=V.+Cherezovauthor=V.+Katritchauthor=R.+Abagyanauthor=P.+Kuhnauthor=H.+Rosenauthor=K.+W%C3%BCthrich&title=The+GPCR+Network%3A+A+Large-Scale+Collaboration+to+Determine+Human+GPCR+Structure+and+Function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The GPCR Network: a large-scale collaboration to determine human GPCR structure and function</span></div><div class="casAuthors">Stevens, Raymond C.; Cherezov, Vadim; Katritch, Vsevolod; Abagyan, Ruben; Kuhn, Peter; Rosen, Hugh; Wuethrich, Kurt</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-34</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) are targeted by ∼30-40% of marketed drugs, and their key roles in normal physiol. and in disease demonstrate that an understanding of their structure and function is valuable to researchers in both basic science and drug discovery.  However, until recently, detailed structural information on this protein family was limited by challenges in X-ray crystallog. anal. of such membrane proteins.  The GPCR Network was created in 2010 with the goal of structurally characterizing 15-25 representative human GPCRs within 5 years, based on an active outreach program addressing an interdisciplinary community of scientists interested in GPCR structure, chem. and biol.  Here, we provide an overview of how this collaborative effort has enabled the structural detn. and characterization of eight human GPCRs so far, and discuss some of the challenges that remain in gaining more detailed insights into structure-function relationships in this receptor superfamily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBDUU5HjYCg7Vg90H21EOLACvtfcHk0lgz0VaAQTAZIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVekurzI&md5=8c303038034b529c6efd3492716fad19</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnrd3859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3859%26sid%3Dliteratum%253Aachs%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DAbagyan%26aufirst%3DR.%26aulast%3DKuhn%26aufirst%3DP.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DW%25C3%25BCthrich%26aufirst%3DK.%26atitle%3DThe%2520GPCR%2520Network%253A%2520A%2520Large-Scale%2520Collaboration%2520to%2520Determine%2520Human%2520GPCR%2520Structure%2520and%2520Function%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D25%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span> </span><span class="NLM_article-title">Structure-Based Drug Screening for G-Protein-Coupled Receptors</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=268-272&author=B.+K.+Shoichetauthor=B.+K.+Kobilka&title=Structure-Based+Drug+Screening+for+G-Protein-Coupled+Receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DStructure-Based%2520Drug%2520Screening%2520for%2520G-Protein-Coupled%2520Receptors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2012%26volume%3D33%26spage%3D268%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheffler, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroeze, W. K.</span><span> </span><span class="NLM_article-title">Magic Shotguns versus Magic Bullets: Selectively Non-Selective Drugs for Mood Disorders and Schizophrenia</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnrd1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=15060530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=353-359&author=B.+L.+Rothauthor=D.+J.+Shefflerauthor=W.+K.+Kroeze&title=Magic+Shotguns+versus+Magic+Bullets%3A+Selectively+Non-Selective+Drugs+for+Mood+Disorders+and+Schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span></div><div class="casAuthors">Roth, Bryan L.; Sheffler, Douglas J.; Kroeze, Wesley K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most common central nervous system disorders - such as depression, bipolar disorder, and schizophrenia - seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies.  Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single mol. targets (i.e., 'magic bullets') have, not surprisingly, been largely unsuccessful.  Here the authors propose that designing selectively non-selective drugs (i.e., 'magic shotguns') that interact with several mol. targets will lead to new and more effective medications for a variety of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSsuUXzmbirVg90H21EOLACvtfcHk0lgz0VaAQTAZIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D&md5=77196583acccca65457fec7a67218463</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnrd1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1346%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DMagic%2520Shotguns%2520versus%2520Magic%2520Bullets%253A%2520Selectively%2520Non-Selective%2520Drugs%2520for%2520Mood%2520Disorders%2520and%2520Schizophrenia%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D353%26epage%3D359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Lipina, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palomo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roder, J. C.</span><span> </span><span class="NLM_article-title">Dual Inhibitor of PDE7 and GSK-3-VP1.15 Acts as Antipsychotic and Cognitive Enhancer in C57BL/6J Mice</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">214</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=205-214&author=T.+V.+Lipinaauthor=V.+Palomoauthor=C.+Gilauthor=A.+Martinezauthor=J.+C.+Roder&title=Dual+Inhibitor+of+PDE7+and+GSK-3-VP1.15+Acts+as+Antipsychotic+and+Cognitive+Enhancer+in+C57BL%2F6J+Mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLipina%26aufirst%3DT.%2BV.%26aulast%3DPalomo%26aufirst%3DV.%26aulast%3DGil%26aufirst%3DC.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DRoder%26aufirst%3DJ.%2BC.%26atitle%3DDual%2520Inhibitor%2520of%2520PDE7%2520and%2520GSK-3-VP1.15%2520Acts%2520as%2520Antipsychotic%2520and%2520Cognitive%2520Enhancer%2520in%2520C57BL%252F6J%2520Mice%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D64%26spage%3D205%26epage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Lipina, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roder, J. C.</span><span> </span><span class="NLM_article-title">Synergistic Interactions between PDE4B and GSK-3: DISC1 Mutant Mice</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1252</span><span class="NLM_x">–</span> <span class="NLM_lpage">1262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2012&pages=1252-1262&author=T.+V.+Lipinaauthor=M.+Wangauthor=F.+Liuauthor=J.+C.+Roder&title=Synergistic+Interactions+between+PDE4B+and+GSK-3%3A+DISC1+Mutant+Mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLipina%26aufirst%3DT.%2BV.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DRoder%26aufirst%3DJ.%2BC.%26atitle%3DSynergistic%2520Interactions%2520between%2520PDE4B%2520and%2520GSK-3%253A%2520DISC1%2520Mutant%2520Mice%26jtitle%3DNeuropharmacology%26date%3D2012%26volume%3D62%26spage%3D1252%26epage%3D1262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Youdim, M. B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buccafusco, J. J.</span><span> </span><span class="NLM_article-title">Multi-Functional Drugs for Various CNS Targets in the Treatment of Neurodegenerative Disorders</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1016%2Fj.tips.2004.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=15629202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktV2m" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=27-35&author=M.+B.+H.+Youdimauthor=J.+J.+Buccafusco&title=Multi-Functional+Drugs+for+Various+CNS+Targets+in+the+Treatment+of+Neurodegenerative+Disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders</span></div><div class="casAuthors">Youdim, Moussa B. H.; Buccafusco, Jerry J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-35</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Individuals with neurodegenerative diseases such as Parkinson's disease or Alzheimer's disease are benefiting from drugs developed to act on a single mol. target.  However, current pharmacol. approaches are limited in their ability to modify significantly the course of the disease, and offer incomplete and transient benefit to patients.  New therapeutic strategies comprise drug candidates designed specifically to act on multiple neural and biochem. targets for the treatment of cognition impairment, motor dysfunction, depression and neurodegeneration.  Examples include the development of single mol. entities that combine 2 or more of the following properties: (i) cholinesterase inhibition; (ii) activation or inhibition of specific subtypes of acetylcholine receptors or α-adrenoceptors; (iii) anti-inflammatory activity; (iv) monoamine oxidase inhibition; (v) catechol-O-Me transferase inhibition; (vi) nitric oxide prodn.; (vii) neuroprotection; (viii) anti-apoptotic activity; and (ix) activation of mitochondrial-dependent cell-survival genes and proteins.  These bi- or multi-functional compds. might provide greater symptomatic efficacy, and better utility as potential neuroprotective disease-modifying drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreBPSKLWPfGLVg90H21EOLACvtfcHk0lh0621BbPrJyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktV2m&md5=0f2bd02614627d98b7e17a7a49905d1a</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2004.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2004.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26aulast%3DBuccafusco%26aufirst%3DJ.%2BJ.%26atitle%3DMulti-Functional%2520Drugs%2520for%2520Various%2520CNS%2520Targets%2520in%2520the%2520Treatment%2520of%2520Neurodegenerative%2520Disorders%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2005%26volume%3D26%26spage%3D27%26epage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Bolea, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juárez-Jiménez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de los Ríos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chioua, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pouplana, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luque, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unzeta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marco-Contelles, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samadi, A.</span><span> </span><span class="NLM_article-title">Synthesis, Biological Evaluation, and Molecular Modeling of Donepezil and <i>N</i>-[(5-(Benzyloxy)-1-methyl-1<i>H</i>-indol-2-yl)methyl]-<i>N</i>-methylprop-2-yn-1-amine Hybrids as New Multipotent Cholinesterase/Monoamine Oxidase Inhibitors for the Treatment of Alzheimer’s Disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8251</span><span class="NLM_x">–</span> <span class="NLM_lpage">8270</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200853t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8251-8270&author=I.+Boleaauthor=J.+Ju%C3%A1rez-Jim%C3%A9nezauthor=C.+de+los+R%C3%ADosauthor=M.+Chiouaauthor=R.+Pouplanaauthor=F.+J.+Luqueauthor=M.+Unzetaauthor=J.+Marco-Contellesauthor=A.+Samadi&title=Synthesis%2C+Biological+Evaluation%2C+and+Molecular+Modeling+of+Donepezil+and+N-%5B%285-%28Benzyloxy%29-1-methyl-1H-indol-2-yl%29methyl%5D-N-methylprop-2-yn-1-amine+Hybrids+as+New+Multipotent+Cholinesterase%2FMonoamine+Oxidase+Inhibitors+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjm200853t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200853t%26sid%3Dliteratum%253Aachs%26aulast%3DBolea%26aufirst%3DI.%26aulast%3DJu%25C3%25A1rez-Jim%25C3%25A9nez%26aufirst%3DJ.%26aulast%3Dde%2Blos%2BR%25C3%25ADos%26aufirst%3DC.%26aulast%3DChioua%26aufirst%3DM.%26aulast%3DPouplana%26aufirst%3DR.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DUnzeta%26aufirst%3DM.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DSamadi%26aufirst%3DA.%26atitle%3DSynthesis%252C%2520Biological%2520Evaluation%252C%2520and%2520Molecular%2520Modeling%2520of%2520Donepezil%2520and%2520N-%255B%25285-%2528Benzyloxy%2529-1-methyl-1H-indol-2-yl%2529methyl%255D-N-methylprop-2-yn-1-amine%2520Hybrids%2520as%2520New%2520Multipotent%2520Cholinesterase%252FMonoamine%2520Oxidase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8251%26epage%3D8270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Tahtouh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkins, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soundararajan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durieu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cochet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delhommel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oberholzer, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreaux, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bazureau, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span> </span><span class="NLM_article-title">Selectivity, Cocrystal Structures, and Neuroprotective Properties of Leucettines, a Family of Protein Kinase Inhibitors Derived from the Marine Sponge Alkaloid Leucettamine B</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">9312</span><span class="NLM_x">–</span> <span class="NLM_lpage">9330</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301034u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9312-9330&author=T.+Tahtouhauthor=J.+M.+Elkinsauthor=P.+Filippakopoulosauthor=M.+Soundararajanauthor=G.+Burgyauthor=E.+Durieuauthor=C.+Cochetauthor=R.+S.+Schmidauthor=D.+C.+Loauthor=F.+Delhommelauthor=A.+E.+Oberholzerauthor=L.+H.+Pearlauthor=F.+Carreauxauthor=J.-P.+Bazureauauthor=S.+Knappauthor=L.+Meijer&title=Selectivity%2C+Cocrystal+Structures%2C+and+Neuroprotective+Properties+of+Leucettines%2C+a+Family+of+Protein+Kinase+Inhibitors+Derived+from+the+Marine+Sponge+Alkaloid+Leucettamine+B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fjm301034u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301034u%26sid%3Dliteratum%253Aachs%26aulast%3DTahtouh%26aufirst%3DT.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DSoundararajan%26aufirst%3DM.%26aulast%3DBurgy%26aufirst%3DG.%26aulast%3DDurieu%26aufirst%3DE.%26aulast%3DCochet%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DR.%2BS.%26aulast%3DLo%26aufirst%3DD.%2BC.%26aulast%3DDelhommel%26aufirst%3DF.%26aulast%3DOberholzer%26aufirst%3DA.%2BE.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DCarreaux%26aufirst%3DF.%26aulast%3DBazureau%26aufirst%3DJ.-P.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DSelectivity%252C%2520Cocrystal%2520Structures%252C%2520and%2520Neuroprotective%2520Properties%2520of%2520Leucettines%252C%2520a%2520Family%2520of%2520Protein%2520Kinase%2520Inhibitors%2520Derived%2520from%2520the%2520Marine%2520Sponge%2520Alkaloid%2520Leucettamine%2520B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9312%26epage%3D9330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">León, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marco-Contelles, J.</span><span> </span><span class="NLM_article-title">Recent Advances in the Multitarget-Directed Ligands Approach for the Treatment of Alzheimer’s Disease</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">139</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1002%2Fmed.20248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=21793014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCktrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=139-189&author=R.+Le%C3%B3nauthor=A.+G.+Garciaauthor=J.+Marco-Contelles&title=Recent+Advances+in+the+Multitarget-Directed+Ligands+Approach+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Leon, Rafael; Garcia, Antonio G.; Marco-Contelles, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">139-189</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  With 27 million cases worldwide documented in 2006, Alzheimer's disease (AD) constitutes an overwhelming health, social, economic, and political problem to nations.  Unless a new medicine capable to delay disease progression is found, the no. of cases will reach 107 million in 2050.  So far, the therapeutic paradigm one-compd.-one-target has failed.  This could be due to the multiple pathogenic mechanisms involved in AD including amyloid β (Aβ) aggregation to form plaques, τ hyperphosphorylation to disrupt microtubule to form neurofibrillary tangles, calcium imbalance, enhanced oxidative stress, impaired mitochondrial function, apoptotic neuronal death, and deterioration of synaptic transmission, particularly at cholinergic neurons.  Approx. 100 compds. are presently been investigated directed to single targets, namely inhibitors of β and γ secretase, vaccines or antibodies that clear Aβ, metal chelators to inhibit Aβ aggregation, blockers of glycogen synthase kinase 3β, enhancers of mitochondrial function, antioxidants, modulators of calcium-permeable channels such as voltage-dependent calcium channels, N-methyl-D-aspartate receptors for glutamate, or enhancers of cholinergic neurotransmission such as inhibitors of acetylcholinesterase or butyrylcholinesterase.  In view of this complex pathogenic mechanisms, and the successful treatment of chronic diseases such as HIV or cancer, with multiple drugs having complementary mechanisms of action, the concern is growing that AD could better be treated with a single compd. targeting two or more of the pathogenic mechanisms leading to neuronal death.  This review summarizes the current therapeutic strategies based on the paradigm one-compd.-various targets to treat AD.  A treatment that delays disease onset and/or progression by 5 years could halve the no. of people requiring institutionalization and/or dying from AD.  © 2011 Wiley Periodicals, Inc.  Med Res Rev.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8YQ_Czzj5brVg90H21EOLACvtfcHk0lgYW_yZt8v98w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCktrvL&md5=b08806a8a4ca71c35a3594338c881e74</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1002%2Fmed.20248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20248%26sid%3Dliteratum%253Aachs%26aulast%3DLe%25C3%25B3n%26aufirst%3DR.%26aulast%3DGarcia%26aufirst%3DA.%2BG.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Multitarget-Directed%2520Ligands%2520Approach%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2013%26volume%3D33%26spage%3D139%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overington, J. P.</span><span> </span><span class="NLM_article-title">Can. We Rationally Design Promiscuous Drugs?</span> <span class="citation_source-journal">Curr. Opin. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1016%2Fj.sbi.2006.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=16442279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=127-136&author=A.+L.+Hopkinsauthor=J.+S.+Masonauthor=J.+P.+Overington&title=Can.+We+Rationally+Design+Promiscuous+Drugs%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Can we rationally design promiscuous drugs?</span></div><div class="casAuthors">Hopkins, Andrew L.; Mason, Jonathan S.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-136</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Structure-based drug design is now used widely in modern medicinal chem.  The application of structural biol. to medicinal chem. has heralded the 'rational drug design' vision of discovering exquisitely selective ligands.  However, recent advances in post-genomic biol. are indicating that polypharmacol. may be a necessary trait for the efficacy of many drugs, therefore questioning the 'one drug, one target' assumption of current rational drug design.  By combining advances in chemoinformatics and structural biol., it might be possible to rationally design the next generation of promiscuous drugs with polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQWdh60x9AHrVg90H21EOLACvtfcHk0lgYW_yZt8v98w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D&md5=8f9e95a41976b8e3ac790f2fff2c406f</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2006.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2006.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DCan.%2520We%2520Rationally%2520Design%2520Promiscuous%2520Drugs%253F%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2006%26volume%3D16%26spage%3D127%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Morphy, J. R.; Harris, C. J.</span> <span class="citation_source-book">Designing Multi-Target Drugs</span>; <span class="NLM_publisher-name">Royal Society of Chemistry</span>: <span class="NLM_publisher-loc">Cambridge, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1039%2F9781849734912" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.+R.+Morphy&author=C.+J.+Harris&title=Designing+Multi-Target+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1039%2F9781849734912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1039%252F9781849734912%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26btitle%3DDesigning%2520Multi-Target%2520Drugs%26pub%3DRoyal%2520Society%2520of%2520Chemistry%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Bajorath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltason, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wawer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lajiness, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Drie, J. H.</span><span> </span><span class="NLM_article-title">Navigating Structure–Activity Landscapes</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">698</span><span class="NLM_x">–</span> <span class="NLM_lpage">705</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=698-705&author=J.+Bajorathauthor=L.+Peltasonauthor=M.+Wawerauthor=R.+Guhaauthor=M.+S.+Lajinessauthor=J.+H.+Van+Drie&title=Navigating+Structure%E2%80%93Activity+Landscapes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DPeltason%26aufirst%3DL.%26aulast%3DWawer%26aufirst%3DM.%26aulast%3DGuha%26aufirst%3DR.%26aulast%3DLajiness%26aufirst%3DM.%2BS.%26aulast%3DVan%2BDrie%26aufirst%3DJ.%2BH.%26atitle%3DNavigating%2520Structure%25E2%2580%2593Activity%2520Landscapes%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D698%26epage%3D705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Dimova, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wawer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wassermann, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">Design of Multitarget Activity Landscapes That Capture Hierarchical Activity Cliff Distributions</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">258</span><span class="NLM_x">–</span> <span class="NLM_lpage">266</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci100477m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFKmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=258-266&author=D.+Dimovaauthor=M.+Wawerauthor=A.+M.+Wassermannauthor=J.+Bajorath&title=Design+of+Multitarget+Activity+Landscapes+That+Capture+Hierarchical+Activity+Cliff+Distributions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Design of multitarget activity landscapes that capture hierarchical activity cliff distributions</span></div><div class="casAuthors">Dimova, Dilyana; Wawer, Mathias; Wassermann, Anne Mai; Bajorath, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">258-266</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An activity landscape model of a compd. data set can be rationalized as a graphical representation that integrates mol. similarity and potency relationships.  Activity landscape representations of different design are utilized to aid in the anal. of structure-activity relationships and the selection of informative compds.  Activity landscape models reported thus far focus on a single target (i.e., a single biol. activity) or at most two targets, giving rise to selectivity landscapes.  For compds. active against more than two targets, landscapes representing multi-target activities are difficult to conceptualize and have not yet been reported.  Herein, a first activity landscape design that integrates compd. potency relationships across multiple targets in a formally consistent manner is presented.  These multi-target activity landscapes are based on a general activity cliff classification scheme and are visualized in graph representations, where activity cliffs are represented as edges.  Furthermore, the contributions of individual compds. to structure-activity relationship discontinuity across multiple targets are monitored.  The methodol. has been applied to derive multi-target activity landscapes for compd. data sets active against different target families.  The resulting landscapes identify single-, dual-, and triple-target activity cliffs and reveal the presence of hierarchical cliff distributions.  From these multi-target activity landscapes, compds. forming complex activity cliffs can be readily selected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriKlLr6TJI67Vg90H21EOLACvtfcHk0ljurNs_9zP1iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFKmt7o%253D&md5=487996ca26f9c0f999b94ce801ac5710</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fci100477m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci100477m%26sid%3Dliteratum%253Aachs%26aulast%3DDimova%26aufirst%3DD.%26aulast%3DWawer%26aufirst%3DM.%26aulast%3DWassermann%26aufirst%3DA.%2BM.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DDesign%2520of%2520Multitarget%2520Activity%2520Landscapes%2520That%2520Capture%2520Hierarchical%2520Activity%2520Cliff%2520Distributions%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D258%26epage%3D266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">Promiscuity Profiles of Bioactive Compounds: Potency Range and Difference Distributions and the Relation to Target Numbers and Families</span> <span class="citation_source-journal">Med. Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1196</span><span class="NLM_x">–</span> <span class="NLM_lpage">1201</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1039%2Fc3md00105a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1196-1201&author=Y.+Huauthor=J.+Bajorath&title=Promiscuity+Profiles+of+Bioactive+Compounds%3A+Potency+Range+and+Difference+Distributions+and+the+Relation+to+Target+Numbers+and+Families"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1039%2Fc3md00105a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3md00105a%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DPromiscuity%2520Profiles%2520of%2520Bioactive%2520Compounds%253A%2520Potency%2520Range%2520and%2520Difference%2520Distributions%2520and%2520the%2520Relation%2520to%2520Target%2520Numbers%2520and%2520Families%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2013%26volume%3D4%26spage%3D1196%26epage%3D1201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">Activity Profile Relationships between Structurally Similar Promiscuous Compounds</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">393</span><span class="NLM_x">–</span> <span class="NLM_lpage">398</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2013&pages=393-398&author=Y.+Huauthor=J.+Bajorath&title=Activity+Profile+Relationships+between+Structurally+Similar+Promiscuous+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DActivity%2520Profile%2520Relationships%2520between%2520Structurally%2520Similar%2520Promiscuous%2520Compounds%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D69%26spage%3D393%26epage%3D398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Designed Multiple Ligands. An Emerging Drug Discovery Paradigm</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6523</span><span class="NLM_x">–</span> <span class="NLM_lpage">6543</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+Multiple+Ligands.+An+Emerging+Drug+Discovery+Paradigm"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0ljTveXw48dSwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520Multiple%2520Ligands.%2520An%2520Emerging%2520Drug%2520Discovery%2520Paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Apsel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazif, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aizenstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span> </span><span class="NLM_article-title">Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">699</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnchembio.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=18849971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=691-699&author=B.+Apselauthor=J.+A.+Blairauthor=B.+Gonzalezauthor=T.+M.+Nazifauthor=M.+E.+Feldmanauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=R.+L.+Williamsauthor=K.+M.+Shokatauthor=Z.+A.+Knight&title=Targeted+Polypharmacology%3A+Discovery+of+Dual+Inhibitors+of+Tyrosine+and+Phosphoinositide+Kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</span></div><div class="casAuthors">Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">691-699</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles.  It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of targets that are structurally divergent.  Here we report the systematic discovery of mols. that potently inhibit both tyrosine kinases and phosphatidylinositol-3-OH kinases, two protein families that are among the most intensely pursued cancer drug targets.  Through iterative chem. synthesis, X-ray crystallog. and kinome-level biochem. profiling, we identified compds. that inhibit a spectrum of new target combinations in these two families.  Crystal structures revealed that the dual selectivity of these mols. is controlled by a hydrophobic pocket conserved in both enzyme classes and accessible through a rotatable bond in the drug skeleton.  We show that compd. I blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kinases and phosphatidylinositol-3-OH kinases.  These mols. demonstrate the feasibility of accessing a chem. space that intersects two families of oncogenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xlegha5YF7Vg90H21EOLACvtfcHk0ljTveXw48dSwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF&md5=4da10a973f6895f92a644ca82ca5cdcd</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.117%26sid%3Dliteratum%253Aachs%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DNazif%26aufirst%3DT.%2BM.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26atitle%3DTargeted%2520Polypharmacology%253A%2520Discovery%2520of%2520Dual%2520Inhibitors%2520of%2520Tyrosine%2520and%2520Phosphoinositide%2520Kinases%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D691%26epage%3D699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Besnard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruda, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abecassis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguiz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norval, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simeons, F. R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stojanovski, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidah, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Constam, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bickerton, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Automated Design of Ligands to Polypharmacological Profiles</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">492</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnature11691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=23235874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=215-220&author=J.+Besnardauthor=G.+F.+Rudaauthor=V.+Setolaauthor=K.+Abecassisauthor=R.+M.+Rodriguizauthor=X.-P.+Huangauthor=S.+Norvalauthor=M.+F.+Sassanoauthor=A.+I.+Shinauthor=L.+A.+Websterauthor=F.+R.+C.+Simeonsauthor=L.+Stojanovskiauthor=A.+Pratauthor=N.+G.+Seidahauthor=D.+B.+Constamauthor=G.+R.+Bickertonauthor=K.+D.+Readauthor=W.+C.+Wetselauthor=I.+H.+Gilbertauthor=B.+L.+Rothauthor=A.+L.+Hopkins&title=Automated+Design+of+Ligands+to+Polypharmacological+Profiles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Automated design of ligands to polypharmacological profiles</span></div><div class="casAuthors">Besnard, Jeremy; Ruda, Gian Filippo; Setola, Vincent; Abecassis, Keren; Rodriguiz, Ramona M.; Huang, Xi-Ping; Norval, Suzanne; Sassano, Maria F.; Shin, Antony I.; Webster, Lauren A.; Simeons, Frederick R. C.; Stojanovski, Laste; Prat, Annik; Seidah, Nabil G.; Constam, Daniel B.; Bickerton, G. Richard; Read, Kevin D.; Wetsel, William C.; Gilbert, Ian H.; Roth, Bryan L.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7428</span>),
    <span class="NLM_cas:pages">215-220</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy and safety of a drug is detd. by its activity profile across many proteins in the proteome.  However, designing drugs with a specific multi-target profile is both complex and difficult.  Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery.  Here is described a new approach for the automated design of ligands against profiles of multiple drug targets.  The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug donepezil (I) into brain-penetrable ligands with either specific polypharmacol. or exquisite selectivity profiles for G-protein-coupled receptors.  Overall, 800 ligand-target predictions of prospectively designed ligands were tested exptl., of which 75% were confirmed to be correct.  Target engagement in vivo is also demonstrated.  The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNu5bwrBD3tbVg90H21EOLACvtfcHk0ljTveXw48dSwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN&md5=ace6cced250cf968d327b482a5bf1798</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1038%2Fnature11691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11691%26sid%3Dliteratum%253Aachs%26aulast%3DBesnard%26aufirst%3DJ.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DAbecassis%26aufirst%3DK.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DShin%26aufirst%3DA.%2BI.%26aulast%3DWebster%26aufirst%3DL.%2BA.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DSeidah%26aufirst%3DN.%2BG.%26aulast%3DConstam%26aufirst%3DD.%2BB.%26aulast%3DBickerton%26aufirst%3DG.%2BR.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DAutomated%2520Design%2520of%2520Ligands%2520to%2520Polypharmacological%2520Profiles%26jtitle%3DNature%26date%3D2012%26volume%3D492%26spage%3D215%26epage%3D220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Bottegoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favia, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recanatini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span> </span><span class="NLM_article-title">The Role of Fragment-Based and Computational Methods in Polypharmacology</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1016%2Fj.drudis.2011.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=21864710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC38Xns12gtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=23-34&author=G.+Bottegoniauthor=A.+D.+Faviaauthor=M.+Recanatiniauthor=A.+Cavalli&title=The+Role+of+Fragment-Based+and+Computational+Methods+in+Polypharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">The role of fragment-based and computational methods in polypharmacology</span></div><div class="casAuthors">Bottegoni, Giovanni; Favia, Angelo D.; Recanatini, Maurizio; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">23-34</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Polypharmacol.-based strategies are gaining increased attention as a novel approach to obtaining potentially innovative medicines for multifactorial diseases.  However, some within the pharmaceutical community have resisted these strategies because they can be resource-hungry in the early stages of the drug discovery process.  Here, we report on fragment-based and computational methods that might accelerate and optimize the discovery of multitarget drugs.  In particular, we illustrate that fragment-based approaches can be particularly suited for polypharmacol., owing to the inherent promiscuous nature of fragments.  In parallel, we explain how computer-assisted protocols can provide invaluable insights into how to unveil compds. theor. able to bind to more than one protein.  Furthermore, several pragmatic aspects related to the use of these approaches are covered, thus offering the reader practical insights on multitarget-oriented drug discovery projects.  We report on fragment-based and computational approaches as possible ways to accelerate and optimize the discovery of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqX_beZ_hY17Vg90H21EOLACvtfcHk0liliHSsL7hhhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xns12gtw%253D%253D&md5=c774326a467a2b8fef62c6e1224c2a78</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DFavia%26aufirst%3DA.%2BD.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DThe%2520Role%2520of%2520Fragment-Based%2520and%2520Computational%2520Methods%2520in%2520Polypharmacology%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D23%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Gaulton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellis, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bento, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Light, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGlinchey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalovich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Lazikani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overington, J. P.</span><span> </span><span class="NLM_article-title">ChEMBL: A Large-Scale Bioactivity Database for Drug Discovery</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">D1100</span><span class="NLM_x">–</span> <span class="NLM_lpage">D1107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1093%2Fnar%2Fgkr777" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=21948594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs12htbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=D1100-D1107&author=A.+Gaultonauthor=L.+J.+Bellisauthor=A.+P.+Bentoauthor=J.+Chambersauthor=M.+Daviesauthor=A.+Herseyauthor=Y.+Lightauthor=S.+McGlincheyauthor=D.+Michalovichauthor=B.+Al-Lazikaniauthor=J.+P.+Overington&title=ChEMBL%3A+A+Large-Scale+Bioactivity+Database+for+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">ChEMBL: a large-scale bioactivity database for drug discovery</span></div><div class="casAuthors">Gaulton, Anna; Bellis, Louisa J.; Bento, A. Patricia; Chambers, Jon; Davies, Mark; Hersey, Anne; Light, Yvonne; McGlinchey, Shaun; Michalovich, David; Al-Lazikani, Bissan; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D1100-D1107</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">ChEMBL is an Open Data database contg. binding, functional and ADMET information for a large no. of drug-like bioactive compds.  These data are manually abstracted from the primary published literature on a regular basis, then further curated and standardized to maximize their quality and utility across a wide range of chem. biol. and drug-discovery research problems.  Currently, the database contains 5.4 million bioactivity measurements for more than 1 million compds. and 5200 protein targets.  Access is available through a web-based interface, data downloads and web services at: https://www.ebi.ac.uk/chembldb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9e9jRENTtubVg90H21EOLACvtfcHk0liliHSsL7hhhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs12htbjN&md5=aedf7793e1ca54b6a4fa272ea3ef7d0e</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkr777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkr777%26sid%3Dliteratum%253Aachs%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DBellis%26aufirst%3DL.%2BJ.%26aulast%3DBento%26aufirst%3DA.%2BP.%26aulast%3DChambers%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DM.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DLight%26aufirst%3DY.%26aulast%3DMcGlinchey%26aufirst%3DS.%26aulast%3DMichalovich%26aufirst%3DD.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DChEMBL%253A%2520A%2520Large-Scale%2520Bioactivity%2520Database%2520for%2520Drug%2520Discovery%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2012%26volume%3D40%26spage%3DD1100%26epage%3DD1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">Systematic Identification of Scaffolds Representing Compounds Active against Individual Targets and Single or Multiple Target Families</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">312</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci300616s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=312-326&author=Y.+Huauthor=J.+Bajorath&title=Systematic+Identification+of+Scaffolds+Representing+Compounds+Active+against+Individual+Targets+and+Single+or+Multiple+Target+Families"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic Identification of Scaffolds Representing Compounds Active against Individual Targets and Single or Multiple Target Families</span></div><div class="casAuthors">Hu, Ye; Bajorath, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">312-326</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Given the enormous growth of compd. activity data we currently observe, we have revisited the previously introduced concepts of privileged substructures and community-selective scaffolds and systematically searched for mol. scaffolds representing compds. active against single targets, multiple targets belonging to the same target family, or targets belonging to different families.  The influence of different types of activity measurements on scaffold assignments has been detd.  Furthermore, scaffold assignments have also been carried out after applying a potency threshold to exclude weakly active compds. from the comparison and address the issue of mol. selectivity.  In both instances, the results were very similar indicating that single-target and single-family scaffolds display target- and family-selective tendencies, resp.  Unexpectedly large nos. of 630 unique single-target, 489 single-family, and 336 multi-family scaffolds have been identified in public domain compd. data that represented relatively large nos. of compds.  Other important findings are that most of the growth in high-confidence compd. activity data has been due to the evaluation of new compds., rather than addnl. measurements for previously tested compds. or analog series for previously explored scaffolds.  The majority of scaffolds have remained in the same category over time.  Activity measurement type-dependent sets of single-target, single-family, and multi-family scaffolds are also provided as an up-to-date scaffold knowledge base.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlBrLCyCzg3bVg90H21EOLACvtfcHk0lgIGrh0_Jq34w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCnsbs%253D&md5=cef563cb1046bad1070ff8b62f8bd552</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fci300616s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci300616s%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DSystematic%2520Identification%2520of%2520Scaffolds%2520Representing%2520Compounds%2520Active%2520against%2520Individual%2520Targets%2520and%2520Single%2520or%2520Multiple%2520Target%2520Families%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D312%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armbruster, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernsberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">Relating Protein Pharmacology by Ligand Chemistry</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1038%2Fnbt1284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=17287757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=197-206&author=M.+J.+Keiserauthor=B.+L.+Rothauthor=B.+N.+Armbrusterauthor=P.+Ernsbergerauthor=J.+J.+Irwinauthor=B.+K.+Shoichet&title=Relating+Protein+Pharmacology+by+Ligand+Chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Relating protein pharmacology by ligand chemistry</span></div><div class="casAuthors">Keiser, Michael J.; Roth, Bryan L.; Armbruster, Blaine N.; Ernsberger, Paul; Irwin, John J.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-206</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The identification of protein function based on biol. information is an area of intense research.  Here the authors consider a complementary technique that quant. groups and relates proteins based on the chem. similarity of their ligands.  The authors began with 65,000 ligands annotated into sets for hundreds of drug targets.  The similarity score between each set was calcd. using ligand topol.  A statistical model was developed to rank the significance of the resulting similarity scores, which are expressed as a min. spanning tree to map the sets together.  Although these maps are connected solely by chem. similarity, biol. sensible clusters nevertheless emerged.  Links among unexpected targets also emerged, among them that methadone, emetine and loperamide (Imodium) may antagonize muscarinic M3, α2 adrenergic and neurokinin NK2 receptors, resp.  These predictions were subsequently confirmed exptl.  Relating receptors by ligand chem. organizes biol. to reveal unexpected relationships that may be assayed using the ligands themselves.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNKEMguhmluLVg90H21EOLACvtfcHk0lgIGrh0_Jq34w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOrsLo%253D&md5=1b7373d52563fca5fe1e893d85f70573</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fnbt1284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1284%26sid%3Dliteratum%253Aachs%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DArmbruster%26aufirst%3DB.%2BN.%26aulast%3DErnsberger%26aufirst%3DP.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DRelating%2520Protein%2520Pharmacology%2520by%2520Ligand%2520Chemistry%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D197%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Altschul, S. F.</span><span> </span><span class="NLM_article-title">Evaluating the Statistical Significance of Multiple Distinct Local Alignments</span>. In  <span class="citation_source-book">Theoretical and Computational Methods in Genome Research</span>; <span class="NLM_contrib-group">Suhai, S.</span>, Ed.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1997</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1007%2F978-1-4615-5903-0_1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&pages=1-14&author=S.+F.+Altschulauthor=S.+Suhai&title=Theoretical+and+Computational+Methods+in+Genome+Research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1007%2F978-1-4615-5903-0_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4615-5903-0_1%26sid%3Dliteratum%253Aachs%26aulast%3DAltschul%26aufirst%3DS.%2BF.%26atitle%3DEvaluating%2520the%2520Statistical%2520Significance%2520of%2520Multiple%2520Distinct%2520Local%2520Alignments%26btitle%3DTheoretical%2520and%2520Computational%2520Methods%2520in%2520Genome%2520Research%26aulast%3DSuhai%26aufirst%3DS.%26pub%3DSpringer%26date%3D1997%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">DeGraw, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochocki, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Distefano, M. D.</span><span> </span><span class="NLM_article-title">Prediction and Evaluation of Protein Farnesyltransferase Inhibition by Commercial Drugs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2464</span><span class="NLM_x">–</span> <span class="NLM_lpage">2471</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901613f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2464-2471&author=A.+J.+DeGrawauthor=M.+J.+Keiserauthor=J.+D.+Ochockiauthor=B.+K.+Shoichetauthor=M.+D.+Distefano&title=Prediction+and+Evaluation+of+Protein+Farnesyltransferase+Inhibition+by+Commercial+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Fjm901613f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901613f%26sid%3Dliteratum%253Aachs%26aulast%3DDeGraw%26aufirst%3DA.%2BJ.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DOchocki%26aufirst%3DJ.%2BD.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DDistefano%26aufirst%3DM.%2BD.%26atitle%3DPrediction%2520and%2520Evaluation%2520of%2520Protein%2520Farnesyltransferase%2520Inhibition%2520by%2520Commercial%2520Drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2464%26epage%3D2471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Carlsson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span> </span><span class="NLM_article-title">Structure-Based Discovery of A2A Adenosine Receptor Ligands</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3748</span><span class="NLM_x">–</span> <span class="NLM_lpage">3755</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100240h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFaqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3748-3755&author=J.+Carlssonauthor=L.+Yooauthor=Z.-G.+Gaoauthor=J.+J.+Irwinauthor=B.+K.+Shoichetauthor=K.+A.+Jacobson&title=Structure-Based+Discovery+of+A2A+Adenosine+Receptor+Ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Discovery of A2A Adenosine Receptor Ligands</span></div><div class="casAuthors">Carlsson, Jens; Yoo, Lena; Gao, Zhan-Guo; Irwin, John J.; Shoichet, Brian K.; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3748-3755</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent detn. of X-ray structures of pharmacol. relevant GPCRs has made these targets accessible to structure-based ligand discovery.  Here we explore whether novel chemotypes may be discovered for the A2A adenosine receptor, based on complementarity to its recently detd. structure.  The A2A adenosine receptor signals in the periphery and the CNS, with agonists explored as anti-inflammatory drugs and antagonists explored for neurodegenerative diseases.  We used mol. docking to screen a 1.4 million compd. database against the X-ray structure computationally and tested 20 high-ranking, previously unknown mols. exptl.  Of these 35% showed substantial activity with affinities between 200 nM and 9 μM.  For the most potent of these new inhibitors, over 50-fold specificity was obsd. for the A2A vs. the related A1 and A3 subtypes.  These high hit rates and affinities at least partly reflect the bias of com. libraries toward GPCR-like chemotypes, an issue that we attempt to investigate quant.  Despite this bias, many of the most potent new ligands were novel, dissimilar from known ligands, providing new lead structures for modulation of this medically important target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzvS6-9T9bd7Vg90H21EOLACvtfcHk0lh9zWhF3nUsUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFaqsL8%253D&md5=c36c941d52d2cec06387d79c4c423d46</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Fjm100240h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100240h%26sid%3Dliteratum%253Aachs%26aulast%3DCarlsson%26aufirst%3DJ.%26aulast%3DYoo%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DZ.-G.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DStructure-Based%2520Discovery%2520of%2520A2A%2520Adenosine%2520Receptor%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3748%26epage%3D3755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Hert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oprea, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">Quantifying the Relationships among Drug Classes</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">755</span><span class="NLM_x">–</span> <span class="NLM_lpage">765</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci8000259" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjt1WqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=755-765&author=J.+Hertauthor=M.+J.+Keiserauthor=J.+J.+Irwinauthor=T.+I.+Opreaauthor=B.+K.+Shoichet&title=Quantifying+the+Relationships+among+Drug+Classes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Quantifying the Relationships among Drug Classes</span></div><div class="casAuthors">Hert, Jerome; Keiser, Michael J.; Irwin, John J.; Oprea, Tudor I.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">755-765</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The similarity of drug targets is typically measured using sequence or structural information.  Here, we consider chemo-centric approaches that measure target similarity on the basis of their ligands, asking how chemoinformatics similarities differ from those derived bioinformatically, how stable the ligand networks are to changes in chemoinformatics metrics, and which network is the most reliable for prediction of pharmacol.  We calcd. the similarities between hundreds of drug targets and their ligands and mapped the relationship between them in a formal network.  Bioinformatics networks were based on the BLAST similarity between sequences, while chemoinformatics networks were based on the ligand-set similarities calcd. with either the Similarity Ensemble Approach (SEA) or a method derived from Bayesian statistics.  By multiple criteria, bioinformatics and chemoinformatics networks differed substantially, and only occasionally did a high sequence similarity correspond to a high ligand-set similarity.  In contrast, the chemoinformatics networks were stable to the method used to calc. the ligand-set similarities and to the chem. representation of the ligands.  Also, the chemoinformatics networks were more natural and more organized, by network theory, than their bioinformatics counterparts: ligand-based networks were found to be small-world and broad-scale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqREaEettV4KbVg90H21EOLACvtfcHk0lh9zWhF3nUsUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjt1WqsrY%253D&md5=628dde363e13134238c9de5dc27acd7e</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fci8000259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci8000259%26sid%3Dliteratum%253Aachs%26aulast%3DHert%26aufirst%3DJ.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DQuantifying%2520the%2520Relationships%2520among%2520Drug%2520Classes%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2008%26volume%3D48%26spage%3D755%26epage%3D765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Reker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, G.</span><span> </span><span class="NLM_article-title">Identifying the Macromolecular Targets of de Novo-Designed Chemical Entities through Self-Organizing Map Consensus</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">4067</span><span class="NLM_x">–</span> <span class="NLM_lpage">4072</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1073%2Fpnas.1320001111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=24591595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtl2msbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=4067-4072&author=D.+Rekerauthor=T.+Rodriguesauthor=P.+Schneiderauthor=G.+Schneider&title=Identifying+the+Macromolecular+Targets+of+de+Novo-Designed+Chemical+Entities+through+Self-Organizing+Map+Consensus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus</span></div><div class="casAuthors">Reker, Daniel; Rodrigues, Tiago; Schneider, Petra; Schneider, Gisbert</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4067-4072</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">De novo mol. design and in silico prediction of polypharmacol. profiles are emerging research topics that will profoundly affect the future of drug discovery and chem. biol.  The goal is to identify the macromol. targets of new chem. agents.  Although several computational tools for predicting such targets are publicly available, none of these methods was explicitly designed to predict target engagement by de novo-designed mols.  Here the authors present the development and practical application of a unique technique, self-organizing map-based prediction of drug equivalence relationships (SPiDER), that merges the concepts of self-organizing maps, consensus scoring, and statistical anal. to successfully identify targets for both known drugs and computer-generated mol. scaffolds.  The authors discovered a potential off-target liability of fenofibrate-related compds., and in a comprehensive prospective application, the authors identified a multitarget-modulating profile of de novo designed mols.  These results demonstrate that SPiDER may be used to identify innovative compds. in chem. biol. and in the early stages of drug discovery, and help investigate the potential side effects of drugs and their repurposing options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD_gPUwcpea7Vg90H21EOLACvtfcHk0lh9zWhF3nUsUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtl2msbg%253D&md5=5322c8755c4aeee029288015d8a55d69</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1320001111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1320001111%26sid%3Dliteratum%253Aachs%26aulast%3DReker%26aufirst%3DD.%26aulast%3DRodrigues%26aufirst%3DT.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DIdentifying%2520the%2520Macromolecular%2520Targets%2520of%2520de%2520Novo-Designed%2520Chemical%2520Entities%2520through%2520Self-Organizing%2520Map%2520Consensus%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26spage%3D4067%26epage%3D4072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Kohonen, T.</span> <span class="citation_source-book">Self-Organizing Maps</span>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1007%2F978-3-642-56927-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=T.+Kohonen&title=Self-Organizing+Maps"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-56927-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-642-56927-2%26sid%3Dliteratum%253Aachs%26aulast%3DKohonen%26aufirst%3DT.%26btitle%3DSelf-Organizing%2520Maps%26pub%3DSpringer%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Anighoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Enrichment Factor Analyses on G-Protein Coupled Receptors with Known Crystal Structure</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">743</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci4000745" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvFWitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=739-743&author=A.+Anighoroauthor=G.+Rastelli&title=Enrichment+Factor+Analyses+on+G-Protein+Coupled+Receptors+with+Known+Crystal+Structure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Enrichment Factor Analyses on G-Protein Coupled Receptors with Known Crystal Structure</span></div><div class="casAuthors">Anighoro, Andrew; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">739-743</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-protein coupled receptors (GPCRs) are highly relevant drug targets.  Four GPCRs with known crystal structure were analyzed with docking (AutoDock4) and postdocking (MM-PBSA) in order to evaluate the ability to recognize known antagonists from a larger database of mol. decoys and to predict correct binding modes.  Moreover, implications on multitarget drug screening are put forward.  The results suggest that these methods may be of interest to the growing field of GPCR structure-based virtual screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGpJ6O40Y6MrVg90H21EOLACvtfcHk0liThwBv51jfUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvFWitb0%253D&md5=b99ed5c128225b5f7ffd8d4334d5a87d</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fci4000745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci4000745%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DEnrichment%2520Factor%2520Analyses%2520on%2520G-Protein%2520Coupled%2520Receptors%2520with%2520Known%2520Crystal%2520Structure%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D739%26epage%3D743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Selvam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tikhonova, I. G.</span><span> </span><span class="NLM_article-title">Addressing Selective Polypharmacology of Antipsychotic Drugs Targeting the Bioaminergic Receptors through Receptor Dynamic Conformational Ensembles</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1761</span><span class="NLM_x">–</span> <span class="NLM_lpage">1774</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci400282q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVGhtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=1761-1774&author=B.+Selvamauthor=S.+L.+Porterauthor=I.+G.+Tikhonova&title=Addressing+Selective+Polypharmacology+of+Antipsychotic+Drugs+Targeting+the+Bioaminergic+Receptors+through+Receptor+Dynamic+Conformational+Ensembles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Addressing Selective Polypharmacology of Antipsychotic Drugs Targeting the Bioaminergic Receptors through Receptor Dynamic Conformational Ensembles</span></div><div class="casAuthors">Selvam, Balaji; Porter, Simon L.; Tikhonova, Irina G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1761-1774</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective polypharmacol., where a drug acts on multiple rather than a single mol. target involved in a disease, emerges to develop a structure-based system biol. approach to design drugs selectively targeting a disease-active protein network.  We focus on the bioaminergic receptors that belong to the group of G-protein-coupled receptors (GPCRs) and represent targets for therapeutic agents against schizophrenia and depression.  Among them, it has been shown that the serotonin (5-HT2A and 5-HT6) and dopamine (D2 and D3) receptors induce a cognition-enhancing effect (group 1), while the histamine (H1) and serotonin (5-HT2C) receptors lead to metabolic side effects and the 5-HT2B serotonin receptor causes pulmonary hypertension (group 2).  Thus, the problem arises to develop an approach that allows identifying drugs targeting only the disease-active receptors, i.e. group 1.  The recent release of several crystal structures of the bioaminergic receptors, involving the D3 and H1 receptors, provides the possibility to model the structures of all receptors and initiate a study of the structural and dynamic context of selective polypharmacol.  In this work, we use mol. dynamics simulations to generate a conformational space of the receptors and subsequently characterize its binding properties applying mol. probe mapping.  All-against-all comparison of the generated probe maps of the selected diverse conformations of all receptors with the Tanimoto similarity coeff. (Tc) enable the sepn. of the receptors of group 1 from group 2.  The pharmacophore built based on the Tc-selected receptor conformations, using the multiple probe maps discovers structural features that can be used to design mols. selective toward the receptors of group 1.  The importance of several predicted residues to ligand selectivity is supported by the available mutagenesis and ligand structure-activity relationship studies.  In addn., the Tc-selected conformations of the receptors for group 1 show good performance in isolation of known ligands from a random decoy.  Our computational structure-based protocol to tackle selective polypharmacol. of antipsychotic drugs could be applied for other diseases involving multiple drug targets, such as oncol. and infectious disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFhv00UaxiCLVg90H21EOLACvtfcHk0liThwBv51jfUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVGhtbk%253D&md5=84bfd85ac645c0212f3cc0dbed9601af</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fci400282q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci400282q%26sid%3Dliteratum%253Aachs%26aulast%3DSelvam%26aufirst%3DB.%26aulast%3DPorter%26aufirst%3DS.%2BL.%26aulast%3DTikhonova%26aufirst%3DI.%2BG.%26atitle%3DAddressing%2520Selective%2520Polypharmacology%2520of%2520Antipsychotic%2520Drugs%2520Targeting%2520the%2520Bioaminergic%2520Receptors%2520through%2520Receptor%2520Dynamic%2520Conformational%2520Ensembles%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D1761%26epage%3D1774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Ripphausen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nisius, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltason, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span> </span><span class="NLM_article-title">Quo Vadis, Virtual Screening? A Comprehensive Survey of Prospective Applications</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8461</span><span class="NLM_x">–</span> <span class="NLM_lpage">8467</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101020z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1GqtrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8461-8467&author=P.+Ripphausenauthor=B.+Nisiusauthor=L.+Peltasonauthor=J.+Bajorath&title=Quo+Vadis%2C+Virtual+Screening%3F+A+Comprehensive+Survey+of+Prospective+Applications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Quo Vadis, Virtual Screening? A Comprehensive Survey of Prospective Applications</span></div><div class="casAuthors">Ripphausen, Peter; Nisius, Britta; Peltason, Lisa; Bajorath, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8461-8467</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Our anal. has revealed that the majority of prospective virtual screening (VS) studies have thus far been reported in only a small no. of journals.  In addn., we have found that docking investigations clearly dominate the prospective VS field at present.  We see an increasing no. of successful VS studies that are based on docking into homol. models, and the potency of such identified hits is on av. higher than for hits identified by docking into X-ray structures, although model-based docking calcns. are more approx. in nature.  In this context, it is interesting to note that NMR structures have thus far only rarely been used in practical VS applications.  Currently there are three times more structure-based virtual screening (SBVS) than ligand-based virtual screening (LBVS) applications available, but LBVS methods identify hits that are on av. more potent.  In particular, nearly all of the still limited no. of LBVS investigations that combine 2D and 3D components yield potent hits.  Furthermore, kinases, G-protein-coupled receptors (GPCRs), and proteases are the most popular VS targets.  For kinases and GPCRs, potent submicromolar VS hits are frequently obtained, in contrast to proteases, where the majority of reported hits are only weakly potent.  However, protein kinases and proteases only represent ∼36 % of all enzymes targeted by VS, and more than 50 % of these enzymes do not belong to the five major families.  Taken together, the results of our anal. have provided us with a rather detailed view of the prospective VS landscape and there have certainly been a few surprises.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHMK13XT0tD7Vg90H21EOLACvtfcHk0liThwBv51jfUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1GqtrnK&md5=c20f82a1869c0ea176b177bc74ad92a4</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Fjm101020z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101020z%26sid%3Dliteratum%253Aachs%26aulast%3DRipphausen%26aufirst%3DP.%26aulast%3DNisius%26aufirst%3DB.%26aulast%3DPeltason%26aufirst%3DL.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DQuo%2520Vadis%252C%2520Virtual%2520Screening%253F%2520A%2520Comprehensive%2520Survey%2520of%2520Prospective%2520Applications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8461%26epage%3D8467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Emerging Topics in Structure-Based Virtual Screening</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1458</span><span class="NLM_x">–</span> <span class="NLM_lpage">1463</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2013&pages=1458-1463&author=G.+Rastelli&title=Emerging+Topics+in+Structure-Based+Virtual+Screening"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DEmerging%2520Topics%2520in%2520Structure-Based%2520Virtual%2520Screening%26jtitle%3DPharm.%2520Res.%26date%3D2013%26volume%3D30%26spage%3D1458%26epage%3D1463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Rastelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degliesposti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Rio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sgobba, M.</span><span> </span><span class="NLM_article-title">Binding Estimation after Refinement, a New Automated Procedure for the Refinement and Rescoring of Docked Ligands in Virtual Screening</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Fjm5006463&amp;key=10.1111%2Fj.1747-0285.2009.00780.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Fjm5006463&amp;key=19207463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Fjm5006463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjt1WhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2009&pages=283-286&author=G.+Rastelliauthor=G.+Degliespostiauthor=A.+Del+Rioauthor=M.+Sgobba&title=Binding+Estimation+after+Refinement%2C+a+New+Automated+Procedure+for+the+Refinement+and+Rescoring+of+Docked+Ligands+in+Virtual+Screening"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Binding estimation after refinement, a new automated procedure for the refinement and rescoring of docked ligands in virtual screening</span></div><div class="casAuthors">Rastelli, Giulio; Degliesposti, Gianluca; Del Rio, Alberto; Sgobba, Miriam</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">283-286</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Binding estn. after refinement (BEAR) is a novel automated computational procedure suitable for correcting and overcoming limitations of docking procedures such as poor scoring function and the generation of unreasonable ligand conformations.  BEAR makes use of mol. dynamics simulation followed by MM-PBSA and MM-GBSA binding free energy ests. as tools to refine and rescore the structures obtained from docking virtual screenings.  As binding estn. after refinement relies on mol. dynamics, the entire procedure can be tailored to the needs of the end-user in terms of computational time and the desired accuracy of the results.  In a validation test, binding estn. after refinement and rescoring resulted in a significant enrichment of known ligands among top scoring compds. compared with the original docking results.  Binding estn. after refinement has direct and straightforward application in virtual screening for correcting both false-pos. and false-neg. hits, and should facilitate more reliable selection of biol. active mols. from compd. databases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_CIA8Wshju7Vg90H21EOLACvtfcHk0lgD6P6D8hBPeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjt1WhtL8%253D&md5=8a113fb4e3ae908b3d70eb97a4c964f5</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2009.00780.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2009.00780.x%26sid%3Dliteratum%253Aachs%26aulast%3DRastelli%26aufirst%3DG.%26aulast%3DDegliesposti%26aufirst%3DG.%26aulast%3DDel%2BRio%26aufirst%3DA.%26aulast%3DSgobba%26aufirst%3DM.%26atitle%3DBinding%2520Estimation%2520after%2520Refinement%252C%2520a%2520New%2520Automated%2520Procedure%2520for%2520the%2520Refinement%2520and%2520Rescoring%2520of%2520Docked%2520Ligands%2520in%2520Virtual%2520Screening%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2009%26volume%3D73%26spage%3D283%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm5006463&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Fjm5006463%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-19%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm5006463" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799561ef9ff2458","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
